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The 90 kDa heat shock proteins (Hsp90) are critical for the maintenance of cellular 
homeostasis and mitigate the effects of cellular stress and therefore, play an important role in cell 
survival. Hsp90, as a molecular chaperone, folds nascent polypeptides and denatured proteins to 
their biologically relevant conformations. Many of the proteins dependent upon Hsp90 are 
essential to the growth and proliferation of cancer cells. In fact, proteins associated with all ten 
hallmarks of cancer are dependent upon the Hsp90 protein folding machinery. Consequently, 
inhibition of Hsp90 represents a combinatorial approach for the treatment of cancer. 17 small 
molecule inhibitors of Hsp90 have entered clinical trials, all of which bind Hsp90 N-terminus and 
exhibit pan-inhibitory activity against the four Hsp90 isoforms: Hsp90, Hsp90, Grp94, and 
Trap1. However, lack of isoform selectivity with current clinical candidates appears detrimental 
as more than 20 clinical trials have failed, citing hepatotoxicity, cardiotoxicity, and peripheral 
neuropathy amongst other side effects. Additionally, pan-inhibition of Hsp90 induces the pro-
survival heat shock response, requiring the escalation of patient doses to overcome increased 
Hsp90 expression. Therefore, alternative approaches for Hsp90 modulation are highly sought after. 
Isoform-selective inhibition of Hsp90 provides an opportunity to address the 
aforementioned detriments associated with pan-Hsp90 N-terminal inhibitors. Hydrolysis of ATP 
by the N-terminal nucleoside binding pocket is required for the maturation of client protein 
substrates, and all four Hsp90’s share >85% identity within this region. Consequently, the 
discovery of isoform-selective inhibitors has been challenging. Described herein is the rationale 
for development of isoform selective inhibitors and the identification of the first isoform selective 
inhibitors of Hsp90 and Hsp90-isoforms. 
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Unlike the N-terminus, inhibition of the Hsp90 C-terminus does not induce the heat shock 
response and hence, C-terminal inhibitors manifest the desired cytotoxic affect against cancer 
cells. However, absence of a co-crystal structure and lack of lead compounds, have resulted in 
limited success towards the development of Hsp90 C-terminal inhibitors. Recently, EGCG, a green 
tea polyphenol, was shown to bind at the C-terminus of Hsp90. Structure activity relationships 
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UNFOLDING THE HSP90 FOLDASOME: STRUCTURE-ACTIVITY 





Hsp90 and Its Natural Product-Based Inhibitors 
I. 1. Introduction 
Molecular chaperones represent a class of proteins that are responsible for the 
conformational maturation of nascent polypeptides into their biologically active conformation, as 
well as the rematuration of denatured proteins. Molecular chaperones work together with co-
chaperones and other partner proteins to facilitate the folding of protein substrates (foldasomes).1-
3 Many of these chaperones are overexpressed in response to conditions that cause cellular stress, 
such as hypoxia, acidosis, and increased/decreased temperature. Heat shock proteins, a class of 
molecular chaperones, were originally identified after cellular exposure to elevated temperatures, 
which led to their overexpression, to refold proteins that were denatured/aggregated at such 
temperatures.4, 5 The 90 kDa heat shock protein (Hsp90) is highly conserved in eukaryotes and 
represents 1-2% of the total cellular protein at ambient temperatures, but can be overexpressed to 
comprise 6% in stressed cells.6-8 Hsp90 is responsible for the maturation of more than 200 client 
proteins, including several therapeutically sought after anticancer targets, such as Her2, Raf, ALK, 
Src, and Akt.6, 9 Due to its central role in oncogenesis, Hsp90 has emerged as a promising target 
for the development of anti-cancer agents.4, 10-14 
Geldanamycin (GDA), an ansamycin class of antibiotic, is a classic example of natural 
product-based drug discovery in medicinal chemistry.15 Analysis of the biological activity 
manifested by GDA led to the discovery that its primary biological target is the 90 kDa heat shock 
protein, Hsp90.16  Many drug development campaigns with GDA have provided drug candidates 
that have entered clinical trials and yielded biological probes that have increased the understanding 
of Hsp90 biology.17, 18 In the last two decades, other natural products have also been shown to bind 
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and modulate the Hsp90 chaperone machinery by various mechanisms.19-31 These natural products 
have served as a starting point for numerous drug development campaigns, which led to the 
discovery of highly efficacious Hsp90 inhibitors.14, 15, 32, 33  
I.2. Hsp90 Structure and Function 
In cells, Hsp90 exists as a homodimer and each 
monomer consists of an N-terminal ATP-binding domain, 
a middle domain connected to the N-terminus by a charged 
linker, and a C-terminal dimerization motif (Figure 1).34-37 
ATP binds to the highly conserved N-terminus, and its 
hydrolysis provides the requisite energy to facilitate client 
protein maturation.  The N-terminal ATP-binding site is 
conserved within the GHKL superfamily of proteins, such 
as Hsp90, histidine kinase, DNA gyrase B, and MutL.38  The GHKL superfamily is characterized 
by the presence of Bergerat ATP-binding fold, in which ATP binds in a unique, bent conformation 
that is in contrast to the typical extended conformation.39 The Bergerat motif consists of three -
helices in a helix-sheet-helix orientation and four interstranded -sheets. The N-terminal ATP-
binding site manifests interactions with residues in the loop region that connects to -helices and 
-sheets.38 The middle domain plays a crucial role in client protein recognition, as well as 
interactions with co-chaperones and other partner proteins. The C-terminus mediates dimerization 
and contains a second nucleotide binding site.  There are four isoforms of Hsp90 in mammals: 
Hsp90α and Hsp90β are localized in the cytosol, Grp94 is found in the endoplasmic reticulum and 




Figure 1. The structure of Hsp90.  




Hsp90α isoform is inducible upon exposure to cellular stress.40, 41 In the human genome, there are 
17 genes that encode for Hsp90, however, only six of them encode the four functional isoforms.42  
I.2.1 Hsp90 Chaperone Cycle 
The Hsp90 chaperone cycle is complex, but advances in technology and small molecule 
probes have provided insights into the catalytic cycle. Several other proteins (co-chaperones and 
partner proteins) associate with Hsp90 during the chaperone cycle and mediate the protein folding 
process (Table 1).43-46 The Hsp90-mediated the protein folding process is catalytic and protein 
maturation is driven by ATP-hydrolysis (Figure 2).47 Succinctly, the Hsp90 chaperone cycle 
begins with the delivery of nascent polypeptides to the Hsp90 complex by a Hsp70-Hsp40 complex 
( Figure 2.3).  This process is mediated by the Hsp70-Hsp90 organizing co-chaperone, HOP 
(Figure 2.2). Upon delivery of the nascent polypeptide, various co-chaperones, immunophilins, 
and partner proteins interact with Hsp90 to form a heteroprotein complex (Figure 2.4).  ATP is 
recruited to the N-terminus (Figure 2.5) and is then hydrolyzed upon p23 association (Figure 2.7). 
Association of p23 increases both the rate of ATP hydrolysis and client protein maturation. 
Following maturation, the client protein is released through opening of the C-terminal dimer 
interface and the heteroprotein complex dissociates to regenerate the Hsp90 homodimer (Figure 
2.1).  
I.2.2 Inhibition of Hsp90 Chaperone Cycle 
Inhibition of either the N- or C-terminus can disrupt the Hsp90 chaperone cycle.  Upon 
disruption of the chaperone cycle by an inhibitor, the client protein is degraded through the 
ubiquitin-proteasome pathway (Figure 2.6).48 Because malignant cells undergo a constant rate of 
proliferation, increased rates of metabolism and protein synthesis are required for survival. This 
leads to an increased tumor dependency upon Hsp90. Therefore, Hsp90 exists primarily as the 
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heteroprotein complex (Figure 2.4) in malignant cells. Conversely, Hsp90 exists as the homodimer 
(Figure 2.1) 




Aha1 Stimulates ATPase activity 
Cdc37 Mediates activation of protein kinase substrates 
CHIP Involved in degradation of unfolded client proteins 
Cyclophilin-40 Peptidyl propyl isomerase 
FKBP51 and 52 Peptidyl propyl isomerases 
HOP Mediates interaction between Hsp90 and Hsp70 
Hsp40 Stabilizes and delivers client proteins to Hsp90 complex 
Hsp70 Stabilizes and delivers client proteins to Hsp90 complex 
p23 Stabilizes closed, clamped substrate bound conformation 
HIP Inhibits ATPase activity of Hsp70 
PP5 Protein phosphatase  
Sgt1 Client adaptor, involved in client recruitment 
Tom70 Translocation of pre-proteins into mitochondrial matrix 
WISp39 Regulates p21 stability 
 
in unstressed or normal cells. Interestingly, the heteroprotein complex possesses more than 200-
fold greater affinity for ATP, when compared to the Hsp90 homodimer. Therefore, inhibitors that 
bind the ATP-binding pocket exhibit an inherent selectivity for the heteroprotein complex, 
resulting in differential selectivity of ~200-fold for cancer verses normal cells.11  Not surprisingly, 
Hsp90 inhibitors accumulate at higher concentrations in tumor tissues than in normal tissues.  
Hsp90 inhibition exhibits therapeutic potential for the treatment of many different diseases. Most 
notably, Hsp90 inhibitors are sought after as anti-cancer agents because many Hsp90-dependent 
client proteins are associated with oncogenic pathways that cause tumor initiation, tumor 
progression and metastasis. As shown in Table 2, Hsp90 client proteins are present in all 10 
hallmarks of cancer, therefore, inhibition of Hsp90 provides a unique opportunity to 
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simultaneously disrupt multiple oncogenic pathways, and thus provides a multi-dimensional attack 
on cancer (a complete listing of Hsp90 clients can be found at 
http://www.picard.ch/downloads/Hsp90interactors.pdf). Hsp90 inhibitors manifest a single drug 
combination approach toward the treatment of cancer.49, 50 Stimulation of Hsp’s (Hsp70, Hsp40, 
Hsp27) by non-toxic molecules has potential therapeutic application in diseases caused by 
misfolded and aggregated proteins. Hence, Hsp90 modulation not only exhibits potential to treat 
cancer, but also several other unrelated disease states including Alzheimer’s, Parkinson’s, 











Table 2. Ten hallmarks of cancer and associated Hsp90 clients  
Hallmarks of Cancer Hsp90 Client Protein(s) 
1. Self-sufficiency in growth signals Raf-1, AKT, Her2, MEK, Bcr-Abl 
2. Insensitivity to anti-growth signals Plk, Wee1, Myc1, CDK4, CDK6, Myt1 
3. Evasion of apoptosis RIP, AKT, p53, c-MET, Apaf-1, Survivin 
4. Limitless replicative potential Telomerase (h-Tert) 
5. Sustained angiogenesis FAK, AKT, Hif-1α, VEGFR, flt-3 
6. Tissue invasion and Metastasis C-MET 
7. Deregulated cellular energetics ARNT, HIF-1α, HMG1, SREBF1 
8. Avoiding immune destruction IRAK3 
9. Tumor-promoting inflammation IL-6, IL-8, IRAK1, IRAK2, IRAK3 
10. Genome instability and mutation FANCA, MAFG, NEK8, NEK9, NEK11 
 
I.3. Hsp90 Inhibitors 
The complexity of the Hsp90 chaperone cycle presents many opportunities to modulate 
Hsp90’s activity. Hsp90 inhibitors can be broadly divided into three classes on the basis of their 
binding to Hsp90: (1) Hsp90 N-terminal inhibitors; (2) Hsp90 C-terminal inhibitors; and (3) 
disrupters of co-chaperone interactions (Figure 3).4, 16, 19, 54-56 Natural products have played an 
essential role in the development of all three classes of inhibitors. At present, only N-terminal 
inhibitors have been evaluated in the clinic as anti-cancer agents. While N-terminal inhibition 
remains the most widely studied and sought after strategy, the latter two approaches are emerging 
as alternative strategies. 22, 57-59 
I.3.1. N-Terminal Inhibitors 
I.3.1.1 Geldanamycin-Based Inhibitors 
7 
Geldanamycin (GDA) (Figure 3) was isolated from the geldanus variant of the filamentous 
soil bacterium, Streptomyces hygroscopicus, in 1970 and subsequently shown to manifest potent 
 antibiotic and growth inhibitory activity against HeLa derived KB cancer cells.60  In subsequent 
years, GDA manifested potent anti-tumor activity against a variety of other cancer cell lines. 
However, Hsp90 was not identified as the biological target of GDA until 1994, when Whitesell 
Figure 3. Representative Hsp90 inhibitors. 
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and co-workers demonstrated that GDA binds Hsp90 to induce the degradation of v-SRC, an 
oncogenic client protein of Hsp90.16 Although GDA manifests excellent potency, its 
hepatotoxicity, low chemical stability, and poor bioavailability prevented it from advancing to 
clinical trials.61  In order to produce new analogues with improved pharmacological properties, 
structure-activity relationship (SAR) studies on GDA have been pursued along with total synthesis, 
semi-synthesis, and genetic engineering of its biosynthetic pathway. These efforts have led to the 
development of derivatives that manifest superior pharmacokinetic and pharmacodynamic 
profiles.  
 
The most efficacious analogues of GDA were produced by semi-synthesis that modified 
the 17-position.17, 62-64  Due to the labile nature of the β-methoxy-α,β-unsaturated quinone, the 17-
methoxy could be easily substituted with various nucleophiles to provide C-17 substituted 
analogues. Replacing the 17-methoxy with alkyl amines produced the greatest biological activities, 
which further stabilized the reactive quinone moiety. These efforts resulted in the development of 
17-allylamino-GDA (17-AAG, Figure 4), which became the first Hsp90 inhibitor to enter in 
clinical trials. 65, 66 
 
 
Figure 4. GDA-Analogues for improved Hsp90 inhibition. ICa50: Measured in p185 
degradation assay (GDA: 70 nM); ICb50: measured in competitive binding assay in MCF-7 cell 
lysate (17-AAG: 20 nM); ECc50: measured Her2 degradation assay (GDA 5 nM). 
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Kosan Biosciences reported the synthesis of more than 60 analogues of the 17-position, as 
well as the C-7 carbamate during their pursuit of GDA analogues.  Modifications to the carbamate 
decreased potency, as the carbamate provides key hydrogen 
bonding interactions with the N-terminal ATP-binding site of 
Hsp90.67 From these studies, 17-(2-dimethylaminoethyl)amino-17-
demethoxygeldanamycin (17-DMAG, Figure 4) was identified as a 
potent inhibitor of Hsp90  (IC50 = 24 nM) with excellent solubility. 
Subsequently 17-DMAG underwent clinical evaluation. 17-AAG 
undergoes cytochrome P450 3A4-mediated oxidation of the alpha 
methylene on the 17-amino substituent, resulting in subsequent 
hydrolysis of the C-N bond to produce the corresponding amine 
analogue (IPI-493, Figure 4). This metabolite manifests growth 
inhibitory activity against breast cancer cells (SKBr3) at 33 nM, 
which is similar to that of 17-AAG.68  Consequently, Infinity Pharmaceuticals developed another 
water soluble GDA analogue, IPI-504 (Figure 4).  For IPI-504, the hydroquinone was more water-
soluble than the corresponding quinone and upon subsequent preclinical studies, IPI-504 was 
found to exhibit excellent properties, which led to its clinical evaluation.69, 70  In 2006, Porter and 
co-workers reported the hydroquinone analogues (Figure 5). These analogues exhibited increased 
binding affinity for Hsp90 compared to the corresponding quinone. These studies paralleled prior 
studies with radicicol and geldanamycin chimeras.64, 70   
  The biological evaluation of GDA and its derivatives have provided significant insights 
into Hsp90’s biological function, as well as established Hsp90 as a promising anti-cancer target.  
GDA has served as a starting point for several medicinal chemistry campaigns and as a result 
        
 
 
Figure 5. Hydroquinone 
analogues of GDA. EC50 
measured in fluorescence 
polarization assay using 
BODIPY-GDA as probe 




several GDA analogues have advanced into clinical trials.71-75  The current focus of GDA research 
has centered on addressing the toxicities associated with the benzoquinone moiety, as well as the 
use of GDA analogues in combination with other therapies in the clinic. 
I.3.1.2. Radicicol-Based Inhibitors 
The resorcinol lactone, radicicol (RDC, Figure 6) was originally isolated from 
Monosporium bonorden in 1953.76  RDC manifested antifungal properties and was later found to 
exhibit anti-tumor properties.  Similar to GDA, RDC was believed to be an inhibitor of the v-Src 
and Ras-Raf-MAPK signaling pathways.24, 77  RDC exhibited a similar biological profile as GDA, 
and in 1998, Schulte and co-workers demonstrated that RDC competes with GDA, for binding to 
Hsp90.  Subsequent experiments showed that, like GDA, RDC binds the N-terminal ATP-binding 
site of Hsp90; however RDC binds in a different orientation.78, 79   
RDC manifests greater affinity for Hsp90 than GDA in vitro (Kd in ATPase assay, 19 nM 
vs. 1.2 μM, respectively). However, the administration of RDC in vivo does not produce anti-tumor 
activity, because RDC is rapidly metabolized to inactive metabolites due to its electrophilic nature 
(allylic epoxide and α,β,γ,δ-unsaturated ketone), which provides no in vivo activity.80  
Consequently, RDC was not considered a viable candidate for clinical evaluation.81  In addition to 
RDC, less electrophilic natural products (Figure 6) Monocillin I, Pochonins A, and Pochonins D, 
have also been identified as Hsp90 inhibitors, although they manifest inferior affinity. 82-84 
RDC attracted the attention of several synthetic groups beginning in the early 1990s, and 
the first total synthesis was reported in 1992. 85, 86 Subsequent routes toward the natural product 
were also developed by the Winssinger and Danishefsky laboratories.87-89 These total syntheses 
allowed for the preparation of the analogues with reduced electrophilicity and enhanced metabolic 




epoxide with a cyclopropyl ring.  Danishefsky and co-workers reported analogues that 
incorporated the cyclopropyl ring (Figure 6), which resulted in a two-fold loss in cellular 
efficacy.90  Additionally, replacement of the epoxide with a difluorocylcopropane ring (Figure 6a)  
significantly decreased activity.  A second strategy to increase the stability of RDC was to modify 
the 2’-ketone of RDC to the corresponding oxime.31, 77 The oxime analogues provided the 
unsubstituted oxime analog, KF25706 (Figure 6a), which manifested comparable potency to RDC 
against various cancer cell lines. Metabolically stable KF25706 was evaluated in xenograft rodent 




   
 
Figure 6. Resorcinol comprising natural products and binding mode of geldanamycin and 
radicicol. (a) Radicicol and related compounds ICa50: represents IC50 values of anti-proliferative 
activity against the MCF-7 breast cancer ICb50 represents IC50 values of a time-resolved 
fluorescence resonance energy transfer (TR-FRET) assay. (b) Binding conformation of GDA 




of substituted oximes was prepared and evaluated for anti-cancer activity.  A mixture of E and Z 
isomers complicated the development of oxime derivatives. However, it was determined that the 
E isomer possesses higher affinity for Hsp90.  Metabolically stable RDC analogues represent a 
promising method to further develop these natural product inhibitors; however, the synthetic 
complexity associated with this scaffold renders this compound difficult for large scale 
production.91 Fortunately, the data obtained from RDC analogues presented a new pharmacophore 
that has been successfully utilized to design new Hsp90 inhibitors. 92-97 
 The resorcinol ring of RDC serves as a valuable pharmacophore for several highly 
efficacious Hsp90 inhibitors (Figure 7).98, 99 Synta pharmaceutical developed the oxazolidinone 
containing, ganetespib (STA-9090, Figure 7), which is currently in 9 different clinical trial 
spanning phase I-II evaluation for the treatment of seven types of cancers.  STA-9090 manifests 
greater efficacy than 17-AAG against various lung cancer cell lines (average IC50 = 6.5 nM vs. 
30.5 nM, respectively), and exhibits greater tumor penetration and an improved toxicity profile in 
preclinical models. 100-102 
A medicinal chemistry campaign utilizing a structure-based approach led to the 
development of another clinical candidate, NYP-AUY922 (Figure 7), which is currently in phase 
II clinical trials for Her-2 positive and estrogen receptor positive metastatic breast cancers. 
AUY922 was also being evaluated in a phase II trial for non-small cell lung cancer (NSCLC) and 
produced a 20% response rate.103-105 AUY922 is also being evaluated for the treatment of patients 
with multiple myeloma in the presence and absence of the proteasome inhibitor, bortezomib. 
However,  results have not been encouraging, as dose tolerance appears to be an issue when 
administered in combination with bortezomib.104, 105 KW-2478 and AT13387 (Figure 7) are 
additional resorcinol-derived Hsp90 inhibitors that have advanced into clinical trials.  KW-2478 
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was developed by Kyowa Hakko Kirin Pharma in Japan through a unique lead optimization 
strategy that included the combination of microbial screening, structure-based drug design, cell-
based screening, and in vivo models.106 This optimization strategy led to the identification of KW-
2478, which manifests 3.8 nM affinity for Hsp90 and low nM anti-proliferative IC50 values against 
various multiple myeloma cell lines.  KW-2478 is currently being evaluated in patients with B-
cell malignancies (phase I) and relapse or refractory multiple myeloma (phase I-II, in combination 
with bortezomib).98 Astex pharmaceuticals developed AT13387 from a fragment-based drug 
discovery approach.  AT13387 manifests an IC50 of 0.71 nM via fluorescence polarization and an 
anti-proliferative IC50 of 48 nM against the HCT116 colon cancer cell line. AT13387 is currently 
in phase I trials for patients with metastatic solid tumors, as well as phase II trial for the treatment 
of gastrointestinal stromal solid tumors, with or without Imatinib.107 
 
I.3.1.3. Chimeric Inhibitors 
One approach to develop new Hsp90 inhibitory scaffolds is to combine the key structural 
features found in both GDA and RDC. This approach offers the potential to retain key interactions 
from both natural products with Hsp90, while simultaneously reducing the structural complexity. 
 
 
Figure 7. Resorcinol-derived Hsp90 inhibitors. IC50 represents anti-proliferation activities.  
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As a result, chimeric inhibitors would allow for identification of structure-activity relationships 
for each natural product. 
The first chimeric inhibitor of Hsp90, radanamycin (Figure 8), focused on maintenance of 
the resorcinol-mediated hydrogen bonding network.96 The quinone moiety manifested a key 
hydrogen bonding network near the solvent-exposed region of the ATP-binding pocket and 
allowed for selective binding to the Hsp90 heteroprotein complex. Amino acids within this region 
were responsible for isomerization of the GDA amide bond, which dictated a high differential 
selectivity for the heteroprotein complex. 14, 93, 108 
Radanamycin was futher modified to generate more effecacious inhibitors using two 
different linkers to connect the quinone and resorcinol ring systems.96 The first approach connected 
the resorcinol ring to the quinone ring via a two carbon-linker containing an amide bond, which 
yielded radamide (Figure 8).95 Radamide inhibited Hsp90 ATPase activity at 5.9 μM compared to 
2.5 μM for GDA and induced the degradation of Her2, an Hsp90-dependent client protein, in MCF-
7 cells.  The second approach connected the quinone to the ester linkage of RDC via a two carbon 
linker (Radester, Figure 8).109   Radester manifested an anti-proliferative IC50 of 13.9 μM against 
MCF-7 cell line. Hsp90 inhibition by radester was confirmed via degradation of Hsp90 client 
proteins, Raf and Her2. Importantly, the hydroquinone derivatives of radamide and radester 
manifested greater affinity for Hsp90 than the corresponding quinones. The hydroquinone 
derivative of radamide inhibited Hsp90’s inherent ATPase activity at 1.8 μM, and induced the 
degradation of Hsp90 client Her-2 levels in MCF-7 cells.  Similarly, the radester-hydroquinone 
derivative manifested an anti-proliferative IC50 of 7.1 μM, and induced the degradation of Her2 
and Raf levels.  Additionally, the macrocyclic chimera, radanamycin manifested anti-proliferative 
activity against MCF-7 cells at 1.2 μM and induced the degradation of Hsp90 client proteins, Her2 
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and Akt.  These studies proved important as Infinity Pharmaceuticals developed a hydroquinone 
derivative of GDA (IPI-504), which is currently undergoing clinical evaluation (see Figure 4).17  
 
I.3.1.4. Purine-Based Inhibitors 
In addition to the GDA and RDC, the natural substrate of Hsp90, ATP, has also been used 
as a starting point for the developing Hsp90 inhibitors.12, 110, 111 Chiosis and co-workers utilized 
the purine moiety of ATP as a template to develop small molecule inhibitors that bind the N-
terminal ATP-binding site. Using a structure-based approach, the purine moiety was linked to an 
aryl ring, which mimicked the unique bent shape adopted by ATP within the N-terminal binding 
pocket. The first inhibitor of this class, PU3 (Figure 9), manifested low micromolar anti-
proliferative activity against various breast cancer cell lines. This early study identified a new class 
of purine based Hsp90 inhibitors and further structure-activity relationship studies resulted in a 
significant improvement in efficacy.110, 112 Further optimization of PU3 led to the identification of 
a more potent compound, PU24FCl (Figure 9). PU24FCl manifested low micromolar anti-
proliferative effects against breast, lung, colon, and prostate cancer cell lines, and induced the 
degradation of Hsp90-dependent client proteins including Her2, Akt, Raf-1 and mutant p53.  In 
vivo analysis PU24FCl revealed tumor specific inhibition of Hsp90, as this compound accumulated 
 
 




in tumor tissues, but rapidly cleared from normal tissue. 113, 114 Administration of PU24FCl 
decreased tumor volume upon dosing of 200mg/kg i.p. every other day for 30 days.  Preliminary 
structure-activity relationship studies led to the development of more efficacious, second 
generation of purine analogues. This series of analogues included derivatives of the phenyl ring, 
and concluded that substituents at the 2-, 4- and 5-positions are important for Hsp90 inhibition 
(Figure 9).115, 116  Researchers at Conforma Therapeutics addressed the low bioavailability 
associated with the purine analogues and incorporated an amino group into the N-9 alkyl chain.117 
Subsequently, phosphoric acid salts of these amines were  evaluated in murine tumor xenograft 
models (Figure 9) and manifested high efficacy. Another important water soluble purine-derived 
inhibitor (PU-H71, Figure 9) was reported by Chiosis and co-workers, and contained a 3-
 
 
Figure 9. Purine-based Hsp90 N-terminal inhibitors. EC50 were determined 
in a competition assay with GDA. ICa50 corresponds to anti-proliferation 





isopropylamino-propyl chain.115 This compound manifested a 16 nM binding affinity for Hsp90 
and an IC50 of 50 nM in Her2 degradation assays.
 This analogue manifested significant efficacy in 
vivo and has advanced into clinical trials for the treatment of patients with low-grade non-
Hodgkins lymphoma, as well as patients advanced malignancies. Later, Conforma Therapeutics 
reported analogues with an amine at the 2-position and a chlorine at the 6-position. The most 
efficacious analogue (BIIB021, Figure 9) also contained a pyridylmethylene group at the 9-
position. BIIB021 manifested 9 nM efficacy in Her2 degradation assays and exhibited 333-fold 
selectivity for tumor cells versus normal cells.118 After successful preclinical studies, this 
compound became the first rationally designed Hsp90 inhibitor to enter clinical trials and is 
currently being evaluated in Phase II trials for gastrointestinal stromal tumors.119 To increase drug 
exposure, researchers at Conforma therapeutics also reported the intravenously administered 
compound, BIIB028 (Figure 9), a phosphate ester prodrug of the homopropargylic alcohol, and it 
too, is currently under phase I clinical evaluation.120   
I.3.1.5. Induction of Heat Shock Response 
  An important consideration, which is often overlooked during development of N-terminal 
Hsp90 inhibitors, is the induction of the pro-survival heat-shock response.121, 122 The heat shock 
response results in increased expression of various Hsp’s including, Hsp90, Hsp70, Hsp27, and 
Hsp42. An Hsp90 bound transcription factor, HSF-1 mediates this pro-survival response. In 
unstressed/normal cells, HSF-1 is bound to Hsp90 and, is inactive.123, 124 Under cellular stress, or 
the administration of an Hsp90 N-terminal inhibitor, heat shock factor-1 (HSF-1) dissociates from 
Hsp90.125 Once released, in the cytosol, HSF-1 is trimerized, hyperphophorylated, and then 
translocated to nucleus, wherein it binds to heat shock element to initiate transcription of Hsp’s 
(Figure 10).126, 127  
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Induction of the heat-shock response is a concern as it negates the cytotoxic effect of 
Hsp90-inhibitors and results in cytostatic activity. Inhibition of the N-terminus by pan-Hsp90 
inhibitors results in increased levels of Hsp90 and Hsp70. Clinical trials have demonstrated that 
induction of the heat-shock response results in both dosing and scheduling issues. In addition, the 
period of target inhibition remains insufficient to obtain necessary levels of oncogenic client 
protein degradation. Hence, alternative methods for Hsp90 inhibition are highly desirable.128, 129 
 
I.3.2. C-Terminal Inhibitors   
I.3.2.1. Discovery of Hsp90 C-Terminal Binding Site  
Unlike N-terminal inhibitors, Hsp90 C-terminal inhibitors do not induce the heat shock 
response at the same concentration they induce client protein degradation.130, 131 The second 
nucleotide binding site at the C-terminus of Hsp90 was not known until 2000.131, 132 Pioneering 
studies by Neckers and co-workers at NCI identified the C-terminal nucleotide binding pocket.130  
Both Hsp90 and DNA gyrase are members of the GHKL superfamily of proteins, and share high 
similarity in their binding sites. In pursuit of new leads for Hsp90 inhibition, Neckers and co-
workers hypothesized that inhibitors of DNA gyrase may also bind Hsp90.131 Hence, novobiocin 
was chosen as a probe to test whether it exhibits toxicity against cancer cells. Their hypothesis was 
confirmed by a concentration-dependent elution of Hsp90 with a novobiocin-sepharose column. 
 
 




Furthermore, novobiocin eluted Hsp90 in a similar manner from GDA-sepharose column. 
However, GDA did not elute Hsp90 from a novobiocin-sepharose column, suggesting an 
alternative binding mode.  In their binding studies with purified Hsp90 fragments, novobiocin did 
not bind the Hsp90 N-terminus of Hsp90. Unexpectedly, novobiocin bound to an Hsp90 fragment 
that contained the C-terminal amino acids, 580-728. Cellular Hsp90 inhibition by novobiocin was 
confirmed via western blot analysis of Hsp90 clients. Like N-terminal inhibitors, novobiocin 
induced the degradation of Raf-1, mutant p53, and her2, at high concentrations (~ 700 M).  
Subsequently, via deletion/mutation studies Neckers and co-workers confirmed that novobiocin 
binds a region that overlaps with the C-terminal dimerization domain. Csermely and co-workers 
reported that occupancy of the N-terminal binding site is required for C-terminal occupation.133 In 
addition, this group determined via oxidative nucleotide cleavage studies, that the C- terminus 
binds both purine and pyrimidine nucleotides, while the N-terminus only binds the purine class of 
nucleotides.134 These studies established the existence of the second ATP-binding site within 
Hsp90 and suggested an alternative approach to modulate Hsp90. 
I.3.2.2. Novobiocin  
 Novobiocin was identified as a lead compound for Hsp90 C-terminal inhibition and to the 
date, it is the most studied Hsp90 C-terminal inhibitor.135-149 Unlike N-terminal inhibitors, there is 
no co-crystal structure of an inhibitor bound to the Hsp90 C-terminus.150, 151 Structure-activity 
relationship studies on novobiocin have provided analogues with improved efficacy, as well as 
selectivity, over DNA gyrase. A summary of these studies is provided in Figure 11. Removal of 
the 4-hydroxy group and 3’-carbamante resulted in DHN1 and DHN2 which manifested >300-fold 





          
 
 
Figure 11. Novobiocin analogues for Hsp90 C-terminal inhibition. 
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over DNA gyrase. Subsequent, optimization of the coumarin core, noviose sugar, and benzamide 
side chain resulted in optimal replacements for these moieties.136, 147, 149, 153 Replacement of  
coumarin core with other aromatic/heteroaromatic cores (KU857, KU890) improved efficacy and 
suggested that the central coumarin core serve as a backbone to project the sugar and benzamide 
side chains within the C-terminal binding pocket.154-156. The complex noviose sugar was replaced 
with alkyl amines. Modification of the benzamides linker with a triazole and urea moiety resulted 
in improved anti-proliferation activities (KU675, KU1023).157, 158 
I.3.2.3. Silybin 
Silybin is the principal component of the flavonolignan extract isolated from the seed of 
milk thistle plants (Silybum marianum) (Figure 12).159 Silybin demonstrated hepato-protective and 
growth inhibitory activity against various cancer cells. Prior studies demonstrated that silybin 
induced depletion of CDK2, CDK4, and cyclin D1 proteins in colon cancer cells.160, 161 Cyclin D1, 
CDK2 and CDK4 are well-known Hsp90-dependent clients, which led to the assumption that 
silybin could be an Hsp90 inhibitor. Subsequently, using a luciferase refolding assay Zhao and co-
workers demonstrated that Hsp90 is a biochemical target for Silybin.58, 162 Silybin induced a 
concentration-dependent degradation of the Hsp90-dependent client proteins Her2, Raf-1, and 
Akt, without affecting Hsp70 or Hsp90 levels. Further SAR studies in the Blagg laboratory showed 
that the C-3 and C-23 hydroxyl groups were not required for activity; however, at least one 
substitution (preferably 4-hydoxyl) on the E-ring was beneficial for activity. The A-ring phenol 
was not required and its removal led to the development of compounds (Figure 12), that manifested 






I.3.3. Disruptors of Hsp90 Interaction with Co-Chaperones and Client Proteins  
Currently, most Hsp90 inhibitors undergoing clinical evaluation are pan-Hsp90 N-terminal 
inhibitors. To overcome the detrimental side effects of these N-terminal inhibitors, there is growing 
interest to identify new Hsp90 modulators that exhibit alternative mechanisms of actions. Over the 
past decade, various natural products have emerged that disrupt interactions between Hsp90 and 
its co-chaperones.56, 57, 116 These compounds represent new chemotypes for the development of 
future Hsp90 inhibitors. Several natural products, such as celastrol, gedunin, and cruentaren A 
have been shown, amongst a plethora of other biochemical and biological effects, to disrupt 
interactions between Hsp90 and its partner proteins. Some of these natural products and their 
mechanisms of action are presented in Figure 13.  
I.3.3.1. Celastrol 
Celastrol is a pentacyclic quinone methide comprising triterpenoid natural product (Figure 
13) is isolated from the root extract of Tripterygium wilfordii Hook F. (also known as Thunder of  
 
 




           
 
 
Figure 13. Disruptors of Hsp90 interaction with co-chaperones and client proteins.     
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God Vine) and has been used in oriental medicine to treat autoimmune disorders and inflammatory 
diseases.163, 164 Upon biological evaluation, celastrol exhibited anti-proliferative, anti-metastatic, 
and pro-apoptotic activities against various cancer cell lines.165 In 2006, Hieronymus and 
coworkers reported that celastrol disrupts Hsp90-related pathways, which contributes to its anti-
cancer activity, and subsequently it was shown to disrupt association of Hsp90 with co-chaperone 
cdc37.30, 166 Celastrol has a high propensity to form covalent adducts with cysteine, which 
contributes to its promiscuity and limits its utility as an Hsp90 modulator.  In addition to celastrol, 
derrubone, withaferin A and, gambogic acid also inhibit Hsp90’s interaction with co-chaperone 
cdc37.167-169  
I.3.3.2. Gedunin 
Gedunin (Figure 13) is a tetranortriterpenoid isolated from the Indian neem tree 
(Azadirachta indica, Meliacae). Gedunin has been used for the treatment of infectious diseases in 
traditional Indian medicine. In addition, gedunin has been shown to exhibited anti-proliferative 
activity against various cancer cell lines including colon, prostate, and ovarian.170, 171 In 2006, 
gedunin was reported to modulate Hsp90’s function and shown to induce degradation of Hsp90 
client proteins.166  Subsequently in 2013, Patwardhan and co-workers reported that gedunin binds 
to Hsp90 co-chaperone p23, and blocks its interaction with Hsp90 and inhibited Hsp90 chaperone 
cycle.172 Gedunin exhibited modest efficacy against cancer cell lines. In order to identify key 
structural features for cytotoxic activity, Brandt and co-workers prepared 19 semisynthetic 
derivatives.59 The ,-unsaturated ketone was found to be important for anti-proliferative activity. 
However, a more active analog could not be identified.  
I.3.3.3. Cruentaren A      
 Cruentaren A (12, Figure 13) is a macrolide isolated from the myxobacterium Byssovorax 
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and manifests low nM anti-proliferative activity against various cancer cell lines. The biological 
target of cruentaren A has been identified as F1F0-ATP synthase, the enzyme responsible for the 
mitochondrial production of ATP.173-176 In 2006, Papathanassiu and coworkers reported that F1F0-
ATP synthase could act as an Hsp90 co-chaperone that provides the energy required for the 
maturation of client proteins.177 Recently, Hall and co-workers demonstrated that incubation of 
cruentaren A disrupted interactions between Hsp90α and F1F0-ATPase synthase.
178 Interestingly, 
inhibition of F1F0-ATPase synthase via cruentaren A induced the degradation of select Hsp90 
client proteins without induction of the heat-shock response. Cruentaren A thus represents a novel 
mechanism to modulate Hsp90 however, limited synthetic accessibility to cruentaren A represents 
an obstacle that has yet to be overcome. 
I. 4. Conclusions & Future Directions 
 Inhibition of Hsp90’s function represents a multifaceted approach to treat cancer due to the 
fact that Hsp90-dependent client proteins are associated with all ten hallmarks of cancer.  
Consequently, Hsp90 has attracted the attention of researchers throughout the world. These efforts 
identified of key interactions within the N-terminal ATP binding pocket, and has led to discovery 
of new classes of Hsp90 inhibitors.  Beginning with the discovery of natural product inhibitors of 
Hsp90 (GDA and RDC), many analogues have been designed to probe the biological function of 
Hsp90, 17 of which have advanced into clinical trials.  While GDA never advanced into clinical 
trials, 17-substituted GDA-analogues have proven to be superior candidates, and advanced to the 
clinic. Likewise, RDC did not advance into clinical trials however, the resorcinol ring of RDC 
provided a key pharmacophore as several medicinal chemistry campaigns have used the resorcinol 
moiety as a starting point to produce candidates that are currently undergoing clinical evaluation. 
The natural substrate of Hsp90, ATP, has also been used to develop purine class of inhibitors that 
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have advanced into clinical trials.   Even though Hsp90 inhibitors have shown promise in clinical 
trials, no compound has yet been approved by the FDA. These somewhat disappointing results 
highlight the need to comprehensively understand the biology of Hsp90 and its isoforms. Two 
major concerns associated with Hsp90 inhibitors are toxicities (ocular-, cardio-, hepato-toxicities), 
and induction of the heat shock response, as both obstacles resulted in the termination of some 
trials, suggesting new approaches to Hsp90 inhibition are needed.  
One strategy that may prove useful to circumvent the known pitfalls from pan-Hsp90 
inhibition is the development of isoform-selective inhibitors. By developing selective inhibitors of 
each isoform, toxicities associated with individual isoforms may be overcome.  Furthermore, upon 
identification of client proteins that are dependent upon each isoform, perhaps more personalized 
treatments can be developed.  An additional strategy involves developing Hsp90 C-terminal 
inhibitors that do not induce the heat shock response at concentrations needed for client protein 
degradation, and therefore should address the dosing and scheduling detriments associated with 
N-terminal inhibitors. Recently, co-chaperone disruptors have emerged as promising alternatives 
to modulate Hsp90. Hsp90 isoform-selective inhibitors, C-terminal inhibitors and, co-chaperone 
disruptors represent promising approaches to overcome limitations of current inhibitors. 
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Synthesis and Structure−Activity Relationships of EGCG Analogues 
II.1. Introduction to EGCG 
Green tea is one of the most popular beverages consumed worldwide and its consumption 
has been associated with many health benefits.1-6 Green tea is composed of alkaloids (caffeine, 
theophylline, and theobromine), amino acids, proteins, carbohydrates, volatile organic 
compounds, and polyphenols.7 The catechins (Figure 14), which are responsible for the some of 
the health benefits attributed to the consumption of green tea polyphenols, are part of the 
polyphenolic component of the green tea.8-10 Epigallocatechin-3-gallate (EGCG) is the most 
abundant catechin found in the green tea (Table 3), and exhibits both antioxidant activity and 
anticancer activity in vitro and in vivo.8, 11-14 Additionally, EGCG  exhibits beneficial effects in 
several diseases including diabetes, Parkinson’s, Alzheimer’s, and obesity.15-20  
EGCG has been shown to be an efficacious agent in cancer chemoprevention against a 
broad range of carcinogens. EGCG acts on multiple signal transduction pathways associated with 
differentiation, apoptosis, inflammation, angiogenesis and metastasis.1, 6, 7, 16  Recent studies have 
provided additional mechanistic insights and revealed that EGCG suppresses the levels of various 
cancer biomarkers.20-24 As a result, EGCG is currently undergoing multiple clinical trials to 
evaluate its chemopreventive activity.25-32 Results from these studies have been encouraging, as 
 
Figure 14. Structure of green tea catechins. 






daily consumption of EGCG delays the onset of cancer and lower the rate of recurrence in breast 
cancer patients. 
Table 3. Catechin concentrations in green tea  





(mg/8 fl oz) 
EGCG 117-442 25-106 
EGC 203-471 49-113 
ECG 17-150 4-36 
EC 25-81 6-19 
 
EGCG also manifests anti-proliferative effects against various types of cancer including 
breast, colon, lung, blood, and skin cancers. EGCG inhibits tumor growth via multiple mechanisms 
of action (Table 4).18, 30, 33-36 In oral cancer cells, EGCG blocked cell division in the G1 phase and 
suppressed mitogenic signal transduction by prohibiting the binding of growth factors to their 
receptors.37 Similarly, EGCG also induced cell cycle arrest in the G0/G1 phase in MCF-7 cells at 
30 M.38 In human lymphoid leukemia cells, EGCG inhibited cell proliferation and induced 
apoptosis.39 Additionally, EGCG has been shown to modulate aberrant epigenetic alternations 
associated with tumor initiation and progression, including DNA methylation. EGCG blocked 
DNA methylation via inhibition of DNA methyltransferases (DNMT’s) in colon cancer (HT-29) 
cells, esophageal cancer (KYSE-150), and prostate cancer (PC3).40-44  EGCG exhibited efficacy in 
xenograft model of breast and pancreatic cancer, and  manifested anti-cancer activity in a human 
prostate cancer progression model.10, 45  
In recent years, an increasing number of studies have been conducted to evaluate EGCG 
as an adjuvant for cancer chemotherapy.9 For example, the co-administration of EGCG with 
traditional cancer chemotherapeutics have resulted in additive or synergistic effects; cisplatin, 
41 
 
tamoxifen, 5-flurouracil, temozolamide exhibited enhanced activity when given in combination 
with EGCG.46-49 These activities  likely result from EGCG’s ability to act as a chemosensitizer 
and to modulate the pharmacokinetics of drugs by inhibition of the P-glycoprotein efflux pumps.10  
Table 4. Molecular Mechanisms of EGCG. 
Molecular Mechanism Molecular Targets References 
Induction of cell cycle 
arrest 
CyclinD, Cyclin E, CDK1, CDK2, 
CDK4, CDK6 
45, 50-52 
Induction of apoptosis Survivin, c-IAP1, c-IAP2, Bcl-
xl,Caspase-3, Caspase-9 
13, 53-56 
Inhibition of proliferation 
and Inflammation 
PI3K, EGFR, COX-2, HIF-1a, AKT, 
ERK,  
45, 57-60 
Angiogenesis HIF-1a, Erb2, VEGFR1 & 2 61-63 
Metastasis MMP2-9, MMP-2, lamanin 64-66 
Epigenetic modifier DNMT’s, HAT,  40, 42, 67 
Proteasomal activity  20S/26S proteasome complex 68, 69 
 
II.1.1. Binding of EGCG to Hsp90 
While EGCG exerts anticancer effects for decades, its association with Hsp90 was not 
identified until recently. Studies on EGCGs chemoprevention effect led to the identification of 
Hsp90 as one of its biological target. In 2005, Palermo and co-workers showed that EGCG blocked 
(AhR)-mediated transcription induced by a potent carcinogen  2,3,7,8-Tetrachlorodibenzodioxin 
(TCDD), by a mechanism that involves Hsp90.70 Aryl hydrocarbon receptor (AhR) is a ligand 
activated transcription factor that mediates toxic effects of numerous toxins including polycyclic 
aryl hydrocarbons (PAH’s), which binds to the AhR. In cytosol, AhR exists in a protein complex 
with Hsp90, p23, and XAP2. Upon binding of PAH’s to AhR, XAP2 is dissociated from the 
complex and the Hsp90-AhR complex translocated to nucleus. Subsequent events lead to the 
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generation of DNA adducts that facilitate carcinogenesis.  EGCG exhibited its chemo-preventive 
activity and inhibited the AhR-mediated carcinogenesis, however, it did not compete for binding 
to AhR. This study led to the discovery of an indirect mechanism of AhR modulation that involved 
the binding of EGCG to the Hsp90 C-terminus. Subsequent affinity purification studies 
demonstrated that EGCG binds to amino acids 538-728 within the Hsp90 C-terminus to inhibit 
AhR-mediated transcription. Additionally, EGCG induced the degradation of other Hsp90 clients 
as well, including Raf1, Her2, and Akt, while levels of Hsp90 and Hsp70 remained unchanged.71  
While EGCG manifests modest efficacy against various cancer cell lines, the poor 
bioavailability and lipophilicity of EGCG along with its metabolically labile functionalities make 
EGCG a poor lead compound for clinical development.72, 73  At the time,  only two natural products 
novobiocin and silybin were known to bind the Hsp90 C-terminus, and therefore EGCG was 
pursued as a probe to further investigate the mechanism by which C-terminal inhibitors modulate 
the Hsp90 protein folding machinery. 
II.2. Proposed EGCG Analogues 
EGCG exhibits antioxidant activity both in vitro and in vivo, which also leads to 
epimerization and/or dimerization (Figure 15) and contributes to its low efficacy and metabolic 
instability.74-77 Epimerization of the methine hydrogen leads to formation of the 
thermodynamically more stable anti product, GCG (Figure 15a), whose activity against Hsp90 has 
not been investigated. EGCG is prone to autoxidation and dimerizes to give theasinensin A, and 
P2 (Figure 15b).  Studies by Suzuki and co-workers have shown that phenols on the B-ring 
facilitates epimerization at C-2, whereas O-methylated derivatives of the 4-phenols prevent 
epimerization.77 Therefore, the design of new EGCG analogues must take these prior studies into 





To probe EGCG’s structure-activity relationships with Hsp90, three series of analogues 
(Figure 16) were pursued; (I) 3’,4’,5’-trimethoxy groups were incorporated into the B-ring, (II) 
compounds omitting substituents on the B-ring were prepared, and (III) compounds lacking the B-
ring were also constructed. Furthermore, the phenols on the A-ring were converted to methyl ethers 
for biological evaluation and finally, the gallic acid moiety (D-ring) of EGCG was replaced with 
various aryl acids for elucidation of additional SAR trends. These aryl acids were chosen to probe 
the effect of substitution at the 3- and 4-position of the D-ring and to incorporate optimized 
novobiocin appendages to evaluate their potential for overlapping binding modes.78-81 
 
Figure 15. Chemical instability of EGCG: (a) Mechanism of epimerization of EGCG; (b) 




II.3. Synthesis and Evaluation of Series I and Series II EGCG Analogues 
II.3.1 Synthesis of Series I Analogues  
Syntheses of the A-, B- and D-ring modified compounds (7a–e and 8a–e) are described in 
Scheme 1. Prior work by Li and co-workers provided rapid access towards preparation of the 
flavon-3-ol core, enlisting the use of a silica/sulfuric acid catalyst to couple electron rich phenols 
(1a–b) with (E)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-ol, which worked surprisingly well and 
led to various substituted A-ring analogues (2a–b).82 Dihydroxylation of the resulting alkenes (2a–
b) with catalytic osmium tetroxide and excess N-methylmorpholine-N-oxide gave the 
corresponding diol’s, 3a–b.83 Various methods have been reported for cyclization and construction 
of the benzopyran core; however, stereochemical control at the 2,3-ring junction depends upon 
substituents on the B-ring.84 Therefore, cyclization of diol’s 3a–b to furnish the  2,3-
dihydrobenzopyran core in a stereoselective manner was pursued via two steps. Treatment of 3a–
b with trimethylorthoacetate in the presence of catalytic pyridinium p-toluenesulfonate, formed  
 




the corresponding orthoesters, which upon the addition of 10% boron trifluoride diethyl etherate 
produced the desired cyclic products. Without purification, the cyclized products were subjected 
to solvolysis conditions to furnish alcohols 4a–b in high yields and with the anti-configuration. 
The 2,3-syn products, 5a–b, were established by Dess-Martin oxidation of the secondary alcohols  
 
(4a–b) to the corresponding ketones, which underwent subsequent reduction with L-selectride to 
give syn products, 5a–b, respectively.85 These flavon-3-ol moieties (5a–b) served as late stage 
intermediates to incorporate additional substitutions onto the D-ring. Aryl acids 6a–e were chosen 
 
Scheme 1. Synthesis of Series I analogues. 
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as replacements for the metabolically labile, gallic ester moiety of EGCG and also represent 
optimized side chains identified from prior studies with the other Hsp90 C-terminal inhibitor, 
novobiocin. Acids 6a–c were purchased from commercial sources and 6d and 6e were synthesized 
following literature procedures. Coupling of the alcohols (5a–b) with aromatic acids 6a–e enlisting 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) and 4-dimethylaminopyrine (DMAP) 
gave the corresponding esters, 7a–j. Hydrogenolysis of 7f–i with palladium/carbon and hydrogen 
gas gave 8a–d in high yield. Cleavage of benzyl ethers of 7j was accomplished using transfer 
hydrogenation using triethylsilane to give the desired 8e.86 
II.3.2. Synthesis of Series II Analogues  
Syntheses of compounds omitting substitution on the B-ring (13a–e and 14a–e) are 
described in Scheme 2. These compounds were synthesized similar to Series I compounds starting 
from commercially available cinnamyl alcohol and phenols 1a and 1b. 
II.3.3. Biological Evaluation of Series I and Series II Analogues 
Upon preparation of the A-, the D-ring modified B-ring substituted EGCG analogues (7a–
e, 8a–e and, 13a–e, 14a–e), these compounds were evaluated against MCF-7 and SKBr3 breast 
cancer cell lines for determination of their anti-proliferative activities (Table 5). The SkBr3 
(estrogen receptor negative, Her2 overexpressing) and the MCF-7 (estrogen receptor positive) cell 
lines were chosen due to the fact that both Her2 and the estrogen receptor are Hsp90-dependent 
client proteins. Four of the D-ring analogues that contain two methoxy groups on the A-ring and 
no substituents on the B-ring (13a–d) were inactive against both MCF-7 and SKBr3 cell lines. 
Only compound 13e manifested significant anti-proliferative activity with an IC50 value of 25.35 
± 5.25 μM against MCF-7 and 36.1 ± 2.51 μM against SKBr3 cell lines. Similar trends were 
observed for compounds (7a–e) containing the 3,4,5-trimethoxy substituents on the B-ring, as only 
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7e was found to be potent with IC50 values of 19.48 ± 2.5 μM and 24.87 ± 3.29 μM against MCF-
7 and SKBr-3 cell lines, respectively. Analogues 14a–e containing phenols on the A-ring were 
more potent when compared to EGCG and analogues with methyl ethers (13a–e). Incorporation 
of a methoxy group at the meta- and the para-positions of the D-ring (14b and 14c) did not alter  
activity when compared to unsubstituted analogue, 14a. Compound 14e was found to be the most 
potent of this series and displayed an IC50 value of 3.99 ± 1.4 μM against the MCF-7 cell line. In 
contrast, compounds with 3-,4-,5-trimethoxy groups on the B-ring (8a–e) were less active when 
compared to analogues without substitution on the B-ring (14a–e). This data suggests that 
substitutions on the B-ring are detrimental to activity, whereas replacement of the gallate ester 
moiety with prenyl benzoate enhances potency. In addition, the MCF-7 cell line was more sensitive 
than the SKBr3 cell line upon administration of these analogues.  
 
 




Table 5.  Anti-proliferative activities produced by A-, B- and the D-ring modified EGCG     
                 analogues  
                                                                   
               





EGCG - - - 74.4 ± 2.19 100.16 ± 0.03  
GDA - - - 0.05 ± 0.03 0.008 ± 0.02 
13a Me H a >100 >100 
13b Me H b >100 >100 
13c Me H c >100 >100 
13d Me H d >100 >100 
13e Me H e 25.35 ± 5.25 36.1 ± 2.51 
7a Me OMe a >100 >100 
7b Me OMe b 91.18 ± 0.76 >100 
7c Me OMe c >100 >100 
7d Me OMe d 88.7 ± 11.31 >100 
7e Me OMe e 19.48 ± 2.5 24.87 ± 3.29 
14a OH H a 15.26 ± 0.57 18.67 ± 0.82 
14b OH H b 13.10 ± 0.86 15.42 ± 1.04 
14c OH H c 13.12 ± 0.54 17.26 ± 2.27 
14d OH H d 14.14 ± 0.73 19.88 ± 3.22 
14e OH H e 3.99 ± 1.49 21.45 ± 4.75 
8a OH OMe a 65.88 ± 2.15 >100 
8b OH OMe b 45.72 ± 0.41 37.92 ± 4.08 
8c OH OMe c 42.80 ± 7.30 62.90 ± 0.70 
8d OH OMe d 47.31 ± 3.39 71.9 ± 2.76 
8e OH OMe e 42.08 ± 1.85 50.4 ± 1.39 
 
II.4. Synthesis and Evaluation of Series III Analogues  
Biological evolution of Series-I and Series-II analogues established that substituents on the 
B-ring of EGCG are not essential for efficacy. In addition, phenols on the A-ring were more 
efficacious that the corresponding methyl ethers. To probe the necessity of the B-ring, a new series 
of compounds was proposed (Series III) than lack the B-ring. As shown in Figure 17, the proposed 
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analogues would also probe the role of individual A-ring phenols. Aryl acids 6a–e were used as 
gallic acid replacements. Additionally, phenols were also incorporated on the D-ring for 
evaluation. 
 
II.4.1. Syntheses of Series IIIa-c Analogues 
Syntheses of analogues that lack the B-ring and contain phenols on the A-ring were 
commenced by the treatment of 3,5-dibenzyloxyphenol (1b, Scheme 3) with allyl bromide in the  
presence of potassium carbonate to give allyl ether 16a.87  3,3-Sigmatropic rearrangement of the 
O-allylated product (16a) gave 17a in high yield. Upjohn dihydroxylation of the resulting olefin 
afforded diol 18a.88 Unfortunately, attempts to cyclize via the orthoester were unsuccessful as only 
the 5-membered benzofuran ring containing product was formed. Therefore, an alternative strategy 
for the cyclization of 19a was pursued. Treatment of the primary alcohol present in 19a with p-
toluenesulfonyl chloride formed of the corresponding p-toluenesulfonic ester, which underwent 
intramolecular cyclization upon exposure to potassium carbonate to give a 1:1 mixture of 5- and 
6-membered rings that were separated by silica gel chromatography. Subsequent coupling of 20a  
with various substituted benzoic acids produced the requisite esters, which underwent 
hydrogenolysis to afford 21a–i, respectively. 
 
 




Upon construction of analogues that lack the B-ring, each phenol on the A-ring was 
systematically investigated. Therefore, derivatives 21i–s that contain only one phenol at either the 
5- or the 7-positions were pursued similar to that described above. Allylation of the phenol (15) 
gave ally ether, 16b. 3,3-Rearrangement of the allyl ether (16b) gave a mixture of two 
regioisomers, 17b and 17c, which upon dihydroxylation and subsequent ring closure gave 20b and 
20c, respectively.  
II.4.2. Biological Evaluation of Series IIIa-c Analogues 
 
 




Table 6. Anti-proliferative activities produced by 3,5-dihydroxychroman-3-ol esters. 
 





21a OH OH H H H 98.24 ± 1.76 >100 
21b OH OH OMe H H 57.75 ± 3.12 50 
21c OH OH H OMe H >100 >100 
21d OH OH OMe OMe H >100 >100 
21e OH OH OMe H OMe 96.50 ± 3.51 >50 
21f OH OH OH H H 61.94 ± 6.85 85.30 ± 5.36 
21g OH OH H OH H >100 >100 
21h OH OH m-OMePh OMe H 21.93 ± 2.27 34.84 ± 16.29 
21i OH OH Prenyl OAc H 10.66 ± 1.09 23. 15 ± 0.25 
21j OH H H H H >100 >100 
21k OH H OMe H H >100 >100 
21l OH H H OMe H >100 >100 
21m OH H m-OMePh OMe H 55.09 ± 5.53 57.73 ± 4.28 
21n OH H Prenyl OAc H 15.94 ± 1.86 25.25 ± 4.05 
21o H OH H H H >100 >100 
21p H OH OMe H H >100 >100 
21q H OH H OMe H >100 >100 
21r H OH m-OMePh OMe H 21.6 ± 2.55 41.72 ± 0.34 
21s H OH Prenyl OAc H 60 ± 7.38 >100 
 
Results from the anti-proliferative studies with compounds 21a–s are summarized in Table 
6. In addition to previously investigated substituents, the effect of hydroxyl substitution on the D-
ring was also explored. Many of the compounds were more potent than EGCG itself. This data 
suggests that methoxy substituents on the D-ring are more beneficial than the naturally occurring 
phenols, and corresponds to an overall pattern represented by O-alkyl substitutions at the 3’-
position being more active than those at the 4’-position.  Data also suggested that aryl and prenyl 
substitution on the D-ring enhanced efficacy, as 21h manifested an IC50 value of 21.93 ± 2.27 µM 
against MCF-7 cells and 41.72 ± 0.34 µM against SKBr3 cells. Compounds containing only one 
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phenolic group at the 5-position on the A-ring showed decreased activity, except for 21s. Similarly, 
compounds with a 7-hydroxyl substitution on the A-ring showed decreased activity with the 
exception of 21n, which manifested enhanced activity and an IC50 value of 55.09 ± 5.53μM against 
the MCF-7 cell line. Similar to the most active analogue produced from the B-ring series, 14e, the 
most active analogue identified in this series was 21i (IC50 ~ 10 µM in MCF-7 cell line), which 
also incorporated the prenylated benzoic ester side chain. 
II.4.3. Synthesis of Series III-d Analogues 
In an effort to further investigate the A-ring, the free phenols were replaced with methyl 
ethers. 5,7-Dimethoxychroman-3-ol (24) was synthesized in two steps using a gold(III)- mediated 
procedure as described by Zhangjie and co-workers (Scheme 4).89 Commencing with 
commercially available 3,5-dimethoxyphenol and enlistment of epichlorohydrin and sodium 
hydride, oxirane 23 was produced, which was treated with gold(III) chloride/silver 
trifluormethanesulfonate catalyst to yield 24. Upon construction of the chroman-3-ol core (24), 
subsequent coupling with various substituted aryl acids furnished the corresponding esters, 25a–
m. Hydrogenolysis of 25i–m produced the final products 26a–e. 
II.4.4. Biological Evaluation of Series III-d Analogues 
Results from anti-proliferative studies for compounds lacking the B-ring are summarized 
in Table 7. The 3-methoxy substituted compound 26b was the most active compound against the 
MCF-7 and the SKBr3 cell lines, and manifested IC50 values 0.78 ± 0.02 μM and 0.88 ± 0.06 μM, 
respectively.  Increasing the length of the side chain decreased activity for compound 25h. The 
phenol was more beneficial at the 4’-position in lieu of the 3’-position. Unfortunately, the 
combination of 3-methoxy and 4-hydroxyl substitutions on the D-ring (26e) did not improve anti-
proliferative activity. Once again, MCF-7 cells exhibited greater sensitivity to these compounds. 
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The IC50 values for 25d and 25e correlated directly with prior studies using novobiocin, suggesting 
a beneficial effect for inclusion of an aryl or prenyl group on the D-ring. 
 
Table 7. Biological evaluation of series III-d. 
 








25a H H H 14.02 ± 0.91 44.605 ± 5.40 
25b OMe H H 0.77 ± .02 0.88 ± 0.06 
25c H OMe H 32.89 ± 2.05 50.40 ± 1.39 
25d m-OMePh OMe H 31.20 ± 18.17 80.13 ± 9.67 
25e Prenyl OAc H 38.66 ± 7.71 47.90 ± 0.71 
25f OMe OMe H 10.89 ± 0.27 36.98 ± 5.24 
25g OMe H OMe 21.8 ± 3.08 29.5 ± 1.5 
25h OEt H H 8.19 ± 0.16 33.35 ± 4.81 
26a OH H H 37.72 ± 6.75 64.11 ± 13.95 
26b H OH H 17.51 ± 0.86 17.73 ± 5.97 
26c OH H OH >100 >100 
26d OH OH H 22.12 ± 1.01 30.63 ± 11.89 
26e OMe OH H 51.29 ± 1.13 76.50 ± 1.10 
 
Scheme 4. Syntheses of series III-d.  
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II.5. Optimization of Linker  
II.5.1. Synthesis of Amide Linker Analogues 
In addition, investigation of the linker connecting the B- and D-rings was pursued. The 
ester linker was replaced with an amide. These amide-based analogues were prepared from 
previously synthesized alcohol 22, which was transformed into azide 27 via Mitsunobu conditions 
with diisopropyl azodicarboxylate, triphenylphosphine and diphenylphosphoryl azide. Azide 
formation was followed by Staudinger reduction with triphenylphosphine to afford amine 28 
(Scheme-5).90 Subsequent coupling of amine 28 with the optimal aryl acids gave the corresponding 
amides, 29a–d.91 Furthermore, the anti-isomer of 13e was also synthesized from 12a. 
 
II.5.2. Biological Evaluation of Amide Linker Analogues 
  The results from biological evaluation of the linker are summarized in table 8. The linker 
between the B- and D-ring was also evaluated and replacement of the ester with an amide (29a–
d) was found detrimental. The anti-isomer of 13e, 30 was also evaluated and found to be less active 
Scheme 5. Synthesis of linker analogues. (a) amide linker analogues; (b) anti-






Scheme 5.  
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(IC50 = 33.7 ± 1.8 against MCF-7 cell line), suggesting that syn-stereochemistry is important for 
inhibitory activity 
Table 8. Anti-proliferative activity produced by analogues containing amide linkers. 
 
Entry R1 R2 MCF-7 (IC50, μM) SKBr3 (IC50, μM) 
29a H H >100 >100 
29b OMe H >100 >100 
29c m-OMePh OMe >100 >100 
29d Prenyl OAc 54.5 ± 0.6 55.2 ± 1.2 
 
II.6. Western Blots Analyses 
After determination of anti-proliferative activity for EGCG analogues, four representative 
compounds were chosen for subsequent western blot analyses to confirm Hsp90 inhibition, based  
on each class of scaffold investigated. Since Hsp90 inhibition induces client protein degradation 
via the ubiquitin-proteasome pathway, immunoblots were used to confirm Hsp90 inhibitory 
activity. As shown in Figure 18, 14e, 25e and 13e induced the degradation of Hsp90 client proteins 
Her2, Raf and p-Akt at concentrations that mirrored the concentration needed to exhibit anti-
proliferative activity, thereby linking Hsp90 inhibition to cell viability. Analogue 25b failed to 
induce client protein degradation, demonstrating that this compound manifests anti-proliferative  
activity through a mechanism independent of Hsp90 inhibition. However, a related compound 
containing the prenylated benzoate side chain, 25e, did exhibit Hsp90 inhibitory activity. Further 
investigation of 14e at increasing concentrations demonstrated client protein degradation in a dose- 
dependent manner, while actin levels remained the same. Actin is not an Hsp90-dependent protein 
56 
 
and is therefore unaffected by Hsp90 inhibition. Similar to other Hsp90 C-terminal inhibitors, the 
levels of Hsp90 were unchanged. 
 
 
                 
                 
Figure 18. Western blot analyses to confirm Hsp90 inhibition. “H” (high) 
represents a concentration 5 × IC50 value, whereas and “L” (low) represents 
a concentration at one-half the IC50 value as determined by anti-
proliferative studies. Concentrations are represented in M. Geldanamycin 





Figure 18: Western blot analyses of MCF-7 cell lysates for Hsp90 client protein 
degradation after 24h of incubation.  (a) Compounds 27b, 27e, 10e and 11e at 
57 
 
II.7. Conclusion and Future Directions  
In summary, the first structure-activity relationships between EGCG and Hsp90 have been 
produced (Figure 19).92 The results obtained suggest that phenols on the A-ring are beneficial  for 
Hsp90 inhibition, while phenols on the D-ring are detrimental. Similar to EGCG, novobiocin also 
binds Hsp90 within amino acids 538-578 and represents another naturally occurring C-terminal 
inhibitor. The inclusion of a novobiocin-derived prenylated benzoic ester was found to be a 
suitable replacement for the gallic acid moiety present on EGCG, and suggests that both 
novobiocin and the EGCG may bind similarly to the Hsp90 C-terminus. Results from these studies 
have led to the development of analogue 14e, which exhibits an 18-fold improvement over EGCG 
and can serve as a probe for further biological investigations.  
The optimized analogue resulting from this work lacks the structural detriments associated 
with EGCG and can be further developed for increased Hsp90 inhibition and better understating 
of the C-terminal binding pocket.  The central benzopyran core of EGCG allows for modifications 
that are inaccessible with the coumarin core of novobiocin. The most efficacious analogue (14e) 
can allow for modification at the 1-, 2-, and 4-positions of the chromane core, which corresponding 
are not amiable for modification with the coumarin ring. The chromane core can further be 
replaced with to 1,2,3,4-tetrahydroquinoline core to probe the binding pocket.  Lead compound, 
14e, represents a new scaffold to probe the Hsp90 C-terminal binding pocket and its further 





II.8. Methods and Experiments 
All reactions were performed in oven-dried glassware under argon atmosphere unless 
otherwise stated. Dichloromethane (DCM), tetrahydrofuran (THF), and toluene were passed 
through a column of activated alumina prior to use. Anhydrous methanol, acetonitrile, N,N-
dimethylformamide (DMF), and dimethoxyethane (DME) were purchased and used without 
further purification. (−)-EGCG was purchased from Sigma-Aldrich and used as obtained. Flash 
column chromatography was performed using silica gel (40−63 μm particle size). The 1H (500 and 
400 MHz) and 13C NMR (125 and 100 MHz) spectra were recorded on 500 and 400 MHz 
spectrometer. Data are reported as p = pentet, q = quartet, t = triplet, d = doublet, s = singlet, br s 
= broad singlet, m = multiplet; coupling constant(s) in Hz. Infrared spectra were obtained using 
FT/IR spectrometer. High resolution mass spectral data were obtained on a time-of-flight mass 
spectrometer and analysis was performed using electrospray ionization.  
Anti-proliferation Assay 
 
MCF-7 and SKBr3 cells were maintained in advanced DMEM/F12 (Gibco) supplemented 
with l-glutamine (2 mM), streptomycin (500 μg/mL), penicillin (100 units/mL), and 10% FBS. 
 
Figure 19. Summary of EGCG structure-activity relationship studies. 
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Cells were grown to confluence in a humidified atmosphere (37 °C, 5% CO2) and seeded 
(2000/well, 100 μL) in 96-well plates, and allowed to attach for 24 h. Compounds or geldanamycin 
at 6 increasing concentrations in DMSO (1% DMSO final concentration) were added, and cells 
were returned to the incubator for 72 h. At 72 h, the cell growth was determined using an 
MTS/PMS cell proliferation kit (Promega) per the manufacturer’s instructions. Cells incubated in 
1% DMSO were used as 100% proliferation, and values were adjusted accordingly. IC50 values 
were calculated from minimum two separate experiments performed in triplicate using GraphPad 
Prism program. 
Western Blot Analysis 
 
MCF-7 cells were cultured as described previously and treated with various concentrations 
of the compound to be tested, geldanamycin in DMSO (1% DMSO final concentration), or vehicle 
(DMSO) for 24 h. Cells were harvested in cold PBS and lysed in M-PER lysis buffer (Sigma) 
containing protease and phosphatase inhibitors (Roche) on ice for 1 h. Lysates were clarified at 
14000g for 15 min at 4 °C. Protein concentrations were determined by using the Pierce BCA assay 
kit per the manufacturer’s instructions. Equal amounts of proteins were electrophoresed under 
reducing conditions, transferred to a PVDF membrane, and immunoblotted with the corresponding 
specific antibodies. Membranes were incubated with an appropriate horseradish peroxidase-
labeled secondary antibody, developed with chemiluminescent substrate, and visualized.  




(E)-3,5-Dimethoxy-2-(3-(3,4,5-trimethoxyphenyl)allyl)phenol (2a): A solution of 3,5-
dimethoxyphenol (2.06 g, 13.4 mmol) and (E)-3,4,5-trimethoxycinnamyl alcohol (3.0 g, 13.4 
mmol) in a solvent mixture of dichloromethane (26 mL) and carbon disulfide (26 mL) was treated 
with 25% H2SO4/SiO2 catalyst (2.2g, 5.36 mmol) at rt. The resulting mixture was stirred for 4 h 
and then filtered through a plug of SiO2. Solvent was removed and the residue purified by flash 
chromatography (SiO2, 1:2 EtOAc/hexanes) to give 2a as an amorphous light yellow solid (1.660 
g, 39.4%): 1H NMR (500 MHz, CDCl3) δ 6.56 (s, 2H), 6.38 (dt, J = 15.8, 1.7 Hz, 1H), 6.23 (dt, J 
= 15.8, 6.2 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H), 6.10 (d, J = 2.3 Hz, 1H), 5.09 (s, 1H), 3.85 (s, 6H), 
3.83 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.54 (dd, J = 6.2, 1.7 Hz, 2H); 13C NMR (125 MHz, CDCl3) 
δ 159.9, 159.0, 155.9, 153.4 (2), 137.6, 133.2, 130.4, 128.1, 106.1, 103.3 (2), 93.9, 91.7, 61.1, 56.2 
(2), 56.0, 55.5, 26.2; IR (KBr) νmax 3379, 3379, 2937, 1620, 1593, 1506, 1421, 1361, 1330, 1201, 
1147, 1053, 817, 707 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C20H25O6, 361.1651, found 
361.1657. 
 
(E)-3,5-Bis(benzyloxy)-2-(3-(3,4,5-trimethoxyphenyl)allyl)phenol (2b): A solution 3,5-
bis(benzyloxy)phenol (5.2 g, 6.97 mmol) and (E)-3,4,5 trimethoxycinnamyl alcohol (3.81 g, 16.97 
mmol) in a solvent mixture of dichloromethane (33 mL) and carbon disulfide (33 mL) was treated 
with 25% H2SO4/SiO2 catalyst (1.11 g, 2.8 mmol) at rt. The resulting mixture was stirred for 4 h 
and then filtered through a plug of SiO2. Solvent was removed and the residue purified by flash 
chromatography (SiO2, 1:3 EtOAc/hexanes) to give 2b (1.970 g, 22.6%) as an amorphous light 
yellow solid: 1H NMR (500 MHz, CDCl3) δ 7.47–7.28 (m, 10H), 6.54 (s, 2H), 6.39 (dt, J = 15.8, 
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1.7 Hz, 1H), 6.30 (d, J = 2.3 Hz, 1H), 6.24 (dt, J = 15.8, 6.3 Hz, 1H), 6.19 (d, J = 2.3 Hz, 1H), 
5.05 (s, 2H), 5.03 (s, 1H), 5.02 (s, 2H), 3.90–3.80 (m, 9H), 3.65–3.56 (m, 2H); 13C NMR (125 
MHz, CDCl3) δ 159.1, 158.2, 155.9, 153.5 (2), 137.6, 137.3, 137.1, 133.3, 130.7, 128.9 (2), 128.8 
(2), 128.7, 128.3 (2), 128.1 (2), 127.8 (2), 127.5, 107.0, 103.4, 95.3, 93.9, 70.6, 70.4, 61.2, 56.3 
(2), 26.6; IR (KBr) νmax 3400, 2937, 1614, 1585, 1454, 1328, 1238, 1126, 1001, 736, 696 cm
–1; 
HRMS (ESI+) m/z [M + Na+] calcd for C32H32NaO6, 535.2097, found 535.2100. 
 
3-(2-Hydroxy-4,6-dimethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)propane-1,2-diol (3a): N-
Methylmorpholine N-oxide (702 mg, 6 mmol) was added to a solution of 2a (1.350 g, 3.75 mmol) 
in a solvent mixture of tetrahydrofuran (12 mL) and H2O (8 mL). The resulting solution was stirred 
for 15 min at rt before the addition osmium tetraoxide (0.04 mmol, 4% solution in water). The 
mixture was stirred for 14 h at rt before quenching with 20% of sodium metabisulfite (12 mL). 
The aqueous layer was extracted with EtOAc (3 × 25 mL), and the combined organic layers were 
washed with saturated sodium chloride solution (50 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated. The residue was purified by flash chromatography (SiO2, 1:10 
acetone/dichloromethane) to afford 3a (1.33 g, 90.4%) as a colorless oil: 1H NMR (500 MHz, 
CDCl3) δ 8.08 (s, 1H), 6.54 (s, 2H), 6.14 (d, J = 2.4 Hz, 1H), 6.03 (d, J = 2.4 Hz, 1H), 4.47 (d, J 
= 6.0 Hz, 1H), 3.98 (ddd, J = 8.0, 6.1, 3.8 Hz, 1H), 3.84 (s, 6H), 3.82 (s, 3H), 3.75 (s, 3H), 3.62 
(s, 3H), 3.44 (br s, 1 H), 3.10–2.92 (m, 1H), 2.85 (dd, J = 14.7, 3.8 Hz, 1H), 2.73 (dd, J = 14.7, 
7.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.1, 159.0, 157.3, 153.4 (2), 137.6, 136.5, 105.6, 
103.9 (2), 94.6, 91.4, 76.9, 76.7, 61.0, 56.3 (2), 55.7, 55.5, 26.5; IR (KBr) νmax 3405, 2932, 1620, 
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1591, 1498, 1439, 1379, 1218, 1146, 1029, 817 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C20H27O8, 395.1706, found 395.1719. 
 
3-(2,4-Bis(benzyloxy)-6-hydroxyphenyl)-1-(3,4,5-trimethoxyphenyl)propane-1,2-diol (3b): 
N-Methylmorpholine N-oxide (444 mg, 3.79 mmol) was added to a solution of 2b (1.0 g, 2.36 
mmol) in a solvent mixture of tetrahydrofuran (7.5 mL) and H2O (5 mL). The resulting solution 
was stirred for 15 min at rt before the addition of osmium tetraoxide (0.02 mmol, 4% solution in 
water). The mixture was stirred for 14 h at rt before quenching with 20% of sodium metabisulfite 
(10 mL). The aqueous layer was extracted with ethyl acetate (3 × 20 mL), and the combined 
organic layers were washed with saturated sodium chloride solution (40 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:10 
acetone/dichloromethane) to afford 3b (595 g, 56.7%) as an amorphous light yellow solid: 1H 
NMR (500 MHz, CDCl3) δ 8.00 (br s, 1 H), 7.47–7.28 (m, 10H), 6.54 (s, 2H), 6.28 (d, J = 2.3 Hz, 
1H), 6.22 (d, J = 2.3 Hz, 1H), 5.06–4.95 (m, 4H), 4.91 (d, J = 3.0 Hz, 1H), 4.52 (d, J = 6.0 Hz, 
1H), 3.77 (d, J = 10.2 Hz, 9H), 3.25 (b rs, 1 H), 3.01–2.95 (m, 1H), 2.83 (dd, J = 14.6, 8.3 Hz, 
1H), 2.74 (br s, 1 H); 13C NMR (125 MHz, CDCl3) δ 159.4, 158.1, 157.6, 153.5 (2), 137.1, 137.0, 
136.4, 129.0, 128.8, 128.7, 128.5, 128.4, 128.3 (2), 128.1, 127.8, 127.5, 127.4, 127.3, 126.9, 106.3, 
103.8 (2), 96.2, 93.7, 70.3 (2), 61.0, 56.3, 56.3, 27.0; IR (KBr) νmax 3446, 2935, 2837, 1591, 1498, 
1456, 1328, 1232, 1126, 1004, 736 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C32H35O8, 




5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-ol (4a): Trimethyl orthoacetate (1.92 
mmol, 250 μL) and pyridinium p-toluenesulfonate (10 mg, 0.032 mmol) were added to a solution 
of 3a (620 mg, 1.6 mmol) in dichloromethane (32 mL) at rt. The resulting mixture was stirred for 
30 min at rt and then cooled to 0 °C before the dropwise addition of boron trifluoride diethyl 
etherate (20 μL, 0.16 mmol). The reaction mixture was warmed to rt and stirred for another 15 min 
before quenching with aqueous acetone (4 mL). Solvent was removed and the residue dissolved in 
methanol (32 mL). Potassium carbonate (240 mg, 1.76 mmol) was added and the mixture stirred 
for 6 h at rt. Methanol was removed, water (25 mL) was added, and the products were extracted 
with ethyl acetate (2 × 30 mL). The combined organic layers were washed with saturated sodium 
chloride solution (50 mL). The organic phase was dried over anhydrous Na2SO4 and filtered. 
Solvent was removed and the residue was purified via flash chromatography (SiO2, 1:4 
EtOAc/hexanes) to yield compound 4a (460 mg, 77.8) as a colorless oil: 1H NMR (500 MHz, 
CDCl3) δ 6.68 (s, 2H), 6.15 (d, J = 2.3 Hz, 1H), 6.12 (d, J = 2.3 Hz, 1H), 4.63 (d, J = 8.5 Hz, 1H), 
4.07 (ddd, J = 9.3, 8.5, 5.8 Hz, 1H), 3.87 (s, 6H), 3.85 (s, 3H), 3.82 (s, 3H), 3.76 (s, 3H), 3.11 (dd, 
J = 16.3, 5.8 Hz, 1H), 2.60 (dd, J = 16.3, 9.3 Hz, 1H), 1.95 (br s, 1 H); 13C NMR (125 MHz, 
CDCl3) δ 159.9, 158.9, 155.4, 153.7 (2), 138.2, 133.6, 104.3 (2), 101.9, 93.2, 92.2, 82.4, 68.5, 
61.0, 56.3 (2), 55.7, 55.6, 28.0; IR (KBr) νmax 3438, 3001, 2916, 2848, 1622, 1593, 1496, 1622, 
2593, 1456, 1361, 1215, 1145, 1120, 810, 667 cm–1; HRMS (ESI+) m/z [M + Na+] calcd for 




5,7-Bis(benzyloxy)-2-(3,4,5-trimethoxyphenyl)chroman-3-ol (4b): Trimethyl orthoacetate 
(0.94 mmol, 120 μL) and pyridinium p-toluene sulfonate (4 mg, 0.016 mmol) were added to a 
solution of 3b (425 mg, 0.78 mmol) in dichloromethane (16 mL) at rt. The resulting mixture was 
stirred for 30 min at rt and then cooled to 0 °C before the dropwise addition of borontrifluoride 
diethyletherate (11 μL, 0.08 mmol) dropwise. The reaction mixture was warmed to rt and stirred 
for another 15 min before quenching with aqueous acetone (3 mL). Solvent was removed and the 
residue dissolved in methanol (16 mL). Potassium carbonate (118 mg, 0.85 mmol) was added and 
mixture stirred for 6 h at rt. Methanol was removed, water (20 mL) was added, and the products 
were extracted with ethyl acetate (2 × 25 mL). The combined organic layers were washed with 
saturated sodium chloride solution (30 mL). The organic phase was dried over anhydrous Na2SO4 
and filtered. Solvent was removed, and the residue was purified via flash chromatography (SiO2, 
1:4 EtOAc/hexanes) to afford 4b (265 mg, 63.3%) as a pale yellow oil: 1H NMR (500 MHz, 
CDCl3) δ 7.49–7.37 (m, 8H), 7.37–7.30 (m, 2H), 6.69 (s, 2H), 6.30 (d, J = 2.3 Hz, 1H), 6.26 (d, J 
= 2.3 Hz, 1H), 5.11–4.96 (m, 4H), 4.65 (d, J = 8.5 Hz, 1H), 4.10 (td, J = 8.9, 5.8 Hz, 1H), 3.88 (s, 
6H), 3.86 (s, 3H), 3.22 (dd, J = 16.3, 5.8 Hz, 1H), 2.69 (dd, J = 16.4, 9.3 Hz, 1H), 1.82 (s, 1H); 
13C NMR (125 MHz, CDCl3) δ 159.0, 157.9, 155.4, 153.7 (2), 137.1, 137.0 (2), 133.5, 128.8 (2), 
128.7 (2), 128.2, 128.1, 127.7, 127.3 (3), 104.3 (2), 102.6, 94.5, 94.1, 82.4, 70.3, 70.1, 68.5, 61.0, 
56.3 (2), 28.2; IR (KBr) νmax 3481, 2935, 1618, 1593, 1498, 1460, 1421, 1346, 1145, 1128, 1022, 




5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-ol (5a): Dess-Martin periodinane 687 
mg, 1.62 mmol, 1.5 eq.) was added to a solution of 4a (421 mg, 1.08 mmol, 1.0 eq.) in 
dichloromethane (10 mL). The resulting mixture was stirred for 2 h before quenching with 15 % 
aqueous solution of sodium thiosulfate (3 mL) and saturated sodium bicarbonate (3 mL). The 
aqueous layer was extracted with dichloromethane (3 × 5 mL) and the combined organic layers 
were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium 
sulfate, filtered, and concentrated. The residue was purified via flash chromatography (SiO2, 1:3 
EtOAc/hexanes) to yield the corresponding ketone which was used further as obtained. A solution 
of the ketone in tetrahydrofuran (2 mL) was added dropwise to a solution of lithium bromide (487 
mg, 5.61 mmol, 5.2 eq.) and L-selectride (1 M solution) (1.41 mL, 1.41 mmol, 1.3 eq.) in 
tetrahydrofuran (8 mL) at -78 °C. The resulting mixture was stirred for 6 h at -78 °C, warmed to 
rt, and quenched with 2.5 M sodium hydroxide solution (5.0 mL), followed by the addition of 
ethanol (3.9 mL) and 35% aqueous hydrogen peroxide solution (1.3 mL). The resulting mixture 
was stirred for 14 h before the addition of ethyl acetate (15 mL). The aqueous layer was extracted 
with ethyl acetate (2 × 10 mL) and the combined organic layers washed with saturated sodium 
chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue purified via flash chromatography (SiO2, 1:2 EtOAc/hexanes) to yield compound 5a as a 
colorless oil (175 mg, 43%). 1H NMR (500 MHz, CDCl3) δ 6.75 (s, 2H), 6.21 (d, J = 2.3 Hz, 1H), 
6.12 (d, J = 2.4 Hz, 1H), 4.93 (s, 1H), 4.44–4.23 (m, 1H), 3.89 (s, 6H), 3.85 (s, 3H), 3.80 (s, 3H), 
3.78 (s, 3H), 3.00–2.93 (m, 1H), 2.89 (dd, J = 17.3, 4.4 Hz, 1H), 1.88 (br s, 1 H); 13C NMR (125 
66 
 
MHz, CDCl3) δ 159.8, 159.4, 155.2, 153.6 (2), 137.5, 134.2, 103.4 (2), 100.4, 93.5, 92.4, 78.8, 
66.6, 61.0, 56.3 (2), 55.6, 55.5, 28.2; IR (KBr) νmax 3460, 2997, 2939, 2839, 1620, 1593, 1498, 
1456, 1419, 1357, 1330, 1317, 1236, 1197, 1145, 1120, 1081, 939, 815, 729 cm–1; HRMS (ESI+) 
m/z [M + H+] calcd for C20H25O7, 377.1600, found 377.1593. 
 
5,7-Bis(benzyloxy)-2-(3,4,5-trimethoxyphenyl)chroman-3-ol (5b): Dess-Martin periodinane 
127 mg, 0.30 mmol, 1.5 eq.) was added to a solution of 4b (106 mg, 0.20 mmol, 1.0 eq.) in 
dichloromethane (2 mL). The resulting mixture was stirred for 2 h before quenching with 15 % 
aqueous solution of sodium thiosulfate (1 mL) and saturated sodium bicarbonate (1mL). The 
aqueous layer was extracted with dichloromethane (3 × 2 mL) and the combined organic layers 
were washed with saturated sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified via flash chromatography (SiO2, 1:3 
EtOAc/hexanes) to yield the corresponding ketone which was used further as obtained. A solution 
of the ketone in tetrahydrofuran (0.5 mL) was added dropwise to a solution of lithium bromide (90 
mg, 1.04 mmol, 5.2 eq.) and L-selectride (1 M solution) (0.26 mL, 0.26 mmol, 1.3 eq.) in 
tetrahydrofuran (1.5 mL) at -78 °C. The resulting mixture was stirred for 6 h at -78 °C, warmed to 
rt, and quenched with 2.5 M sodium hydroxide solution (1.0 mL), followed by the addition of 
ethanol (1.35 mL) and 35% aqueous hydrogen peroxide solution (0.45 mL). The resulting mixture 
was stirred for 14 h before the addition of ethyl acetate (4 mL). The aqueous layer was extracted 
with ethyl acetate (2 × 5 mL) and the combined organic layers washed with saturated sodium 
chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
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residue purified via flash chromatography (SiO2, 1:2 EtOAc/hexanes) to yield compound 5b. 
Obtained as an amorphous pale yellow solid (72 mg, 68%): 1H NMR (500 MHz, CDCl3) δ 7.44–
7.34 (m, 10H), 6.75 (s, 2H), 6.32 (d, J = 2.3 Hz, 1H), 6.30 (d, J = 2.3 Hz, 1H), 5.06–5.00 (m, 4H), 
4.97 (s, 1H), 4.30 (d, J = 4.3 Hz, 1H), 3.91 (s, 6H), 3.87 (s, 3H), 3.07 (dd, J = 17.4, 2.5 Hz, 1H), 
2.98 (dd, J = 17.3, 4.5 Hz, 1H), 1.78 (br s, 1 H); 13C NMR (125 MHz, CDCl3) δ 159.0, 158.5, 
155.3, 153.7 (2), 137.2 (2), 137.1, 134.1, 128.8 (2), 128.7 (2), 128.2, 128.1, 127.8 (2), 127.4 (2), 
103.4 (2), 101.1, 94.9, 94.4, 78.9, 70.4, 70.2, 66.8, 61.1, 56.4 (2), 28.5; IR (KBr) νmax 3461, 2925, 
2834, 1593, 1458, 1375, 1236, 1145, 1126, 1078, 1010, 813, 738, 696 cm–1; HRMS (ESI+) m/z 
[M + H+] calcd for C32H33O7, 529.2226, found 529.2234. 
 
5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl Benzoate (7a): Benzoyl chloride (14 
μL, 0.12 mmol) in dichloromethane (0.5 mL) was added to a solution of 5a (15 mg, 0.04 mmol) 
and 4-dimethylaminopyridine (24 mg, 0.2 mmol) in dichloromethane 1 (mL) at 0 °C and stirred 
for 6 h at rt. The solvent was removed and the residue purified via flash chromatography (SiO2, 
1:4 EtOAc/hexanes) to give the desired ester 7a (17 mg, 89.4%) as a colorless oil: 1H NMR (500 
MHz, CDCl3) δ 8.02–7.89 (m, 2H), 7.59–7.47 (m, 1H), 7.42–7.33 (m, 2H), 6.72 (s, 2H), 6.27 (d, 
J = 2.3 Hz, 1H), 6.14 (d, J = 2.3 Hz, 1H), 5.69 (td, J = 3.5, 1.3 Hz, 1H), 5.09 (t, J = 1.0 Hz, 1H), 
3.82 (s, 3H), 3.80 (d, J = 1.7 Hz, 6H), 3.71 (s, 6H), 3.10–3.05 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 165.5, 159.6, 158.9, 155.5, 153.1 (2), 137.7, 133.3, 133.1, 130.0, 129.7 (3), 128.3 (2), 
103.8 (2), 100.2, 93.4, 92.0, 78.0, 68.5, 60.8, 55.9, 55.4 (2), 26.1; IR (KBr) νmax 2910, 2848, 1718, 
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1595, 1461, 1271, 1118 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C27H29O8, 481.1862 found 
481.1863. 
 
5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 3-Methoxybenzoate (7b): A solution 
of 5a (12 mg, 0.03 mmol) in dichloromethane (0.5 mL) was added to a solution of 3-
methoxybenzoic acid (10 mg, 0.06 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (13 mg, 0.06 mmol), and 4-dimethylaminopyridine (8 mg, 0.06 mmol) in 
dichloromethane (1 mL) at 0 °C. The resulting mixture was stirred for 6 h at rt, diluted with 
dichloromethane (5 mL) and washed with saturated sodium bicarbonate (2 × 4 mL) solution. The 
organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was 
purified via flash chromatography (SiO2, 1:3 EtOAc/hexanes) to give the desired ester product 7b 
as a colorless oil (13 mg, 80.4%): 1H NMR (500 MHz, CDCl3) δ 7.56 (dt, J = 7.7, 1.2 Hz, 1H), 
7.48 (dd, J = 2.7, 1.5 Hz, 1H), 7.30–7.26 (m, 1H) 7.05 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.72 (s, 
2H), 6.26 (d, J = 2.3 Hz, 1H), 6.13 (d, J = 2.4 Hz, 1H), 5.67 (td, J = 3.6, 1.3 Hz, 1H), 5.08 (s, 1H), 
3.81 (s, 3H), 3.81–3.78 (m, 9H), 3.73 (s, 6H), 3.07 (d, J = 3.5 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ 165.4, 159.6, 158.9, 155.5, 153.1 (2), 137.7, 133.3, 131.3, 129.3 (2), 122.0, 119.1, 114.7, 
103.8 (2), 100.1, 93.4, 92.0, 78.0, 68.6, 60.8, 55.9 (2), 55.4 (3), 26.0; IR (KBr) νmax 2937, 1718, 
1622, 1593, 1498, 1456, 1274, 1218, 1124, 1047, 754 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 




5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 4-Methoxybenzoate (7c): 4-
Methoxybenzoyl chloride (10 μL, 0.07 mmol) in dichloromethane (0.5 mL) was added to a 
solution of 5a (13 mg, 0.035 mmol) and 4-dimethylaminopyridine (13 mg, 0.1 mmol) in 
dichloromethane 0.7 (mL)–pyridine (0.3 mL) at 0 °C. The resulting mixture was stirred for 6 h at 
rt, solvent was removed, and the residue was purified via flash chromatography (SiO2, 1:3 
EtOAc/hexanes) to give the desired ester 7c (15 mg, 87.4%) as a colorless oil: 1H NMR (500 MHz, 
CDCl3) δ 7.77–7.55 (m, 2H), 6.66–6.53 (m, 2H), 6.46 (s, 2H), 6.01 (d, J = 2.3 Hz, 1H), 5.88 (d, J 
= 2.3 Hz, 1H), 5.41 (td, J = 3.5, 1.3 Hz, 1H), 4.82 (s, 1H), 3.58 (s, 3H), 3.57 (s, 3H), 3.55 (s, 3H), 
3.54 (s, 3H), 3.48 (s, 6H), 2.80 (d, J = 3.5 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 165.2, 163.4, 
159.6, 158.9, 155.5, 153.1 (2), 133.4, 131.8 (2), 122.4, 113.5 (2), 103.9 (2), 100.3, 93.4, 91.9, 78.1, 
68.0, 60.8, 55.9 (2), 55.4 (4), 26.1; IR (KBr) νmax 2927, 1731, 1604, 1591, 1508, 1458, 1458, 1419, 
1373, 1326, 1255, 1234, 1126, 1099, 846, 763 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C28H31O9, 511.1968, found 511.1961. 
 
5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 3′,6-dimethoxy-[1,1′-biphenyl]-3-
carboxylate (7d):  A solution of 5a (15 mg, 0.04 mmol) in dichloromethane (0.5 mL) was added 
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to a solution of 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (21 mg, 0.08 mmol), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (16 mg, 0.08 mmol), and 4-
dimethylaminopyridine (9.6 mg, 0.08 mmol) in dichloromethane (1 mL) at 0 °C. The resulting 
mixture was stirred for 6 h at rt, diluted with dichloromethane (5 mL), and washed saturated 
sodium bicarbonate (2 × 4 mL) solution. The organic layer was dried over anhydrous sodium 
sulfate, filtered and concentrated. The residue was purified via flash chromatography (SiO2, 1:3 
EtOAc/hexanes) to give the desired ester 7d (15 mg, 62.5%) as a colorless oil: 1H NMR (500 MHz, 
CDCl3) δ 7.95 (dd, J = 8.6, 2.3 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.02 
(ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 6.99 (dd, J = 2.6, 1.6 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 6.90 (ddd, 
J = 8.3, 2.6, 1.0 Hz, 1H), 6.75 (s, 2H), 6.25 (d, J = 2.3 Hz, 1H), 6.13 (d, J = 2.3 Hz, 1H), 5.65 
(ddd, J = 4.2, 2.9, 1.3 Hz, 1H), 5.16–5.02 (m, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.81 (s, 3H), 3.80 (s, 
3H), 3.79 (s, 3H), 3.69 (s, 6H), 3.07 (t, J = 3.3 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 165.3, 
160.3, 159.6, 159.3, 158.9, 155.5, 153.1 (2), 138.7, 133.4, 132.4, 131.0, 130.4 (2), 129.1, 122.5, 
121.9, 115.1, 113.0, 110.5, 103.8 (2), 100.3, 93.4, 92.0, 78.0, 68.4, 60.8, 55.9 (2), 55.8, 55.4 (2), 
55.3, 26.1; IR (KBr) νmax 2927,2848, 1716, 1593, 1496, 1456, 1361, 1238, 1126, 771 cm
–1; HRMS 
(ESI+) m/z [M + H+] calcd for C35H37O10, 617.2387, found 617.2382. 
 
5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-
yl)benzoate (7e): A solution of 5a (24 mg, 0.064 mmol) in dichloromethane (0.5 mL) was added 
to a solution of 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid (32 mg, 0.13 mmol), N-(3-
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dimethylamino-propyl)-N′-ethylcarbodiimide hydrochloride (26 mg, 0.13 mmol), and 4-
dimethylaminopyridine (15 mg, 0.13 mmol) in dichloromethane (1 mL) at 0 °C. The resulting 
mixture was stirred for 6 h at rt, diluted with dichloromethane (5 mL) and washed saturated sodium 
bicarbonate solution (2 × 4 mL). The organic layer was dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified via flash chromatography (SiO2, 1:4 
EtOAc/hexanes) to give the desired ester 7e (28 mg, 72.5%) as a colorless oil: 1H NMR (500 MHz, 
CDCl3) δ 7.84 (d, J = 2.1 Hz, 1H), 7.81 (dd, J = 8.3, 2.2 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.69 
(s, 2H), 6.26 (d, J = 2.3 Hz, 1H), 6.13 (d, J = 2.4 Hz, 1H), 5.67 (td, J = 3.4, 1.2 Hz, 1H), 5.14 
(dddd, J = 7.3, 5.8, 2.9, 1.4 Hz, 1H), 5.08 (br s, 1 H), 3.81 (s, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 3.71 
(s, 6H), 3.21 (d, J = 7.2 Hz, 2H), 3.05 (d, J = 3.3 Hz, 2H), 2.30 (s, 3H), 1.72 (s, 3H), 1.66 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 168.8, 164.9, 159.6, 158.9, 155.4, 153.1 (2), 152.7, 137.8, 134.0, 
133.9, 133.3, 131.8, 128.6, 127.8, 122.4, 120.7, 103.8 (2), 100.0, 93.3, 92.0, 77.9, 68.4, 60.8, 56.0, 
55.4 (3), 28.6, 25.7 (2), 20.9, 17.8; IR (KBr) νmax 2921, 2850, 1716, 1593, 1458, 1282, 1201, 1142, 
1010, 948, 813 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C34H39O10, 607.2543, found 607.2541. 
 
5,7-Bis(benzyloxy)-2-(3,4,5-trimethoxyphenyl)chroman-3-yl Benzoate (7f): Benzoyl chloride 
(8 μL, 0.064 mmol) in dichloromethane (0.5 mL) was added to a solution of 5b (17 mg, 0.032 
mmol) and 4-dimethylaminopyridine (12 mg, 0.092 mmol) in dichloromethane (0.7 mL) with 
pyridine (0.3 mL) at 0 °C. The solvent was removed and the residue purified via flash 
chromatography (SiO2, 1:8 EtOAc/hexanes) to give the desired ester, 7f (16 mg, 83.5%), as an 
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amorphous white solid: 1H NMR (500 MHz, CDCl3) δ 8.01–7.96 (m, 2H), 7.63 (d, J = 1.7 Hz, 
1H), 7.53–7.34 (m, 12H), 6.72 (s, 2H), 6.38 (d, J = 2.3 Hz, 1H), 6.32 (d, J = 2.3 Hz, 1H), 5.71 
(ddd, J = 4.1, 3.0, 1.3 Hz, 1H), 5.10 (d, J = 3.8 Hz, 1H), 5.08–5.01 (m, 4H), 3.80 (s, 3H), 3.71 (s, 
6H), 3.18–3.10 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 172.0, 165.5, 158.8, 158.0, 155.6, 153.1, 
137.7, 136.9, 136.8, 133.8, 133.3, 133.2, 130.2, 130.0, 129.8 (2), 129.3, 128.6 (2), 128.6, 128.5, 
128.3 (2), 128.0, 127.9 (2), 127.6, 127.2, 100.9, 94.8, 94.0, 78.1, 70.2, 70.0, 68.5, 60.8, 55.9 (2), 
26.3; IR (KBr) νmax 2929,, 2839, 1716, 1616, 1591, 1506, 1456, 1361, 1226, 1149, 1126, 1041, 
811, 754 cm–1; HRMS (ESI+) m/z [M + Na+] calcd for C39H36 NaO8, 655.2308, found 655.2307. 
 
5,7-Bis(benzyloxy)-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 3-Methoxybenzoate (7g): 3-
Methoxybenzoyl chloride (9 μL, 0.064 mmol) in dichloromethane (0.5 mL) was added to a 
solution of 5b (17 mg, 0.032 mmol) and 4-dimethylaminopyridine (12 mg, 0.092 mmol) in 
dichloromethane 0.7 (mL) with pyridine (0.3 mL) at 0 °C. The resulting mixture was stirred for 6 
h at rt. The resulting mixture was stirred for 6 h at rt. The solvent was removed and the residue 
purified via flash chromatography (SiO2, 1:8 EtOAc/hexanes) to give the desired ester 7g (16 mg, 
85.1%) as an amorphous white solid: 1H NMR (500 MHz, CDCl3) δ 7.58 (dt, J = 7.7, 1.2 Hz, 1H), 
7.50–7.30 (m, 12H), 7.07 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 6.72 (s, 2H), 6.37 (d, J = 2.3 Hz, 1H), 
6.31 (d, J = 2.3 Hz, 1H), 5.68 (ddd, J = 4.2, 3.0, 1.3 Hz, 1H), 5.17–5.03 (m, 4H), 5.03 (s, 1H), 
3.80 (s, 6H), 3.73 (s, 6H), 3.17–3.11 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 165.4, 159.5, 158.8, 
158.0, 155.6, 153.1 (2), 137.7, 136.9, 136.8, 133.3, 131.3, 129.3, 128.6 (3), 128.5, 128.0, 127.9 
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(3), 127.6, 127.2 (2), 122.1, 119.1, 114.7, 103.8 (2), 100.8, 94.8, 94.0, 78.0, 70.2, 70.0, 68.6, 60.8, 
55.9, 55.4, 26.2; IR (KBr) νmax 2931, 2664, 1716, 1593, 1506, 1456, 1361, 1269, 1217, 1126, 1070. 
1008 cm–1; HRMS (ESI+) m/z [M + Na+] calcd for C40H38NaO9, 685.2414, found 685.2401. 
 
5,7-Bis(benzyloxy)-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 4-Methoxybenzoate (7h): 4-
Methoxybenzoyl chloride (9 μL, 0.064 mmol) in dichloromethane (0.7 mL) was added to a 
solution of 5b (17 mg, 0.032 mmol) and 4-dimethylaminopyridine (12 mg, 0.092 mmol) in 
dichloromethane (0.7 mL) with pyridine (0.3 mL) at 0 °C. The resulting mixture was stirred for 6 
h at rt. The solvent was removed and the residue purified via flash chromatography (SiO2, 1:8 
EtOAc/hexanes) to give the desired ester product 7h (17 mg, 87.4%) as an amorphous white solid: 
1H NMR (500 MHz, CDCl3) δ 7.98–7.89 (m, 2H), 7.49–7.44 (m, 2H), 7.44–7.31 (m, 8H), 6.88–
6.84 (m, 2H), 6.71 (s, 2H), 6.37 (d, J = 2.3 Hz, 1H), 6.31 (d, J = 2.3 Hz, 1H), 5.68 (tt, J = 3.1, 1.2 
Hz, 1H), 5.08 (s, 1H), 5.08–5.01 (m, 4H), 3.84 (s, 3H), 3.80 (s, 3H), 3.72 (s, 6H), 3.12 (t, J = 3.0 
Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 165.2, 163.5, 158.7, 158.0, 155.6, 153.1, 137.7, 136.9, 
136.8, 133.3 (2), 131.8, 128.6 (2), 128.5 (2), 128.0 (2), 127.9 (2), 127.6 (2), 127.2, 122.4, 113.5 
(2), 103.9 (2), 101.0, 94.8, 93.9, 78.1, 70.2, 70.0, 68.0, 60.8, 60.0, 55.9, 55.5, 26.4; IR (KBr) νmax 
3348, 2952, 2927, 1716, 1506, 1417, 1257, 1168, 1126, 1035, 821 cm–1; HRMS (ESI+) m/z [M + 





biphenyl]-3-carboxylate (7i): A solution of 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (35 
mg, 0.135 mmol) in THF (5 mL) was treated with thionyl chloride (20 μL, 0.27 mmol). The 
resulting solution was heated at reflux for 3 h, cooled to rt before the solvent was removed. The 
crude was dissolved in dichloromethane (0.5 mL) and added to a solution of 5b (18 mg, 0.045 
mmol) and 4-dimethylaminopyridine (22 mg, 0.18 mmol) in dichloromethane (0.7 mL) with 
pyridine (0.3 mL) at 0 °C. The resulting mixture was stirred for 6 h at rt, the solvent was removed, 
and the residue was purified via flash chromatography (SiO2, 1:3 EtOAc/hexanes) to give the 
desired ester, 7i (28 mg, 83%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.97 (dd, J = 8.6, 
2.2 Hz, 1H), 7.93 (d, J = 2.2 Hz, 1H), 7.44 (d, J = 1.3 Hz, 1H), 7.43–7.29 (m, 10H), 7.03 (dt, J = 
7.7, 1.2 Hz, 1H), 7.00 (dd, J = 2.6, 1.5 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.91 (ddd, J = 8.3, 2.6, 
1.0 Hz, 1H), 6.71 (s, 2H), 6.37 (d, J = 2.3 Hz, 1H), 6.30 (d, J = 2.3 Hz, 1H), 5.67 (td, J = 3.6, 1.4 
Hz, 1H), 5.10 (s, 1H), 5.07–5.01 (m, 4H), 3.86–3.79 (m, 9H), 3.69 (s, 6H), 3.15 (d, J = 3.6 Hz, 
2H); 13C NMR (125 MHz, CDCl3) δ 165.6, 160.6, 159.5, 159.0, 158.2, 155.8, 153.3 (2), 138.9, 
137.1, 137.1, 133.6, 132.6, 131.3, 130.7, 129.3, 128.9, 128.8 (2), 128.3 (2), 128.2 (2), 127.8 (2), 
127.4 (2), 122.7, 122.1, 115.4, 113.2, 110.7, 104.0 (2), 101.3, 95.0, 94.2, 78.3, 70.4, 70.2, 68.6, 
61.1, 56.2, 56.1 (2), 55.5, 26.5; IR (KBr) νmax 3434, 2929, 1712, 1616, 1593, 1500, 1456, 2440, 
2303, 1238, 1149, 1126, 1027, 821, 736,698 cm–1; HRMS (ESI+) m/z [M + Na+] calcd for 





en-1-yl)benzoate (7j): A solution of 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid (33.5 mg, 
0.135 mmol) in THF (5 mL) was treated with thionyl chloride (20 μL, 0.27 mmol). The resulting 
solution was heated at 70 °C for 3 h and cooled to rt and concentrated. The residue was dissolved 
in dichloromethane (0.5 mL) and added to a solution of 5b (18 mg, 0.045 mmol) and 4-
dimethylaminopyridine (22 mg, 0.18 mmol) in dichloromethane (0.7 mL) with pyridine (0.3 mL) 
at 0 °C. The resulting mixture was stirred for 6 h at rt. The solvent was removed and the residue 
purified via flash chromatography (SiO2, 1:3 EtOAc/hexanes) to give the desired ester, 7j (26.6 
mg, 78%), as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 2.1 Hz, 1H), 7.74 (dd, J 
= 8.4, 2.2 Hz, 1H), 7.52–7.46 (m, 2H), 7.44–7.36 (m, 2H), 7.39–7.28 (m, 6H), 7.01 (d, J = 8.4 Hz, 
1H), 6.79 (s, 2H), 6.29–6.37 (m, 2H), 5.76 (ddd, J = 4.3, 2.9, 1.4 Hz, 1H), 5.22 (m, 1H), 5.15 (m, 
3H), 5.00 (s, 2H), 3.81 (s, 3H), 3.77 (s, 6H), 3.20 (d, J = 7.4 Hz, 2H), 3.19–3.06 (m, 2H), 2.31 (s, 
3H), 1.71 (d, 1.6 Hz, 3H), 1.66 (d, J = 1.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 169.0, 165.1, 
156.7, 155.1, 153.3, 152.9 (2), 152.1, 137.7, 136.9, 136.6, 134.3, 134.1, 133.0, 132.0, 128.9, 128.8 
(2), 128.3 (2), 128.2 (2), 127.8 (1), 127.4 (2), 127.3 (2), 122.6, 120.8, 103.5 (2), 102.6, 93.0, 92.9, 
78.2, 71.5, 70.5, 68.0, 61.0, 56.2 (2), 28.8, 26.5, 25.9, 21.0, 18.0; IR (KBr) νmax 2960, 2925, 1714, 
1604, 1456, 1353, 1261, 1236, 1174, 1126, 1012, 819 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 




5,7-Dihydroxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl benzoate (8a): Compound 7f (15 mg, 
0.023 mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred 
for 18 h under a hydrogen atmosphere. The suspension was filtered through a small pad of celite. 
The eluent was concentrated and the residue purified by flash chromatography (SiO2, 
acetone/dichloromethane 1:8) to give the desired product 8a (9.5 mg, 88.5%) as a colorless oil: 1H 
NMR (500 MHz, CDCl3) δ 7.99–7.86 (m, 2H), 7.53 (ddt, J = 8.7, 7.2, 1.3 Hz, 1H), 7.45–7.33 (m, 
2H), 6.70 (s, 2H), 6.19 (d, J = 2.3 Hz, 1H), 5.98 (d, J = 2.3 Hz, 1H), 5.70 (ddd, J = 4.3, 2.8, 1.3 
Hz, 1H), 5.09 (br s, 1H), 3.80 (s, 3H), 3.70 (s, 6H), 3.15–3.00 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 165.6, 156.1, 155.3 (2), 155.1 (2), 153.1, 137.7, 133.3, 129.8(2), 129.7 (3), 128.4, 103.8 
(2), 98.9, 96.5, 96.1, 77.9, 68.3, 60.9, 55.9 (2), 25.8 cm–1; IR (KBr) νmax 3421, 2931, 2850, 1717, 
1596, 1465, 1276, 1126, 756 cm–1; HRMS (ESI-) m/z [M – H+] calcd for C25H23O8, 451.1393, 
found 451.1412. 
 
5,7-Dihydroxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 3-Methoxybenzoate (8b): 
Compound 7g (14 mg, 0.021 mmol) and palladium/carbon (10%) were suspended in 
tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. The suspension was 
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filtered through a small pad of celite. The eluent was concentrated and the residue purified by flash 
chromatography (SiO2, acetone/dichloromethane 1:8) to afford 8b (9 mg, 89%) as a colorless oil: 
1H NMR (500 MHz, CDCl3) δ 7.55 (dt, J = 7.7, 1.2 Hz, 1H), 7.45 (dd, J = 2.7, 1.5 Hz, 1H), 7.30–
7.26 (m, 1H), 7.06 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.70 (s, 2H), 6.18 (d, J = 2.3 Hz, 1H), 5.94 (d, 
J = 2.3 Hz, 1H), 5.68 (ddd, J = 4.2, 2.8, 1.3 Hz, 1H), 5.43 (s, 1H), 5.29 (s, 1H), 5.13–5.06 (m, 1H), 
3.80 (s, 3H), 3.77 (s, 3H), 3.70 (s, 6H), 3.20–3.02 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 165.6, 
159.5, 156.0, 155.4, 155.2, 153.1 (2), 137.6, 133.4, 131.1, 129.4, 122.0, 119.4, 114.6, 103.8 (2), 
98.8, 96.3, 96.1, 77.9, 68.6, 60.8, 55.9, 55.4 (2), 25.7; IR (KBr) νmax 3419, 3404, 3010, 2927, 2852, 
1716, 1596, 1463, 1274, 1128,1105, 754 cm–1; HRMS (ESI+) m/z [M – H+] calcd for C26H25O9, 
481.1499, found 481.1509. 
 
5,7-Dihydroxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 4-Methoxybenzoate (8c): 7h (14 mg, 
0.021 mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred 
for 18 h under a hydrogen atmosphere. The suspension was filtered through a small pad of celite. 
The eluent was concentrated and the residue purified by flash chromatography (SiO2, 
acetone/dichloromethane 1:8) to give 8c (9 mg, 89%) as a colorless oil: 1H NMR (500 MHz, 
CD3OD) δ 7.93–7.76 (m, 2H), 6.98–6.90 (m, 2H), 6.79 (s, 2H), 6.00 (q, J = 2.3 Hz, 2H), 5.63 
(ddd, J = 4.7, 2.3, 1.2 Hz, 1H), 5.14 (s, 1H), 3.83 (s, 3H), 3.70 (s, 3H), 3.67 (s, 6H), 3.07 (dd, J = 
17.4, 4.6 Hz, 1H), 2.95–2.86 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 165.2, 163.8, 156.2, 155.5, 
155.3, 153.3, 137.3, 133.5, 132.0 (3),122.4, 113.8 (2), 104.0 (2), 99.2, 96.6, 96.2, 78.2, 68.1, 63.0, 
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56.1, 55.7 (2), 26.0; IR (KBr) νmax 3419, 2931, 2842, 1701, 1604, 1506, 1458, 1361, 1257, 1166, 




carboxylate (8d): Compound 7i (25 mg, 0.032 mmol) and palladium/carbon (10%) were 
suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. The 
suspension was filtered through a small pad of celite. The eluent was concentrated and the residue 
purified by flash chromatography (SiO2, acetone/dichloromethane 1:8) to give 8d (17.4 mg, 91%) 
as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 8.00–7.85 (m, 2H), 7.32 (t, J = 7.9 Hz, 1H), 7.07–
6.96 (m, 2H), 6.96–6.85 (m, 2H), 6.69 (s, 2H), 6.16 (d, J = 2.3 Hz, 1H), 5.96 (d, J = 2.3 Hz, 1H), 
5.71–5.62 (m, 2H), 5.52 (s, 1H), 5.09 (s, 1H), 3.83 (d, J = 3.7 Hz, 6H), 3.79 (d, J = 0.6 Hz, 3H), 
3.67 (s, 6H), 3.09 (d, J = 3.4 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 165.7, 160.6, 159.4, 156.2, 
155.6, 155.4, 153.3 (2), 138.8, 133.6, 132.6, 131.2, 130.6, 129.3 (2), 122.5, 122.1, 115.3, 113.2, 
110.7, 103.9 (2), 99.2, 96.6, 96.3, 78.1, 68.5, 61.0, 56.1, 56.0, 55.5, 53.6, 29; IR (KBr) νmax 3429, 
2931, 2851, 1699, 1604, 1508, 1476, 1248, 1166, 1145, 1098, cm–1; HRMS (ESI+) m/z [M + H+] 





yl)benzoate (8e): A solution of palladium acetate (1 mg, 0.004 mmol), trimethylamine (7 μL, 
0.047 mmol), triethylsilane (34 μL, 0.208 in dichloromethane (0.5 mL) was stirred for 15 min 
before the addition of 7j (20 mg, 0.026 mmol) in dichloromethane (0.4 mL). The resulting mixture 
was stirred for 15 h, quenched with saturated ammonium chloride (2 mL), and extracted with 
diethyl ether (3 × 4 mL). The combined organic layers were washed with saturated sodium chloride 
solution and dried over anhydrous Na2SO4. Solvent was removed, and the residue was purified via 
flash chromatography (SiO2, 5:95 MeOH/DCM) to give 8e (4 mg, 18.9%) as a colorless oil: 
1H 
NMR (500 MHz, CDCl3) δ 7.71 (dd, J = 6.4, 2.4 Hz, 2H), 6.67 (s, 3H), 6.43 (d, J = 2.2 Hz, 1H), 
6.23 (d, J = 2.2 Hz, 1H), 5.74 (s, 1H), 5.66–5.59 (m, 1H), 5.36 (br s, 1 H), 5.22 (dddt, J = 7.3, 5.8, 
2.9, 1.5 Hz, 1H), 4.97 (s, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 3.32 (d, J = 7.4 Hz, 2H), 3.07–2.99 (m, 
2H), 2.30 (d, J = 5.3 Hz, 3H), 1.80–1.64 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 170.1, 165.6, 
159.2, 156.0, 155.0, 153.3 (2), 150.0, 137.9, 136.0, 133.2, 132.2, 130.0, 127.1 (2), 122.2, 121.0, 
115.7, 104.8, 103.9 (2), 103.1, 102.1, 78.2, 67.7, 61.0, 56.2, 29.7, 26.0 (2), 21.4, 18.1; IR (KBr) 
νmax 3412, 2937, 2843, 1715, 1693, 1562, 1473, 1126 cm
–1; HRMS (ESI-) m/z [M – H+] calcd for 




2-Cinnamyl-3,5-dimethoxyphenol (9a): A solution of 3,5-dimethoxy phenol (1a) (2.3 g, 14.91 
mmol) and cinnamyl alcohol (2.0 g, 14.91 mmol) in a solvent mixture of dichloromethane (30 mL) 
and carbon disulfide (30 mL) was treated with 25% H2SO4/SiO2 catalyst (2.4 g, 5.96 mmol) at rt. 
The resulting mixture was stirred for 4 h and then filtered through a plug of SiO2. Solvent was 
removed and the residue purified by flash chromatography (SiO2, 1:9 EtOAc/hexanes) to give 9a 
(1.735 g, 43.15%) as an amorphous light yellow solid: 1H NMR (500 MHz, CDCl3) δ 7.37–7.26 
(m, 2H), 7.30 (dd, J = 7.2, 1.7 Hz, 2H), 7.23–7.17 (m, 1H), 6.48 (dt, J = 16.0, 1.7 Hz, 1H), 6.34 
(dt, J = 15.9, 6.3 Hz, 1H), 6.15 (d, J = 2.3 Hz, 1H), 6.11 (d, J = 2.3 Hz, 1H), 5.06 (s, 1H), 3.82 (s, 
3H), 3.80 (s, 3H), 3.56 (d, J = 1.6 Hz, 1H), 3.55 (d, J = 1.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) 
δ 159.9, 159.0, 155.9, 137.4, 130.6, 128.6 (2), 128.6, 128.5, 127.3, 126.3, 106.1, 93.9, 91.8, 56.0, 
55.5, 26.4; IR (KBr) νmax 3367, 1614, 1596, 1454, 1423, 1201, 1147, 1097, 1053, 811, 736, 692 
cm–1; HRMS (ESI+) m/z [M + H+] calcd for C17H19O3, 271.1334, found 271.1336. 
 
3,5-bis(benzyloxy)-2-cinnamylphenol (9b): A solution of 3,5-bis(benzyloxy)phenol (1b) (3.3 g, 
9.98 mmol) and cinnamyl alcohol (1.34 g, 9.98 mmol) in a solvent mixture of dichloromethane 
(20 mL) and carbon disulfide (20 mL) was treated with 25% H2SO4/SiO2 catalyst (1.59g, 3.99 
mmol) at rt. The resulting mixture was stirred for 4 h and then filtered through a plug of SiO2. 
Solvent was removed and the residue purified by flash chromatography (SiO2, 1:8 EtOAc/hexanes) 
to give 9b (1.425 g, 33.7%) as an amorphous light yellow solid: 1H NMR (400 MHz, CDCl3) δ 
7.48–7.29 (m, 15H), 6.53–6.44 (m, 1H), 6.39–6.30 (m, 1H), 6.29 (d, J = 2.2 Hz, 1H), 6.18 (d, J = 
2.3 Hz, 1H), 5.03 (m, 5H), 3.60 (dd, J = 6.5, 1.6 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 159.0, 
81 
 
158.1, 155.9, 137.5, 137.2, 137.0 (2), 128.8 (2), 128.7 (2), 128.6 (3), 128.5, 128.2, 128.0, 127.8, 
127.5 (2), 127.3, 126.3 (2), 107.0, 95.3, 93.9, 70.5, 70.3, 26.7; IR (KBr) νmax 3419, 3028, 2925, 
1618, 1596, 1452, 1436,1375, 1147, 1091, 734, 696 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C29H27O3, 423.1960, found 423.1966.IR (KBr) νmax  cm
-1.  
 
3-(2-Hydroxy-4,6-dimethoxyphenyl)-1-phenylpropane-1,2-diol (10a): N-Methylmorpholine 
N-oxide (1.26g, 10.76 mmol) was added to a solution of 9a (1.7g, 6.33 mmol) in a solvent mixture 
of tetrahydrofuran (18 mL) and H2O (12 mL). The resulting solution was stirred for 15 min at rt 
before the addition osmium tetraoxide (0.1 mmol, 4% solution in water). The mixture was stirred 
for 14 h at rt before quenching with 20% of sodium metabisulfite (15 mL). The aqueous layer was 
extracted with ethyl acetate (3 × 25 mL) and the combined organic layers were washed with 
saturated sodium chloride solution (50 mL), dried over anhydrous Na2SO4, filtered and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:2 EtOAc/hexanes) to 
afford 10a (1.55 g, 81%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.98 (br s, 1 H), 7.43–
7.37 (m, 2H), 7.37–7.32 (m, 3H), 6.17 (d, J = 2.4 Hz, 1H), 6.03 (d, J = 2.4 Hz, 1H), 4.55 (d, J = 
6.6 Hz, 1H), 4.04 (ddd, J = 7.4, 6.5, 3.8 Hz, 1H), 3.77 (s, 3H), 3.59 (s, 3H), 3.23 (br s, 1 H), 2.84 
(dd, J = 14.8, 3.8 Hz, 1H), 2.74 (dd, J = 14.8, 7.4 Hz, 1H), 2.46 (br s, 1 H); 13C NMR (125 MHz, 
CDCl3) δ 160.2, 158.9, 157.5, 140.6, 128.7 (2), 128.5 (2), 127.2, 105.5, 76.9, 76.5, 94.6, 91.5, 55.5 
(2), 26.2; IR (KBr) νmax 3348, 2837, 1622, 1593, 1496, 1456, 1338, 1199, 1147, 1105, cm
–1; HRMS 





Methylmorpholine N-oxide (393 mg, 3.36 mmol) was added to a solution of 9b (0.9g, 2.1 mmol) 
in a solvent mixture of tetrahydrofuran (9 mL) and H2O (6 mL). The resulting solution was stirred 
for 15 min at rt before the addition osmium tetraoxide (0.02 mmol, 4% solution in water). The 
mixture was stirred for 14 h at rt before quenching with 20% of sodium metabisulfite (10 mL). 
The aqueous layer was extracted with ethyl acetate (3 × 20 mL) and the combined organic layers 
were washed with saturated sodium chloride solution (40 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:3 
EtOAc/hexanes) to afford 10b (0.78g, 80.1%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 
8.03 (s, 1H), 7.46–7.36 (m, 5H), 7.36–7.29 (m, 6H), 7.27–7.25 (m, 2H), 7.19–7.06 (m, 2H), 6.29 
(d, J = 2.3 Hz, 1H), 6.21 (d, J = 2.4 Hz, 1H), 5.01 (s, 2H), 4.90–4.82 (m, 2H), 4.56 (d, J = 6.8 Hz, 
1H), 4.04 (ddd, J = 8.5, 6.7, 3.5 Hz, 1H), 3.32 (s, 1H), 2.93 (dd, J = 14.7, 3.5 Hz, 1H), 2.75 (dd, J 
= 14.6, 8.4 Hz, 1H), 2.46 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 159.3, 158.0, 157.7, 140.4, 137.1, 
137.0, 128.8 (5), 128.7 (2), 128.6, 128.2, 127.8 (4), 127.2 (2), 127.0 (2), 106.3, 96.1, 93.6, 70.3 
(2), 26.6; IR (KBr) νmax 3363, 3330 3087, 3031, 1701, 1620, 1598, 1452, 1375, 1147, 1099, 815, 
698 cm-1; HRMS (ESI+) m/z [M + H+] calcd for C29H29O5, 457.2015, found 457.2028. 
 
5,7-Dimethoxy-2-phenylchroman-3-ol (11a): Trimethyl orthoacetate (2.50 mmol, 300 μL) and 
pyridinium p-toluenesulfonate (9 mg, 0.036 mmol) were added to a solution of 10a (600 mg, 1.92 
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mmol) in dichloromethane (36 mL) at rt. The resulting mixture was stirred for 30 min at rt and 
then cooled to 0 °C before the dropwise addition of boron trifluoride diethyl etherate (25 μL, 0.192 
mmol). The reaction mixture was warmed to rt and stirred for another 15 min before quenching 
with aqueous acetone (4 mL). Solvent was removed and the residue was dissolved in methanol (32 
mL). Potassium carbonate (225 mg, 1.84 mmol) was added and the mixture stirred for 6 h at rt. 
Methanol was removed, water (25 mL) was added, and the products were extracted with ethyl 
acetate (2 × 30 mL). The organic layers were combined and washed with saturated sodium chloride 
solution (60 mL). The organic phase was dried over anhydrous Na2SO4 and filtered. Solvent was 
removed, and the residue was purified via flash chromatography (SiO2, 1:4 EtOAc/hexanes) to 
yield compound 11a (422 mg, 77.7%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.47–7.34 
(m, 5H), 6.16 (d, J = 2.3 Hz, 1H), 6.12 (d, J = 2.3 Hz, 1H), 4.79 (d, J = 7.8 Hz, 1H), 4.11 (td, J = 
8.1, 5.5 Hz, 1H), 3.81 (s, 3H), 3.77 (s, 3H), 3.00 (dd, J = 16.4, 5.5 Hz, 1H), 2.63 (dd, J = 16.4, 8.4 
Hz, 1H), 1.71 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 159.7, 158.8, 155.1, 138.1, 128.8 (2), 128.6 
(2), 127.1, 101.4, 93.0, 91.9, 81.7, 68.2, 55.5, 55.4, 27.2; IR (KBr) νmax 3446, 2937, 2839, 1618, 
1593, 1496, 1213, 1143, 1120, 1051, 1022, 813, 761, 689 cm–1; HRMS (ESI+) m/z [M + H+] calcd 
for C17H19O4, 287.1283, found 287.1270. 
 
5,7-Bis(benzyloxy)-2-phenylchroman-3-ol (11b): Trimethyl orthoacetate (1.48 mmol, 188 μL) 
and pyridinium p-toluenesulfonate (6 mg, 0.012 mmol) were added to a solution of 10b (560 mg, 
1.22 mmol) in dichloromethane (24 mL) at rt. The resulting mixture was stirred for 30 min and 
cooled to 0 °C before the addition of borontrifluoride diethyletherate (18 μL, 0.24 mmol) dropwise. 
The reaction mixture was warmed to rt and stirred for another 15 min before quenching with 
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aqueous acetone (4 mL). Solvent was removed, and the residue was dissolved in methanol (18 
mL). Potassium carbonate (185 mg, 1.34 mmol) was added and mixture stirred for 6 h at rt. 
Methanol was removed, water (20 mL) was added and the products extracted with ethyl acetate (2 
× 25 mL). The combined organic layers were washed with saturated sodium chloride solution (60 
mL). The organic phase was dried over anhydrous Na2SO4 and filtered. Solvent was removed and 
the residue was purified via flash chromatography (SiO2, 1:4 EtOAc/hexanes) to yield compound 
11b (420 mg, 78.2%) as a pale yellow oil: 1H NMR (400 MHz, CDCl3) δ 7.61–7.23 (m, 15H), 
6.28–6.09 (m, 2H), 5.09–4.76 (m, 4H), 4.73 (d, J = 7.9 Hz, 1H), 4.07 (td, J = 8.4, 5.6 Hz, 1H), 
3.05 (dd, J = 16.5, 5.5 Hz, 1H), 2.65 (dd, J = 16.4, 8.6 Hz, 1H); IR (KBr) νmax 3460, 2912, 1617, 
1592, 1375, 1145, 1126, 1076, 973, 813, 696 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C29H27O4, 439.1909, found 439.1897. 
 
5,7-Dimethoxy-2-phenylchroman-3-ol (12a): Dess-Martin periodinane (937 mg, 2.20 mmol, 1.5 
eq.) was added to a solution of 11a (421 mg, 1.47 mmol, 1.0 eq.) in dichloromethane (15 mL). The 
resulting mixture was stirred for 2 h before quenching with 15 % aqueous solution of sodium 
thiosulfate (5 mL) and saturated sodium bicarbonate (5 mL). The aqueous layer was extracted with 
dichloromethane (3 × 10 mL) and the combined organic layers were washed with saturated sodium 
chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified via flash chromatography (SiO2, 1:4 EtOAc/hexanes) to yield the 
corresponding ketone which was used further as obtained. A solution of the ketone in 
tetrahydrofuran (3 mL) was added dropwise to a solution of lithium bromide (663 mg, 7.64 mmol, 
5.2 eq.) and L-selectride (1 M solution) (1.91 mL, 1.91 mmol, 1.3 eq.) in tetrahydrofuran at -78 
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°C. The resulting mixture was stirred for 6 h at -78 °C, warmed to rt, and quenched with 2.5 M 
sodium hydroxide solution (6.86 mL), followed by the addition of ethanol (5.10 mL) and 35% 
aqueous hydrogen peroxide solution (1.70 mL). The resulting mixture was stirred for 14 h before 
the addition of ethyl acetate (20 mL). The aqueous layer was extracted with ethyl acetate (2 × 15 
mL) and the combined organic layers washed with saturated sodium chloride solution (30 mL), 
dried over anhydrous sodium sulfate, filtered, and concentrated. The residue purified via flash 
chromatography (SiO2, 1:4 EtOAc/hexanes) to yield compound 12a as a colorless oil (232 mg, 
55%): 1H NMR (400 MHz, CDCl3) δ 7.58–7.52 (m, 2H), 7.45 (dd, J = 8.4, 6.7 Hz, 2H), 7.43–7.33 
(m, 1H), 6.23 (d, J = 2.3 Hz, 1H), 6.15 (d, J = 2.3 Hz, 1H), 5.05 (s, 1H), 4.34 (s, 1H), 3.82 (s, 3H), 
3.80 (d, J = 0.7 Hz, 3H), 3.04–2.82 (m, 2H), 1.73 (br s, 1 H); 13C NMR (125 MHz, CDCl3) δ 
159.9, 159.5, 155.4, 138.4, 129.0, 128.8, 128.3, 126.5, 126.4, 100.4, 93.5, 92.4, 78.8, 66.6, 55.7, 
55.6, 28.3; IR (KBr) νmax 3451, 1952, 2923, 2854, 1618, 1593, 1203, 1145, 1118, 1058, 968, 811, 
746, 700 cm–1; HRMS (ESI+) m/z [M + H+] C17H19O4, 287.1283, found 287.1277. 
 
5,7-Bis(benzyloxy)-2-phenylchroman-3-ol (12b): Dess-Martin periodinane (609 mg, 1.44 mmol, 
1.5 eq.) was added to a solution of 11b (421 mg, 0.96 mmol, 1.0 eq.) in dichloromethane (10 mL). 
The resulting mixture was stirred for 2 h before quenching with 15 % aqueous solution of sodium 
thiosulfate (3 mL) and saturated sodium bicarbonate (3 mL). The aqueous layer was extracted with 
dichloromethane (3 × 10 mL) and the combined organic layers were washed with saturated sodium 
chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified via flash chromatography (SiO2, 1:3 EtOAc/hexanes) to yield the 
corresponding ketone which was used further as obtained. A solution of the ketone in 
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tetrahydrofuran (2 mL) was added dropwise to a solution of lithium bromide (429 mg, 4.99 mmol, 
5.2 eq.) and L-selectride (1 M solution) (1.24 mL, 1.24 mmol, 1.3 eq.) in tetrahydrofuran at -78 
°C. The resulting mixture was stirred for 6 h at -78 °C, warmed to rt, and quenched with 2.5 M 
sodium hydroxide solution (4.45 mL), followed by the addition of ethanol (3.30 mL) and 35% 
aqueous hydrogen peroxide solution (1.10 mL). The resulting mixture was stirred for 14 h before 
the addition of ethyl acetate (14 mL). The aqueous layer was extracted with ethyl acetate (2 × 10 
mL) and the combined organic layers washed with saturated sodium chloride solution (20 mL), 
dried over anhydrous sodium sulfate, filtered, and concentrated. The residue purified via flash 
chromatography (SiO2, 1:3 EtOAc/hexanes) to yield compound 11b as a pale yellow oil (198 mg, 
47%). 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.65–7.31 (m, 15H), 6.23 (d, J = 2.3 Hz, 1H), 
6.16 (d, J = 2.3 Hz, 1H), 5.62 (dt, J = 7.6, 4.9 Hz, 1H), 5.13 (d, J = 5.3 Hz, 1H), 4.99 (d, J = 1.9 
Hz, 4H), 3.25 (dd, J = 14.6, 4.9 Hz, 1H), 2.89 (dd, J = 14.6, 8.0 Hz, 1H), 1.75 (br s, 1 H); IR (KBr) 
νmax 3449, 2954, 2842, 1618, 1593, 1498, 1458, 1198, 1145, 1120, 1080, 729 cm
–1; HRMS (ESI+) 
m/z [M + Na+] calcd for C29H26NaO4, 461.1729, found 461.1724. 
 
5,7-Dimethoxy-2-phenylchroman-3-yl benzoate (13a): Benzoyl chloride (8 μL, 0.07 mmol) in 
dichloromethane (0.5 mL) was added to a solution of 12a (10 mg, 0.035 mmol) and 4-
dimethylaminopyridine (11 mg, 0.08 mmol) in dichloromethane (1 mL) at 0 °C. The resulting 
mixture was stirred for 6 h at rt. Solvent was removed and the residue purified via flash 
chromatography (SiO2, 1:8 EtOAc/hexanes) to give the desired ester 13a as an amorphous white 
solid: (11 mg, 88.8%): 1H NMR (500 MHz, CDCl3) δ 7.95–7.87 (m, 2H), 7.56–7.47 (m, 3H), 7.41–
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7.28 (m, 5H), 6.27 (d, J = 2.3 Hz, 1H), 6.12 (d, J = 2.3 Hz, 1H), 5.69 (ddd, J = 4.1, 3.2, 1.4 Hz, 
1H), 5.21 (m, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.15–3.02 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 
165.9, 159.9, 159.1, 155.7, 138.0, 133.1, 130.2, 129.9 (2), 128.5 (4), 128.3 (2), 126.7, 100.4, 93.5, 
92.1, 78.0, 68.8, 55.6 (2), 26.1; IR (KBr) νmax 2956, 1935, 2839, 1714, 1593, 1458, 1419, 1361, 
1257, 1147, 1124, 1101, 1029, 1006, 846, 813, 769 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C24H23O5, 391.1545, found 391.1538. 
 
5,7-Dimethoxy-2-phenylchroman-3-yl 3-Methoxybenzoate (13b): A solution of 12a (8 mg, 
0.027 mmol) in dichloromethane (0.5 mL) was added to a solution of 3-methoxybenzoic acid (8 
mg, 0.05 mmol), N-(3-dimethylamino-propyl)-N′-ethylcarbodiimide hydrochloride (9.5 mg, 0.05 
mmol), and 4-dimethylaminopyridine (6 mg, 0.05 mmol) in dichloromethane (1 mL) at 0 °C. The 
resulting mixture was stirred for 6 h at rt and then diluted with dichloromethane (5 mL). The 
organic phase was washed with saturated sodium bicarbonate solution (2 × 4 mL). The organic 
layer was dried over anhydrous sodium sulfate, filtered and solvent removed. The residue was 
purified via flash chromatography (SiO2, 1:8 EtOAc/hexanes) to give the desired ester 13b (9 mg, 
76.9%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.56–7.46 (m, 3H), 7.42 (dd, J = 2.7, 1.5 
Hz, 1H), 7.38–7.30 (m, 2H), 7.29 (t, J = 2.6 Hz, 1H), 7.27–7.21 (m, 1H), 7.04 (ddd, J = 8.3, 2.7, 
1.0 Hz, 1H), 6.26 (d, J = 2.3 Hz, 1H), 6.12 (d, J = 2.3 Hz, 1H), 5.67 (ddd, J = 4.1, 3.2, 1.4 Hz, 
1H), 5.21 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.78 (s, 3H), 3.10–3.04 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 165.8, 159.9, 159.6, 159.1, 155.7, 138.0, 131.5, 129.5 (2), 128.5 (2), 128.3, 126.7, 122.3, 
119.6, 114.4, 100.3, 93.5, 92.1, 77.9, 69.0, 55.6 (3), 26.0; IR (KBr) νmax 2925, 2837, 1718, 1618, 
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1593, 1319, 1274, 1220, 1147, 1105, 1041, 958, 910, 811, 752, 696 cm–1; HRMS (ESI+) m/z [M 
+ H+] calcd for C25H25O6, 421.1651, found 421.1642 
 
5,7-Dimethoxy-2-phenylchroman-3-yl 4-methoxybenzoate (13c): A solution of 12a (10 mg, 
0.035 mmol) in dichloromethane (0.5 mL) was added to a solution 4-methoxybenzoic acid (18 mg, 
0.07 mmol), N-(3-Dimethylamino-propyl)-N′-ethylcarbodiimide hydrochloride (13.5 mg, 0.07 
mmol), and 4-dimethylaminopyridine (9 mg, 0.07 mmol) in dichloromethane (1 mL) at 0 °C. The 
resulting mixture was stirred for 6 h at rt and then diluted with dichloromethane (5 mL). The 
organic phase was washed with saturated sodium bicarbonate solution (2 × 4 mL). The organic 
layer was dried over anhydrous sodium sulfate, filtered and the solvent removed. The residue was 
purified via flash chromatography (SiO2, 1:8 EtOAc/hexanes) to give the desired ester 13c as a 
colorless oil (9.5 mg, 81.1%): 1H NMR (500 MHz, CDCl3) δ 7.93–7.83 (m, 2H), 7.57–7.49 (m, 
2H), 7.36–7.30 (m, 2H), 7.28 (d, J = 7.0 Hz, 1H), 6.87–6.82 (m, 2H), 6.26 (d, J = 2.3 Hz, 1H), 
6.12 (d, J = 2.3 Hz, 1H), 5.66 (td, J = 3.7, 1.5 Hz, 1H), 5.20 (s, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 
3.78 (s, 3H), 3.08–3.04 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 165.6, 163.5, 159.8, 159.1, 155.7, 
138.1, 131.9 (2), 128.5 (2), 128.2 (2), 126.7, 122.6, 113.7 (2), 100.5, 93.5, 92.1, 78.0, 68.4, 55.6 
(3), 26.1; IR (KBr) νmax 2958, 2935, 2839, 1716, 1618, 1255, 1203, 1147, 1101, 1029, 906, 846, 




(5,7-Dimethoxy-2-phenylchroman-3-yl 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylate (13d): 
A solution of 12a (10 mg, 0.035 mmol) in dichloromethane (0.5 mL) was added to a solution of 
3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (18 mg, 0.07 mmol), N-(3-dimethylamino-
propyl)-N′-ethylcarbodiimide hydrochloride (13.5 mg, 0.07 mmol), and 4-dimethylaminopyridine 
(9 mg, 0.07 mmol) in dichloromethane (1 mL) at 0 °C. The resulting mixture was stirred for 6 h at 
rt and then diluted with dichloromethane (5 mL). The organic phase was washed with saturated 
sodium bicarbonate solution (2 × 4 mL), dried over anhydrous sodium sulfate, filtered and 
concentrated. The residue was purified via flash chromatography (SiO2, 1:7 EtOAc/hexanes) to 
give the desired ester 13d (14 mg, 76%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.94–
7.84 (m, 2H), 7.58–7.48 (m, 2H), 7.38–7.31 (m, 3H), 7.31–7.28 (m, 1H), 7.05 (ddd, J = 7.6, 1.6, 
1.0 Hz, 1H), 7.01 (dd, J = 2.6, 1.6 Hz, 1H), 6.96–6.87 (m, 2H), 6.24 (d, J = 2.3 Hz, 1H), 6.11 (d, 
J = 2.3 Hz, 1H), 5.65 (td, J = 3.7, 1.5 Hz, 1H), 5.21 (s, 1H), 3.84 (d, J = 0.7 Hz, 6H), 3.80 (s, 3H), 
3.78 (s, 3H), 3.11–3.04 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 165.5, 160.2, 159.6, 159.3, 158.9, 
155.5, 138.8, 137.9, 132.5, 131.0, 130.2, 129.0 (2), 128.3, 128.1 (2), 126.5, 122.5, 122.0, 115.2, 
112.9, 110.5, 100.2, 93.3, 91.9, 77.8, 68.5, 55.8, 55.4 (2), 55.3, 25.8; IR (KBr) νmax 2933, 1716, 
1616, 1595, 1298, 1245, 1205, 1147, 1108, 1027, 918, 813, 696, 649 cm–1; HRMS (ESI+) m/z [M 




5,7-Dimethoxy-2-phenylchroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (13e): A 
solution of 12a (20 mg, 0.07 mmol) in dichloromethane (0.5 mL) was added to a solution of 4-
acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid (35 mg, 0.14 mmol), N-(3-dimethylamino-
propyl)-N′-ethylcarbodiimide hydrochloride (27 mg, 0.14 mmol) and 4-dimethylaminopyridine 
(25 mg, 0 0.21 mmol) in dichloromethane (1 mL) at 0 °C. The resulting mixture was stirred for 6 
h at rt, diluted with dichloromethane (5 mL) and washed saturated sodium bicarbonate solution (2 
× 4 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent 
removed. The residue was purified via flash chromatography (SiO2, 1:7 EtOAc/hexanes) to give 
the desired ester 13e (20 mg, 55.5%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 
2.1 Hz, 1H), 7.76 (dd, J = 8.4, 2.1 Hz, 1H), 7.50 (dd, J = 7.9, 1.4 Hz, 2H), 7.34 (m, 3H), 7.01 (d, 
J = 8.4 Hz, 1H), 6.25 (d, J = 2.3 Hz, 1H), 6.11 (d, J = 2.3 Hz, 1H), 5.68–5.57 (m, 1H), 5.22–5.15 
(m, 2H), 3.81 (s, 3H), 3.78 (s, 3H), 3.21 (d, J = 7.3 Hz, 2H), 3.05 (d, J = 3.5 Hz, 2H), 2.31 (s, 3H), 
1.75 (d, J = 1.5 Hz, 3H), 1.71–1.62 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 170.10, 155.48, 
154.11, 151.35, (2), 136.7 (2), 128.4 (5), 128.3(5), 126.14, 111.2 (2), 104.6, 102.9, 78.23, 66.5, 
60.7, 60.4 (2), 31.0, 29.7, 26.8, 20.7; IR (KBr) νmax 2925, 1760, 1716, 1593, 1369, 1201, 1147, 
1108, 813 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C31H33O7, 517.2226, found 517.2215. 
 
5,7-Bis(benzyloxy)-2-phenylchroman-3-yl benzoate (13f): A solution of 12b (20 mg, 0.046 
mmol) in dichloromethane (0.5 mL) was added to a solution of benzoic acid (11 mg, 0.09 mmol), 
N-(3-dimethylamino-propyl)-N′-ethylcarbodiimide hydrochloride (18 mg, 0.09 mmol) and 4-
dimethylaminopyridine (12 mg, 0.09 mmol) in dichloromethane (1 mL) at 0 °C. The resulting 
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mixture was stirred for 6 h at rt, diluted with dichloromethane (5 mL) and washed with saturated 
sodium bicarbonate (2 × 4 mL) solution. The organic layer was dried over anhydrous sodium 
sulfate, filtered and concentrated. The residue was purified via flash chromatography (SiO2, 1:7 
EtOAc/hexanes) to give the desired ester 13f (23 mg, 93%) as a colorless oil: 1H NMR (500 MHz, 
CDCl3) δ 7.97–7.91 (m, 2H), 7.55–7.51 (m, 3H), 7.50–7.44 (m, 2H), 7.42–7.30 (m, 13H), 6.38 (d, 
J = 2.3 Hz, 1H), 6.31 (d, J = 2.3 Hz, 1H), 5.72 (ddd, J = 4.4, 2.9, 1.4 Hz, 1H), 5.22 (s, 1H), 5.06 
(d, J = 4.9 Hz, 2H), 5.02 (d, J = 2.6 Hz, 2H), 3.21–3.08 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 
165.7, 158.8, 158.0, 155.6, 137.7, 136.9, 136.8, 133.0, 129.9 (2), 129.7 (2), 128.6 (2), 128.5 (2), 
128.3 (4), 128.1, 128.0, 127.9, 127.6 (2), 127.2 (2), 126.5, 100.9, 94.7, 93.9, 77.8, 70.2, 70.0, 68.6, 
26.1; IR (KBr) νmax 2952, 2923, 2852, 1716, 1616, 1269, 1147, 1107, 1027, 1002, 906, 811, 739 
cm–1; HRMS (ESI+) m/z [M + Na+] calcd for C36H30NaO5, 565.1991, found 565.1998. 
 
5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)chroman-3-yl 3-Methoxybenzoate (13g):A 
solution of 12b (12 mg, 0.03 mmol) in dichloromethane (0.5 mL) was added to a solution of 3-
methoxybenzoic acid (10 mg, 0.06 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (13 mg, 0.06 mmol), and 4-dimethylaminopyridine (8 mg, 0.06 mmol) in 
dichloromethane (1 mL) at 0 °C. The resulting mixture was stirred for 6 h at rt, diluted with 
dichloromethane (5 mL) and washed with saturated sodium bicarbonate (2 × 4 mL) solution. The 
organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was 
purified via flash chromatography (SiO2, 1:3 EtOAc/hexanes) to give the desired ester product 13g 
as a colorless oil (13 mg, 80.4%): 1H NMR (500 MHz, CDCl3) δ 7.56 (dt, J = 7.7, 1.2 Hz, 1H), 
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7.48 (dd, J = 2.7, 1.5 Hz, 1H), 7.30–7.26 (m, 1H) 7.05 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.72 (s, 
2H), 6.26 (d, J = 2.3 Hz, 1H), 6.13 (d, J = 2.4 Hz, 1H), 5.67 (td, J = 3.6, 1.3 Hz, 1H), 5.08 (s, 1H), 
3.81 (s, 3H), 3.81–3.78 (m, 9H), 3.73 (s, 6H), 3.07 (d, J = 3.5 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ 165.4, 159.6, 158.9, 155.5, 153.1 (2), 137.7, 133.3, 131.3, 129.3 (2), 122.0, 119.1, 114.7, 
103.8 (2), 100.1, 93.4, 92.0, 78.0, 68.6, 60.8, 55.9 (2), 55.4 (3), 26.0; IR (KBr) νmax 2937, 1718, 
1622, 1593, 1498, 1456, 1274, 1218, 1124, 1047, 754 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C28H31O9, 511.1968, found 511.1977. 
 
5,7-Bis(benzyloxy)-2-phenylchroman-3-yl 4-Methoxybenzoate (13h): A solution of 12b (20 
mg, 0.046 mmol) in dichloromethane (0.5 mL) was added to a solution of 4-methoxybenzoic acid 
(14 mg, 0.09 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (18 mg, 
0.09 mmol), and 4-dimethylaminopyridine (12 mg,0 0.09 mmol) in dichloromethane (1 mL) at 0 
°C. The resulting mixture was stirred for 6 h at rt and then diluted with dichloromethane (5 mL). 
The organic phase was washed with saturated sodium bicarbonate solution (2 × 4 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified via flash 
chromatography (SiO2, 1:7 EtOAc/hexanes) to give the desired ester 13h (22 mg, 85%) as a 
colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 2.0 Hz, 1H), 7.89–7.85 (m, 1H), 7.53–
7.49 (m, 2H), 7.49–7.44 (m, 2H), 7.44–7.30 (m, 11H), 6.86 (d, J = 2.0 Hz, 1H), 6.85 (d, J = 2.1 
Hz, 1H), 6.37 (d, J = 2.3 Hz, 1H), 6.30 (d, J = 2.3 Hz, 1H), 5.69 (ddd, J = 4.5, 2.9, 1.5 Hz, 1H), 
5.21 (br s, 1 H), 5.06 (d, J = 4.8 Hz, 2H), 5.04–5.00 (m, 2H), 3.83 (s, 3H), 3.19–3.05 (m, 2H); 13C 
NMR (125 MHz, CDCl3) δ 165.4, 163.4, 158.8, 158.0, 155.6, 137.8, 136.9, 136.8, 131.8, 128.6, 
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128.5 (3), 128.3 (3), 128.1 (2), 128.0, 127.9 (2), 127.6 (2), 127.2, 126.5, 122.4, 113.5 (2), 101.0, 
94.7, 93.8, 77.9, 70.2, 69.9, 68.2, 55.4, 26.1; IR (KBr) νmax 2925, 2852, 1716, 1147, 1095, 1026, 
798, cm–1; HRMS (ESI+) m/z [M + Na+] calcd for C37H32NaO6, 595.2097, found 595.2109. 
 
5,7-Bis(benzyloxy)-2-phenylchroman-3-yl 3′,6-Dimethoxy-[1,1′-biphenyl]-3-carboxylate 
(13i): A solution of 12b (20 mg, 0.045 mmol) in dichloromethane (0.5 mL) was added to a solution 
of 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (25 mg, 0.09 mmol), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (18 mg, 0.09 mmol), and 4-
dimethylaminopyridine (11 mg, 0.09 mmol) in dichloromethane (1 mL) at 0 °C. The resulting 
mixture was stirred for 6 h at rt and the diluted with dichloromethane (5 mL). The organic phase 
was washed with saturated sodium bicarbonate solution. The organic layer was dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified via flash 
chromatography (SiO2, 1:4 EtOAc/hexanes) to give the desired ester 13i (27 mg, 90%) as a 
colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.94–7.89 (m, 2H), 7.55–7.52 (m, 2H), 7.48–7.44 (m, 
2H), 7.42–7.29 (m, 12H), 7.09–7.04 (m, 1H), 7.03 (dd, J = 2.6, 1.5 Hz, 1H), 6.96–6.89 (m, 2H), 
6.36 (d, J = 2.3 Hz, 1H), 6.30 (d, J = 2.3 Hz, 1H), 5.68 (ddd, J = 4.3, 3.1, 1.5 Hz, 1H), 5.22 (br s, 
1 H), 5.04 (d, J = 3.5 Hz, 2H), 5.02 (d, J = 2.2 Hz, 2H), 3.85 (s, 3H), 3.84 (s, 3H), 3.20–3.11 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 165.5, 160.2, 159.2, 158.7, 157.9, 155.6, 138.8, 137.9, 136.9, 
136.8, 132.5, 131.0, 130.2, 129.0, 128.6 (3), 128.5 (2), 128.3, 128.1, 128.0, 127.9 (2), 127.6 (2), 
127.2, 126.5, 122.4, 122.0, 115.2 (2), 112.9, 110.5, 101.0, 94.7, 93.8, 77.8, 70.2, 69.9, 68.5, 55.8, 
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55.3, 26.0; IR (KBr) νmax 2952, 2923, 2852, 1716, 1558, 1456, 1245, 1145, 1101, 1026, 798 cm
–1; 
HRMS (ESI+) m/z [M + H+] calcd for C44H39O7, 679.2696, found 679.2682. 
 
5,7-Bis(benzyloxy)-2-phenylchroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoate 
(13j): A solution of 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid (34 mg, 0.138 mmol) in 
THF (5 mL) was treated with thionyl chloride (20 μL, 0.276 mmol). The resulting solution was 
heated at 70 °C for 3 h, cooled to rt, and concentrated. The residue was dissolved in 
dichloromethane (0.5 mL) and added to a solution of 12b (20 mg, 0.046 mmol) and 4-
dimethylaminopyridine (22 mg, 0.184 mmol) in dichloromethane (1 mL) 0 °C. The resulting 
mixture was stirred for 6 h at rt. The solvent was removed, and the residue was purified via flash 
chromatography (SiO2, 1:7 EtOAc/hexanes) to give the ester 13j (22.5 mg, 83.5%) as a colorless 
oil: 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 2.2 Hz, 1H), 7.69 (dd, J = 8.4, 2.2 Hz, 1H), 7.46–
7.35 (m, 5H), 7.34–7.22 (m, 10H), 6.94 (d, J = 8.4 Hz, 1H), 6.28 (d, J = 2.3 Hz, 1H), 6.21 (d, J = 
2.3 Hz, 1H), 5.58 (ddd, J = 4.3, 3.1, 1.5 Hz, 1H), 5.17–5.06 (m, 2H), 5.00–4.89 (m, 4H), 3.13 (d, 
J = 7.5 Hz, 2H), 3.04 (t, J = 2.6 Hz, 2H), 2.23 (s, 3H), 1.67 (q, J = 1.3 Hz, 3H), 1.60 (d, J = 1.3 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 168.9, 165.1, 158.8, 158.0, 155.5, 152.5, 137.8, 136.9, 
136.8, 134.0, 133.7, 131.9, 128.7, 128.6 (2), 128.5 (2), 128.4 (2), 128.1, 128.0, 127.9 (2), 127.8 
(2), 127.6 (2), 127.2, 126.4, 122.3, 120.8, 100.8, 94.6, 93.8, 77.7, 70.2, 70.0, 68.7, 29.7, 28.5, 26.1, 
20.9, 17.84; IR (KBr) νmax 2921, 2852, 1760, 1716, 1616, 1373, 1257, 1201, 1149, 1114, 1027, 




5,7-Dihydroxy-2-phenylchroman-3-yl Benzoate (14a): Compound 13f (20 mg, 0.036 mmol) and 
palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a 
hydrogen atmosphere. The suspension was filtered through a small pad of celite. The eluent was 
concentrated and the residue purified by flash chromatography (SiO2, Acetone/dichloromethane 
1:12) to give 14a (12 mg, 90%) as a colorless oil: 1H NMR (500 MHz, CD3OD) δ 7.87–7.79 (m, 
2H), 7.56–7.47 (m, 3H), 7.43–7.34 (m, 2H), 7.31–7.19 (m, 3H), 6.01 (d, J = 2.3 Hz, 1H), 5.98 (d, 
J = 2.3 Hz, 1H), 5.66 (ddd, J = 4.6, 2.4, 1.3 Hz, 1H), 5.23 (s, 1H), 3.08 (dd, J = 17.5, 4.6 Hz, 1H), 
2.93 (ddd, J = 17.6, 2.5, 0.9 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 167.1, 158.0, 157.9, 157.1, 
139.9, 134.2, 131.2, 130.5, 129.5 (2), 129.1 (2), 128.8 (2), 127.5 (2), 99.1, 96.7, 95.8, 78.6, 70.6, 
26.7; IR (KBr) νmax 3427, 2921, 2848, 1701, 1560, 1473, 1271, 1097 cm
–1; HRMS (ESI+) m/z [M 
+ H+] calcd for C22H19O5, 363.1232, found 363.1241. 
 
5,7-Dihydroxy-2-phenylchroman-3-yl 3-Methoxybenzoate (14b): Compound 13g (20 mg, 
0.034 mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred 
for 18 h under a hydrogen atmosphere. The suspension was filtered through a small pad of celite. 
The eluent was concentrated and the residue purified by flash chromatography (SiO2, 
acetone/dichloromethane 1:10) to give 14b (20 mg, 89%) as a colorless oil: 1H NMR (500 MHz, 
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CDCl3) δ 7.50 (dt, J = 7.7, 1.2 Hz, 3H), 7.41 (dd, J = 2.7, 1.5 Hz, 1H), 7.38–7.30 (m, 2H), 7.31–
7.27 (m, 2H), 7.05 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.17 (d, J = 2.4 Hz, 1H), 5.99 (d, J = 2.4 Hz, 
1H), 5.67 (ddd, J = 4.4, 2.9, 1.5 Hz, 1H), 5.21 (br s, 1 H), 5.18 (br s, 1 H), 5.05 (br s, 1 H), 3.79 
(s, 3H), 3.22–3.00 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 166.0, 159.6, 156.2, 155.5, 155.3, 
137.8, 131.3, 129.6, 128.5, 128.4 (2), 126.6 (2), 122.3, 119.7, 114.4, 99.1, 96.5, 96.2, 77.8, 68.9, 
55.6, 25.7; IR (KBr) νmax 3359, 2923, 2852, 1714, 1631, 1461, 1274, 1103, 754, cm
–1; HRMS 
(ESI-) m/z [M – H+] calcd for C23H19O6, 391.1182, found 391.1181. 
 
5,7-Dihydroxy-2-phenylchroman-3-yl 4-Methoxybenzoate (14c): Compound 13h (16 mg, 
0.027 mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred 
for 18 h under a hydrogen atmosphere. The suspension was filtered through a small pad of Celite. 
The eluent was concentrated and the residue purified by flash chromatography (SiO2, 
acetone/dichloromethane 1:10) to afford 14c (10 mg, 91%) as a colorless oil: 1H NMR (500 MHz, 
(CD3)2CO) δ 8.20 (d, J = 1.3 Hz, 1H), 8.00 (d, J = 1.2 Hz, 1H), 7.72–7.67 (m, 2H), 7.51–7.41 (m, 
2H), 7.25–7.16 (m, 2H), 7.16–7.08 (m, 1H), 6.84–6.79 (m, 2H), 5.95 (s, 2H), 5.53 (ddd, J = 4.7, 
2.4, 1.4 Hz, 1H), 5.21 (s, 1H), 3.71 (s, 3H), 2.99 (dd, J = 17.7, 4.4 Hz, 1H), 2.87 (ddd, J = 17.4, 
2.4, 0.9 Hz, 1H); 13C NMR (125 MHz, (CD3)2CO) δ 165.7, 164.6, 158.0, 157.6, 156.9, 139.9, 
132.3 (2), 129.0 (2), 128.6 (2), 127.5, 123.4, 114.7 (2), 98.9, 96.7, 95.9, 78.2, 69.6, 56.0, 26.6; IR 
(KBr) νmax 3369, 2925, 2852, 1714, 1604, 1512, 1456, 1257, 1168, 1101, 1029, 667 cm
–1; HRMS 




5,7-Dihydroxy-2-phenylchroman-3-yl 3′,6-Dimethoxy-[1,1′-biphenyl]-3-carboxylate (14d): 
Compound 13i (20 mg, 0.029 mmol) and palladium/carbon (10%) were suspended in 
tetrahydrofuran (2 mL) and stirred for 18 h under hydrogen atmosphere. The suspension was 
filtered through a small pad of Celite. The eluent was concentrated and the residue purified by 
flash chromatography (SiO2, acetone/dichloromethane 1:9) to give 14d (13 mg, 89%) as a colorless 
oil: (500 MHz, CDCl3) 
1H NMR δ 7.83–7.78 (m, 2H), 7.45–7.39 (m, 2H), 7.31–7.22 (m, 3H), 
7.23–7.20 (m, 1H), 6.98 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 6.93 (dd, J = 2.6, 1.6 Hz, 1H), 6.88–6.80 
(m, 2H), 6.08 (d, J = 2.2 Hz, 1H), 5.91 (d, J = 2.4 Hz, 1H), 5.57 (tt, J = 3.3, 1.5 Hz, 1H), 5.13 (s, 
1H), 5.01 (s, 1H), 4.91 (s, 1H), 3.76 (d, J = 1.4 Hz, 6H), 3.08–2.95 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 165.8, 160.5, 159.4, 156.2, 155.5, 155.3, 138.9, 137.9, 132.7, 131.2, 130.5, 129.2, 128.5 
(2), 128.3 (2), 126.7, 122.5, 122.2, 115.5, 113.1, 110.7, 99.2, 96.6, 96.2, 77.9, 68.6, 56.0, 55.5, 
25.7; IR (KBr) νmax 3374, 2952, 2852, 1714, 1558, 1456, 1271, 1101, 1026 cm
–1; HRMS (ESI+) 
m/z [M + H+] calcd for C30H27O7, 499.1757, found 499.1744. 
 
5,7-Dihydroxy-2-phenylchroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (14e): A 
solution of palladium acetate (2 mg, 0.008 mmol), trimethylamine (13 μL, 0.09 mmol), and 
triethylsilane (64 μL, 0.405) in dichloromethane (0.8 mL) was stirred for 15 min before the 
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addition of 13j (30 mg, 0.045 mmol) in dichloromethane (0.4 mL). The resulting mixture was 
stirred for 15 h, quenched with saturated ammonium chloride (2 mL), and extracted with diethyl 
ether (3 × 4 mL). The combined organic layers were washed with saturated sodium chloride 
solution and dried over anhydrous Na2SO4. The solvent was removed and residue purified via flash 
chromatography (SiO2, 5:95 MeOH/DCM) to give 14e (4 mg, 18.9%) as a colorless oil: 
1H NMR 
(500 MHz, CDCl3) δ 7.71–7.63 (m, 2H), 7.51–7.45 (m, 2H), 7.33–7.25(m, 3H), 6.69 (d, J = 8.2 
Hz, 1H), 6.42 (d, J = 2.2 Hz, 1H), 6.22 (d, J = 2.2 Hz, 1H), 5.68–5.56 (m, 2H), 5.26 (m, 2H), 5.13 
(d, J = 1.2 Hz, 1H), 3.32 (d, J = 7.2 Hz, 2H), 3.06 (t, J = 3.2 Hz, 2H), 2.30 (s, 3H), 1.81–1.72 (m, 
6H); 13C NMR (125 MHz, CDCl3) δ 170.0, 165.8, 158.9, 156.0, 154.9, 150.0, 137.7, 135.9, 132.2, 
130.0 (2), 128.5 (2), 128.3 (2), 126.9, 126.6, 122.2, 121.1, 115.7, 104.7, 103.0, 101.9, 78.0, 67.9, 
29.6, 26.1 (2), 21.4, 18.1; IR (KBr) νmax 3432, 2922, 1701, 1562, 1471, 1101, 1271, 1093 cm
–1; 
HRMS (ESI-) m/z [M – H+] calcd for C29H27O7, 487.1757, found 487.1755. 
 
3-(Benzyloxy)phenol (15): A solution of resorcinol (4g, 36.3 mmol), potassium carbonate (12.5 
g, 90.7 mmol), and benzyl bromide (4.75 mL, 40 mmol) in acetonitrile (130 mL) heated as reflux 
for 12 h. Solvent was removed, water (100 mL) was added, and the mixture was extracted with 
ethyl acetate (3 × 100 mL). The combined organic layers were washed with saturated sodium 
chloride solution (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated. The residue 
was purified by flash chromatography (SiO2, 1:6 EtOAc/Hexaes) to afford 17 as colorless oil (3.5 
g, 21.7%): 1H NMR (500 MHz, CDCl3) δ 7.48 −7.31 (m, 5H), 7.15 (t, J = 8.2 Hz, 1H), 6.58 (ddd, 
J = 8.3, 2.4, 0.9 Hz, 1H), 6.50 (t, J = 2.3 Hz, 1H), 6.45 (ddd, J = 8.0, 2.4, 0.9 Hz, 1H), 5.05 (s, 2H); 
4.71 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 160.37, 156.83, 137.06, 130.39, 128.81, 128.20 (2), 
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127.69 (2), 108.21, 107.56, 102.63, 70.22; IR (KBr) νmax 3309, 2925, 2869, 1595, 1488, 1456, 
1380, 1284, 1215, 1147, 1026, 837, 763, 736 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C13H13O2, 
201.0916; found 201.0916. 
 
(((5-(Allyloxy)-1,3-phenylene)bis(oxy))bis(methylene))dibenzene (16a): A solution of 1b (1.2 
g, 3.9 mmol), potassium carbonate (2.17g, 15.7 mmol), and allyl bromide (0.44 mL, 5.1 mmol) in 
dimethylformamide (40 mL) was heated at 90 °C for 12 h. The reaction mixture was cooled to rt, 
diluted with ethyl acetate (200 mL), and washed with water (3 × 100 mL) and then saturated 
sodium chloride solution (100 mL). The organic phase was dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2 1:9 
EtOAc/hexanes) to give 16a (1.62 g, 89%) as a light yellow oil: 1H NMR (400 MHz, CDCl3) δ 
7.51–7.29 (m, 10H), 6.27 (t, J = 2.2 Hz, 1H), 6.21 (d, J = 2.1 Hz, 2H), 6.04 (ddt, J = 17.2, 10.6, 
5.4 Hz, 1H), 5.40 (dq, J = 17.3, 1.6 Hz, 1H), 5.29 (dq, J = 10.5, 1.4 Hz, 1H), 5.01 (s, 4H), 4.49 
(dt, J = 5.4, 1.5 Hz, 2 H); 13C NMR (125 MHz, CDCl3) δ 160.8 (2), 160.6, 137.0 (2), 133.3, 128.8 
(4), 128.2 (2), 127.8 (4), 118.0, 95.0, 94.9 (2), 70.3 (2), 69.1; IR (KBr) νmax 3390, 2975, 2908, 
2864, 1622, 1591, 1506, 1434, 1213, 1159, 1110, 1066, 1043, 933, 810, 703 cm–1; HRMS (ESI+) 
m/z [M + H+] calcd for C23H23O3, 347.1647, found 347.1647. 
 
1-(Allyloxy)-3-(benzyloxy)benzene (16b): A solution of 15 (2.45g, 12.3 mmol), potassium 
carbonate (6.62g, 49.2 mmol), allyl bromide (1.34 mL, 16 mmol), and dimethylformamide (60 
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mL) was stirred for 12 h at 90 °C. The reaction mixture was cooled to rt, diluted with EtOAc (200 
mL), and washed with water (3 × 100 mL times) and saturated sodium chloride solution (100 mL). 
The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:9 EtOAc/hexanes) to give 16b (2.8g, 
95.2%) as light yellow oil: 1H NMR (500 MHz, CDCl3) δ 7.47–7.43 (m, 2H), 7.42–7.38 (m, 2H), 
7.37–7.32 (m, 1H), 7.19 (t, J = 8.1 Hz, 1H), 6.63–6.57 (m, 2H), 6.55 (ddd, J = 8.2, 2.3, 0.9 Hz, 
1H), 6.06 (ddt, J = 17.2, 10.6, 5.3 Hz, 1H), 5.42 (dq, J = 17.2, 1.6 Hz, 1H), 5.29 (dq, J = 10.5, 1.4 
Hz, 1H), 5.06 (s, 2H), 4.53 (dt, J = 5.3, 1.5 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 160.2, 160.0, 
137.3, 133.4, 130.1, 128.8 (2), 128.2 (2), 127.7, 117.9, 107.5, 107.4, 102.3, 70.2, 69.0; IR (KBr) 
νmax 3031, 2866, 1591, 1490, 1454, 1379, 1288, 1261, 1178, 1149, 1039, 1027, 927, 835, 734, 696 
cm–1; HRMS (ESI+) m/z [M + Na+] calcd for C16H16NaO2, 263.1048, found 263.1053. 
 
2-Allyl-3,5-bis(benzyloxy)phenol (17a): Compound 16a (1.62 g, 4.66 mmol) was dissolved in 
N,N-diethylaniline (23 mL) and heated at 210 °C for 12 h. The reaction mixture was cooled to rt, 
diluted with ethyl acetate (200 mL), and washed with 1 N HCl (3 × 100 mL) and then saturated 
sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:8 EtOAc/hexanes) to 
afford 17a (1.215g, 75%) as a pale yellow oil: 1H NMR (400 MHz, CDCl3) δ 7.47–7.32 (m, 10H), 
6.27 (d, J = 2.3 Hz, 1H), 6.19 (d, J = 2.3 Hz, 1H), 5.98 (ddt, J = 16.3, 10.0, 6.1 Hz, 1H), 5.18 (q, 
J = 1.8 Hz, 1H), 5.13 (dq, J = 5.0, 1.7 Hz, 1H), 5.07 (s, 1H), 5.02 (s, 2H), 5.01 (s, 2H), 3.46 (dt, J 
= 6.2, 1.7 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 161.9, 160.5, 158.3, 137.0 (2), 136.9, 128.8 
(4), 128.2 (2), 127.8 (4), 116.0, 106.3, 95.0, 92.9, 70.3, 69.1, 26.3; IR (KBr) νmax 2925, 2867, 1596, 
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1456, 1375, 1213, 1153, 1058, 927, 817, 736 cm–1; HRMS (ESI-) m/z [M – H+] calcd for C23H21O3, 
345.1491, found 345.1503. 
 
3-(2,4-Bis(benzyloxy)-6-hydroxyphenyl)propane-1,2-diol (18a): A solution of 17a (1.062g, 3.1 
mmol), osmium tetraoxide (0.03 mmol, 4% aqueous solution), and N-methylmorphline N-oxide 
(575 mg, 4.9 mmol) in tetrahydrofuran-water (13 mL-9 mL) was stirred for 12 h before quenching 
with 10% aqueous sodium metabisulfite. The aqueous layer was extracted with ethyl acetate (3 × 
50 mL), and the combined organic layers were washed with saturated sodium chloride solution 
(100 mL). The solvent was removed and the residue purified by flash chromatography (SiO2, 2:5 
EtOAc/hexanes) to afford 18a (744 mg, 64%) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) 
δ 8.77 (s, 1H), 7.50 (dd, J = 8.1, 1.4 Hz, 2H), 7.48–7.44 (m, 2H), 7.39 (td, J = 7.9, 7.5, 1.5 Hz, 
4H), 7.36–7.30 (m, 2H), 6.32 (d, J = 2.3 Hz, 1H), 6.20 (d, J = 2.3 Hz, 1H), 5.10 (s, 2H), 5.05 (s, 
2H), 4.65 (d, J = 5.2 Hz, 1H), 3.91 (br s, 1 H), 3.81 (d, J = 6.1 Hz, 1H), 3.53 (br s, 1 H), 3.41 (dd, 
J = 11.3, 6.4 Hz, 1H), 2.96 (dd, J = 14.1, 5.0 Hz, 1H), 2.79 (dd, J = 14.1, 6.8 Hz, 1H); 13C NMR 
(125 MHz, (CD3)2CO) δ 159.9, 159.1 (2), 138.7 (2), 129.4 (2), 129.3 (2), 128.9, 128.7, 128.6, 
128.5, 128.2, 107.6, 96.8, 96.8, 93.6, 74.1, 70.9, 70.5, 66.6, 27.8; IR (KBr) νmax 3298, 1616, 1598, 
1452, 1436, 1375, 1217, 1147, 1105, 1045, 1027, 908, 813, 736, 696, 649 cm–1; HRMS (ESI+) 
m/z [M + H+] calcd for C23H25O5, 381.1702, found 381.1709. 
 
3-(4-(Benzyloxy)-2-hydroxyphenyl)propane-1,2-diol (18b): Compound 16b (2.7g, 11.23 mmol) 
was dissolved in N,N-diethylaniline (70 mL) and heated at 210 °C for 12 h. The reaction mixture 
102 
 
was cooled to rt, diluted with ethyl acetate (200 mL), and washed with 1 N HCl (3 × 100 mL) and 
then with saturated sodium chloride solution. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The residue was purified by flash chromatography (SiO2, 1:8 
EtOAc/hexanes) to give a mixture of 17b and 17c. A solution of the mixture of 17b and 17c (2.02g, 
8.41 mmol), osmium tetraoxide (0.168 mmol, 4% aqueous solution), and N-methylmorphline N-
oxide (1.67g, 14.29 mmol) in tetrahydrofuran–water (18 mL–12 mL) was stirred for 12 h before 
quenching with 10% aqueous sodium metabisulfite. The aqueous phase was extracted with ethyl 
acetate (3 × 200 mL), the combined organic layers were washed with saturated sodium chloride 
solution, and solvent was removed. The residue was purified by flash chromatography (1:5 
acetone–DCM) to afford 18b (1.24g) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 7.49–
7.43 (m, 2H), 7.427.35 (m, 2H), 7.34–7.27 (m, 1H), 6.99 (d, J = 8.3 Hz, 1H), 6.49 (d, J = 2.6 Hz, 
1H), 6.45 (dd, J = 8.2, 2.5 Hz, 1H), 5.06 (s, 2H), 3.90 (tt, J = 6.9, 4.4 Hz, 1H), 3.54–3.49 (m, 1H), 
3.47–3.40 (m, 1H), 2.83–2.75 (m, 1H), 2.74–2.66 (m, 1H); 13C NMR (125 MHz, (CD3)2CO) δ 
159.6, 157.7, 138.6, 132.6, 129.2, 129.1, 128.4 (2), 128.2, 118.8, 106.7, 103.8, 74.2, 70.2, 66.2, 
35.3; IR (KBr) νmax 3311, 2931, 1618, 1585, 1506, 1454, 1279, 1286, 1166, 1108, 1024, 842, 736, 
696 cm–1; HRMS (ESI-) m/z [M – H+] calcd for C16H17O4, 273.1127, found 273.1129. 
 
3-(2-(Benzyloxy)-6-hydroxyphenyl)propane-1,2-diol (18c): A solution of the mixture of 17b 
and 17c (2.02g, 8.41 mmol), osmium tetraoxide (0.168 mmol, 4% aqueous solution), and N-
methylmorphline N-oxide (1.67g, 14.29 mmol) in tetrahydrofuran–water (18 mL–12 mL) was 
stirred 12 h before quenching with 10% aqueous sodium metabisulfite. The aqueous phase was 
extracted with ethyl acetate (3 × 200 mL), and the combined organic layers were washed with 
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saturated sodium chloride solution. The solvent was removed and the residue purified by flash 
chromatography (1:5 acetone–DCM) to afford 18c (0.8 g) as a colorless oil which was used as is 
in the next step: 1H NMR (500 MHz, (CD3)2CO) δ 8.70 (s, 1H), 7.53–7.48 (m, 2H), 7.42–7.35 (m, 
2H), 7.35–7.29 (m, 1H), 7.02 (t, J = 8.2 Hz, 1H), 6.59 (dd, J = 8.3, 1.0 Hz, 1H), 6.52 (dd, J = 8.1, 
1.0 Hz, 1H), 5.10 (s, 2H), 4.86–4.48 (m, 1H), 3.97 (tdd, J = 6.7, 5.3, 4.0 Hz, 1H), 3.83 (br s, 1 H), 
3.55 (dd, J = 11.2, 4.0 Hz, 1H), 3.43 (dd, J = 11.2, 6.6 Hz, 1H), 3.04 (dd, J = 13.8, 5.3 Hz, 1H), 
2.89 (dd, J = 13.8, 6.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 157.47, 156.58, 136.82, 128.69 
(2), 128.10 (2), 127.40 (2), 112.99, 110.56, 104.13, 72.83, 70.54, 65.24, 26.59; IR (KBr) νmax 3334, 
2929, 1618, 1583, 1506, 1454, 1279, 1286, 1217, 1166, 1045, 1025, 849 cm–1; HRMS (ESI-) m/z 
[M – H+] calcd for C16H17O4, 273.1127, found 273.1127. 
 
3-(2,4-Bis(benzyloxy)-6-hydroxyphenyl)-2-hydroxypropyl 4-Methylbenzenesulfonate (19a): 
Pyridine (0.46 mL, 5.8 mmol) was added to a solution of 18a (500 mg, 1.37 mmol) and p-
toluenesulfonyl chloride (282 mg, 1.5 mmol) in dichloromethane (14 mL) at 0 °C. The resulting 
mixture was stirred for 12 h at rt before quenching with 2 N HCl (20 mL). The aqueous layer was 
extracted with dichloromethane (2 × 30 mL). The combined organic layers were washed with 
saturated sodium chloride solution, dried over anhydrous Na2SO4, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 2:5 EtOAc/hexanes) to give 19a (427 mg, 
58%) as a pale yellow oil: 1H NMR (500 MHz, (CD3)2CO) δ 8.51 (s, 1H), 7.72–7.67 (m, 2H), 
7.50–7.44 (m, 4H), 7.43–7.37 (m, 6H), 7.37–7.30 (m, 2H), 6.31 (d, J = 2.4 Hz, 1H), 6.19 (d, J = 
2.3 Hz, 1H), 5.07 (s, 2H), 5.04 (s, 2H), 4.84 (d, J = 4.5 Hz, 1H), 4.11–3.94 (m, 2H), 3.95–3.70 (m, 
1H), 2.42 (s, 3H); 13C NMR (125 MHz, (CD3)2CO) δ 160.0, 159.1, 158.0, 145.7, 138.4 (2), 130.8 
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(2), 129.4 (2), 129.3 (2), 128.6 (5), 128.5 (2), 128.1 (2), 106.1, 96.2, 93.3, 75.2, 70.6, 70.4, 70.2, 
28.0, 21.5; IR (KBr) νmax 3334, 2925, 1625, 1506, 1361, 1174, 1108, 1095, 975 cm
–1; HRMS 
(ESI+) m/z [M + H+] calcd for C30H31O7S, 535.1790, found 535.1773. 
 
3-(4-(Benzyloxy)-2-hydroxyphenyl)-2-hydroxypropyl 4-Methylbenzenesulfonate (19b): 
Pyridine (0.46 mL, 5.8 mmol) was added to a solution of 18b (500 mg, 1.37 mmol) and p-
toluenesulfonyl chloride (282 mg, 1.5 mmol) in dichloromethane (14 mL) at 0 °C. The resulting 
mixture was stirred for 12 h at rt before quenching with 2 N HCl (20 mL). The aqueous layer was 
extracted with dichloromethane (2 × 30 mL). The combined organic layers were washed with 
saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 2:5 EtOAc/hexanes) to 
give 19b (0.97g, 58.6%) as a pale yellow oil: 1H NMR (500 MHz, (CD3)2CO) δ 8.50 (br s, 1 H), 
7.82–7.74 (m, 2H), 7.50–7.43 (m, 4H), 7.43–7.2 (m, 3H), 6.92 (d, J = 8.2 Hz, 1H), 6.48 (d, J = 
2.5 Hz, 1H), 6.42 (dd, J = 8.3, 2.5 Hz, 1H), 5.03 (s, 2H), 4.17–3.97 (m, 3H), 3.89 (dd, J = 9.9, 6.7 
Hz, 1H), 2.76–2.67 (m, 2H), 2.45 (s, 3H); 13C NMR (125 MHz, (CD3)2CO) δ 159.8 (2), 145.8, 
138.6, 134.1, 132.8, 130.9, 130.8, 129.3 (2), 128.8, 128.7, 128.6 (2), 117.56, 128.4, 106.8, 103.5, 
74.3, 70.4, 70.3, 34.9, 21.5; IR (KBr) νmax 3348, 2928, 1627, 1361, 1174, 1108, 1096 cm
–1; HRMS 




3-(2-(Benzyloxy)-6-hydroxyphenyl)-2-hydroxypropyl 4-Methylbenzenesulfonate (19c): 
Pyridine (0.47 mL, 15.4 mmol) was added to a solution of 28c (410 mg, 1.5 mmol) and p-
toluenesulfonyl chloride (310 mg, 1.7 mmol) in dichloromethane (14 mL) at 0 °C. The resulting 
mixture was stirred for 12 h at rt before quenching with 2 N HCl (20 mL). The aqueous layer was 
extracted with dichloromethane (2 × 30 mL). The combined organic layers were washed with 
saturated sodium chloride solution (40 mL), dried over anhydrous Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 2:5 EtOAc/hexanes) to 
give 19c (367 mg, 57%) as a pale yellow oil and was used as is in the next step. 
 
5,7-Bis(benzyloxy)chroman-3-ol (20a): Potassium carbonate (115 mg, 0.83 mmol) was added to 
a solution of 19a (277 mg, 0.58 mmol) in methanol (2.6 mL), and the resulting mixture was stirred 
for 6 h at rt. Methanol was removed, and the residue was partitioned between water (5 mL) and 
dichloromethane (5 mL) The aqueous layer was extracted with dichloromethane (2 × 5 mL). The 
combined organic layers were washed with saturated sodium chloride solution, dried over 
anhydrous Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:5 EtOAc/hexanes) to give 20a (86 mg, 46%) as a colorless oil: 
1H NMR (500 MHz, 
CDCl3) δ 7.45–7.37 (m, 8H), 7.34 (ddt, J = 7.4, 4.0, 1.7 Hz, 2H), 6.26 (d, J = 2.3 Hz, 1H), 6.18 
(d, J = 2.3 Hz, 1H), 5.02 (s, 2H), 5.01 (s, 2H), 4.33–4.15 (m, 1H), 4.15–3.97 (m, 2H), 2.93 (dd, J 
= 17.0, 5.0 Hz, 1H), 2.75 (dd, J = 17.0, 4.5 Hz, 1H), 1.89 (br s, 1 H); 13C NMR (125 MHz, CDCl3) 
δ 158.9, 158.4, 155.2, 137.1, 137.1, 128.8 (2), 128.7, 128.7, 128.2, 128.1, 127.8, 127.7, 127.4 (2), 
101.6, 94.8, 94.0, 70.3, 70.1, 69.8, 63.2, 28.4; IR (KBr) νmax 3392, 2925, 2871, 1616, 1591, 1496, 
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1456, 1145, 1122, 1062, 1027, 811, 696 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C23H23O4, 
363.1596, found 363.1596. 
 
7-(Benzyloxy)chroman-3-ol (20b): Potassium carbonate (440 mg, 3.18 mmol) was added to a 
solution of 19b (830 mg, 1.98 mmol) in methanol (5 mL), and the resulting solution was stirred 
for 6 h at rt. Methanol was removed, and the residue was partitioned between water (10 mL) and 
dichloromethane (10 mL). The aqueous layer was extracted with dichloromethane (2 × 10 mL). 
The combined organic layers were washed with saturated sodium chloride solution, dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:5 EtOAc/hexanes) to give the desired product 20b (200 mg, 40%) as a 
colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.51–7.30 (m, 5H), 7.04 (d, J = 8.0 Hz, 1H), 6.52–
6.45 (m, 2H), 5.03 (s, 2H), 4.98–4.80 (m, 1H), 3.84 (dd, J = 12.0, 3.3 Hz, 1H), 3.74 (dd, J = 12.0, 
6.4 Hz, 1H), 3.19 (dd, J = 15.1, 9.4 Hz, 1H), 2.94 (ddd, J = 15.1, 7.2, 1.2 Hz, 1H), 2.07 (br s, 1 
H); 13C NMR (125 MHz, CDCl3) δ 161.4, 159.7, 137.2, 128.8 (2), 128.1 (2), 127.6, 125.2, 118.9, 
107.3, 97.5, 84.3, 70.5, 65.2, 30.8; IR (KBr) νmax 3382, 2927, 1614, 1494, 1145, 1029 cm
–1; HRMS 
(ESI+) m/z [M + Na+] calcd for C16H16NaO3, 279.0097, found 279.1002. 
 
5-(Benzyloxy)chroman-3-ol (20c): Potassium carbonate (262 mg, 0.61 mmol) was added to a 
solution of 19c (135 mg, 0.98 mmol) in methanol (2 mL), and the resulting solution was stirred 
for 6 h at rt. Methanol was removed, the residue was partitioned between water (5 mL) and 
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dichloromethane (5 mL) The aqueous layer was extracted with dichloromethane (2 × 5 mL). The 
combined organic layers were washed with saturated sodium chloride solution, dried over 
anhydrous Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:5 EtOAc/hexanes) to give the desired product 20c (70 mg, 45%) as a colorless oil: 
1H 
NMR (500 MHz, CD3OD) δ 7.49–7.43 (m, 2H), 7.37 (ddd, J = 7.7, 6.4, 1.2 Hz, 2H), 7.30 (td, J = 
7.1, 1.4 Hz, 1H), 7.01 (t, J = 8.2 Hz, 1H), 6.55 (dd, J = 8.3, 1.1 Hz, 1H), 6.43 (dd, J = 8.1, 1.1 Hz, 
1H), 5.07 (s, 2H), 4.15 (qd, J = 5.8, 2.6 Hz, 1H), 4.08 (ddd, J = 10.8, 2.7, 1.5 Hz, 1H), 3.88 (ddd, 
J = 10.7, 6.4, 1.5 Hz, 1H), 2.99 (ddd, J = 17.3, 5.3, 1.6 Hz, 1H), 2.66 (dd, J = 17.1, 5.9 Hz, 1H); 
13C NMR (125 MHz, CD3OD) δ 158.8, 156.3, 139.0, 129.5, 128.8, 128.3, 128.1 (2), 110.5, 110.3, 
104.8 (2), 71.0, 70.3, 63.7, 29.3; IR (KBr) νmax 3388, 2928, 1616, 1591, 1496, 1146, 1061, 1027 
cm–1; HRMS (ESI+) m/z [M + Na+] calcd for C16H16NaO3, 279.0997, found 279.0993. 
 
5,7-Dihydroxychroman-3-yl Benzoate (21a): A solution of 20a (14 mg, 0.04 mmol) in 
dichloromethane (0.5 mL) was added to a stirred solution of benzoic acid (10 mg, 0.08 mmol), 
N,N′-dicyclohexylcarbodiimide (17 mg, 0.08 mmol), and 4-dimethylaminopyridine (4.8 mg, 0.04 
mmol) in dichloromethane (1 mL) at 0 °C. The resulting solution was stirred for 6 h at rt and then 
filtered. The eluent was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 
mL) and then saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers 
were washed with saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:4 
EtOAc/hexanes) to afford 5,7-bis(benzyloxy)chroman-3-yl benzoate (16.2 mg, 90%) as a colorless 
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oil, which was used as is for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 8.10–7.99 (m, 2H), 
7.65–7.48 (m, 1H), 7.47–7.29 (m, 11H), 6.28 (d, J = 2.3 Hz, 1H), 6.22 (d, J = 2.3 Hz, 1H), 5.54 
(d, J = 6.6 Hz, 1H), 4.32 (ddd, J = 11.4, 4.9, 1.8 Hz, 1H), 4.26–4.17 (m, 1H), 3.10 (ddd, J = 17.5, 
5.4, 1.2 Hz, 1H), 3.00–2.90 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 166.2, 158.9, 158.1, 
155.4,137.1 (2), 133.3, 130.0, 128.8, 128.8 (2), 128.5 (3), 128.2, 128.1, 127.8 (3), 127.4 (2), 101.4, 
94.8, 93.9, 70.4, 70.2, 67.0, 66.1, 25.3. 5,7-Bis(benzyloxy)chroman-3-yl benzoate (16.2 mg, 0.034 
mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 
h under a hydrogen atmosphere. The suspension was filtered through a small pad of celite. The 
eluent was concentrated and the residue purified by flash chromatography (SiO2, 1:1 
EtOAc/hexanes) to give 21a (8 mg, 81.6%) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 
8.32 (s, 1H), 8.05 (s, 1H), 8.02–7.91 (m, 2H), 7.71–7.59 (m, 1H), 7.57 - 7.44 (m, 2H), 6.05 (d, J 
= 2.3 Hz, 1H), 5.91 (d, J = 2.3 Hz, 1H), 5.60–5.41 (m, 1H), 4.34–4.31 (m, 1H), 4.23–4.20 (m, 
1H), 3.02 (ddd, J = 17.1, 5.3, 1.2 Hz, 1H), 2.90–2.83 (m, 1H); 13C NMR (125 MHz, (CD3)2CO) δ 
166.4, 157.9, 157.5, 156.5, 134.1, 131.3 (2), 130.3 (2), 129.5, 99.2, 96.5, 95.8, 67.4, 67.3, 25.6; IR 
(KBr) νmax 3385, 2933, 2840, 1716, 1622, 1593, 1496, 1452, 1272, 1201, 1145, 1056, 813, 711 
cm–1; HRMS (ESI+) m/z [M + H+] calcd for C16H14O5, 287.0919, found 287.0912. 
 
5,7-Dihydroxychroman-3-yl 3-Methoxybenzoate (21b): A solution of 20a (14 mg, 0.04 mmol) 
in dichloromethane (0.5 mL) was added to a stirred solution of 3-methoxybenzoic acid (12 mg, 
0.08 mmol), N,N′-dicyclohexylcarbodiimide (17 mg, 0.08 mmol), and 4-dimethylaminopyridine 
(4.8 mg, 0.04 mmol) in dichloromethane (1 mL) at 0 °C. The resulting solution was stirred for 6 h 
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at rt and then filtered. The eluent was diluted with dichloromethane (5 mL) and washed with 0.5 
N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The combined 
organic layers were washed with saturated sodium chloride solution (4 mL), dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:4 EtOAc/hexanes) to afford 5,7-bis(benzyloxy)chroman-3-yl 3-methoxybenzoate (18 mg, 
89%) as a colorless oil, which was used as is for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 
7.58 (dt, J = 7.7, 1.2 Hz, 1H), 7.51 (dd, J = 2.7, 1.5 Hz, 1H), 7.43–7.25 (m, 11H), 7.06 (ddd, J = 
8.2, 2.7, 1.0 Hz, 1H), 6.23 (d, J = 2.3 Hz, 1H), 6.17 (d, J = 2.2 Hz, 1H), 5.48 (ddq, J = 6.6, 5.1, 2.2 
Hz, 1H), 4.98 (s, 4H), 4.30–4.22 (m, 1H), 4.21–4.14 (m, 1H), 3.80 (s, 3H), 3.11–3.01 (m, 1H), 
2.94–2.84 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 166.4, 159.9, 159.2, 158.3, 155.6, 137.3 (2), 
131.8, 129.8, 129.1, 129.0 (2), 128.5, 128.4, 128.1 (2), 127.7 (2), 122.7, 119.9, 114.8, 101.7, 95.0, 
94.1, 70.6, 70.4, 67.3, 66.5, 55.9, 25.6. 5,7-Bis(benzyloxy)chroman-3-yl 3-methoxybenzoate (18 
mg, 0.036 mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and 
stirred for 18 h under hydrogen atmosphere. The suspension was filtered through a small pad of 
celite. The eluent was concentrated and the residue purified by flash chromatography (SiO2, 1:1 
EtOAc/hexanes) to give 21b (11 mg, 96%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.60 
(ddd, J = 7.7, 1.5, 1.0 Hz, 1H), 7.53 (dd, J = 2.7, 1.5 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.09 (ddd, 
J = 8.3, 2.7, 1.0 Hz, 1H), 6.03 (d, J = 2.3 Hz, 1H), 5.99 (d, J = 2.4 Hz, 1H), 5.54–5.45 (m, 1H), 
5.43–5.33 (m, 1H), 5.24 (s, 1H), 4.29 (ddd, J = 11.4, 5.0, 1.8 Hz, 1H), 4.20 (ddd, J = 11.4, 2.3, 
1.0 Hz, 1H), 3.83 (s, 3H), 3.04 (ddd, J = 16.9, 5.4, 1.2 Hz, 1H), 2.88 (ddd, J = 16.9, 4.5, 1.7 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 166.3, 159.7, 155.7, 155.4, 155.3, 131.3, 129.7, 122.4, 119.8, 
114.6, 99.5, 96.3, 96.1, 66.9, 66.2, 55.7, 24.9; IR (KBr) νmax 3404, 2960, 1716, 1596, 1469, 1278, 
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1224, 1099, 933, 752 cm–1; HRMS (ESI-) m/z [M – H+] calcd for C17H15O6, 315.0869, found 
315.0830. 
 
5,7-Dihydroxychroman-3-yl 4-Methoxybenzoate (21c): A solution of 20a (13 mg, 0.036 mmol) 
in dichloromethane (0.5 mL) was added to a stirred solution of 4-methoxybenzoic acid (11 mg, 
0.072 mmol), N,N′-dicyclohexylcarbodiimide (17 mg, 0.08 mmol), and 4-dimethylaminopyridine 
(4.8 mg, 0.04 mmol) in dichloromethane (1 mL) at 0 °C. The resulting solution was stirred for 6 h 
at rt and then filtered. The eluent was diluted with dichloromethane (5 mL) and washed with 0.5 
N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The combined 
organic layers were washed with saturated sodium chloride solution (4 mL), dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:4 EtOAc/hexanes) to afford 5,7-bis(benzyloxy)chroman-3-yl 4-methoxybenzoate (16.7 
mg, 93.8%) as a colorless oil, which was used as is for hydrogenolysis: 1H NMR (500 MHz, 
CDCl3) δ 8.01–7.96 (m, 2H), 7.52–7.29 (m, 10H), 6.94–6.85 (m, 2H), 6.27 (d, J = 2.3 Hz, 1H), 
6.21 (d, J = 2.3 Hz, 1H), 5.57–5.46 (m, 1H), 5.02 (s, 4H), 4.30 (ddd, J = 11.4, 5.0, 1.8 Hz, 1H), 
4.24–4.17 (m, 1H), 3.86 (s, 3H), 3.08 (ddd, J = 17.4, 5.5, 1.2 Hz, 1H), 2.98–2.88 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 165.9, 163.7, 158.8, 158.1, 155.4, 137.1 (2), 132.7, 131.4, 130.6, 129.3, 
128.8, 128.8, 128.2, 128.1, 127.8 (2), 127.4 (2), 122.6, 113.7 (2), 101.5, 94.7, 93.8, 76.9, 70.3, 
67.1, 65.9, 55.5, 25.4. 5,7-Bis(benzyloxy)chroman-3-yl 4-methoxybenzoate (16.2 mg, 0.033 
mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 
h under a hydrogen atmosphere. The suspension was filtered through a small pad of celite. The 
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eluent was concentrated and the residue purified by flash chromatography (SiO2, 1:1 
EtOAc/hexanes) to give 21c (10 mg, 98%) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 
8.30 (s, 1H), 8.04 (s, 1H), 7.99–7.88 (m, 2H), 7.03–6.94 (m, 2H), 6.05 (d, J = 2.3 Hz, 1H), 5.90 
(d, J = 2.3 Hz, 1H), 5.42 (dtd, J = 5.4, 4.5, 2.2 Hz, 1H), 4.24 (ddd, J = 11.4, 4.7, 1.9 Hz, 1H), 4.19 
(ddt, J = 11.5, 1.9, 0.9 Hz, 1H), 3.86 (s, 3H), 3.00 (ddd, J = 17.2, 5.3, 1.2 Hz, 1H), 2.83 (ddd, J = 
17.2, 4.4, 1.9 Hz, 1H); 13C NMR (125 MHz, (CD3)2CO) δ 166.1 (2), 164.6, 157.8, 157.5, 156.5, 
132.4 (2), 123.5, 114.7, 99.2, 96.5, 95.7, 67.3, 66.9, 56.0, 25.6; IR (KBr) νmax 3404, 2958, 1716, 
1596, 14266, 1284 1224, 1098 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C17H17O6, 317.1025, 
found 317.1029. 
 
5,7-Dihydroxychroman-3-yl 3,4-Dimethoxybenzoate (21d): A solution of 20a (12 mg, 0.033 
mmol) in dichloromethane (0.5 mL) was added to a stirred solution of 4-methoxybenzoic acid 3,4-
methoxybenzoic acid (14 mg, 0.066 mmol), N,N′-dicyclohexylcarbodiimide (14 mg, 0.066 mmol), 
and 4-dimethylaminopyridine (4.8 mg, 0.04 mmol) in dichloromethane (1 mL) at 0 °C. The 
resulting solution was stirred for 6 h at rt and then filtered. The eluent was diluted with 
dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and then with saturated sodium 
bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with saturated sodium 
chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered, and the solvent was 
removed. The residue was purified by flash chromatography (SiO2, 1:4 EtOAc/hexanes) to afford 
5,7-bis(benzyloxy)chroman-3-yl 3,4-methoxybenzoate (17 mg, 95%) as a colorless oil which was 
used as for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 8.5, 2.0 Hz, 1H), 7.52 (d, 
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J = 2.0 Hz, 1H), 7.50–7.29 (m, 10H), 6.85 (d, J = 8.4 Hz, 1H), 6.27 (d, J = 2.3 Hz, 1H), 6.21 (d, J 
= 2.3 Hz, 1H), 5.51 (qd, J = 5.1, 2.4 Hz, 1H), 5.02 (d, J = 2.1 Hz, 4H), 4.29 (ddd, J = 11.3, 5.2, 1.7 
Hz, 1H), 4.24 (s, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.10 (ddd, J = 17.3, 5.6, 1.1 Hz, 1H), 2.93 (ddd, 
J = 17.3, 4.6, 1.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.1, 158.9, 158.1, 155.4, 153.4, 148.8, 
137.1 (2), 128.9 (2), 128.8, 128.3 (2), 128.2 (2), 127.8, 127.5 (2), 124.2, 122.7, 112.3, 110.4, 101.6, 
94.8, 93.9, 70.4, 70.2, 67.2, 66.0, 56.3 (2), 25.4. 5,7-Bis(benzyloxy)chroman-3-yl 3,4-
methoxybenzoate (17 mg, 0.032 mmol) and palladium/carbon (10%) were suspended in 
tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. The suspension was 
filtered through a small pad of celite. The eluent was concentrated and the residue purified by flash 
chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21d (9.5 mg, 86%) as colorless oil: 
1H NMR 
(500 MHz, (CD3)2CO) δ 8.30 (s, 1H), 8.04 (s, 1H), 7.58 (dd, J = 8.5, 2.0 Hz, 1H), 7.50 (d, J = 2.0 
Hz, 1H), 7.02 (d, J = 8.5 Hz, 1H), 6.05 (d, J = 2.3 Hz, 1H), 5.90 (d, J = 2.3 Hz, 1H), 5.41 (qd, J 
= 4.7, 2.5 Hz, 1H), 4.21 (td, J = 4.2, 3.5, 1.4 Hz, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 3.01 (ddd, J = 
17.1, 5.3, 1.1 Hz, 1H), 2.88–2.73 (m, 1H); 13C NMR (125 MHz (CD3)2CO) δ 166.2, 157.9, 157.5, 
156.6, 154.7, 150.0, 124.4, 123.5, 113.2, 111.8, 99.3, 96.5, 95.7, 78.1, 67.1, 56.3, 56.2, 25.7; IR 
(KBr) νmax 3404, 2921, 1699, 1515, 1271, 1145, 1022, 761, 667 cm
–1; HRMS (ESI+) m/z [M + H+] 
calcd for C18H19O7, 347.1131, found 347.1128. 
 
5,7-Dihydroxychroman-3-yl 3,5-Dimethoxybenzoate (21e): A solution of 20a (13 mg, 0.036 
mmol) in dichloromethane (0.5 mL) was added to a stirred solution of 4-methoxybenzoic acid 3,5-
dimethoxybenzoic acid (13 mg, 0.072 mmol), N,N′-dicyclohexylcarbodiimide (17 mg, 0.08 
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mmol), and 4-dimethylaminopyridine (4.8 mg, 0.04 mmol) in dichloromethane (1 mL) at 0 °C. 
The resulting solution was stirred for 6 h at rt and then filtered. The eluent was diluted with 
dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL), and then with saturated sodium 
bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with saturated sodium 
chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:4 EtOAc/hexanes) to afford 5,7-
bis(benzyloxy)chroman-3-yl 3,5-dimethoxybenzoate (17.8 mg, 94.6%) as a colorless oil, which 
was used as is for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 7.46–7.32 (m, 10H), 7.17 (d, J 
= 2.4 Hz, 2H), 6.64 (t, J = 2.4 Hz, 1H), 6.27 (d, J = 2.3 Hz, 1H), 6.20 (d, J = 2.2 Hz, 1H), 5.50 (qd, 
J = 5.1, 2.3 Hz, 1H), 5.02 (d, J = 2.4 Hz, 4H), 4.28 (ddd, J = 11.3, 5.3, 1.7 Hz, 1H), 4.25–4.18 (m, 
1H), 3.81 (s, 6H), 3.16–3.04 (m, 1H), 2.92 (ddd, J = 17.3, 4.6, 1.6 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 166.1, 160.8 (2), 158.9, 158.1, 155.4, 137.1 (2), 132.1, 128.9 (2), 128.8 (2), 128.3, 128.2 
(2), 127.8 (2), 127.5, 107.7 (2), 105.8, 101.4, 94.8, 93.9, 70.4, 70.2, 67.0, 66.4, 55.8 (2), 25.4. 5,7-
Bis(benzyloxy)chroman-3-yl 3,5-dimethoxybenzoate (17 mg, 0.032 mmol) and palladium/carbon 
(10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. 
The suspension was filtered through a small pad of celite. The eluent was concentrated and the 
residue purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21e (9.5 mg, 86%) 
as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 8.31 (s, 1H), 8.04 (s, 1H), 7.10 (d, J = 2.4 Hz, 
2H), 6.72 (t, J = 2.4 Hz, 1H), 6.05 (d, J = 2.3 Hz, 1H), 5.90 (d, J = 2.3 Hz, 1H), 5.53–5.35 (m, 
1H), 4.32–4.16 (m, 2H), 3.81 (s, 6H), 3.15–2.95 (m, 1H), 2.86–2.82 (m, 1H); 13C NMR (125 MHz, 
(CD3)2CO) δ 166.1, 161.8 (2), 157.8, 157.4, 156.4, 133.2, 108.1 (2), 105.6, 99.1, 96.4, 95.6, 77.1, 
67.5, 67.2, 55.9, 25.5; IR (KBr) νmax 1916, 2848, 1702, 1683, 1558, 1244, 1145, 1103, cm
–1; 




5,7-Dihydroxychroman-3-yl 3-Hydroxybenzoate (21f): A solution of 20a (14 mg, 0.039 mmol) 
in dichloromethane (0.5 mL) was added to a stirred solution of 4-(benzyloxy)benzoic acid (13 mg, 
0.072 mmol), N,N′-dicyclohexylcarbodiimide (16 mg, 0.077 mmol), and 4-dimethylaminopyridine 
(4.8 mg, 0.04 mmol) in dichloromethane (1 mL) at 0 °C. The resulting solution was stirred for 6 h 
at rt and then filtered. The eluent was diluted with dichloromethane (5 mL) and washed with 0.5 
N HCl (2 × 4 mL) and saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic 
layers were washed with saturated sodium chloride solution (4 mL), dried over anhydrous sodium 
sulfate, filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:4 
EtOAc/hexanes) to afford 5,7-bis(benzyloxy)chroman-3-yl 3-(benzyloxy)benzoate (19 mg, 
86.3%), which was used further as obtained: 1H NMR (500 MHz, CDCl3) δ 7.63 (ddd, J = 5.7, 2.5, 
1.2 Hz, 2H), 7.46–7.30 (m, 16H), 7.16 (ddd, J = 8.3, 2.6, 1.1 Hz, 1H), 6.28 (d, J = 2.3 Hz, 1H), 
6.21 (d, J = 2.3 Hz, 1H), 5.69–5.44 (m, 1H), 5.09 (s, 2H), 5.02 (d, J = 5.2 Hz, 4H), 4.30 (ddd, J = 
11.5, 5.0, 1.8 Hz, 1H), 4.25–4.13 (m, 1H), 3.09 (ddd, J = 17.5, 5.6, 1.2 Hz, 1H), 2.93 (ddd, J = 
17.5, 4.4, 1.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.1, 158.9, 158.8, 158.1, 155.4, 137.0 
(2), 136.7, 131.5, 129.6 (2), 128.8 (3), 128.7, 128.3, 128.2, 128.1 (2), 127.9 (2), 127.8 (2), 127.4 
(2), 122.7, 120.4, 115.6, 101.4, 94.8, 93.9, 70.4 (2), 70.2, 67.0, 66.3, 25.3. 5,7-
Bis(benzyloxy)chroman-3-yl 3-(benzyloxy)benzoate (18 mg, 0.031 mmol) and palladium/carbon 
(10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. 
The suspension was filtered through a small pad of celite. The eluent was concentrated and the 
residue purified by flash chromatography (SiO2, 1:9 acetone/dichloromethane) to give 21f (8.6 
mg, 92.6%) as a colorless oil: 1H NMR (500 MHz, MeOD) δ 7.83 (d, J = 8.8 Hz, 2H), 6.79 (d, J 
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= 8.8 Hz, 2H), 5.94 (d, J = 2.3 Hz, 1H), 5.84 (d, J = 2.3 Hz, 1H), 5.37 (ddd, J = 5.3, 4.5, 2.7 Hz, 
1H), 4.19 (ddd, J = 11.4, 4.9, 1.8 Hz, 1H), 4.14 (dd, J = 11.4, 2.1 Hz, 1H), 2.95 (ddd, J = 17.1, 
5.4, 1.1 Hz, 1H), 2.77 (ddd, J = 17.1, 4.5, 1.7 Hz, 1H); 13C NMR (125 MHz, (CD3)2CO) δ 166.2, 
158.3, 157.7, 157.4, 156.4, 132.6, 130.5, 121.5, 121.0, 116.7, 99.1, 96.3, 95.6, 67.6, 67.2, 25.5; IR 
(KBr) νmax 3384, 2910, 1848, 1699, 1436, 1290, 1145 cm
–1; HRMS (ESI-) m/z [M – H–] calcd for 
C16H13O6, 301.0712, found 301.0717. 
 
5,7-Bis(benzyloxy)chroman-3-yl 4-hydroxybenzoate (21g): A solution of 20a (14 mg, 0.039 
mmol) in dichloromethane (0.5 mL) was added to a stirred solution of 4-(benzyloxy)benzoic acid 
(13 mg, 0.072 mmol), N,N′-dicyclohexylcarbodiimide (16 mg, 0.077 mmol), and 4-
dimethylaminopyridine (4.8 mg, 0.04 mmol) in dichloromethane (1 mL) at 0 °C. The resulting 
solution was stirred for 6 h at rt and filtered. The eluent was diluted with dichloromethane (5 mL) 
and washed with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) 
solution. The combined organic layers were washed with saturated sodium chloride solution (4 
mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by 
flash chromatography (SiO2, 1:4 EtOAc/hexanes) to afford 5,7-bis(benzyloxy)chroman-3-yl 4-
(benzyloxy)benzoate (20 mg, 90.4%) as a colorless oil, which was used as is for hydrogenolysis: 
1H NMR (500 MHz, CDCl3) δ 8.06–7.90 (m, 2H), 7.50–7.30 (m, 15H), 7.02–6.91 (m, 2H), 6.27 
(d, J = 2.3 Hz, 1H), 6.21 (d, J = 2.3 Hz, 1H), 5.50 (dp, J = 7.0, 2.4 Hz, 1H), 5.12 (s, 2H), 5.02 (s, 
4H), 4.30 (ddd, J = 11.4, 5.0, 1.8 Hz, 1H), 4.20 (dd, J = 11.2, 2.4 Hz, 1H), 3.08 (ddd, J = 17.5, 5.5, 
1.1 Hz, 1H), 2.92 (ddd, J = 17.5, 4.4, 1.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 165.9, 162.8, 
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158.8, 158.1, 155.4, 137.1 (2), 136.4, 132.1(2), 128.9 (4), 128.8 (2), 128.4, 128.2, 128.1, 127.8, 
127.7, 127.4 (4), 122.8. 114.6 (2), 101.5, 94.8, 93.8, 70.4, 70.3, 70.1, 67.1, 65.8, 25.3. 
Bis(benzyloxy)chroman-3-yl 4-(benzyloxy)benzoate (18 mg, 0.031 mmol) and palladium/carbon 
(10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. 
The suspension was filtered through a small pad of celite. The eluent was concentrated and the 
residue purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21g (9.8 mg, 97%) 
as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 9.15 (s, 1H), 8.29 (s, 1H), 8.03 (s, 1H), 7.85 
(d, J = 8.7 Hz, 2H), 6.97–6.83 (m, 2H), 6.05 (d, J = 2.3 Hz, 1H), 5.90 (d, J = 2.3 Hz, 1H), 5.57–
5.28 (m, 1H), 4.23 (ddd, J = 11.4, 4.7, 1.8 Hz, 1H), 4.18 (ddt, J = 11.4, 2.1, 0.9 Hz, 1H), 2.99 
(ddd, J = 17.0, 5.4, 1.1 Hz, 1H), 2.82 (ddd, J = 17.0, 4.4, 1.7 Hz, 1H); 13C NMR (125 MHz, 
(CD3)2CO) δ 166.2, 160.7, 159.8, 159.4, 156.1, 133.1, 108.7, 108.1, 101.1, 94.2, 92.2, 67.3, 66.8, 
55.8, 55.5, 25.3; IR (KBr) νmax 3363, 2962, 2927, 1683, 1608, 1355, 1272, 1166, 1143, 1099, 1014, 
769 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C16H15O6, 303.0869, found 303.0878. 
 
5,7-Dihydroxychroman-3-yl 3′,6-Dimethoxy-[1,1′-biphenyl]-3-carboxylate (21h): A solution 
of 20a (11 mg, 0.03 mmol) in dichloromethane (0.5 mL) was added to a stirred solution of 3′,6-
dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (16 mg, 0.06 mmol), N,N′-dicyclohexylcarbodiimide 
(13 mg, 0.06 mmol), and 4-dimethylaminopyridine (4.8 mg, 0.04 mmol) in dichloromethane (1 
mL) 0 °C. The resulting solution was stirred for 6 h at rt and filtered. The eluent was diluted with 
dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and then with saturated sodium 
bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with saturated sodium 
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chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, EtOAc/hexanes) to afford 5,7-
bis(benzyloxy)chroman-3-yl 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylate (17.5 mg, 96.1%) as a 
colorless oil, which was used as is for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 8.14–7.87 
(m, 2H), 7.49–7.29 (m, 11H), 7.09 (dt, J = 7.7, 1.3 Hz, 1H), 7.04 (dd, J = 2.6, 1.5 Hz, 1H), 6.97 
(d, J = 8.6 Hz, 1H), 6.91 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.26 (d, J = 2.3 Hz, 1H), 6.20 (d, J = 2.3 
Hz, 1H), 5.51 (dd, J = 5.2, 2.3 Hz, 1H), 5.01 (d, J = 4.2 Hz, 4H), 4.34–4.25 (m, 1H), 4.24–4.19 
(m, 1H), 3.71 (s, 3H), 3.79 (s, 3H), 3.10 (ddd, J = 17.3, 5.7, 1.2 Hz, 1H), 2.92 (ddd, J = 17.3, 4.7, 
1.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.0, 160.5, 159.4, 158.9, 158.1, 155.4, 139.0, 137.1 
(2), 132.7, 131.4, 130.6, 129.3 (2), 128.8 (3), 128.2, 128.1 (3), 127.8, 127.4, 122.6, 122.2, 115.4, 
113.1, 110.7, 101.6, 94.7, 93.8, 77.0, 70.4, 67.1, 65.9, 56.0, 55.5, 25.4. 5,7-
Bis(benzyloxy)chroman-3-yl 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylate (17 mg, 0.028 mmol) 
and palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under 
a hydrogen atmosphere. The suspension was filtered through a small pad of celite. The eluent was 
concentrated and the residue purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 
21h (11.1 mg, 93.2%) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 8.3 (br s , 1 H), 8.03 
(br s, 1 H), 7.97 (dd, J = 8.7, 2.2 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H), 7.37–7.29 (m, 1H), 7.19 (d, J 
= 8.7 Hz, 1H), 7.10–7.00 (m, 2H), 6.91 (ddd, J = 8.3, 2.6, 1.1 Hz, 1H), 6.04 (d, J = 2.3 Hz, 1H), 
5.89 (d, J = 2.3 Hz, 1H), 5.50–5.35 (m, 1H), 4.33–4.23 (m, 1H), 4.22–4.18 (m, 1H), 3.89 (s, 3H), 
3.81 (s, 3H), 3.01 (ddd, J = 17.1, 5.3, 1.2 Hz, 1H), 2.92–2.80 (m, 1H); 13C NMR (125 MHz, 
(CD3)2CO) δ 166.0, 161.4, 160.4, 157.8, 157.4, 156.5, 139.9, 132.7, 131.7, 131.3, 129.9, 123.5, 
122.5, 116.0, 113.6, 112.1, 99.2, 96.4, 95.7, 67.3, 67.0, 55.5 (2), 25.6; IR (KBr) νmax 3355, 2923, 
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1701, 1606,1458, 1251, 1145, 1031, 752, 667 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C24H23O7, 423.1444, found 423.1454. 
 
5,7-Dihydroxychroman-3-yl 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (21i): 4-Acetoxy-
3-(3-methylbut-2-en-1-yl)benzoic acid (34 mg, 0.137 mmol) and thionyl chloride (33 μL, 0.27 
mmol) in tetrahydrofuran (5 mL) were heated at reflux for 3 h, cooled to rt and concentrated. The 
residue was dissolved in dichloromethane (0.5 mL) and added to a stirred solution of 20a (25 mg, 
0.069 mmol) in dichloromethane (0.7 mL) with trimethylamine (0.3 mL) under at 0 °C. The 
resulting mixture was stirred for 6 h and concentrated, and the residue was purified by flash 
chromatography (SiO2, 1:4 EtOAc/hexanes) to give 5,7-bis(benzyloxy)chroman-3-yl 4-acetoxy-
3-(3-methylbut-2-en-1-yl)benzoate (34 mg, 85%) as a colorless oil, which was used as is for 
hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 2.1 Hz, 1H), 7.87 (dd, J = 8.4, 2.2 Hz, 
1H), 7.47–7.31 (m, 10H), 7.07 (d, J = 8.4 Hz, 1H), 6.27 (d, J = 2.3 Hz, 1H), 6.20 (d, J = 2.3 Hz, 
1H), 5.51 (dp, J = 7.2, 2.5 Hz, 1H), 5.19 (tdt, J = 5.9, 2.9, 1.4 Hz, 1H), 5.02 (s, 4H), 4.30 (ddd, J 
= 11.4, 5.0, 1.8 Hz, 1H), 4.20 (dd, J = 11.3, 2.1 Hz, 1H), 3.25 (d, J = 7.2 Hz, 2H), 3.07 (ddd, J = 
17.6, 5.4, 1.2 Hz, 1H), 2.93 (ddd, J = 17.3, 4.4, 1.7 Hz, 1H), 2.32 (s, 3H), 1.72 (d, J = 1.6 Hz, 3H), 
1.68 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 169.0, 165.6, 158.9, 158.1, 155.3, 152.9, 137.1, 137.0, 
134.1, 134.0, 132.2, 129.0, 128.8, 128.7, 128.2 (2), 128.1 (2), 127.8 (4), 127.4 (2), 122.6, 121.1, 
101.4, 94.7, 93.8, 70.4, 70.2, 67.0, 66.1, 29.9, 28.9, 25.9, 21.1, 18.1. A solution of palladium 
acetate (5 mg, 0.023 mg), trimethylamine (15 μL, 0.108 mmol), triethylsilane (82 μL, 0.108) in 
dichloromethane (0.8 mL) was stirred for 15 min before the slow addition of a solution of 5,7-
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bis(benzyloxy)chroman-3-yl 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (34 mg, 0.057 mmol) 
in dichloromethane (0.4 mL).  The resulting mixture was stirred for 15 h, quenched with saturated 
ammonium chloride (2 mL) and extracted with ether (3 × 4 mL). The combined organic layers 
were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography (silica, 5:95 
MeOH/DCM) to afford 21i (15.2 mg, 54.8%) as a colorless oil: 1H NMR (500 MHz, CDCl3): δ 
7.92 (dd, J = 13.7, 2.2 Hz, 1H), 7.86 (dd, J = 8.4, 2.2 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.03–5.99 
(m, 1H), 5.96 (d, J = 2.4 Hz, 1H), 5.50 (ddt, J = 7.2, 4.8, 2.4 Hz, 1H), 5.18 (dddd, J = 7.3, 5.8, 
2.9, 1.5 Hz, 1H), 4.29 (ddd, J = 11.5, 4.9, 1.9 Hz, 1H), 4.24–4.14 (m, 1H), 3.25 (d, J = 7.2 Hz, 
2H), 3.07–2.98 (m, 1H), 2.87 (ddd, J = 16.9, 4.4, 1.8 Hz, 1H), 2.32 (s, 3H), 1.72 (q, J = 1.3 Hz, 
3H), 1.68 (d, J = 1.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 169.1, 165.7, 155.4, 155.3 (2), 152.9, 
134.2, 134.1, 132.2, 129.0, 127.9, 122.6, 121.0, 99.4, 96.3, 96.0, 66.9, 65.9, 28.9, 25.9, 24.9, 21.1, 
18.1; IR (KBr) νmax 3363, 2921, 1703, 1606, 1252, 1146 cm
–1; HRMS (ESI+) m/z [M + H+] calcd 
for C23H25O7, 413.1600, found 413.1617. 
 
7-Hydroxychroman-3-yl Benzoate (21j): A solution of 20b (15 mg, 0.06 mmol) in 
dichloromethane (0.5 mL) was added to a stirred solution benzoic acid (14 mg, 0.12 mmol), N,N′-
dicyclohexylcarbodiimide (24 mg, 0.12 mmol), and 4-dimethylaminopyridine (7.2 mg, 0.06 
mmol) at 0 °C. The resulting solution was stirred for 6 h at rt and then filtered. The eluent was 
diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and then with 
saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with 
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saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:8 EtOAc/hexanes) to 
afford 7-(benzyloxy)chroman-3-yl benzoate as a colorless oil (21 mg, 90%), which was used as is 
for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 8.04–7.93 (m, 2H), 7.56 (ddt, J = 8.8, 7.2, 1.3 
Hz, 1H), 7.47–7.37 (m, 6H), 7.37–7.31 (m, 1H), 6.98 (dt, J = 8.4, 1.0 Hz, 1H), 6.60 (dd, J = 8.4, 
2.5 Hz, 1H), 6.54 (d, J = 2.5 Hz, 1H), 5.51 (qd, J = 4.8, 2.2 Hz, 1H), 5.04 (s, 2H), 4.34 (ddd, J = 
11.5, 4.9, 1.9 Hz, 1H), 4.25 (ddd, J = 11.5, 2.1, 1.1 Hz, 1H), 3.22 (ddt, J = 16.6, 5.1, 1.2 Hz, 1H), 
2.98 (ddd, J = 16.8, 4.5, 1.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.2, 158.7, 154.7, 137.2, 
133.4, 130.7, 130.1, 130.0 (2), 128.8 (2), 128.6 (2), 128.2 (2), 127.7, 111.4, 108.9, 102.7, 70.3, 
67.1, 66.4, 29.9. 7-(Benzyloxy)chroman-3-yl benzoate (14 mg, 0.04 mmol) and palladium/carbon 
(10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. 
The suspension was filtered through a small pad of celite. The eluent was concentrated and the 
residue purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21j (11.1 mg, 90.4%) 
as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 8.04–7.93 (m, 2H), 7.54 (ddt, J = 8.7, 7.7, 1.3 
Hz, 1H), 7.40 (ddt, J = 7.3, 6.3, 1.0 Hz, 2H), 6.92 (dt, J = 8.1, 0.9 Hz, 1H), 6.42 (dd, J = 8.2, 2.6 
Hz, 1H), 6.38 (d, J = 2.5 Hz, 1H), 5.49 (qd, J = 4.8, 2.2 Hz, 1H), 4.71 (s, 1H), 4.32 (ddd, J = 11.5, 
4.8, 1.9 Hz, 1H), 4.23 (dtd, J = 11.5, 1.5, 0.8 Hz, 1H), 3.18 (ddt, J = 16.6, 5.1, 1.1 Hz, 1H), 3.02–
2.89 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 166.3, 155.3, 154.8, 133.4, 130.8 (2), 130.1, 130.0, 
128.6 (2), 111.4, 108.9, 103.5, 67.1, 66.4, 29.8; IR (KBr) νmax 3392, 2925, 1716, 1699, 1519, 1456, 





7-Hydroxychroman-3-yl 3-Methoxybenzoate (21k): A solution of 20b (11 mg, 0.04 mmol) in 
dichloromethane (0.5 mL) was added to a stirred solution 3-methoxybenzoic acid (12 mg, 0.08 
mmol), N,N′-dicyclohexylcarbodiimide (17 mg, 0.08 mmol), and 4-dimethylaminopyridine (5 mg, 
0.04 mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then filtered. 
The eluent was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and 
saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with 
saturated sodium chloride solution (4 mL), dried over anhydrous Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:8 EtOAc/hexanes) to 
afford 7-(benzyloxy)chroman-3-yl 3-methoxybenzoate (15 mg, 89.5) as a colorless oil, which was 
used as is for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 7.59 (dt, J = 7.7, 1.2 Hz, 1H), 7.53 
(dd, J = 2.7, 1.5 Hz, 1H), 7.48–7.43 (m, 2H), 7.42–7.36 (m, 2H), 7.37–7.30 (m, 2H), 7.10 (ddd, J 
= 8.3, 2.7, 1.0 Hz, 1H), 6.98 (dt, J = 8.5, 0.9 Hz, 1H), 6.59 (dd, J = 8.4, 2.5 Hz, 1H), 6.53 (d, J = 
2.5 Hz, 1H), 5.50 (qd, J = 4.9, 2.3 Hz, 1H), 5.04 (s, 2H), 4.33 (ddd, J = 11.5, 5.0, 1.8 Hz, 1H), 4.25 
(ddd, J = 11.3, 2.4, 1.2 Hz, 1H), 3.87 (s, 3H), 3.21 (ddt, J = 16.6, 5.1, 1.1 Hz, 1H), 3.02–2.90 (m, 
1H); 13C NMR (125 MHz, CDCl3) δ 166.1, 159.7, 158.7, 154.7, 137.2, 131.4, 130.6, 129.6, 128.8 
(2), 128.2 (2), 127.7, 122.4, 119.7, 114.5, 111.4, 108.9, 102.7, 70.3, 67.1, 66.5, 55.6, 29.9. 7-
(Benzyloxy)chroman-3-yl 3-methoxybenzoate (11 mg, 0.028 mmol) and palladium/carbon (10%) 
were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. The 
suspension was filtered through a small pad of celite. The eluent was concentrated and the residue 
purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21k (7.5 mg, 89.4%) as a 
colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.58 (dt, J = 7.7, 1.2 Hz, 1H), 7.52 (dd, J = 2.7, 1.5 
Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.09 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 6.92 (dt, J = 8.2, 1.0 Hz, 
1H), 6.43 (dd, J = 8.2, 2.5 Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 5.49 (qd, J = 4.9, 2.3 Hz, 1H), 4.81 
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(brs, 1H), 4.32 (ddd, J = 11.5, 4.9, 1.9 Hz, 1H), 4.24 (ddt, J = 11.4, 1.8, 1.0 Hz, 1H), 3.84 (s, 3H), 
3.19 (ddt, J = 16.7, 5.2, 1.2 Hz, 1H), 3.03–2.84 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 166.2, 
159.7, 155.3, 154.8, 131.4, 130.9, 129.6, 122.4, 119.8, 114.5, 111.3, 108.9, 103.5, 67.1, 66.5, 55.7, 
29.9; IR (KBr) νmax 3384, 2910, 2848, 1701, 1635, 1508, 1259, 1164, 1116, 667 cm
–1; HRMS 
(ESI+) m/z [M + H+] calcd for C17H17O5, 301.1076, found 301.1076. 
 
7-Hydroxychroman-3-yl 4-Methoxybenzoate (21l): A solution of 20b (11 mg, 0.04 mmol) in 
dichloromethane (0.5 mL) was added to a stirred solution of 4-methoxybenzoic acid (12 mg, 0.08 
mmol), N,N′-dicyclohexylcarbodiimide (17 mg, 0.08 mmol), and 4-dimethylaminopyridine (4.8 
mg, 0.04 mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then 
filtered. The eluent was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 
mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers 
were washed with saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, 
filtered and concentrated. The residue was purified by flash chromatography (SiO2, 1:8 
EtOAc/hexanes) to afford 7-(benzyloxy)chroman-3-yl 4-methoxybenzoate (15.5 mg, 79.2%) as a 
colorless oil, which was used as for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 8.05–7.90 (m, 
2H), 7.48–7.31 (m, 5H), 7.01–6.95 (m, 1H), 6.93–6.83 (m, 2H), 6.59 (dd, J = 8.4, 2.6 Hz, 1H), 
6.53 (d, J = 2.6 Hz, 1H), 5.49 (qd, J = 4.8, 2.2 Hz, 1H), 5.04 (s, 2H), 4.32 (ddd, J = 11.4, 4.9, 1.9 
Hz, 1H), 4.24 (ddd, J = 11.4, 2.3, 1.2 Hz, 1H), 3.85 (s, 3H), 3.20 (ddt, J = 16.7, 5.1, 1.1 Hz, 1H), 
3.03–2.84 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 166.0, 163.7, 158.6, 154.8, 137.2, 132.0, 130.7, 
128.8 (2), 128.2, 127.7 (2), 122.5 (2), 113.8 (2), 111.6, 108.9, 102.7, 70.3, 67.2, 66.0, 55.6, 29.9. 
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7-(Benzyloxy)chroman-3-yl 4-methoxybenzoate (11 mg, 0.028 mmol) and palladium/carbon 
(10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. 
The suspension was filtered through a small pad of celite. The eluent was concentrated and the 
residue purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21l (8 mg, 94.3%) as 
a colorless oil: 1H NMR (500 MHz, CDCl3) δ 8.00–7.88 (m, 2H), 6.93 (dt, J = 8.3, 0.9 Hz, 1H), 
6.91–6.87 (m, 2H), 6.43 (dd, J = 8.2, 2.5 Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 5.48 (qd, J = 4.8, 2.2 
Hz, 1H), 4.78 (br s, 1 H), 4.32 (ddd, J = 11.5, 4.9, 1.9 Hz, 1H), 4.23 (dtd, J = 11.5, 1.5, 0.8 Hz, 
1H), 3.85 (s, 3H), 3.18 (ddt, J = 16.5, 5.0, 1.2 Hz, 1H), 2.95 (dtd, J = 16.7, 2.4, 1.3 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 166.0, 163.7, 155.3, 154.8, 132.0, 130.9 (2), 122.5 (2), 113.8, 111.5, 
108.8, 103.5, 67.2, 66.0, 55.7, 29.9; IR (KBr) νmax 3392, 2918, 2848, 1701, 1606, 1510, 1458, 
1259, 1164, 1108, 1022 cm–1; HRMS (ESI+) m/z [M + H+] calcd for C17H17O5, 301.1076, found 
301.1071. 
 
7-Hydroxychroman-3-yl 3′,6-Dimethoxy-[1,1′-biphenyl]-3-carboxylate (21m): A solution of 
20b (10 mg, 0.039 mmol) in dichloromethane (0.5 mL) was added to a stirred solution 4-
methoxybenzoic acid (12 mg, 0.08 mmol), N,N′-dicyclohexylcarbodiimide (17 mg, 0.08 mmol), 
and 4-dimethylaminopyridine (4.8 mg, 0.04 mmol) under argon at 0 °C. The resulting solution was 
stirred for 6 h at rt and then filtered. The filtrate was diluted with dichloromethane (5 mL) and 
washed with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. 
The combined organic layers were washed with saturated sodium chloride solution (4 mL), dried 
over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
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chromatography (SiO2, 1:8 EtOAc/hexanes) to afford 7-(benzyloxy)chroman-3-yl 3′,6-dimethoxy-
[1,1′-biphenyl]-3-carboxylate (17 mg, 87.4%) as a colorless oil, which was used further as obtained 
for hydrogenolysis): 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 8.4 Hz, 2H), 7.48–7.42 (m, 2H), 
7.42–7.36 (m, 2H), 7.37–7.31 (m, 2H), 7.08 (dt, J = 7.7, 1.2 Hz, 1H), 7.04 (dd, J = 2.6, 1.6 Hz, 
1H), 6.99–6.95 (m, 2H), 6.91 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 6.58 (dd, J = 8.4, 2.6 Hz, 1H), 6.53 
(d, J = 2.5 Hz, 1H), 5.49 (qd, J = 5.0, 2.4 Hz, 1H), 5.03 (s, 2H), 4.31 (ddd, J = 11.4, 5.2, 1.7 Hz, 
1H), 4.25 (ddd, J = 11.4, 2.5, 1.1 Hz, 1H), 3.21 (dd, J = 16.6, 5.1 Hz, 1H), 3.06–2.90 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 166.0, 160.6, 159.5, 158.7, 154.8, 138.9, 137.2, 132.6, 131.3, 130.7, 
130.6, 129.3, 128.8 (2), 128.2, 127.7 (2), 122.5, 122.2, 115.4, 113.1, 111.6, 110.7, 108.9, 102.7, 
70.3, 67.2, 66.2, 56.0, 55.5, 30.0. 7-(Benzyloxy)chroman-3-yl 3′,6-dimethoxy-[1,1′-biphenyl]-3-
carboxylate (12 mg, 0.024 mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran 
(2 mL) and stirred for 18 h under a hydrogen atmosphere. The suspension was filtered through a 
small pad of celite. The eluent was concentrated and the residue purified by flash chromatography 
(SiO2, 1:1 EtOAc/hexanes) to give 21m (9 mg, 91.4%) as a colorless oil: 
1H NMR (500 MHz, 
CDCl3) δ 8.01–7.94 (m, 2H), 7.34 (t, J = 7.9 Hz, 1H), 7.10–7.05 (m, 1H), 7.03 (dd, J = 2.6, 1.6 
Hz, 1H), 6.97 (d, J = 8.6 Hz, 1H), 6.95–6.88 (m, 2H), 6.42 (dd, J = 8.2, 2.6 Hz, 1H), 6.38 (d, J = 
2.5 Hz, 1H), 5.48 (qd, J = 5.0, 2.4 Hz, 1H), 4.73 (br s, 1 H), 4.31 (ddd, J = 11.4, 5.1, 1.8 Hz, 1H), 
4.24 (ddd, J = 11.5, 2.4, 1.1 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.19 (ddt, J = 16.6, 5.0, 1.2 Hz, 
1H), 3.03–2.90 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 166.0, 160.6, 159.5, 155.3, 154.8, 138.9, 
132.7, 131.3, 130.9, 130.6, 129.3, 122.5, 122.2, 115.5, 113.1, 111.5, 110.8, 108.9, 103.5, 67.2, 
66.2, 56.0, 55.5, 30.0; IR (KBr) νmax 3411, 2921, 1701, 1598, 1510, 1278, 1224, 1155, 1116, 1043, 




7-Hydroxychroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (21n): 4-Acetoxy-3-
(3-methylbut-2-en-1-yl)benzoic acid (39 mg, 0.156 mmol) and thionyl chloride (38 μL, 0.312 
mmol) in THF (5 mL) were heated at reflux for 3 h under argon, cooled to rt, and concentrated. 
The residue was dissolved in dichloromethane (0.5 mL) and added dropwise to a stirred solution 
of 20b (20 mg, 0.078) in dichloromethane (0.7 mL) with trimethylamine (0.3 mL) under argon at 
0 °C. The resulting mixture was stirred for 6 h at rt before solvent was removed. The residue was 
purified by flash chromatography (SiO2 1:4 EtOAc/hexanes) to give 7-benzyloxychroman-3-yl 4-
acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (26 mg, 84%) as a colorless oil, which was used as for 
hydrogenolysis: 1H NMR (400 MHz, CDCl3) δ 7.90–7.82 (m, 2H), 7.48–7.37 (m, 4H), 7.37–7.31 
(m, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.97 (dt, J = 8.3, 0.9 Hz, 1H), 6.59 (dd, J = 8.4, 2.6 Hz, 1H), 
6.53 (d, J = 2.5 Hz, 1H), 5.49 (qd, J = 4.7, 2.2 Hz, 1H), 5.18 (dddd, J = 7.3, 5.8, 2.9, 1.5 Hz, 1H), 
5.04 (s, 2H), 4.33 (ddd, J = 11.6, 4.8, 1.9 Hz, 1H), 4.28–4.16 (m, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 
3.21 (m, 3H), 3.04–2.90 (m, 1H), 2.32 (s, 3H), 1.72 (q, J = 1.3 Hz, 3H), 1.70–1.64 (m, 3H). A 
solution of palladium acetate (1.3 mg, 0.006 mg), trimethylamine (4 μL, 0.03 mmol), triethylsilane 
(24 μL, 0.15) in dichloromethane (0.8 mL) was stirred for 15 min under argon before the addition 
of a solution of 7-benzyloxychroman-3-yl 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (15 mg, 
0.03 mmol) in dichloromethane (0.4 mL). The resulting mixture was stirred for 15 h, quenched 
with saturated ammonium chloride (2 mL) and extracted with ether (3 × 4 mL). The combined 
organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium 
sulfate, filtered and concentrated. The residue was purified by flash chromatography (SiO2, 1:2 
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EtOAc/hexanes) to give 21n (14.8 mg, 53.4%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 
7.88 (d, J = 2.1 Hz, 1H), 7.84 (dd, J = 8.4, 2.2 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.92 (dt, J = 8.3, 
0.9 Hz, 1H), 6.46–6.40 (m, 1H), 6.38 (d, J = 2.5 Hz, 1H), 5.49 (qd, J = 4.7, 2.2 Hz, 1H), 5.17 
(dddt, J = 7.3, 5.9, 2.9, 1.4 Hz, 1H), 4.63 (s, 1H), 4.32 (ddd, J = 11.5, 4.8, 1.9 Hz, 1H), 4.22 (dt, J 
= 11.4, 1.6 Hz, 1H), 3.24 (d, J = 7.2 Hz, 2H), 3.18 (ddt, J = 16.7, 5.1, 1.2 Hz, 1H), 2.94 (ddd, J = 
16.5, 4.7, 1.8 Hz, 1H), 2.32 (s, 3H), 1.72 (q, J = 1.3 Hz, 3H), 1.67 (d, J = 1.3 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) δ 167.8, 164.4, 154.0, 153.6, 151.7, 132.9, 130.9, 129.6 (2), 127.7, 126.7, 
121.4, 119.7, 110.1, 107.6, 102.2, 65.8, 65.1, 28.7, 27.7, 24.6, 19.8, 16.8; IR (KBr) νmax 3419, 
2823, 2854, 1716, 1596, 1456, 1286, 1201, 1163, 1054, 796 cm–1; HRMS (ESI+) m/z [M + H+] 
calcd for C23H25O6, 397.1651, found 397.1642. 
 
5-Hydroxychroman-3-yl Benzoate (21o): A solution of 20c (9 mg, 0.035 mmol), in 
dichloromethane (0.5 mL) was added to a stirred solution of benzoic acid (8.6 mg, 0.07 mmol), 
N,N′-dicyclohexylcarbodiimide (23 mg, 0.11 mmol) and 4-dimethylaminopyridine (4.2 mg, 0.035 
mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then filtered. The 
filtrate was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and 
saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with 
saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:9 EtOAc/hexanes) to 
give 5-(benzyloxy)chroman-3-yl benzoate (21 mg, 90%) as a colorless oil, which was used as is 
for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 8.08–7.97 (m, 2H), 7.66–7.50 (m, 1H), 7.49–
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7.28 (m, 7H), 7.12 (tt, J = 8.3, 0.8 Hz, 1H), 6.57 (ddd, J = 14.2, 8.3, 1.0 Hz, 2H), 5.56 (dtd, J = 
5.3, 4.4, 2.2 Hz, 1H), 5.08 (s, 2H), 4.34 (ddd, J = 11.4, 4.9, 1.9 Hz, 1H), 4.23 (ddd, J = 11.4, 2.2, 
1.1 Hz, 1H), 3.17 (ddt, J = 18.0, 5.7, 1.0 Hz, 1H), 3.03 (ddd, J = 17.8, 4.3, 1.7 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 166.2, 157.5, 155.0, 137.2, 133.3, 130.2, 130.0 (2), 128.8, 128.5 (2), 128.1 
(2), 127.5 (2), 127.4, 109.8, 108.9, 103.9, 70.2, 66.8, 66.0, 25.7. 5-(Benzyloxy)chroman-3-yl 
benzoate (5 mg, 0.014 mmol) and palladium/carbon (10%) were suspended in tetrahydrofuran (2 
mL) and stirred for 18 h under a hydrogen atmosphere The suspension was filtered through a small 
pad of celite. The eluent was concentrated and the residue purified by flash chromatography (SiO2, 
1:1 EtOAc/hexanes) to give 21o (3 mg, 93%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 
8.10–7.92 (m, 2H), 7.62–7.47 (m, 1H), 7.47–7.35 (m, 2H), 7.01 (t, J = 8.1 Hz, 1H), 6.52 (dd, J = 
8.2, 1.0 Hz, 1H), 6.38 (dd, J = 8.0, 1.0 Hz, 1H), 5.55 (tdd, J = 5.2, 4.4, 2.2 Hz, 1H), 4.84 (br s, 1 
H), 4.33 (ddd, J = 11.4, 4.9, 1.9 Hz, 1H), 4.22 (dt, J = 11.6, 1.5 Hz, 1H), 3.12 (dd, J = 17.4, 5.5 
Hz, 1H), 2.97 (ddd, J = 17.5, 4.3, 1.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.3, 155.3, 154.5, 
133.4, 130.1, 130.0, 128.6 (2), 127.7 (2), 109.4, 107.4, 107.2, 66.8, 65.9, 25.3. IR (KBr) νmax 3374, 
2921, 1703, 1681,1476, 1098, 770 cm–1; HRMS (ESI-) m/z [M – H+] calcd for C16H13O4, 269.0814, 
found 269.0804. 
 
5-Hydroxychroman-3-yl 3-Methoxybenzoate (21p): A solution of 20c (14 mg, 0.055 mmol) in 
dichloromethane (0.5 mL) was added to a stirred solution of 3-methoxybenzoic acid (17 mg, 0.11 
mmol), N,N′-dicyclohexylcarbodiimide (23 mg, 0.11 mmol) and 4-dimethylaminopyridine (8 mg, 
0.11 mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then filtered. 
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The eluent was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and 
then with saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers were 
washed with saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, and 
filtered and the solvent removed. The residue was purified by flash chromatography (SiO2, 1:9 
EtOAc/hexanes) to afford 5-(benzyloxy)chroman-3-yl 3-methoxybenzoate (19 mg, 90%) as a 
colorless oil, which was used as is for hydrogenolysis: 1H NMR (400 MHz, CDCl3) δ 7.61 (dt, J 
= 7.7, 1.3 Hz, 1H), 7.54 (dd, J = 2.7, 1.5 Hz, 1H), 7.47–7.29 (m, 6H), 7.15–7.05 (m, 2H), 6.57 
(ddd, J = 10.7, 8.3, 1.0 Hz, 2H), 5.63–5.49 (m, 1H), 5.08 (s, 2H), 4.32 (ddd, J = 11.4, 5.1, 1.8 Hz, 
1H), 4.26–4.18 (m, 1H), 3.83 (s, 3H), 3.17 (dd, J = 17.8, 5.5 Hz, 1H), 3.09–2.95 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 166.1, 159.7, 157.5, 155.0, 137.2, 131.5, 129.6, 128.8 (2), 128.1, 127.6, 127.4 
(2), 122.4, 119.7, 114.5, 109.8, 108.8, 103.9, 70.2, 66.7(2), 66.2, 55.7. 5-(Benzyloxy)chroman-3-
yl 3-methoxybenzoate (18 mg, 0.044 mmol) and palladium/carbon (10%) were suspended in 
tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. The suspension was 
filtered through a small pad of celite. The eluent was concentrated and the residue purified by flash 
chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21p (12.9 mg, 92.4%) as a colorless oil: 
1H 
NMR (500 MHz, CDCl3) δ 7.53 (dt, J = 7.7, 1.3 Hz, 1H), 7.46 (dd, J = 2.7, 1.5 Hz, 1H), 7.24 (t, 
J = 8.0 Hz, 1H), 7.02 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 6.93 (t, J = 8.1 Hz, 1H), 6.44 (dd, J = 8.3, 
1.0 Hz, 1H), 6.31 (dd, J = 8.0, 1.0 Hz, 1H), 5.54–5.43 (m, 1H), 4.87 (s, 1H), 4.27–4.21 (m, 1H), 
4.15 (dt, J = 11.4, 1.6 Hz, 1H), 3.75 (s, 3H), 3.06 (dd, J = 17.4, 5.5 Hz, 1H), 2.90 (ddd, J = 17.4, 
4.6, 1.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.2, 159.7, 155.3, 154.5, 131.4, 129.6, 127.7, 
122.4, 119.8, 114.5, 109.4, 107.4, 107.2, 66.8, 66.1, 55.7, 25.3. IR (KBr) νmax cm
–1 ; HRMS (ESI-




5-Hydroxychroman-3-yl 4-Methoxybenzoate (21q): A solution of 20c (11 mg, 0.042 mmol) in 
dichloromethane (0.5 mL) was added to a stirred solution of 4-methoxybenzoic acid (13 mg, 0.09 
mmol), N,N′-dicyclohexylcarbodiimide (18 mg, 0.085 mmol) and 4-dimethylaminopyridine (5 
mg, 0.05 mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then 
filtered. The filtrate was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 
mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers 
were washed with saturated sodium chloride solution (4 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:9 
EtOAc/hexanes) to give 5-(benzyloxy)chroman-4-yl 3-methoxybenzoate (15 mg, 91.5%) as a 
colorless oil, which was used as is for hydrogenolysis: 1H NMR (500 MHz, CDCl3) δ 8.09–7.85 
(m, 2H), 7.50–7.30 (m, 5H), 7.11 (t, J = 8.2 Hz, 1H), 6.97–6.83 (m, 2H), 6.60–6.56 (m, 1H), 6.57–
6.52 (m, 1H), 5.63–5.48 (m, 1H), 5.06 (s, 2H), 4.31 (ddd, J = 11.4, 5.0, 1.9 Hz, 1H), 4.27–4.17 (m, 
1H), 3.85 (s, 3H), 3.16 (dd, J = 17.8, 5.5 Hz, 1H), 3.01 (ddd, J = 17.8, 4.4, 1.7 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 166.0, 163.7, 157.5, 155.1, 137.3, 132.1, 128.8 (2), 128.1 (2), 127.5 (2), 
127.4, 122.6, 113.8 (2), 109.8, 109.0, 103.8, 70.2, 66.9, 65.7, 55.6, 25.7. 5-(Benzyloxy)chroman-
4-yl 3-methoxybenzoate (5 mg, 0.014 mmol) and palladium/carbon (10%) were suspended in 
tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen atmosphere. The suspension was 
filtered through a small pad of celite. The eluent was concentrated and the residue purified by flash 
chromatography (SiO2, 1:1 EtOAc/hexanes) to give 21q (3.5 mg, 93%) as a colorless oil: 
1H NMR 
(500 MHz, CDCl3) δ 8.10–7.92 (m, 2H), 7.64–7.49 (m, 1H), 7.49–7.38 (m, 2H), 7.02 (t, J = 8.1 
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Hz, 1H), 6.53 (dd, J = 8.2, 1.0 Hz, 1H), 6.40 (dd, J = 8.0, 1.0 Hz, 1H), 5.56 (tdd, J = 5.2, 4.4, 2.2 
Hz, 1H), 4.86 (s, 1H), 4.35 (ddd, J = 11.4, 4.9, 1.9 Hz, 1H), 4.23 (dt, J = 11.6, 1.6 Hz, 1H), 3.14 
(dd, J = 17.4, 5.5 Hz, 1H), 2.99 (ddd, J = 17.5, 4.3, 1.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
166.3, 155.3, 154.5 (2), 133.4 (2), 130.1, 130.0, 128.6, 127.7, 109.4 (2), 107.4, 107.2, 66.8, 65.9, 
25.3; IR (KBr) νmax 3384, 2921, 1701, 1683, 1606, 1471, 1259, 1168, 1099, 771 cm
–1; HRMS 
(ESI-) m/z [M – H+] calcd for C17H15O5, 299.0920, found 299.0928. 
 
5-Hydroxychroman-3-yl 3′,6-Dimethoxy-[1,1′-biphenyl]-3-carboxylate (21r): A solution of 
22c (11 mg, 0.042 mmol), in dichloromethane (0.5 mL) was added to a stirred solution of 3′,6-
dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (22 mg, 0.085 mmol), N,N′-
dicyclohexylcarbodiimide (18 mg, 0.085 mmol), and 4-dimethylaminopyridine (5 mg, 0.0042 
mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then filtered. The 
filtrate was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and 
saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with 
saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:8 EtOAc/hexanes) to 
afford 7-(benzyloxy)chroman-3-yl 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylate (18 mg, 85%) as 
a colorless oil, which was used further as obtained: 1H NMR (400 MHz, CDCl3) δ 8.07–7.92 (m, 
2H), 7.49–7.28 (m, 6H), 7.19–7.05 (m, 2H), 7.04 (dd, J = 2.7, 1.6 Hz, 1H), 6.97 (d, J = 8.5 Hz, 
1H), 6.91 (ddd, J = 8.4, 2.7, 1.0 Hz, 1H), 6.60–6.54 (m, 2H), 5.54 (qd, J = 5.1, 2.4 Hz, 1H), 5.08 
(s, 2H), 4.30 (ddd, J = 11.3, 5.2, 1.7 Hz, 1H), 4.23 (dd, J = 11.6, 2.1 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 
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3H), 3.18 (dd, J = 17.7, 5.6 Hz, 1H), 3.10–2.90 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 166.0, 
160.5, 159.4, 157.5, 155.0, 138.9, 137.2, 132.6, 131.3, 130.6, 129.2, 128.7 (2), 128.1, 127.5 (2), 
127.4, 122.6, 122.2, 115.4, 113.2, 110.7, 109.8, 109.0, 103.9, 70.2, 66.8, 65.9, 56.0, 55.5, 25.8. 7-
(Benzyloxy)chroman-3-yl 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylate (18 mg, 0.036 mmol) and 
palladium/carbon (10%) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a 
hydrogen atmosphere. The suspension was filtered through a small pad of celite. The eluent was 
concentrated and the residue purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 
21r (13 mg, 88.2%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.96–7.88 (m, 2H), 7.25 (t, 
J = 7.9 Hz, 1H), 7.00 (dt, J = 7.6, 1.2 Hz, 1H), 6.96 (dd, J = 2.6, 1.5 Hz, 1H), 6.94–6.87 (m, 2H), 
6.83 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.44 (dd, J = 8.3, 1.0 Hz, 1H), 6.31 (dd, J = 8.0, 1.1 Hz, 1H), 
5.55–5.34 (m, 1H), 4.86 (br s, 1 H), 4.22 (ddd, J = 11.3, 5.2, 1.7 Hz, 1H), 4.16 (ddd, J = 11.4, 2.4, 
1.2 Hz, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.06 (dd, J = 17.3, 5.6 Hz, 1H), 2.92–2.83 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 166.0, 160.6, 159.4, 155.3, 154.5, 138.9, 132.7, 131.3, 130.7, 129.3, 
127.6, 122.5, 122.2, 115.4, 113.2, 110.7, 109.4, 107.4, 107.3, 66.9, 65.7, 56.0, 55.5, 25.4; IR (KBr) 
νmax 3396, 2933, 2837, 1712, 1598, 1469, 1440, 1249, 1031, 771, 711 cm
–1; HRMS (ESI+) m/z [M 
+ H+] calcd for C24H23O6, 407.1495, found 407.1482. 
 
5-Hydroxychroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (21s): A solution of 
20c (10 mg, 0.04 mmol), in dichloromethane (0.5 mL) was added to a stirred solution of 4-acetoxy-
3-(3-methylbut-2-en-1-yl)benzoic acid (20 mg, 0.08 mmol), N,N′-dicyclohexylcarbodiimide (16 
mg, 0.08 mmol), and 4-dimethylaminopyridine (5 mg, 0.042 mmol) under argon at 0 °C. The 
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resulting solution was stirred for 6 h at rt and filtered. The filtrate was diluted with dichloromethane 
(5 mL) and washed with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 
mL) solution. The combined organic layers were washed with saturated sodium chloride solution 
(4 mL), dried over anhydrous sodium sulfate filtered and solvent was removed. The residue was 
purified by flash chromatography (SiO2, 1:8 EtOAc/hexanes) to give 5-(benzyloxy)chroman-3-yl 
4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (13 mg, 72.2%) as a colorless oil, which was used 
as is in the next step: 1H NMR (500 MHz, CDCl3) δ 7.94–7.83 (m, 2H), 7.45–7.29 (m, 5H), 7.10 
(t, J = 8.3 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.62–6.55 (m, 2H), 5.67–5.48 (m, 1H), 5.18 (dddd, J 
= 7.2, 5.8, 2.9, 1.4 Hz, 1H), 5.07 (s, 2H), 4.31 (ddd, J = 11.4, 4.9, 1.9 Hz, 1H), 4.26–4.17 (m, 1H), 
3.25 (d, J = 7.1 Hz, 2H), 3.14 (dd, J = 17.8, 5.4 Hz, 1H), 3.01 (ddd, J = 17.8, 4.4, 1.8 Hz, 1H), 2.32 
(s, 3H), 1.71 (q, J = 1.3 Hz, 3H), 1.67 (d, J = 1.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 169.0, 
165.6, 157.5, 155.0, 152.9, 137.2, 134.1, 132.2, 129.0, 128.7 (2), 128.1, 128.0 (2), 127.5 (2), 127.4, 
122.6, 121.0, 109.8, 108.8, 103.9, 70.2, 66.7, 66.0, 28.9, 25.9, 25.7, 21.1, 18.1. For benzyl group 
removal, a solution of palladium acetate (1 mg, 0.004 mmol), trimethylamine (4 μL, 0.025 mmol), 
and triethylsilane (19 μL, 0.0112) in DCM (0.8 mL) was stirred for 15 min under argon before the 
addition of a solution of 5-(benzyloxy)chroman-3-yl 4-acetoxy-3-(3-methylbut-2-en-1-
yl)benzoate (12 mg, 0.025 mmol) in dichloromethane (0.2 mL) reaction was stirred for 15 h. The 
reaction mixture was quenched with saturated ammonium chloride (2 mL) and extracted with ether 
(3 × 4 mL). The combined organic layers were washed with saturated sodium chloride solution, 
dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:2 EtOAc/hexanes) to afford 21s as colorless oil: 
1H NMR (500 MHz, CDCl3) δ 8.02–7.67 
(m, 2H), 7.05 (d, J = 8.3 Hz, 1H), 7.03–6.98 (m, 1H), 6.53 (dd, J = 8.3, 1.1 Hz, 1H), 6.43 (dd, J = 
8.1, 1.0 Hz, 1H), 5.52 (tdd, J = 5.1, 4.2, 2.1 Hz, 1H), 5.17 (dddt, J = 7.3, 5.8, 2.9, 1.4 Hz, 1H), 4.31 
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(ddd, J = 11.5, 4.8, 2.0 Hz, 1H), 4.24–4.12 (m, 1H), 3.24 (d, J = 7.2 Hz, 2H), 3.05 (dd, J = 17.6, 
5.3 Hz, 1H), 2.94 (ddd, J = 17.5, 4.4, 1.8 Hz, 1H), 2.32 (s, 3H), 1.71 (q, J = 1.3 Hz, 3H), 1.69–
1.65 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 168.8, 165.4, 155.0, 154.6, 152.7, 133.9, 131.9, 
128.8, 127.8 (2), 127.1, 122.4, 120.8, 110.8, 110.5, 109.5, 66.4, 66.0, 28.7, 25.8, 25.7, 20.9, 17.8; 
IR (KBr) νmax 3429, 2854, 1716, 1595, 1458, 1286, 1161, 1054 cm
–1; HRMS (ESI+) m/z [M + H+] 
calcd for C23H25O6, 397.1651, found 397.1662. 
 
5,7-Dimethoxychroman-3-yl Benzoate (25a): A solution of 24 (10 mg, 0.04 mmol), in 
dichloromethane (0.5 mL) was added to a stirred solution of benzoic acid (12 mg, 0.1 mmol), N,N′-
dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 4-dimethylaminopyridine (5 mg, 0.042 
mmol) under argon at 0 °C . The resulting solution was stirred for 6 h at rt and then filtered. The 
filtrate was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and then 
with saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers were washed 
with saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:7 EtOAc/hexanes) to 
afford 25a (13 mg, 90%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 8.14–7.91 (m, 2H), 7.55 
(ddt, J = 7.6, 6.8, 1.1 Hz, 1H), 7.47–7.37 (m, 2H), 6.11 (s, 2H), 5.52 (tdt, J = 5.5, 4.5, 1.9 Hz, 1H), 
4.32 (dddd, J = 11.4, 4.9, 1.9, 0.9 Hz, 1H), 4.21 (ddd, J = 11.5, 2.2, 1.2 Hz, 1H), 3.79 (dd, J = 2.9, 
0.9 Hz, 6H), 3.09–2.94 (m, 1H), 2.88 (ddd, J = 17.4, 4.3, 1.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) 
δ 166.3, 159.8, 159.1, 155.3, 133.4, 130.3, 130.1 (2), 128.6 (2), 100.8, 93.4, 92.0, 67.1, 66.2, 55.7, 
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55.6, 25.1; IR (KBr) νmax 2931, 1716, 1620, 1591, 1499, 1456, 1145, 1045, 754 cm
–1; HRMS 
(ESI+) m/z [M + H+] calcd for C18H19O5, 315.1232, found 315.1239. 
 
5,7-Dimethoxychroman-3-yl 3-Methoxybenzoate (25b): A solution of 24 (10 mg, 0.04 mmol), 
in dichloromethane (0.5 mL) was added to a stirred solution of 3-methoxybenzoic acid (15 mg, 
0.1 mmol), N,N′-dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 4-dimethylaminopyridine (5 
mg, 0.042 mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then 
filtered. The filtrate was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 
mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers 
were washed with saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:6 
EtOAc/hexanes) to afford 25b (13 mg, 80%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.61 
(dt, J = 7.7, 1.2 Hz, 1H), 7.54 (dd, J = 2.7, 1.5 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.09 (ddd, J = 
8.3, 2.7, 1.1 Hz, 1H), 6.10 (d, J = 1.2 Hz, 2H), 5.69–5.42 (m, 1H), 4.30 (ddd, J = 11.4, 5.1, 1.8 
Hz, 1H), 4.24–4.16 (m, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.02 (ddd, J = 17.5, 5.6, 1.3 
Hz, 1H), 2.86 (ddd, J = 17.4, 4.5, 1.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.2, 159.8, 159.7, 
159.0, 155.3, 131.5, 129.6, 122.4, 119.6, 114.5, 100.7, 93.4, 92.0, 67.0, 66.3, 55.7, 55.6, 55.6, 25.1; 
IR (KBr) νmax 2935, 2839, 1716, 1622, 1593, 1498, 1456, 1276, 1145, 1045, 754 cm
–1; HRMS 




5,7-Dimethoxychroman-3-yl 4-Methoxybenzoate (25c): A solution of 24 (10 mg, 0.04 mmol), 
in dichloromethane (0.5 mL) was added to a stirred solution of 4-methoxybenzoic acid (15 mg, 
0.1 mmol), N,N′-dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 4-dimethylaminopyridine (5 
mg, 0.042 mmol) under argon at 0 °C. The resulting solution was stirred for 6 h at rt and then 
filtered. The filtrate was diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 
mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers 
were washed with saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:6 
EtOAc/hexanes) to afford 25c (14 mg, 86%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.98 
(ddd, J = 10.7, 5.1, 2.6 Hz, 2H), 7.27 (td, J = 4.5, 1.5 Hz, 1H), 6.89 (ddd, J = 8.5, 5.7, 2.6 Hz, 
2H), 6.10 (m, 2H), 5.56–5.37 (m, 1H), 4.29 (m, 1H), 4.26–4.12 (m, 1H), 3.88–3.81 (s, 3H), 3.78 
(s, 6H), 3.10–2.93 (m, 1H), 2.85 (dddd, J = 17.5, 5.7, 4.3, 2.3 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 166.0, 163.7, 159.8, 159.0, 155.3, 132.1 (2), 122.7, 113.8 (2), 100.9, 93.3, 91.9, 67.1, 
65.8, 55.6, 55.6 (2), 25.1; IR (KBr) νmax 2935, 1716, 1620, 1593, 1499, 1456, 1145, 1043 cm
–1; 
HRMS (ESI+) m/z [M + H+] calcd for C19H21O6, 345.1338, found 345.1347. 
 
5,7-Dimethoxychroman-3-yl 3′,6-Dimethoxy-[1,1′-biphenyl]-3-carboxylate (25d): A solution 
of 24 (10 mg, 0.04 mmol), in dichloromethane (0.5 mL) was added to a stirred solution of 3′,6-
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dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (15 mg, 0.1 mmol), N,N′-dicyclohexylcarbodiimide 
(20.6 mg, 0.1 mmol), and 4-dimethylaminopyridine (5 mg, 0.042 mmol) under argon at 0 °C. The 
resulting solution was stirred for 6 h at rt and then filtered. The filtrate was diluted with 
dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and then with saturated sodium 
bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with saturated sodium 
chloride solution (4 mL), dried over anhydrous Na2SO4, filtered, and concentrated. The residue 
was purified by flash chromatography (SiO2, 1:6 EtOAc/hexanes) to afford 25d (18.4 mg, 82%) 
as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 8.06–7.97 (m, 2H), 7.34 (t, J = 7.9 Hz, 1H), 7.08 
(dt, J = 7.7, 1.2 Hz, 1H), 7.04 (dd, J = 2.6, 1.5 Hz, 1H), 6.97 (d, J = 8.6 Hz, 1H), 6.91 (ddd, J = 
8.2, 2.6, 0.9 Hz, 1H), 6.10 (s, 2H), 5.54–5.42 (m, 1H), 4.28 (ddd, J = 11.3, 5.2, 1.7 Hz, 1H), 4.21 
(ddd, J = 11.2, 2.3, 1.1 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.02 (ddd, J 
= 17.4, 5.6, 1.2 Hz, 1H), 2.85 (ddd, J = 17.2, 4.6, 1.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
166.0, 160.5, 159.7, 159.4, 159.0, 155.3, 139.0, 132.6, 131.3, 130.6, 129.2, 122.7, 122.2, 115.4, 
113.1, 110.7, 100.9, 93.3, 91.9, 67.1, 66.0, 56.0, 55.62, 55.6, 55.5, 25.2. IR (KBr) νmax 2954, 2931, 
1712, 1595, 1498, 1456, 1436, 1247, 1215, 1052, 813, 756 cm–1; HRMS (ESI+) m/z [M + Na+] 
calcd for C26H26NaO7, 473.1576, found 473.1566. 
 
5,7-Dimethoxychroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (25e): A solution 
of 24 (20 mg, 0.08 mmol) in dichloromethane (1 mL) was added to a stirred solution of 4-acetoxy-
3-(3-methylbut-2-en-1-yl)benzoic acid (48 mg, 0.19 mmol), N,N′-dicyclohexylcarbodiimide (40 
mg, 0.19 mmol), and 4-dimethylaminopyridine (12 mg, 0.084 mmol) under argon at 0 °C. The 
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resulting solution was stirred for 6 h at rt and then filtered. The filtrate was diluted with 
dichloromethane (10 mL) and washed with 0.5 N HCl (2 × 8 mL) and then with saturated sodium 
bicarbonate (2 × 8 mL) solution. The combined organic layers were washed with saturated sodium 
chloride solution (8 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:7 EtOAc/hexanes) to afford 25e (17 mg, 
53%) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 2.1 Hz, 1H), 7.86 (dd, J = 8.4, 
2.2 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.18 (s, 2H), 5.57–5.44 (m, 1H), 5.18 (dddd, J = 7.2, 5.8, 
2.8, 1.4 Hz, 1H), 4.30 (ddd, J = 11.4, 4.9, 1.9 Hz, 1H), 4.25 – 4.02 (m, 1H), 3.79 (s, 3H), 3.78 (s, 
3H), 3.25 (d, J = 7.2 Hz, 2H), 2.99 (ddd, J = 17.3, 5.4, 1.2 Hz, 1H), 2.86 (ddd, J = 17.4, 4.4, 1.8 
Hz, 1H), 2.32 (s, 3H), 1.72 (q, J = 1.2 Hz, 3H), 1.69–1.63 (m, 3H); 13C NMR (125 MHz, CDCl3) 
δ 169.1, 165.7, 159.8, 159.0, 155.2, 152.9, 134.1 (2), 132.1, 129.0, 128.1, 122.6, 121.1, 100.7, 
93.3, 91.9, 66.9, 66.2, 55.6, 55.6, 28.9, 25.9, 25.1, 21.1, 18.1; IR (KBr) νmax 2937, 2844, 1737, 
1622, 2595, 1242, 1218, 1201, 1145, 1128, 1058, 811 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C25H29O7, 441.1913, found 441.1894. 
 
5,7-Dimethoxychroman-3-yl 3,4-Dimethoxybenzoate (25f): A solution of 24 (5 mg, 0.025 
mmol) in dichloromethane (0.5 mL) was added to a stirred solution of 3,4-dimethoxybenzoic acid 
(9 mg, 0.05 mmol), N,N′-dicyclohexylcarbodiimide (10 mg, 0.05 mmol), and 4-
dimethylaminopyridine (3 mg, 0.025 mmol) under argon at 0 °C. The resulting solution was stirred 
for 6 h at rt and then filtered. The filtrate was diluted with dichloromethane (5 mL) and washed 
with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The 
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combined organic layers were washed with saturated sodium chloride solution (4 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:6 EtOAc/hexanes) to afford 25f (10 mg, 71.4%) as a colorless oil: 
1H 
NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 8.4, 2.0 Hz, 1H), 7.52 (d, J = 2.0 Hz, 1H), 6.85 (d, J = 
8.5 Hz, 1H), 6.10 (s, 2H), 5.57–5.41 (m, 1H), 4.28 (ddd, J = 11.3, 5.1, 1.8 Hz, 1H), 4.21 (ddd, J = 
11.3, 2.2, 1.1 Hz, 1H), 3.92 (d, J = 8.3 Hz, 6H), 3.79 (d, J = 4.1 Hz, 6H), 3.02 (ddd, J = 17.2, 5.5, 
1.2 Hz, 1H), 2.86 (ddd, J = 17.3, 4.5, 1.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 159.9 (2), 159.5 
(2), 155.4 (2), 138.5, 128.8, 128.3, 126.5, 100.5, 93.5, 92.4, 78.9, 66.6, 55.7 (2), 55.6 (2), 28.4; IR 
(KBr) νmax 2931, 1701, 1558, 1458, 1419, 1271, 732 cm
–1; HRMS (ESI+) m/z [M + Na+] calcd for 
C20H22NaO7, 397.1263, found 397.1269. 
 
5,7-Dimethoxychroman-3-yl 3,5-Dimethoxybenzoate (25g): A solution of 24 (5 mg, 0.025 
mmol) in dichloromethane (0.5 mL) was added to a stirred solution of 3,4-dimethoxybenzoic acid 
(9 mg, 0.05 mmol), N,N′-dicyclohexylcarbodiimide (10 mg, 0.05 mmol), and 4-
dimethylaminopyridine (3 mg, 0.025 mmol) under argon at 0 °C. The resulting solution was stirred 
for 6 h at rt and then filtered. The filtrate was diluted with dichloromethane (5 mL) and washed 
with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The 
combined organic layers were washed with saturated sodium chloride solution (4 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:6 EtOAc/hexanes) to afford 25g (11.9 mg, 85%) as a colorless oil: 
1H 
NMR (500 MHz, CDCl3) δ 7.16 (d, J = 2.4 Hz, 2H), 6.64 (t, J = 2.4 Hz, 1H), 6.10 (s, 2H), 5.57–
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5.43 (m, 1H), 4.28 (ddd, J = 11.3, 5.2, 1.7 Hz, 1H), 4.21 (ddd, J = 11.3, 2.4, 1.1 Hz, 1H), 3.85–
3.73 (m, 12H), 3.02 (ddd, J = 17.3, 5.5, 1.2 Hz, 1H), 2.85 (ddd, J = 17.4, 4.7, 1.7 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 159.9 (2), 159.5 (2), 155.4 (2), 138.5, 128.8, 128.3, 126.5, 100.5 (2), 
93.5, 92.4, 78.9, 66.6, 55.7, 55.6 (2), 28.4. IR (KBr) νmax 2931, 1701, 1558, 1458, 1419, 1271, 732 
cm–1; HRMS (ESI+) m/z [M + Na+] calcd for C20H22NaO7, 397.1263, found 397.1269. 
 
5,7-Dimethoxychroman-3-yl 3-Ethoxybenzoate (25h): A solution of 24 (10 mg, 0.04 mmol) in 
dichloromethane (0.5 mL) was added to a stirred solution of 3-ethoxybenzoic acid, N,N′-
dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 4-dimethylaminopyridine (5 mg, 0.042 
mmol) under argon at 0 °C. The resulting solution was stirred for 6 h and filtered. The filtrate was 
diluted with dichloromethane (5 mL) and washed with 0.5 N HCl (2 × 4 mL) and then with 
saturated sodium bicarbonate (2 × 4 mL) solution. The combined organic layers were washed with 
saturated sodium chloride solution (4 mL), dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:6 EtOAc/hexanes) to 
afford 25h (14 mg, 82.3%) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 7.52 (ddd, J = 7.7, 
1.5, 1.0 Hz, 1H), 7.46 (dd, J = 2.6, 1.5 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.16 (ddd, J = 8.2, 2.7, 
1.0 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H), 6.06 (d, J = 2.4 Hz, 1H), 5.50–5.41 (m, 1H), 4.32 (ddd, J = 
11.5, 4.5, 2.0 Hz, 1H), 4.22 (ddt, J = 11.5, 1.9, 0.9 Hz, 1H), 4.07 (q, J = 7.0 Hz, 2H), 3.79 (s, 3H), 
3.76 (s, 3H), 2.99 (ddd, J = 17.3, 5.2, 1.1 Hz, 1H), 2.89–2.78 (m, 1H), 1.36 (t, J = 7.0 Hz, 3H); 
13C NMR (125 MHz, (CD3)2CO) δ 166.2, 160.7, 160.0, 159.8, 156.1, 132.5, 130.5, 122.3, 120.1, 
115.9, 101.1, 94.2, 92.2, 67.3, 67.1, 64.3, 55.8, 55.5, 25.4, 15.0; IR (KBr) νmax 2910, 1718, 1622, 
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1593, 1498, 1423, 1274, 1217, 1145, 1051, 754 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C20H23O6, 359.1495, found 359.1483. 
 
5,7-Dimethoxychroman-3-yl 3-(Benzyloxy)benzoate (25i): A solution of 24 (10 mg, 0.04 
mmol), in dichloromethane (0.5 mL) was added to a stirred solution of 3-(benzyloxy)benzoic acid 
(23 mg, 0.1 mmol) (17 mg, 0.1 mmol), N,N′-dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 
4-dimethylaminopyridine (5 mg, 0.042 mmol) under argon at 0 °C. The resulting solution was 
stirred for 6 h at rt then filterd. The filtrate was diluted with dichloromethane (5 mL) and washed 
with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The 
combined organic layers were washed with saturated sodium chloride solution (4 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:5 EtOAc/hexanes) to afford 25i (18 mg, 90%) as a pale yellow 
amorphous solid: 1H NMR (500 MHz, CDCl3) δ 7.62 (dd, J = 7.2, 1.5 Hz, 2H), 7.48–7.36 (m, 4H), 
7.37–7.27 (m, 2H), 7.19–7.12 (m, 1H), 6.11 (s, 2H), 5.50 (ddt, J = 5.3, 4.2, 2.5 Hz, 1H), 5.09 (s, 
2H), 4.31 (ddd, J = 11.3, 4.9, 1.9 Hz, 1H), 4.20 (ddd, J = 11.4, 2.2, 1.2 Hz, 1H), 3.79 (s, 3H), 3.77 
(s, 3H), 3.02 (ddd, J = 17.4, 5.5, 1.2 Hz, 1H), 2.87 (ddd, J = 17.4, 4.3, 1.8 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 166.1, 159.8, 159.0, 158.8, 155.3, 136.7, 131.6, 129.6 (2), 128.9 (2), 128.3, 127.8, 
122.7, 120.4, 115.6, 100.7, 93.4, 92.0, 70.4, 67.0, 66.3, 55.6, 55.6, 25.1; IR (KBr) νmax 2918, 1701, 
1683, 1558, 15036, 1458, 1203, 1145, cm–1; HRMS (ESI+) m/z [M + H+] calcd for C25H25O6, 




5,7-Dimethoxychroman-3-yl 4-(Benzyloxy)benzoate (25j): A solution of 24 (10 mg, 0.04 mmol) 
in dichloromethane (0.5 mL) was added to a stirred solution of 4-(benzyloxy)benzoic acid (23 mg, 
0.1 mmol) (23 mg, 0.1 mmol), N,N′-dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 4-
dimethylaminopyridine (5 mg, 0.042 mmol) under argon at 0 °C. The resulting solution was stirred 
for 6 h at rt and then filtered. The filtrate was diluted with dichloromethane (5 mL) and washed 
with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The 
combined organic layers were washed with saturated sodium chloride solution (4 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:5 EtOAc/hexanes) to afford 25j (17 mg, 85%) as a colorless oil: 
1H NMR 
(500 MHz, CDCl3) δ 7.62 (dd, J = 7.2, 1.5 Hz, 2H), 7.46–7.37 (m, 4H), 7.36–7.29 (m, 2H), 7.21–
7.04 (m, 1H), 6.11 (s, 2H), 5.50 (ddt, J = 5.3, 4.2, 2.5 Hz, 1H), 5.09 (s, 2H), 4.31 (ddd, J = 11.3, 
4.9, 1.9 Hz, 1H), 4.20 (ddd, J = 11.4, 2.2, 1.2 Hz, 1H), 3.81–3.78 (m, 6H), 3.02 (ddd, J = 17.4, 5.5, 
1.2 Hz, 1H), 2.87 (ddd, J = 17.4, 4.3, 1.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 165.9, 162.8, 
159.7, 159.0, 155.3, 136.4, 132.1 (2), 128.9 (2), 128.4, 127.7 (2), 122.9, 114.6 (2), 100.8, 93.3, 
91.9, 70.3, 67.1, 65.8, 55.6, 55.6, 25.1. IR (KBr) νmax 2918, 2817, 1701, 1683, 1558, 1503, 1458, 




5,7-Dimethoxychroman-3-yl 3,5-Bis(benzyloxy)benzoate (25k): A solution of 24 (10 mg, 0.04 
mmol), in dichloromethane (0.5 mL) was added to a stirred solution of 3,5-bis(benzyloxy)benzoic 
acid (33.4 mg, 0.1 mmol), N,N′-dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 4-
dimethylaminopyridine (5 mg, 0.042 mmol) under argon at 0 °C. The resulting solution was stirred 
for 6 h at rt and then filtered. The filtrate was diluted with dichloromethane (5 mL) and washed 
with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The 
combined organic layers were washed with saturated sodium chloride solution (4 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:5 EtOAc/hexanes) to afford 25k (22 mg, 88%) as an amorphous pale 
yellow solid: 1H NMR (500 MHz, CDCl3) δ 7.51–7.27 (m, 12H), 6.79 (t, J = 2.3 Hz, 1H), 6.11 (s, 
2H), 5.47 (qd, J = 5.0, 2.2 Hz, 1H), 5.04 (s, 4H), 4.29 (ddd, J = 11.4, 5.0, 1.8 Hz, 1H), 4.25–4.12 
(m, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 3.01 (ddd, J = 17.4, 5.5, 1.1 Hz, 1H), 2.85 (ddd, J = 17.4, 4.5, 
1.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.0, 159.9 (2), 159.8, 159.0, 155.3, 136.6 (2), 132.1, 
128.9 (4), 128.4 (4), 127.9 (2), 108.8 (2), 107.3, 100.7, 93.4, 92.0, 70.5 (2), 66.9, 66.5, 55.6, 55.6, 
25.1; IR (KBr) νmax 2955, 2852, 1697, 1596, 1456, 1145, 1251, 1009, 769 cm
–1; HRMS (ESI+) 
m/z [M + H+] calcd for C32H31O7, 527.2070, found 527.2087. 
 
5,7-Dimethoxychroman-3-yl 3,4-Bis(benzyloxy)benzoate (25l): A solution of 24 (9 mg, 0.04 
mmol), in dichloromethane (0.5 mL) was added to a stirred solution of 3,4-bis(benzyloxy)benzoic 
acid (33.4 mg, 0.1 mmol), N,N′-dicyclohexylcarbodiimide (20.6 mg, 0.1 mmol), and 4-
dimethylaminopyridine (5 mg, 0.042 mmol) under argon at 0 °C. The resulting solution was stirred 
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for 6 h at rt and then filtered. The filtrate was diluted with dichloromethane (5 mL) and washed 
with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. The 
combined organic layers were washed with saturated sodium chloride solution (4 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:5 EtOAc/hexanes) to afford 25l (20.8 mg, 92%) as an amorphous pale 
yellow solid: 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 2.0 Hz, 1H), 7.58 (dd, J = 8.4, 2.0 Hz, 
1H), 7.48–7.40 (m, 4H), 7.40–7.29 (m, 6H), 6.88 (d, J = 8.4 Hz, 1H), 6.11 (s, 2H), 5.56–5.39 (m, 
1H), 5.22 (s, 2H), 5.17 (s, 2H), 4.27 (ddd, J = 11.3, 4.9, 1.8 Hz, 1H), 4.22–4.14 (m, 1H), 3.79 (s, 
3H), 3.78 (s, 3H), 2.98 (ddd, J = 17.3, 5.5, 1.2 Hz, 1H), 2.83 (ddd, J = 17.4, 4.3, 1.7 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 165.9, 159.8, 159.0, 155.3, 153.1, 148.4, 137.0, 136.7, 128.8 (3), 128.7, 
128.2, 128.1, 127.7 (2), 127.3 (2), 124.4, 123.1, 115.8, 113.3, 100.8, 93.3, 91.9, 71.3, 71.0, 67.0, 
65.9, 55.6, 55.6, 25.1. IR (KBr) νmax 2921, 2848, 1699, 1618, 1510, 1454, 1290, 1203, 1058 cm
–1; 
HRMS (ESI+) m/z [M + H+] calcd for C32H31O7, 527.2070, found 527.2081. 
 
5,7-Dimethoxychroman-3-yl 4-(Benzyloxy)-3-methoxybenzoate (25m): A solution of 24 (20 
mg, 0.1 mmol), in dichloromethane (0.5 mL) was added to a stirred solution of 4-(benzyloxy)-3-
methoxybenzoic acid (49 mg, 0.19 mmol), N,N′-dicyclohexylcarbodiimide (39 mg, 0.19 mmol), 
and 4-dimethylaminopyridine (12 mg, 0.1 mmol) under argon at 0 °C. The resulting solution was 
stirred for 6 h at rt and then filtered. The filtrate was diluted with dichloromethane (5 mL) and 
washed with 0.5 N HCl (2 × 4 mL) and then with saturated sodium bicarbonate (2 × 4 mL) solution. 
The combined organic layers were washed with saturated sodium chloride solution (4 mL), dried 
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over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:5 EtOAc/hexanes) to afford 25m (34 mg, 81%) as an amorphous pale 
yellow solid: IR (KBr) νmax 2921, 2848, 1699, 1618, 1510, 1454, 1290, 1203, 1058 cm
–1; HRMS 
(ESI+) m/z [M + H+] calcd for C26H27O7, 451.1757, found 451.1668. 
 
5,7-Dimethoxychroman-3-yl 3-Hydroxybenzoate (26a): Palladium/carbon (10%) and 25i (18 
mg, 0.03 mmol) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen 
atmosphere. The suspension was filtered through a small plug of celite. The eluent was 
concentrated and the residue purified by flash chromatography (SiO2, 1:3 EtOAc/hexanes) to give 
26a (8.8 mg, 92.6%) as a colorless oil: 1H NMR (500 MHz, CD3CN) δ 7.41 (ddd, J = 7.7, 1.6, 1.0 
Hz, 1H), 7.33 (dd, J = 2.6, 1.6 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.24–7.16 (m, 1H), 7.03 (ddd, J 
= 8.1, 2.6, 1.1 Hz, 1H), 6.14 (d, J = 2.3 Hz, 1H), 6.07 (d, J = 2.3 Hz, 1H), 5.52–5.36 (m, 1H), 4.30 
(ddd, J = 11.7, 4.2, 2.1 Hz, 1H), 4.15 (ddt, J = 11.6, 1.9, 1.0 Hz, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 
2.92 (ddd, J = 17.4, 5.2, 1.1 Hz, 1H), 2.86–2.71 (m, 1H). 13C NMR (125 MHz, CD3CN) δ 166.5, 
160.7, 159.9, 157.9, 156.1, 132.6, 130.8, 122.5, 121.9, 118.3, 117.0, 94.2, 92.4, 67.4, 67.0, 56.2, 
55.9, 25.1. IR (KBr) νmax 3335, 2918, 1701, 1683, 1558, 15036, 1458, 1203, 1145, cm
–1. HRMS 




5,7-Dimethoxychroman-3-yl 4-Hydroxybenzoate (26b): Palladium/carbon (10%) and 25j (12 
mg, 0.028 mmol) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a hydrogen 
atmosphere. The suspension was filtered through a small pad of celite. The eluent was concentrated 
and the residue purified by flash chromatography (SiO2, 1:3 EtOAc/hexanes) to give the 26b (9 
mg, 90%) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 9.16 (s, 1H), 7.88–7.80 (m, 2H), 
6.94–6.86 (m, 2H), 6.14 (d, J = 2.3 Hz, 1H), 6.05 (d, J = 2.3 Hz, 1H), 5.49–5.36 (m, 1H), 4.29 
(ddd, J = 11.5, 4.6, 2.0 Hz, 1H), 4.24–4.14 (m, 1H), 3.79 (s, 3H), 3.75 (s, 3H), 2.97 (ddd, J = 17.3, 
5.3, 1.1 Hz, 1H), 2.80 (ddd, J = 17.3, 4.0, 1.9 Hz, 1H); 13C NMR (125 MHz, (CD3)2CO) δ 166.1, 
162.7, 160.7, 159.8, 156.1, 132.5 (2), 122.4, 116.0 (2), 101.2, 94.2, 92.2, 67.4, 66.4, 55.8, 55.5, 
25.5. IR (KBr) νmax 3365, 2956, 2852, 1701, 1596, 1456, 1214, 1145, 1051, 767 cm
–1; HRMS 
(ESI+) m/z [M + Na+] calcd for C18H18 NaO6, 353.1001, found 353.0991. 
 
5,7-Dimethoxychroman-3-yl 3,5-Dihydroxybenzoate (26c): Palladium/carbon (10%) and 25k 
(12 mg, 0.028 mmol) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a 
hydrogen atmosphere. The suspension was filtered through a small pad of celite. The eluent was 
concentrated and the residue purified by flash chromatography (SiO2, 1:1 EtOAc/hexanes) to give 
26c (12 mg, 91%) as a colorless oil: 1H NMR (500 MHz, (CD3)2CO) δ 8.58 (s, 2H), 6.96 (d, J = 
2.3 Hz, 2H), 6.56 (t, J = 2.3 Hz, 1H), 6.15 (d, J = 2.3 Hz, 1H), 6.05 (d, J = 2.3 Hz, 1H), 5.43 (dtd, 
J = 5.5, 4.1, 1.9 Hz, 1H), 4.31 (ddd, J = 11.6, 4.3, 2.1 Hz, 1H), 4.19 (ddt, J = 11.7, 1.9, 1.0 Hz, 
1H), 3.79 (s, 3H), 3.75 (s, 3H), 2.97 (ddd, J = 17.6, 5.4, 1.2 Hz, 1H), 2.82–2.74 (m, 1H); 13C NMR 
(125 MHz, (CD3)2CO) δ 166.2, 160.7, 159.8 (2), 159.4, 156.1, 133.1, 108.7, 108.1, 101.1, 94.2, 
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92.2, 67.3, 66.8, 55.8, 55.5 (2), 25.3. IR (KBr) νmax 3365, 3330, 2956, 2850, 1697, 1596, 1456, 
1361, 1145, 1054, 1004, 769, cm–1; HRMS (ESI+) m/z [M + H+] calcd for C18H19O7, 347.1131, 
found 347.1134. 
 
5,7-Dimethoxychroman-3-yl 3,4-Dihydroxybenzoate (26d): Palladium/carbon (10%) and 25l 
(18 mg, 0.034 mmol) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h under a 
hydrogen atmosphere. The suspension was filtered through a small pad of celite. The eluent was 
concentrated and the residue purified by flash chromatography (SiO2, 1:3 EtOAc/hexanes) to give 
the desired product 26d (11 mg, 92%) as a colorless oil: 1H NMR (500 MHz, (CD3)2 CO) δ 7.45 
(d, J = 2.1 Hz, 1H), 7.41 (dd, J = 8.3, 2.0 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 6.15 (d, J = 2.3 Hz, 
1H), 6.10–6.04 (m, 1H), 5.49–5.38 (m, 1H), 4.29 (ddd, J = 11.5, 4.4, 2.0 Hz, 1H), 4.22–4.14 (m, 
1H), 3.80 (s, 3H), 3.76 (s, 3H), 2.97 (ddd, J = 17.4, 5.5, 1.2 Hz, 1H); 13C NMR (125 MHz, (CD3)2 
CO)) δ 159.9, 160.2 (2), 158.1 (2), 123.6 (2), 122.85, 117.21, 115.9, 101.3, 94.3, 92.3, 67.47, 66.4, 
55.9, 55.6, 25.5; IR (KBr) νmax 3381, 3321, 2924, 2839, 1698, 16120, 1510, 1456, 1203, 1056, 728 
cm–1; HRMS (ESI+) m/z [M + H+] calcd for C18H19O7, 347.1131, found 347.1125: 
 
5,7-Dimethoxychroman-3-yl 4-Hydroxy-3-methoxybenzoate (26e): Palladium/carbon (10%) 
and 25m (24 mg, 0.053 mmol) were suspended in tetrahydrofuran (2 mL) and stirred for 18 h 
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under a hydrogen atmosphere. The suspension was filtered through a small pad of Celite. The 
eluent was concentrated and the residue purified by flash chromatography (SiO2, 1:3 
EtOAc/hexanes) to give the desired product 26e (17 mg, 91%) as a colorless oil: 1H NMR (500 
MHz, CDCl3) δ 7.60 (dd, J = 8.4, 1.9 Hz, 1H), 7.52 (d, J = 1.9 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 
6.10 (s, 2H), 6.07 (s, 1H), 5.47 (dq, J = 7.5, 2.6 Hz, 1H), 4.28 (ddd, J = 11.3, 5.1, 1.8 Hz, 1H), 
4.24–4.16 (m, 1H), 3.92 (s, 3H), 3.78 (d, J = 3.5 Hz, 6H), 3.01 (ddd, J = 17.5, 5.6, 1.2 Hz, 1H), 
2.85 (ddd, J = 17.3, 4.6, 1.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 165.8, 159.6, 158.2, 155.2, 
150.2, 146.1, 124.5, 122.1, 114, 111.8, 100.6, 93.1, 91.7, 66.9, 65.8, 56.1, 55.4, 55.3, 24.9; IR 
(KBr) νmax 3385, 2939, 2841, 1699, 1612, 1508, 1214, 1145, 729 cm
–1; HRMS (ESI+) m/z [M + 
H+] calcd for C19H21O7, 361.1287, found 361.1278. 
 
3-Azido-5,7-dimethoxychroman (27): A solution of 24 (75, 0.36 mmol) and triphenylphosphine 
(161 mg, 0.61) in tetrahydrofuran (2.5 mL) at 0 °C was treated with diisopropyl azodicarboxylate 
(120 μL, 0.61 mmol) and diphenylphosphoryl azide (130 μL, 0.61 mmol). The resulting mixture 
was stirred for 15 h at 25 °C before the solvent was removed. The residue was purified by flash 
chromatography (SiO2, 1:20 EtOAc/hexanes) to give 27 (75 mg, 83.9%) as a light yellow oil: 
1H 
NMR (500 MHz, CDCl3) δ 6.09 (d, J = 2.4 Hz, 1H), 6.06 (d, J = 2.4 Hz, 1H), 4.15 (ddd, J = 10.8, 
2.6, 1.3 Hz, 1H), 4.02 (ddd, J = 10.9, 6.4, 1.5 Hz, 1H), 3.96 (qd, J = 6.0, 2.6 Hz, 1H), 3.80 (s, 3H), 
3.76 (s, 3H), 2.95 (ddd, J = 16.7, 5.5, 1.4 Hz, 1H), 2.71 (ddd, J = 16.7, 6.0, 1.5 Hz, 1H). 13C NMR 
(125 MHz, CDCl3) δ 159.0, 157.9, 154.1, 99.3, 92.3, 91.2, 66.3, 54.7, 54.6, 52.4, 23.8; IR (KBr) 
νmax 2931, 2847, 2113, 1558, 1456, 1276,811 cm
–1; HRMS (ESI+) m/z [M + H+] calcd for 




5,7-Dimethoxychroman-3-amine (28): To a solution of 27 and triphenylphosphine in THF (3 
mL) was added water (22 μL, 0.93 mmol) and the solution stirred for 30 h at rt. The solvent was 
removed and the residue purified via flash chromatography (silica gel 3:97 MeOH/CHCl3) to give 
28 (55 mg, 83%) as a yellow oil: 1H NMR (500 MHz, CDCl3) δ 6.23–5.87 (m, 2H), 4.09 (ddd, J 
= 10.5, 2.8, 1.5 Hz, 1H), 3.84–3.79 (m, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.34 (tdd, J = 6.8, 5.5, 2.9 
Hz, 1H), 2.88 (ddd, J = 16.5, 5.5, 1.5 Hz, 1H), 2.36 (ddd, J = 16.4, 6.6, 1.2 Hz, 1H), 2.04 (d, J = 
5.5 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 159.7, 159.1, 155.3, 101.7, 93.2, 91.8, 71.3, 55.6, 
55.5, 44.0, 28.9; HRMS (ESI+) m/z [M + H+] calcd for C11H16NO3, 210.1130, found 210.1133. 
 
N-(5,7-Dimethoxychroman-3-yl)benzamide (29a): Benzoic acid (15 mg, 0.12 mmol) and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (19 mg, 0.14 mmol) were added to a 
solution of alcohol 28 (12 mg, 0.057 mmol) in dichloromethane (0.7 mL) with pyridine (0.3 mL). 
The resulting mixture was stirred for 16 h, and then the reaction mixture was diluted with 
dichloromethane (2 mL). The organic phase was washed with saturated sodium bicarbonate (2 × 
2 mL) and saturated sodium chloride solution (3 mL). The organic layer was dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:2 Hexanes/EtOAc) to give 29a (12 mg, 81%) as a pale yellow oil: 
1H NMR (500 MHz, 
CDCl3) δ 7.78–7.66 (m, 2H), 7.54–7.46 (m, 1H), 7.41 (tt, J = 6.6, 1.4 Hz, 2H), 6.39 (d, J = 8.0 
Hz, 1H), 6.17–5.90 (m, 2H), 4.70 (ddtd, J = 7.5, 5.5, 3.5, 1.8 Hz, 1H), 4.26 (ddd, J = 10.9, 3.8, 
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2.1 Hz, 1H), 4.15 (dd, J = 10.9, 1.8 Hz, 1H), 3.78 (d, J = 1.1 Hz, 6H), 2.91 (dd, J = 17.2, 5.7 Hz, 
1H), 2.78 (ddd, J = 17.1, 3.2, 2.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 167.4, 159.9, 159.4, 
155.3, 134.5, 131.8, 128.7 (2), 127.2 (2), 101.0, 93.5, 92.2, 68.3, 55.6, 55.6, 42.6, 25.6; IR (KBr) 
νmax 3307, 2925, 2850, 1645, 1635, 1622, 1539, 1521, 1145, 1122, 813, 756 cm
–1; HRMS (ESI+) 
m/z [M + H+] calcd for C18H20NO4, 314.1392, found 314.1391. 
 
N-(5,7-Dimethoxychroman-3-yl)-3-methoxybenzamide (29b): 3-Methoxybenzoic acid (15 mg, 
0.12 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (19 mg, 0.14 
mmol) were added to a solution of alcohol 28 (12 mg, 0.057 mmol) in dichloromethane (0.7 mL) 
with pyridine (0.3 mL). The resulting mixture was stirred for 16 h at rt, and then the reaction 
mixture was diluted with dichloromethane (2 mL). The organic phase was washed with saturated 
sodium bicarbonate (2 × 2 mL) and saturated sodium chloride solution (3 mL). The organic layer 
was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by 
flash chromatography (SiO2, 1:2 Hexanes/EtOAc) to give 29b (12 mg, 70%) as a pale yellow oil: 
1H NMR (500 MHz, CDCl3) δ 7.26 (dd, J = 2.6, 1.6 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.14 (dt, J 
= 7.7, 1.3 Hz, 1H), 6.94 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 6.30 (d, J = 8.0 Hz, 1H), 6.02 (d, J = 2.4 
Hz, 1H), 6.01 (d, J = 2.4 Hz, 1H), 4.60 (dtt, J = 7.7, 3.8, 1.8 Hz, 1H), 4.17 (ddd, J = 10.9, 3.9, 2.1 
Hz, 1H), 4.11–4.01 (m, 1H), 3.77 (s, 3H), 3.70 (s, 6H), 2.83 (dd, J = 17.1, 5.7 Hz, 1H), 2.69 (ddd, 
J = 17.2, 3.4, 2.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 167.3, 160.0, 159.9, 159.4, 155.3, 136.0, 
129.7, 119.0, 117.9, 112.7, 100.9, 93.5, 92.2, 68.2, 55.7, 55.6 (2), 42.6, 25.5; IR (KBr) νmax 3363, 
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2921, 2850, 1712, 1681, 1498, 1454, 1272, 1145, 771 cm–1; HRMS (ESI+) m/z [M + H+] calcd for 
C19H22NO5, 344.1498, found 344.1498. 
 
N-(5,7-Dimethoxychroman-3-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide (29c): 3′,6-
Dimethoxy-[1,1′-biphenyl]-3-carboxylic acid (25 mg, 0.1 mmol) and N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (19 mg, 0.12 mmol) were added to a solution of alcohol 28 
(10 mg, 0.048 mmol) in dichloromethane (0.7 mL) with pyridine (0.3 mL). The resulting mixture 
was stirred for 16 h, and then the reaction mixture was diluted with dichloromethane (2 mL) and 
organic phase was washed with saturated sodium bicarbonate (2 × 2 mL) and saturated sodium 
chloride solution (2 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:2 Hexanes/EtOAc) to 
give 29c (19.3 mg, 90%) as an amorphous light yellow solid: 1H NMR (500 MHz, CDCl3) δ 7.76 
(dd, J = 8.6, 2.4 Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.39–7.30 (m, 1H), 7.08 (dt, J = 7.7, 1.1 Hz, 
1H), 7.04 (dd, J = 2.6, 1.6 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 6.91 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 
6.32 (d, J = 7.9 Hz, 1H), 6.09 (d, J = 2.4 Hz, 1H), 6.08 (d, J = 2.4 Hz, 1H), 4.68 (ddt, J = 7.8, 3.9, 
1.9 Hz, 1H), 4.24 (ddd, J = 10.8, 4.0, 2.0 Hz, 1H), 4.15 (dd, J = 10.7, 1.9 Hz, 1H), 3.84 (s, 6H), 
3.77 (s, 6H), 2.92 (dd, J = 17.1, 5.7 Hz, 1H), 2.76 (ddd, J = 17.2, 3.5, 1.9 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 166.9, 159.8, 159.5, 159.3 (2), 155.3, 139.1, 130.7, 129.8, 129.3, 128.4, 126.9, 
122.2, 115.4, 113.1, 110.9, 101.1, 93.5, 92.2, 68.3, 56.0, 55.6, 55.6, 55.5, 42.6, 25.6; IR (KBr) νmax 
3315, 2931 1620, 1596, 1531, 1498, 1249, 1201, 1249, 1215, 1145, 1051, 752 cm–1; HRMS (ESI+) 




4-((5,7-Dimethoxychroman-3-yl)carbamoyl)-2-(3-methylbut-2-en-1-yl)phenyl Acetate (29d): 
4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid (47 mg, 0.19 mmol) and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (37 mg, 0.24 mmol) were added to a 
solution of alcohol 28 (20 mg, 0.096 mmol), in dichlormethane (1.4 mL) with pyridine (0.6 mL). 
The resulting mixture was stirred for 16 h and then the reaction mixture was diluted with 
dichloromethane (4 mL). The organic phase was washed with saturated NaHCO3 (2 × 4 mL) and 
saturated sodium chloride solution (4 mL). The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The residue was purified by flash chromatography (SiO2, 1:2 
Hexanes/EtOAc) to give 29d (33 mg, 77%) as an amorphous light yellow solid: 1H NMR (500 
MHz, CDCl3) δ 7.66 (d, J = 2.2 Hz, 1H), 7.54 (dd, J = 8.3, 2.3 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 
6.34 (d, J = 8.0 Hz, 1H), 6.12 (d, J = 2.3 Hz, 1H), 6.10 (d, J = 2.3 Hz, 1H), 5.20 (dddd, J = 7.2, 
5.8, 2.9, 1.4 Hz, 1H), 4.68 (dtt, J = 7.6, 3.6, 1.7 Hz, 1H), 4.26 (ddd, J = 10.9, 3.8, 2.1 Hz, 1H), 
4.15 (dd, J = 10.8, 1.8 Hz, 1H), 3.80 (s, 6H), 3.27 (d, J = 7.2 Hz, 2H), 2.91 (dd, J = 17.1, 5.6 Hz, 
1H), 2.86–2.71 (m, 1H), 2.33 (s, 3H), 1.74 (s, 3H), 1.72–1.66 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 169.2, 166.9, 159.9, 159.4, 155.3, 151.5, 134.4, 134.0, 132.5, 129.6, 125.7, 122.6, 121.1, 100.9, 
93.5, 92.2, 68.2, 55.6, 55.6, 42.6, 29.0, 25.9, 25.5, 21.1, 18.1; IR (KBr) νmax 3325, 2932 1623, 
1602, 1596, 1531, 1496, 1249, 1201, 1251, 1215, 1145, 749 cm–1; HRMS (ESI+) m/z [M + Na+] 




5,7-Dimethoxy-2-phenylchroman-3-yl 4-Acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (30): A 
solution of 11a (20 mg, 0.07 mmol) in dichloromethane (0.5 mL) was added to a solution of 4-
acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid (36 mg, 0.14 mmol), N-(3-dimethylamino-
propyl)-N′-ethylcarbodiimide hydrochloride (27 mg, 0.14 mmol) and 4-dimethylaminopyridine 
(25 mg, 0 0.21 mmol) in dichloromethane (1 mL) at 0 °C. The resulting mixture was stirred for 6 
h at rt, diluted with dichloromethane (5 mL) and washed saturated sodium bicarbonate solution (2 
× 4 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent 
removed. The residue was purified via flash chromatography (SiO2, 1:7 EtOAc/hexanes) to give 
the desired ester 30 (21 mg, 58.1 %) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 
2.1 Hz, 1H), 7.77 (dd, J = 8.4, 2.2 Hz, 1H), 7.44 – 7.40 (m, 2H), 7.37 – 7.32 (m, 2H), 7.32 – 7.28 
(m, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.22 (d, J = 2.3 Hz, 1H), 6.12 (d, J = 2.3 Hz, 1H), 5.54 (td, J = 
6.5, 5.2 Hz, 1H), 5.27 (d, J = 6.4 Hz, 1H), 5.19 (tdt, J = 7.3, 2.9, 1.5 Hz, 1H), 3.79 (m, 6H), 3.23 
(d, J = 7.3 Hz, 2H), 3.00 (dd, J = 16.8, 5.2 Hz, 1H), 2.81 (ddd, J = 16.7, 6.5, 0.9 Hz, 1H), 2.32 (s, 
3H), 1.75 (q, J = 1.3 Hz, 3H), 1.68 (d, J = 1.4 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 169.0, 
165.3, 160.0, 158.8, 155.0, 152.8, 138.2, 134.1, 134.0, 132.0, 128.9 (2), 128.8, 128.5, 128.0, 126.6 
(2), 122.5, 121.0, 100.8, 93.2, 92.0, 78.7, 70.3, 55.6, 55.6, 28.8, 25.9, 24.0, 21.1, 18.0.IR (KBr) 
νmax 2929, 1762, 1713, 1593, 1369, 1201, 1118, 816 cm
–1; HRMS (ESI+) m/z [M + H+] calcd for 
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The Development of Grp94-Selective Inhibitors 
III.1. Introduction 
Hsp90 is responsible for the conformational maturation of more than 200 substrates (client 
proteins).1, 2 Many of which are associated with cell signaling, making it a highly sought after 
target for the development of antitumor agents, as multiple signaling nodes can be disrupted 
simultaneously through Hsp90 inhibition.3, 4 There are four Hsp90 isoforms: Hsp90and Hsp90 
are located in the cytosol, Grp94 resides in the endoplasmic reticulum, and Trap1 is localized to 
mitochondria.5, 6 Each of these isoforms forms a complex with various co-chaperones and partner 
proteins to fold individual substrate proteins.7-10 There are currently 17 molecules undergoing 
clinical trials that bind the Hsp90 N-terminal ATP-binding site. Unfortunately, all of these 
molecules are pan-inhibitors and target all four Hsp90 isoforms with similar affinity.11-13 Pan-
inhibitory activity of current clinical candidates appears detrimental, as results from clinical trials 
have reported hepatotoxicity, cardiotoxicity, ocular toxicity, bone metastasis and peripheral 
neuropathy amongst other side effects.14-18  
 An additional problem associated with all pan-inhibitors of the Hsp90 N-terminal ATP-
binding site is that they induce Hsp70 and Hsp90 expression (pro-survival heat shock response) at 
the same concentrations required for client protein degradation, making both scheduling and 
dosing of these drugs extremely difficult.12, 19-21 Induction of the pro-survival heat shock response 
by pan-inhibitors requires the administration of drugs at higher doses and with an increased 
frequency, which pushes the patient towards toward the maximum tolerated dose, resulting in 
toxicity.20 Consequently, alternative methods to inhibit the Hsp90 protein folding machinery are 
needed that do not induce this pro-survival heat shock response.22-24 Selective inhibition of 
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individual isoforms represents one approach to overcome the detriments associated with pan-
inhibition of all Hsp90’s.25-28 
 The expression of Hsp90 isoforms can vary among cancers, suggesting an inherent 
dependence of cancer upon individual isoforms.29-38 In addition, Hsp90 isoforms exhibit specificity 
for client proteins substrates via interactions with co-chaperones, which suggests that Hsp90 
isoforms should be targeted individually.32, 39, 40 Some isoform-specific clients have been identified 
and therefore, isoform-selective Hsp90 inhibitors are likely to provide a therapeutic opportunity 
that minimizes on-target toxicity by limiting the number of clients affected via pan-Hsp90 
inhibition.28, 41-44 Therefore, selective-inhibitors of individual isoforms are highly sought after and 
their development represents a new paradigm in Hsp90 research. This chapter focuses on the 
development of Grp94-selective inhibitors.   
III.2. Grp94 
Glucose-regulated protein 94 (Grp94) is encoded by the HSP90B1 gene and is located in 
the lumen of the endoplasmic reticulum. Grp94 is not expressed in unicellular organisms and is 
ubiquitously expressed in human cells.6, 45, 46 Grp94 is responsible for the maturation and 
degradation of a client proteins associated with cell-to-cell signaling and immunity (innate and 
adaptive).47-50 In addition, Grp94 plays a key role in cellular adhesion and migration through 
maintaining cell polarity and the intracellular-trafficking of integrins.50-52 Unlike the cytosolic 
isoforms, Grp94 is not overexpressed via the heat shock response, it is upregulated following 
induction of ER stress (calcium imbalance, hypoxia, redox stress).53 Grp94 is essential for 
embryonic development and stem cell maintenance as observed by siRNA knockdown studies.54  
Grp94 is responsible for maturation and trafficking of a restricted number of proteins as 
shown in Table 1.47 These client proteins include, Toll-like receptors (1, 2, 4, and 9), IGF-I, IGF-
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II, integrins, and Her2. Many of these client proteins are implicated in various diseases, including 
liver cancer, multiple myeloma, rheumatoid arthritis and glaucoma.55-58 In fact, small molecule 
inhibitors of Grp94 are therapeutically useful for the treatment of such diseases.27, 55, 56, 58 As stated 
earlier, Grp94 is only essential during embryonic development, and therefore, its inhibition 
represents a non-toxic therapeutic application. 
Grp94 is overexpressed in some cancers and is generally associated with more aggressive 
tumor growth and poor prognosis.36, 59, 60 Recently, Hua and co-workers showed that Grp94 is 
required for the growth and survival of multiple myeloma cells.61 Inhibition of Grp94, by a Grp94-
selective inhibitor, WS-13, resulted in decreased cell proliferation. This response is mediated by 
LRP6, a Grp94 client, which is a co-receptor for the Wnt receptor, frizzled. Grp94 inhibition limits 
the LRP6 expression at the cell surface which blocks the Wnt/-catenin signaling pathway, and 
results in decreased cell proliferation. Hence, Grp94 inhibition decreases cell proliferation, and 
induces apoptosis. Another client of Grp94 is Her2, which is a receptor tyrosine kinase and an 
oncogenic protein. Recent studies by Patel and co-workers showed that siRNA knockdown of 
Grp94 in Her2 overexpressing SkBr3 cells resulted in decreased expression of Her2 at the cell 
surface.62 Additionally, Grp94 inhibitors successfully decreased the levels of Her2 in SkBr3 cell 
lysates.  
Grp94’s clientele includes some integrins (2, 4, 7, L, 2), which play a key role in 
cell adhesion and migration.47 Grp94 is responsible for the maturation as well as intracellular 
trafficking of these proteins. Grp94 knockdown or pharmacological inhibition downregulates the 
expression of integrins, which results in decreased migration.27, 52 Hence, Grp94 inhibitors 




Table 9. Grp94 client proteins. (IP: immunoprecipitation, KO: Knock-out) 





ADAMTS9 + + + 
Apolipoprotein B +   
Cartilage +   
Collagen +  + 
EGF-R +  + 
Erb2    
Golgi apparatus casein Kinase +   
Ig chains +   
IGF-I  +  
IGF-II + + + 
IFN- +   
IL-12p80 + + + 
Insulin receptor IRS-1   + 
Integrins CD49d, 4, 7, L, 2  +  
MHC class II +   
Bile-salt dependent lipase  + + 
Thrombospondin +   
Thyroglobulin +   
TLR1, TLR2, TLR4 + +  
TLR9 + +  
WFS1 +   
1 antitypsin +   
Protein C +   
HSV glycoprotein +   
 
Grp94 inhibitors have also demonstrated efficacy in in vivo models of glaucoma, a disease 
caused by increased intraocular pressure caused by mutant myocilin aggregates.27, 55, 56  Mutations 
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in myocilin cause it to accumulate in endoplasmic reticulum (ER) of trabecular meshwork cells 
leading to dysregulation of humor outflow, which results in elevated intraocular pressure and 
toxicity.  Grp94 recognizes mutant myocilin aggregates as abnormal, but fails to promote their 
clearance via ERAD (Endoplasmic reticulum associated protein degradation). However, 
disruption of the Grp94-myocilin complex through knockdown or pharmacological inhibition 
results in the clearance of myocilin aggregates through autophagic mechanism. Grp94 inhibitors 
have been shown to downregulate the levels of various myocilin mutants that result in primary 
open angle glaucoma.27, 56 
III.3. Ligand Occupation of Grp94 N-Terminal ATP-Binding Pocket 
The N-terminal ATP binding site is highly identical amongst Hsp90 isoforms (Figure 
20a).63, 64 However, one key difference that is present in Grp94 and not in other Hsp90 isoforms is 
the insertion of 5-amino acid sequence into the primary sequence (182186, Figure 20, highlighted 
in red). While this sequence does not comprise the binding pocket, its effect on the tertiary structure 
of Grp94 is significant. Grp94 adopts different conformations upon ligand binding, these 
conformations result in additional sub-pockets within the N-terminus (vide infra), which can be 
exploited for the development of Grp94-selective inhibitors.65, 66  
III.3.1 Binding of Geldanamycin to Grp94 
Geldanamycin (GDA), a pan-Hsp90 inhibitor that binds to both Hsp90 and Grp94 in 
similar binding modes (Figure 21) manifests interactions that are conserved amongst both 
isoforms.66 The C-7 carbamate makes a hydrogen bond with Asp 149 (Asp93 in Hsp90), while 
one oxygen of the quinone ring interacts with Asp110 (Asp54 in Hsp90) and Lys 114 (Lys58 in 
Hsp90).  Additionally, GDA also provides favorable hydrophobic interactions with multiple 
residues including Met154, Leu163, Val197, and Phe199. The quinone binds in a cis-amide 
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conformation to both Grp94 and Hsp90. The binding affinity of GDA for Grp94 (170 nM) is 
higher than for Hsp90; this difference has not been rationalized.  
 
III.3.2 Binding of NECA to Grp94 
A broad spectrum adenosine A2 receptor agonist, 5’-Nethylcarboxamidoadenosine 
(NECA) was the first Grp94-selctive inhibitor identified (Figure22).67 In order to understand 
NECA’s interactions with Grp94, Gewirth and co-workers solved the co-crystal structure of NECA 
bound to Grp94. As expected, the adenine moiety of NECA exhibited similar interactions with 
Grp94 as observed in the ATP/Grp94 complex.63, 68 Overlay of this co-crystal structure with  
 
Figure 20. Differences between Hsp90 vs Grp94. (a) Sequence alignment of Hsp90 
isoforms. (b) Overlay of apo-Hsp90 (colored in green) and apo-Grp94 (colored in blue 





Hsp90 provided an explanation for the observed selectivity over Hsp90. As mentioned 
previously, the 5-amino acid insertion alters the tertiary structure of Grp94, which leads to        
 
repositioning of Ala167 and Lys168 within the binding pocket. These reorganizations induce a 
secondary binding pocket that is not present in Hsp90. As shown in Figure 22b, the 5’-ethyl 















Figure 21. Binding of Geldanamycin to Grp94 (PDB: 2EXL) and Hsp90(PDB: 1YET). 





  Geldanamycin 
167 
 




               
Figure 22. Binding of NECA to Grp94. (a) Structure of NECA; (b) NECA bound to 
Grp94 (PDB: 1QY5); putative position of Lys and Ala (represented as lines for Hsp90) 
is labeled in black. 
 
 
     
Figure 23. Rationale for observed selectivity of NECA for Grp94. (a) Co-crystal 
structure of NECA bound to Grp94 (PDB:1QY5); (b) NECA modeled in Hsp90-
binding pocket (PDB: 2FXS), steric interaction between Gly121 and ethyl group of 
NECA is circled. 
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III.3.3. Binding of Radamide Grp94 
 
Co-crystallization of radamide with Hsp90 demonstrated radamide to exist in a trans-amide 
conformation within the binding pocket (Figure 24a).66 However, the co-crystal structure of 
radamide bound to Grp94 revealed the presence of two distinct conformations within the binding 
pocket (50% occupancy of each): the conformations contained a cis-amide or a trans-amide 
orientation (Figure 24b). The cis-amide conformation of radamide orients the quinone moiety 
directly towards the exclusive secondary binding pocket present in Grp94, and provides 
opportunity to develop Grp94-selctive inhibitors.  
III.4. Development of Grp94-Selective Inhibitors  
Prior studies in the Blagg laboratory have established that the quinone moiety is 
dispensable for Grp94 inhibition, which led to the development of compound 33 (Grp94 Kd = 20 
M). Structure-activity relationship studies were conducted on the phenyl ring.  A summary of 
these prior studies is provided in Figure 25. Chloride substituents at the 2- and the 3-position were 
advantageous, and a bromide at the 4-position proved most beneficial. The 4-bromophenyl amide 
 
Figure 24. Binding of radamide to Grp94 versus Hsp90. Co-crystal structures 




was the best compound resulting from this series, which manifested an apparent Kd of 1.5 M 
against Grp94. 
 
Simultaneous studies in the Blagg laboratory led to the 
development of the first rationally designed Grp94-selective 
inhibitor, BnIm.25 BnIm was developed by incorporation of a 
bioisosteric replacement (imidazole) of the cis-amide of radamide 
(Figure 25).  Grp94-selective inhibition was determined in cells by a 
decrease in Grp94-mediated Toll-like receptor trafficking to the cell 
surface and the lack of cytosolic Hsp90 client protein degradation. BnIm manifested apparent Kd 
of 1.14 M against Grp94. BnIm was co-crystallized with Grp94 and analysis of its co-crystal 
structure provided useful information about its binding interactions. Further development of BnIm 
analogues was pursued in parallel with radamide analogues. 
III.4.1 Development of Radamide Analogues as Grp94 Inhibitors 
Based on prior studies, the development of radamide and BnIm analogues was pursued for 
selective Grp94 inhibition. Additionally, a resorcinol-isoindoline scaffold was also sought. In an  
 
 
Figure 25. Summary of prior studies on radamide -derived Grp94 inhibitors. 
 
       
 






effort to further improve Grp94-selective binding, tertiary amides were proposed (Figure 27), 
which were expected to favor the cis-amide conformation by making the cis-conformation lower 
in energy, and therefore providing Grp94-selectivity. In a second series of analogues, heterocyclic 
anilines were introduced in lieu of the phenyl ring. Due to the -rich nature of the secondary 
binding pocket, replacement of the phenyl ring with heterocycles was hypothesized to improve 
 interactions and thereby improve affinity for Grp94. Additionally, electron withdrawing 
heterocycles were thought to enhance isomerization to the cis-amide conformation.  
III.4.1.1. Synthesis of Radamide Analogues  
The synthesis of proposed analogues 
started with previously reported 34. 1-Ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDCI) 
mediated coupling of 34, with requisite anilines 
(Figure 27) gave the amide products, and subsequent removal of tert-butyldimethylsilyl ethers 
 
Figure 27. Proposed radamide analogues for improved Grp94-inhibiton.  
 
 




utilizing tetra-n-butylammonium fluoride (TBAF) afforded the desired analogues, 3550 
(Scheme-6) 
 III.4.1.2. Evaluation of Radamide Analogues  
 
 
               
Figure 28. Evaluation of radamide analogues. 
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Once prepared, compounds 3550 were evaluated via a fluorescence polarization assay at 
25 M. This fluorescence polarization assay is a competitive binding assay that utilizes FITC-
labeled geldenamycin as a tracer.69, 70 The compounds of interest were evaluated for their ability 
to displace this tracer (FITC-GDA).69 The bound tracer is normalized to a DMSO control and is 
inversely proportional to the affinity of an inhibitor. For comparison, BnIm and compound 33 were 
used as positive controls. As shown in Figure 28, the tertiary amide containing compounds 35–37 
did not exhibit selectivity. Introduction of 2-pyridine, 1,2-diazene, 1,6-diazene, 3,5-diazene, 
thiazole, 1,2,4-thiadiazole, and 1,3,4-thidiazole were beneficial, as these compounds exhibited 
improved binding affinity for Grp94 at 25 M. The 2-pyridine containing analogue (38) was the 
best amongst this series and chosen for further development. As described earlier, halogen 
substitutions were beneficial on phenyl amide 33 and therefore, chloride and bromide substituents 
were incorporated onto the pyridine ring. Evaluation of compounds 4550 provided 49, which 
manifested affinity similar to 38 and provided a substantial improvement in selectivity for Grp94 
versus Hsp90.  
III.4.2. The Development of BnIm Analogues as Grp94 Inhibitors 
The binding of BnIm to Grp94 induced a conformational change in Grp94 compared to 
radamide bound Grp94.66 As shown in Figure 29a, BnIm bound to Grp94 shifts the N-terminal 
“lid” to a partially closed conformation (green), which contrasts with the open conformation that 
is observed when radamide bound Grp94 (colored red). This closed “lid” orientation resulted in 
repositioning of key amino acid residues (Phe195, Val 197, Phe199, Tyr200, Trp223) (Figure 29b). 
As a result of this conformational change, the phenyl side chain of BnIm projected toward Trp223. 
Additionally, the resorcinol moiety of BnIm was oriented 180° compared to radamide. The phenyl 
ring of BnIm produced multiple hydrophobic contacts with Trp223, Phe197, Val197. When 
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evaluating the co-crystal structures, it was envisioned that substitution at the 4-position would be 
tolerated and would produce improved affinity. Additionally, replacement of the phenyl side chain 
with heterocycles could also enhance  interactions between the ligand and the protein due to 
the -rich nature of this binding region (Scheme 7).  
 
III.4.2.1. Synthesis of BnIm Analogues 
The proposed compounds were synthesized by use of a multicomponent reaction.25 
Aldehyde (51) was prepared following a reported procedure, which upon treatment with the 
requisite benzyl amines, ammonium bicarbonate, and glyoxal produced the corresponding 
imidazole.71 Cleavage of tert-butyldimethylsilyl ethers in presence of tetra-n-butylammonium 
fluoride gave the desired products, 5260 (Scheme 7).  
III.4.2.2. Evaluation of BnIm Analogues 
At first, compounds 5260 were evaluated at a 25 M concentration in a fluorescence 
polarization assay. As shown in Figure 30, incorporation of the 4-methyl substituent significantly 
increased selectivity for Grp94 and maintained affinity compared to BnIm. However, the inclusion  
 
Figure 29. Binding of BnIm to Grp94. (a) Overlay of co-crystal structures of BnIm (“lid” is 
colored as green, Blagg and Gewirth, unpublished results) and radamide (“lid” is colored as 
red PDB: 2GFD) bound to Grp94. (b) reorientation of side chains (shown in sticks) in BnIm 
bound Grp94, the position of side chains in radamide bound Grp94 is shown in lines. (c) 





of extended alkyl chains were not tolerated and resulted in decreased affinity due to the steric 
clashes with the protein. Compound 52 was chosen from the 25 M screening to determine its 
apparent Kd against Hsp90 and Grp94, which manifested an apparent Kd of 730 nM and 34-fold 
selectivity for Grp94. Replacement of the phenyl side chain with heterocycles was more beneficial. 
Compounds 57 and 58 improved affinities for Grp94 and maintained selectivity. Molecular 
modeling studies suggested that the selectivity of 57 could be improved by the inclusion of a 
methyl group onto the 5-position of a furan ring. The overlay of energy minimized structures, 52 
and 57 indicated the 5-position of the furan to aligned similarly to the 4-position of phenyl ring 
 
Scheme 7. Synthesis of BnIm analogues.  
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within the Grp94-binding pocket. Evaluation of the 5-methylfuran analogue confirmed this 
hypothesis, as 60 manifested ~41-fold selectivity for Grp94.  
Table 10. Apparent Kd of BnIm analogues 






BnIm 1.14 + 0.1 13.1 + 1.1 12 
52 0.73 + 0.1 25.2 + 2.1 34 
56 1.5 + 0.1 3.77 + 0.4 3 
57 0.55 + 0.06 5.91 + 0.88 11 
58 0.47 + 0.07 3.92 + 0.51 8 
59 2.14 + 0.22 6.54 + 0.86 3 
60 0.65 + 0.1 26.6 + 2.3 41 
Figure 30. Evaluation of BnIm analogues. 
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III.4.3. Development of Resorcinol-Isoindoline 
Class of Grp94 Inhibitors 
   As previously mentioned, the co-crystal 
structure of BnIm demonstrated a re-orientation of the 
protein, as well as a 180° rotation of the resorcinol ring. 
An overlay of BnIm’s co-crystal structures with Grp94 
and Hsp90 revealed the conformational change, 
which formed an exclusive sub-pocket near the ester of 
BnIm as shown in Figure 31. Based on these 
observations, it was hypothesized that ligands targeting this region of the Grp94 binding pocket 
would provide selectivity for Grp94 versus other Hsp90 isoforms. Therefore, in pursuit of more 
efficacious Grp94 inhibitors, modifications to the resorcinol ring were pursued.  
Modifications at the 5-position of the resorcinol ring of BnIm were deemed difficult, and 
consequently an alternative scaffold was pursued to rapidly access analogues that bind to this 
unique sub-pocket. After careful consideration, the resorcinol-isoindoline compound 61 was 
chosen for the development of 5-resorcinol analogues. Compound 61 is derived from a known 
Hsp90 inhibitor, AT13387 (Figure 32a) and was synthesized following literature procedure.72, 73 
For selective Grp94-inhibiton, the incorporation of alkyl esters and aryl groups onto the 5-position 
was proposed, via the preparation of compounds 6264 to gain understating of the binding pocket. 
Compounds 62 and 63 were designed to mimic ester moiety of BnIm, and compound 64 was 
proposed to produce hydrophobic interactions with the sub-pocket. In parallel to these studies, 
Patel and co-workers identified a purine-derived inhibitor PU-WS13 (Figure 32a) that also take 
advantage of this Grp94 sub-pocket.44, 74 They screened a library of Hsp90 inhibitors against all 
 
 
 Figure 31. An overlay of co-crystal 
structure of BnIm bound to 
Hsp90green and Grp94 (blue).  
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Hsp90 isoforms and identified, PU-WS13  as Grp94-selctive inhibitors. Compounds 6265 were 
then proposed to confirm their findings as they encompass optimal aryl substitutions obtained from 
their studies. 
III.4.3.1 Syntheses of Resorcinol-Isoindoline Analogues 
 
Synthesis of the proposed analogues began via the preparation of 69 following literature  
procedures.75 As shown in Scheme 8, the proposed analogues were prepared via palladium 
catalyzed cross-coupling reactions with 69. A palladium catalyzed decrboxylative coupling 
reaction of 69 enlisting ethyl potassium oxalate, palladium (II) trifluoroacetate, and 1,3-
Bis(diphenylphosphino)propane (dppp), and subsequent cleavage of the benzyl ethers furnished 
the desired compound, 62.76 Transesterification of 62 in the presence of methanol gave methyl 
Figure 32. Development of resorcinol-isoindoline class of Grp94-selective inhibitors. (a) 
Structure of AT13387 and PU-WS13. (b) Proposed resorcinol-isoindoline compounds for 
selective Grp94 inhibition. 
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ester, 63. N-methyl aniline in 64 was coupled by the use of  
Tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in the presence of RuPhos.
77 For the 
syntheses of compounds 6568, the requisite thiols were coupled enlisting (Pd2(dba)3), sodium 
tert-butoxide, and XPhos to give corresponding thioethers.78 However, this reaction did not work  
for synthesis of 68, as 2,4-dichlorobenzethiol is sterically hindered and is an electronically 
disfavored coupling partner. Instead, synthesis of 65 was accomplished with palladium acetate 
(Pd(OAc)2) and the Josiphos ligand.
79, 80 The benzyl ethers of these intermediates phenyl thioethers 
were cleaved via boron tribromide to furnish the corresponding resorcinol products 6568.  
 
III.4.3.2. Evaluation of Resorcinol-Isoindoline Class of Grp94 Inhibitors 
Binding affinity of compounds 6268 were determined against Hsp90 and Grp94 in the 
FP assay and summarized in Table 11. Aryl thioether containing compounds, 6568, manifested  
 
 
Scheme 8. Synthesis of resorcinol-isoindoline class of Grp94 inhibitors.  
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low nM affinity for Grp94. Surprisingly, these compounds did not manifest selectivity over 
Hsp90Similarly, N-methyl aniline containing 64 manifested apparent Kd of 17 nM against 
Grp94 and manifested only a two-fold selectivity over Hsp90. The most selective compound of 
this series was the 2,4-dichlorophenyl thioether 68, which manifested 8-fold selectivity for Grp94. 
Incorporation of a methyl ester (63) at the 5-position did not increase affinity for Hsp90 or Grp94. 
Conversely, the ethyl ester 62 manifested IC50 of 0.77 M with 5-fold selectivity for Grp94.  
Table 11. Evaluation of resorcinol-isoindoline class of Grp94 inhibitors 






BnIm 1.14 + 0.1 13.1 + 1.1 12 
62 0.77 + 0.1 3.52 + 2.3 5 
63 >10 >10 - 
64 0.017 + 0.003 0.034 + 0.008 2 
65 0.021 + 0.003 0.066+ 0.006 3 
66 0.033 + 0.002 0.075 + 0.004 2 
67 0.031 + 0.003 0.029 + 0.010 - 
68 0.059 + 0.006 0.460 + 0.006 8 
 
These results were unexpected as these compounds were predicted to selectively bind 
Grp94. The excellent binding affinities against Hsp90 indicate that these substitutions are also 
accommodated within the Hsp90 ATP-binding pocket. In depth analysis of various co-crystal 
structures of  Hsp90 revealed that some purine-derived ligands induce an extra binding channel 
in Hsp90, which is not usually induced with resorcinol derived inhibitors.44, 81 Overlay of these 
purine-bound co-crystal structures with our resorcinol based inhibitors revealed this binding 
channel in Hsp90 expands about the 5-position of the resorcinol ring (Figure 33a and 33b).  An 
overlay of two co-crystal structures of purine based inhibitors (PU-H36 and PU-H54) bound to 
Hsp90 (PDB: 3O0I) and Grp94 (PDB: 3O2F) suggests that the phenyl ring attached to a sulfanyl 
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linker can bind both Grp94 and Hsp90.74 As shown in Figure 33b, an 80° tortional rotation about 
the sulfanyl linker can project the 8-phenyl ring into the Hsp90-specific binding channel from 
the Grp94-specific subpocket. When compound 65 was modeled in these co-crystal structures, the 
rotation about the sulfanyl linker indicated that the phenyl ring could be accommodated in both 
the Hsp90 and Grp94 binding pockets, resulting in no selectivity (Figure 33c & 33d).  
 
These results indicate that modification at the 5-position of the resorcinol may induce an 
opening of a binding channel that is similar to that observed with purine inhibitors, resulting in the 
inhibition of Grp94 and Hsp90For selective Grp94 inhibition, incorporation of a linker-less aryl 
group at the 5-position was therefore proposed. A linker appears to be required to project 5-aryl 
substituents towards the Hsp90-specific binding pocket (Figure 33d) and hence, the omission of 
a nitrogen or sulfur linker would produce a molecule that induces a steric clash with Phe138 within 
the Hsp90binding site. However, this modification should be accommodated in the Grp94-
                    
Figure 33. Binding modes of compound 61 and 65. (a) Compound 61 modeled in different co-
crystal structures of Hsp90, with and without additional binding pocket around 5-position of 
resorcinol ring. (green, PDB: 3O0I, orange, PDB: 2XAB). (b) Overlay of purine based-
inhibitors bound to Hsp90(Green PDB: 3O0I) and Grp94 (blue, PDB: 3O2F). (c) Proposed 
binding mode of 65 in Grp94; (d) Proposed binding mode of 65 in Hsp90. (e) Structures of 
PU-H36 and PU-H54. 
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binding pocket. To test this hypothesis, two molecules containing a phenyl and a furan attached to 
the 5-position of resorcinol ring were proposed. As shown in Figure 34, a furan will be 
accommodated in the Grp94 binding pocket as the oxygen would interact favorably with Asn107.   
 
Analogues 70 and 71 were synthesized via a Suzuki cross-coupling reaction between 
phenyl boronic acid or 2-furylboronic acid with 69, followed by hydrogenolysis (Scheme 9). These 
molecules were evaluated via a fluorescence polarization assay for their affinity and selectivity 
(Table 12). Analogue 71 manifested an apparent Kd of 220 nM for Grp94 with 35-fold selectivity 
over Hsp90. Unfortunately, 70 did not bind at the highest concentration tested (100 M). 
Table 12. Apparent Kd values of des-linker analogues 70 and 71 






BnIm 1.14 + 0.1 13.1 + 1.1 12 
70 >100 >100 - 
71 0.22 + 0.029 7.79 + 1.02 35 
 
III.5. Conclusions and Future Directions 
 
Scheme 9. Syntheses of compounds 70 and 71. 
 
 Figure 34. Overlay of proposed binding 
modes of 71in Hsp90 (green, PDB 




The co-crystal structures of several pan-Hsp90 inhibitors bound to Hsp90, Hsp90 and 
Grp94 provided strong rationale for the structure-based design of Grp94-selective inhibitors. Three 
different scaffolds were evaluated during the pursuit of selective Grp94-selective inhibitors. 
Studies on the pan-Hsp90 inhibitor, radamide generated improved Grp94-selective inhibitors and 
modifications to the aryl side chain of BnIm provided a 40-fold selective analog with an apparent 
Kd of 650 nM.  The resorcinol-isoindoline scaffold was also evaluated to probe the second 
exclusive sub-pocket of Grp94, which led to the identification of the highly efficacious Grp94-
selective inhibitor 71, which can serve as a starting point for the development of more potent 
inhibitors. Evaluation of compound 71 against Her2-positive cancer cells and multiple myeloma 
cells is currently underway.  In collaboration with Chad Dickey’s lab at the University of South 
Florida, compound 71 will be evaluated for the potential treatment of glaucoma. Together, these 
Grp94-selective inhibitors will enable identification of more Grp94-specific client proteins and 
lead to the further understanding of the Grp94-dependent processes. 
III.6. Methods and Experiments 
All reactions were performed in oven-dried glassware under argon atmosphere unless 
otherwise stated. Dichloromethane (DCM), tetrahydrofuran (THF), and toluene were passed 
through a column of activated alumina prior to use. Anhydrous methanol, acetonitrile, and N-
methyl-2-pyrrolidone (NMP) were purchased and used without further purification. Flash column 
chromatography was performed using silica gel (40−63 μm particle size). The 1H (500 and 400 
MHz) and 13C NMR (125 and 100 MHz) spectra were recorded on 500 and 400 MHz spectrometer. 
Data are reported as p = pentet, q = quartet, t = triplet, d = doublet, s = singlet, br s = broad singlet, 
m = multiplet; coupling constant(s) in Hz. Infrared spectra were obtained using FT/IR 
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spectrometer. High resolution mass spectral data were obtained on a time-of-flight mass 
spectrometer and analysis was performed using electrospray ionization.  
Fluorescence Polarization Assay 
The assay was performed in 96-well format in black, flat bottom plates (Santa Cruz 
Biotechnology) with a final volume of 100 μL. 25 μL of assay buffer (20 mM HEPES, pH 7.3, 50 
mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 0.01% NP-40) 
containing 6 nM FITC-GDA (fluorescent tracer, stock in DMSO and diluted in assay buffer) and 
50 μL of assay buffer containing 10 nM of either Grp94 or Hsp90α were added to each well. 
Compounds were tested in triplicate wells (1% DMSO final concentration). For each plate, wells 
containing buffer only (background), tracer in buffer only (low polarization control), and protein 
and tracer in buffer with 1% DMSO (high polarization control) were included. Plates were 
incubated at 4 °C with rocking for 24 h. Polarization values (in mP units) was measured at 37 °C 
with an excitation filter at 485 nm and an emission filter at 528 nm. Polarization values were 
correlated to % tracer bound and compound concentrations. The concentration of inhibitor at 
which the tracer was 50% displaced represents apparent Kd. 
General method for amide formation for compounds 35–36 and 38–50 
To a solution of acid 34 (0.05 mmol), EDCI·HCl (0.12 mmol), and pyridine (0.13 mmol) 
in dichloromethane (1 mL) was added the corresponding aniline (0.1 mmol) and stirred at room 
temperature under argon overnight. Upon complete consumption of acid 34, the solvent was 
removed and the residue dissolved in THF (1 mL). The reaction mixture was then treated with 
TBAF (0.2 mmol) and stirred for 30 min, and upon completion saturated aqueous NH4Cl was 
added and extracted with ethyl acetate. The combined organic layers were then dried over Na2SO4, 
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filtered, and concentrated to give a crude oil. The residue was purified via flash chromatography 
(SiO2, 49:1 CH2Cl2/MeOH) to afford the desired amides. 
 
 
Methyl 3-chloro-4,6-dihydroxy-2-(3-(methyl(phenyl)amino)-3-oxopropyl)benzoate (35): 
28 mg, 77% yield, white amorphous solid: 1H NMR (400 MHz, CDCl3–MeOD) δ 7.34 (dd, J = 8.4, 
6.8 Hz, 2H), 7.31–7.23 (m, 2H), 7.15–7.08 (m, 2H), 6.33 (s, 1H), 3.87 (s, 3H), 3.25 (d, J = 7.5 Hz, 
5H), 2.35–2.27 (m, 2H); 13C NMR (CDCl3–CH3OH, 125 MHz) δ 172.9, 171.0, 162.1, 157.9, 
143.7, 142.3, 130.0 (2), 128.1, 127.2 (2), 114.8, 106.0, 102.3, 52.4, 37.6, 33.4, 28.9; (ESI+) m/z 
[M+H+] calcd for C18H19ClNO5, 364.0952; found 364.0943. 
 
 
Methyl 3-chloro-2-(3-(ethyl(phenyl)amino)-3-oxopropyl)-4,6-dihydroxybenzoate (36): 
30 mg, 79% yield, white amorphous solid: 1H NMR (500 MHz, CDCl3–CD3OD) δ 7.34 (t, 
J = 7.7 Hz, 2H), 7.31–7.24 (m, 2H), 7.06 (dd, J = 7.3, 1.7 Hz, 2H), 6.33 (d, J = 4.0 Hz, 1H), 3.87 
(d, J = 3.9 Hz, 3H), 3.70 (q, J = 7.1 Hz, 3H), 3.27–3.19 (m, 2H), 2.34–2.16 (m, 2H), 1.07 (td, 
J = 7.2, 3.4 Hz, 3H); 13C NMR (CDCl3– CD3OD, 125 MHz) δ 172.3, 171.0, 162.0, 157.9, 142.3, 
141.9, 129.9 (2), 128.3 (2), 128.2, 114.7, 106.1, 102.2, 52.4, 44.3, 33.7, 28.8, 13.0; (ESI+) m/z 





Methyl 3-chloro-4,6-dihydroxy-2-(3-(isopropyl(phenyl)amino)-3-oxopropyl)benzoate (37):  
A solution of benzyl protected acid 1a (100 mg, 0.22 mmol) in dichloromethane was treated with 
oxalyl chloride (23 μL, 0.33 mmol) under argon atmosphere and then stirred at room temperature 
for 2 h. The solvent was then removed and the residue was placed under high vacuum for 30 min 
to remove any unreacted oxalyl chloride. The residue was then re-dissolved in dry CH2Cl2 (3 mL), 
cooled to 0 °C, and was treated sequentially with diisopropylethyl amine (57 μL, 0.33 mmol) and 
N-isopropylaniline (72 μL, 0.33 mmol). The resulting mixture was stirred at room temperature 
overnight under Ar. The solvent was removed and the residue was passed through a short pad of 
silica (1:1, ethyl acetate/Hexanes) and was concentrated to afford the amide crude product, which 
was dissolved in methanol (5 mL) and treated with Pd/C (10%). The resulting suspension was 
charged with a hydrogen balloon and stirred under H2 at room temperature for 16 h, filtered 
through celite, concentrated, and purified by flash chromatography (SiO2, 1:1 EtOAc/Hexanes) to 
afford compound 51 (30 mg, 35% yield over 2 steps) as a white solid. 1H NMR (400 MHz, 
CDCl3): δ 7.45–7.27 (m, 13H), 7.06–7.12 (m, 2H), 6.41 (s, 1H), 5.07 (hept, J = 6.8 Hz, 1H), 5.04 
(s, 2H), 4.98 (s, 2H), 3.88 (s, 3H), 3.03–2.93 (m, 2H), 2.30–2.21 (m, 2H), 1.08 (d, J = 6.8 Hz, 6 
H). 13C NMR (125 MHz, CDCl3): δ 171.1, 167.5, 155.4, 154.5, 138.6, 138.3, 136.2, 135.9, 130.3, 
129.2, 128.6, 128.5, 128.1, 127.9, 126.9, 126.8, 118.4, 115.5, 98.2, 70.9, 70.8, 52.4, 45.8, 34.4, 





Methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyridin-2-ylamino)propyl)benzoate (38):  10 mg, 
62 %, pale yellow amorphous solid:1H NMR (500 MHz, (CD3)2CO) δ 8.39–8.07 (m, 2H), 7.80 
(dd, J = 8.7, 7.4, 1.8 Hz, 1H), 7.10 (dd, J = 7.3, 4.8, 1.1 Hz, 1H), 6.55 (s, 1H), 3.99 (s, 3H), 3.57–
3.42 (m, 2H), 2.98–2.77 (m, 2H). 13C NMR (125 MHz, (CD3)2CO) δ 171.60, 162.34, 158.67, 
153.19, 148.85, 143.11, 138.72, 120.02, 114.86, 114.29, 108.11, 103.12, 52.92, 36.62, 28.77. 
HRMS (ESI+) m/z [M+Na+] calcd for C16H15ClN2O5Na, 373.0669; found, 373.0630. 
 
 
Methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyridazin-3-ylamino)propyl)benzoate (39): 
26 mg, yield 74%, white amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 10.04 (s, 1H), 8.92 
(dd, J = 4.7, 1.5 Hz, 1H), 8.47 (dd, J = 9.0, 1.5 Hz, 1H), 7.63 (dd, J = 9.0, 4.7 Hz, 1H), 6.52 (s, 
1H), 3.94 (s, 3H), 3.54–3.38 (m, 2H), 2.99–2.84 (m, 2H); 13C NMR (125 MHz, (CD3)2CO) δ 
158.78, 149.10, 142.85, 128.79, 118.60, 118.54, 103.20, 52.93, 36.60, 28.60; HRMS (ESI+) m/z 
[M+Na+] calcd for C15H14ClN3O5Na, 374.0520; found 374.0534. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyrimidin-2-ylamino)propyl)benzoate (40):  
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21 mg, yield 60%, white amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 9.04 (d, J = 1.3 Hz, 
2H), 8.83 (s, 1H), 6.51 (s, 1H), 3.94 (s, 3H), 3.57–3.31 (m, 2H), 2.82–2.69 (m, 2H); 13C NMR 
(125 MHz, (CD3)2CO): δ 171.7, 171.2, 158.6, 154.2, 148.0, 147.9, 142.7, 135.6, 135.5, 114.8, 




Methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyrimidin-5-ylamino)propyl)benzoate (41): 
23 mg, 66% yield, white amorphous solid: 1H NMR (400 MHz, CDCl3– CD3OD) δ 9.01 (s, 2H), 
8.84 (s, 1H), 6.42 (s, 1H), 3.91 (s, 3H), 3.59–3.36 (m, 2H), 2.70–2.51 (m, 2H); 13C NMR (CDCl3, 
125 MHz): δ 172.1, 170.9, 162.0, 158.1, 152.9, 147.6 (2), 141.8, 114.8 (2), 106.2, 102.6, 52.6, 
35.7, 28.2; (ESI+) m/z [M+H+] calcd for C15H15ClN3O5, 352.0712; found 352.0712. 
 
 
Methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(thiazol-2-ylamino)propyl)benzoate (42): 30 mg, 
84% yield, white amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 7.40 (d, J = 3.6 Hz, 1H), 
7.11 (d, J = 3.6 Hz, 1H), 6.52 (s, 1H), 3.94 (s, 3H), 3.57–3.34 (m, 2H), 2.98–2.78 (m, 2H); 13C 
NMR ((CD3)2CO, 125 MHz) δ 171.3, 170.7, 162.4, 158.9, 158.7, 142.7, 138.5, 114.9, 113.9, 







(43): 28 mg, 78% yield, white amorphous solid: 1H NMR (500 MHz, CDCl3– CD3OD) δ 8.79 (d, 
J = 0.9 Hz, 1H), 6.44 (d, J = 0.9 Hz, 1H), 3.89 (d, J = 0.9 Hz, 3H), 3.62–3.30 (m, 2H), 2.93–2.40 
(m, 4H); 13C NMR(CDCl3– CD3OD, 125 MHz): 171.0, 170.9, 162.3, 159.5, 158.1, 148.0, 141.3, 





(44): 19 mg, 53% yield, white amorphous solid: 1H NMR (400 MHz, CDCl3– CD3OD) δ 8.19 (s, 
1H), 7.72 (s, 1H), 6.36 (s, 1H), 3.83 (s, 3H), 3.50–3.32 (m, 2H), 2.91–2.69 (m, 2H); 13C NMR 
(CDCl3– CD3OD, 125 MHz): δ 179.3, 176.3, 174.5, 163.0, 162.2.161.6, 144.8, 118.6, 110.2, 







(45): 27 mg, 70% yield, white amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 10.88 (1H, br 
s), 9.48 (1H, br s)8.09 (dd, J = 8.2, 1.8 Hz, 1H), 7.80–7.58 (m, 1H), 7.00 (dd, J = 7.9, 1.7 Hz, 1H), 
6.63–6.10 (m, 1H), 3.93 (s, 3H), 3.46–3.10 (m, 2H), 2.91–2.55 (m, 2H); 13C NMR (125 MHz, 
(CD3)2CO) δ 172.1, 171.5, 158.8, 153.3, 149.6, 143.1, 142.2, 119.9 (2), 115.0, 112.8, 108.3, 103.3, 




(46): 21 mg, 55% yield, white amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 8.36 (dd, 
J = 4.7, 1.6 Hz, 1H), 7.92 (dd, J = 8.0, 1.6 Hz, 1H), 7.27 (ddd, J = 8.0, 4.7, 0.6 Hz, 1H), 6.52 (s, 
1H), 3.97 (s, 3H), 3.55–3.39 (m, 2H), 3.00–2.76 (m, 2H). 13C NMR (125 MHz, (CD3)2CO) δ 171.4, 
171.28, 158.6, 149.3, 147.5, 143.2 (2), 139.3, 122.9 (2), 114.8, 108.14, 103.1, 52.9, 35.9, 28.8; 




(47): 31 mg, 71% yield, white amorphous solid: 1H NMR (400 MHz, CDCl3–MeOD) δ 8.47 (dd, 
J = 4.7, 1.6 Hz, 1H), 7.98 (dd, J = 8.0, 1.6 Hz, 1H), 7.27–7.22(m, 1H), 6.34 (s, 1H), 3.85 (s, 3H), 
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3.35–3.29 (m, 2H), 2.91–2.65 (m, 2H). 13C NMR (125 MHz, CDCl3,): δ 172.8, 170.0, 161.2, 156.9, 
149.7, 147.8, 141.7, 140.6, 124.9, 120.3, 113.8, 105.0, 101.4, 51.6, 36.3, 26.6. (ESI+) m/z [M+Na+] 




(48): 31 mg, 71% yield, white amorphous solid: 1H NMR (400 MHz, CDCl3– CD3OD) δ 8.47 (dd, 
J = 4.7, 1.6 Hz, 1H), 7.98 (dd, J = 8.0, 1.6 Hz, 1H), 7.27–7.22(m, 1H), 6.34 (s, 1H), 3.85 (s, 3H), 
3.35–3.29 (m, 2H), 2.91–2.65 (m, 2H). 13C NMR (125 MHz, CDCl3,): δ 172.8, 170.0, 161.2, 156.9, 
149.7, 147.8, 141.7, 140.6, 124.9, 120.3, 113.8, 105.0, 101.4, 51.6, 36.3, 26.6. (ESI+) m/z [M+Na+] 




(49): 29 mg, 68% yield, white amorphous solid: 1H NMR (500 MHz, CDCl3–MeOD) δ 8.31–8.19 
(m, 1H), 8.19–8.05 (m, 1H), 7.84–7.71 (m, 1H), 6.54–6.28 (m, 1H), 3.94 (s, 3H), 3.42–3.35 (m, 
2H), 2.63 (dq, J = 12.7, 3.8, 2.1 Hz, 2H); 13C NMR (CDCl3– CD3OD, 125 MHz): δ 171.5, 170.9, 
162.1, 158.2, 150.2, 148.6, 141.6, 141.0, 115.5, 114.8, 114.5, 106.1, 102.6, 52.6, 36.4, 28.3. (FAB) 






benzoate (50): 12 mg, 28% yield, gray amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 6.53 
(s, 1H), 3.94 (s, 4H), 3.59–3.43 (m, 2H), 3.05–2.84 (m, 2H). 13C NMR (125 MHz, (CD3)2CO): δ 
171.7, 161.6, 158.7, 142.2, 134.8, 130.6, 114.9, 108.1, 103.3, 79.3, 53.0, 35.2, 21.1. HRMS (ESI+) 
m/z [M+H+] calcd for C13H12BrClN3O5S: 435.9370; found 435.9377. 
General procedure for multicomponent cyclization reaction: 
Requisite benzyl amines (0.26 mmol, 1.0 eq.) were added to a stirred solution of 9 (125 
mg, 0.26 mmol, 1.0 eq.) in wet methanol (2 mL) and stirring continued for 30 min at rt before the 
addition of NH4HCO3 (0.26 mmol) and glyoxal (0.26 mmol). After stirring for 12 h, 
tetrabutylammonium fluoride (0.52 mL of 1 M solution in THF, 0.52 mmol) was added and then 
stirred for 30 min before the reaction was quenched with saturated ammonium chloride solution 
(10 mL) and extracted with ethyl acetate (3 × 10 mL). The organic layers were combined, dried 
(Na2SO4), filtered, and concentrated. The residue was purified via flash chromatography (SiO2, 




(52): 44 mg (43%), off-white amorphous solid. 1H NMR (500 MHz, CD3OD) δ 7.15 (d, J = 7.9 
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Hz, 2H), 7.03 (d, J = 1.4 Hz, 1H), 7.00–6.96 (m, 2H), 6.94 (d, J = 1.5 Hz, 1H), 6.39 (s, 1H), 5.05 
(s, 2H), 3.77 (s, 3H), 3.37–3.30 (m, 2H), 2.97–2.89 (m, 2H), 2.31 (s, 3H). 13C NMR(125 MHz, 
MeOD) δ 171.3, 160.9, 159.0, 148.8, 141.5, 138.9, 135.1, 130.5 (2), 127.9 (2), 127.1, 121.8, 115.0, 
110.1, 103.3, 52.8, 50.1, 31.5, 27.3, 21.1. HRMS (ESI+) m/z [M + H]+ for C21H22ClN2O4, 




(53):37 mg (39%), off white amorphous solid. 1H NMR (500 MHz, CDCl3, CD3OD) δ 7.14 (d, J 
= 8.1 Hz, 2H), 7.11–7.08 (m, 1H), 6.98–6.91 (m, 2H), 6.85 (d, J = 1.5 Hz, 1H), 6.44 (s, 1H), 4.96 
(s, 3H), 3.54–3.45 (m, 2H), 3.04 (t, J = 7.9 Hz, 2H), 2.59 (q, J = 7.6 Hz, 2H), 1.17 (td, J = 7.6, 1.0 
Hz, 3H). 13C NMR (125 MHz, CDCl3, CD3OD) δ 170.6, 162.1, 158.2, 147.2, 145.0, 140.9, 132.1, 
128.8 (2), 127.2 (2), 124.2, 120.6, 114.9, 106.2, 103.0, 50.0, 49.9, 30.7, 28.6, 25.6, 15.6. HRMS 
(ESI+) m/z [M + H]+ for C22H24ClN2O4, 415.1425; found 415.1432. 
 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-isopropylbenzyl)-1H-imidazol-2 yl)ethyl)benzoate 
(54): 25 mg (22%), white amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 8.1 Hz, 
2H), 7.03 (s, 1H), 6.90 (d, J = 8.2 Hz, 2H), 6.80 (d, J = 1.5 Hz, 1H), 6.49 (s, 1H), 4.95 (s, 2H), 
3.79 (s, 3H), 3.50 (t, J = 7.9 Hz, 2H), 3.00–2.92 (m, 2H), 2.82 (hept, J = 6.9 Hz, 1H), 1.16 (d, J = 
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7.0 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 170.63, 162.91, 157.32, 149.25, 147.18, 127.20 (2), 
126.81 (2), 120.19, 114.50, 106.24, 103.00, 99.98, 52.76, 49.56, 33.81, 30.77, 29.72, 23.93 (2). 




(55): 37 mg (39%), off white amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.79 (q, J = 7.8, 6.0 
Hz, 2H), 7.61–7.36 (m, 2H), 7.20–7.12 (m, 1H), 7.05 (s, 1H), 6.57 (s, 1H), 5.44–5.25 (m, 2H), 
4.00 (s, 3H), 3.57 (q, J = 7.7 Hz, 2H), 3.02 (t, J = 7.9 Hz, 2H). 13C NMR (125 MHz, CDCl3): 
170.4, 161.5, 158.0, 147.8, 142.0, 141.2, 132.8, (2), 127.7, 127.4, 127.0 (2), 120.2, 118.2, 114.5, 




Methyl 3-chloro-2-(2-(1-(furan-3-ylmethyl)-1H-imidazol-2-yl)ethyl)-4,6 Dihydroxybenzoate 
(56): 40 mg (41%), off-white amorphous solid. 1H NMR (500 MHz, CDCl3, CD3OD) δ 7.30 (d, J 
= 1.6 Hz, 1H), 7.20 (s, 1H), 6.84 (dd, J = 2.7, 1.4 Hz, 1H), 6.78 (d, J = 1.4 Hz, 1H), 6.36 (d, J = 
2.0 Hz, 1H), 6.15 (d, J = 1.9 Hz, 1H), 4.80 (s, 2H), 3.78 (d, J = 1.9 Hz, 3H), 3.39 (tt, J = 8.9, 2.5 
Hz, 2H), 2.95–2.80 (m, 2H). 13C NMR (125 MHz, CDCl3, CD3OD): δ 170.8, 161.8, 158.1, 147.3, 
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144.1, 141.6, 141.6, 140.1, 126.7, 121.0, 119.6, 114.7, 109.4, 106.2, 102.5, 52.4, 41.0, 30.8, 26.1. 




(57): 44 mg (45%), off-white amorphous solid. 1H NMR (500 MHz, CDCl3, CD3OD) δ 7.31 (dt, 
J = 2.4, 1.2 Hz, 1H), 6.87 (dd, J = 2.4, 1.4 Hz, 1H), 6.83 (d, J = 1.5 Hz, 1H), 6.40 (d, J = 1.8 Hz, 
1H), 6.26 (dt, J = 3.5, 1.7 Hz, 1H), 6.18 (d, J = 3.3 Hz, 1H), 4.94 (d, J = 1.6 Hz, 2H), 3.82 (d, J = 
1.9 Hz, 3H), 3.46 (ddd, J = 10.2, 6.1, 2.0 Hz, 2H), 2.95 (ddd, J = 9.8, 5.9, 1.5 Hz, 2H). 13C NMR 
(125 MHz, CDCl3, CD3O) δ 170.9, 162.0, 158.2, 149.1, 147.4, 143.2, 141.8, 126.9, 119.7, 114.8, 
110.6, 108.8, 106.2, 102.6, 52.6, 42.6, 30.8, 26.1. HRMS (ESI+) m/z [M + H]+ for C18H18ClN2O5, 




benzoate (58): 37 mg (37%), yellow amorphous solid. 1H NMR (400 MHz, CDCl3, CD3OD) δ 
7.23 (dd, J = 5.1, 1.3 Hz, 1H), 6.95 (d, J = 1.5 Hz, 1H), 6.92 (dd, J = 5.1, 3.5 Hz, 1H), 6.87 (dd, J 
= 3.5, 1.9 Hz, 2H), 6.43 (s, 1H), 5.17 (d, J = 0.9 Hz, 2H), 3.84 (s, 3H), 3.56–3.44 (m, 2H), 3.01–
2.92 (m, 2H). 13C NMR (125 MHz, CDCl3, CD3OD) δ 170.9, 162.1, 158.2, 147.3, 141.7, 138.5, 
127.2, 126.9, 126.4, 126.2, 119.7, 114.9, 106.2, 102.7, 52.6, 44.7, 30.9, 26.2. HRMS (ESI+) m/z 






benzoate (59): 8 mg (27%), yellow amorphous solid. 1H NMR (400 MHz, CDCl3, CD3OD) δ 7.25 
(d, J = 4.8 Hz, 1H), 6.98–6.92 (m, 2H), 6.83 (d, J = 1.5 Hz, 1H), 6.81–6.78 (m, 1H), 6.37 (s, 1H), 
4.97 (s, 2H), 3.79 (s, 3H), 3.43–3.37 (m, 2H), 2.95–2.88 (m, 2H). 13C NMR (126 MHz, CDCl3, 
CD3OD) δ 174.48, 165.67, 162.02, 151.06, 145.03, 140.31, 131.26, 130.04, 129.39, 126.69, 
124.00, 118.61, 110.15, 106.53, 56.40, 49.27, 34.49, 29.68. HRMS (ESI+) m/z [M + H]+ for 




ethyl)benzoate (60): 46 mg (46%), off white amorphous solid. 1H NMR (400 MHz, CDCl3, 
CD3OD) δ 6.87 (d, J = 1.4 Hz, 1H), 6.84 (d, J = 1.4 Hz, 1H), 6.41 (s, 1H), 6.08 (d, J = 3.1 Hz, 1H), 
5.84 (dd, J = 3.0, 1.2 Hz, 1H), 4.88 (s, 2H), 3.84 (s, 3H), 3.49–3.42 (m, 2H), 3.08–2.93 (m, 2H), 
2.18 (d, J = 1.0 Hz, 3H). 13C NMR (125 MHz, CDCl3, CD3OD) δ 171.0, 162.2, 158.3, 153.1, 147.3, 
147.1, 141.9, 126.7, 119.7, 114.9, 109.7, 106.5, 106.1, 102.6, 52.6, 42.7, 30.9, 26.2, 13.5. HRMS 





Ethyl 2,4-dihydroxy-5-(isoindoline-2-carbonyl)benzoate (62):  A biotage microwave vial was 
charged with 69 (150mg, 0.29 mmol, 1 eq.), ethyl potassium oxalate (68 mg, 0.44 mmol, 1.5 eq.), 
1,3-Bis(diphenylphosphino)propane ( 9mg, 0.021 mmol, 0.075 eq.), and palladium (II) 
trifluoroacetate (5mg, 0.015 mmol, 0.05 eq.). The tube was sealed with a cap lined with a 
disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before the 
addition of N-methyl 2-pyrrolidone (0.7 mL) by syringe. The resulting mixture was heated at 150 
°C for 24 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). 
Solvent was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl 
acetate/hexanes) to give the corresponding 5-ester product, which was used further as obtained, 
and taken in dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron 
tribromide (0.6 mL). The resulting mixture was stirred for 6 h, quenched with saturated sodium 
bicarbonate solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The combined 
organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue purified with flash chromatography (SiO2, 
1:2 ethyl acetate/hexanes) to give the desired product 62 as white amorphous solid (15 mg, 15 %). 
1H NMR (500 MHz, CDCl3) δ 12.21 (s, 1H), 11.19 (s, 1H), 8.29 (s, 1H), 7.34 (s, 4H), 6.54 (s, 1H), 
5.12 (s, 4H), 4.45 (q, J = 7.1 Hz, 2H), 1.44 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 
170.2, 169.6, 167.4, 165.6, 135.9 (2), 131.8 (2), 128.2 (2), 122.8, 109.7, 105.0, 104.6, 55.4, 53.8, 





Methyl 2,4-dihydroxy-5-(isoindoline-2-carbonyl)benzoate (63): A solution of 62 (20 mg, 0.06 
mmol, 1.0 eq.) in methanol was heated at 80 °C for 14 h in presence of 1,8 
Diazabicyclo[5.4.0]undec-7-ene (2 L, 0.012 mmol, 0.2 eq.). The solvent was removed and the 
residue purified with flash chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the desired 
product 63 as white amorphous solid (14 mg, 73%). 1H NMR (400 MHz, CDCl3 δ 12.27 (s, 1H), 
11.13 (s, 1H), 8.28 (s, 1H), 7.34 (s, 4H), 6.55 (d, J = 0.7 Hz, 1H), 5.12 (s, 4H), 3.99 (d, J = 0.7 Hz, 
3H). 13C NMR (125 MHz, CDCl3) δ 170.2, 169.6, 167.4, 165.6, 135.9 (2), 131.8 (2), 128.2 (2), 
122.8, 109.9, 105.2, 104.8, 55.4, 53.8, 52.7.  HRMS (ESI+) m/z [M+H+] calcd for C17H16NO5, 
314.1028, found, 314.1023.  
 
 
(2-Hydroxy-5-(methyl(phenyl)amino)phenyl)(isoindolin-2-yl)methanone (64): A biotage 
microwave vial was charged with 69 (180mg, 0.35 mmol, 1 eq.), N-methylaniline (45 L, 0.42 
mmol, 1.2 eq.), RuPhos (7 mg, 0.014 mmol, 0.04 eq), Tris(dibenzylideneacetone)dipalladium(0) 
(16mg, 0.017 mmol, 0.05 eq.), sodium tert-butoxide (40 mg, 0.53 mmol, 1.5 eq.). The tube was 
sealed with a cap lined with a disposable Teflon septum. The tube was evacuated and purged with 
nitrogen (3 times), before the addition of toluene (3.0 mL) by syringe. The resulting mixture was 
heated at 120 °C for 18 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl 
acetate). Solvent was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl 
acetate/hexanes) to give the corresponding 5-substituted product, which was used further as 
obtained, and taken in dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution 
of boron tribromide (0.6 mL). The resulting mixture was stirred for 6 h, quenched with saturated 
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sodium bicarbonate solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The 
combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated.  The residue purified with flash 
chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the desired product 64 as white 
amorphous solid (47 mg, 38 %). 1H NMR (500 MHz, CDCl3) δ 11.59 (s, 1H), 7.38 (s, 1H), 7.33 – 
7.21 (m, 6H), 6.90 (tt, J = 7.3, 1.1 Hz, 1H), 6.81 – 6.75 (m, 2H), 6.70 (s, 1H), 6.43 (s, 1H), 4.97 
(s, 4H), 3.23 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 170.2, 161.5, 149.6, 157.1, 135.7 (2), 129.3 
(3), 127.8 (2), 127.3, 127.1, 122.5 (2), 119.5, 114.7, 110.1, 103.7, 54.7, 53.8, 40.3. HRMS (ESI-) 
m/z [MH+] calcd for C22H19NO5, 359.1396, found 359.1387. 
 
 
(5-((3,4-Dimethylphenyl)thio)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (65): A 
biotage microwave vial was charged with 69 (180mg, 0.35 mmol, 1 eq.), 3,4-dimethylbenzenethiol 
(54 mg, 0.38 mmol, 1.1 eq.), 1,1 ferrocenediyl-bis(diphenylphosphine) (20 mg, 0.035 mmol, 0.1 
eq), Tris(dibenzylideneacetone)dipalladium(0) (17mg, 0.018 mmol, 0.05 eq.), N,N-
diisopropylethylamine (67 L, 0.39 mmol, 1.1 eq.). The tube was sealed with a cap lined with a 
disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before the 
addition of toluene (3.0 mL) by syringe. The resulting mixture was heated at 120 °C for 18 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to 
give the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
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(0.6 mL). The resulting mixture was stirred for 6 h, quenched with saturated sodium bicarbonate 
solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layers 
were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium 
sulfate, filtered, and concentrated. The residue purified with flash chromatography (SiO2, 1:2 ethyl 
acetate/hexanes) to give the desired product 65 as white amorphous solid (34 mg, 25 %). 1H NMR 
(500 MHz, CDCl3) δ 12.06 (s, 1H), 7.90 (s, 1H), 7.38 – 7.29 (m, 3H), 7.04 (d, J = 7.9 Hz, 1H), 
6.92 (d, J = 2.1 Hz, 1H), 6.87 – 6.81 (m, 2H), 6.70 (s, 1H), 5.08 (s, 4H), 2.28 – 2.13 (m, 6H). 13C 
NMR (125 MHz, CDCl3) δ 170.0, 165.2, 161.1, 138.2, 137.5, 135.4, 132.7, 130.8, 128.1 (2), 128.1 
(2), 124.5 (2), 122.8, 111.1, 107.0, 104.1, 55.7, 53.8, 20.1, 19.5. HRMS (ESI+) m/z [M+H+] calcd 
for C23H22NO3S, 392.1320, found 392.1317. 
 
 
(5-((3,5-Dimethylphenyl)thio)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (66): A 
biotage microwave vial was charged with 69 (180mg, 0.35 mmol, 1 eq.), 3,5-dimethylbenzenethiol 
(54 mg, 0.38 mmol, 1.1 eq.), 1,1′-ferrocenediyl-bis(diphenylphosphine) (20 mg, 0.035 mmol, 0.1 
eq.), Tris(dibenzylideneacetone)dipalladium(0) (17mg, 0.018 mmol, 0.05 eq.), N,N’-
diisopropylethylamine (67 L, 0.39 mmol, 1.1 eq.). The tube was sealed with a cap lined with a 
disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before the 
addition of toluene (3.0 mL) by syringe. The resulting mixture was heated at 120 °C for 18 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to 
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give the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.6 mL). The resulting mixture was stirred for 6 h, quenched with saturated sodium bicarbonate 
solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layers 
were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium 
sulfate, filtered, and concentrated. The residue purified with flash chromatography (SiO2, 1:2 ethyl 
acetate/hexanes) to give the desired product 66 as white amorphous solid (42 mg, 31 %). 1H NMR 
(500 MHz, CDCl3 δ 12.09 (s, 1H), 7.83 (s, 1H), 7.31 (dt, J = 6.4, 3.3 Hz, 3H), 7.05 – 7.02 (m, 1H), 
6.93 – 6.87 (m, 1H), 6.80 (s, 1H), 6.71 (s, 1H), 6.64 (d, J = 8.0 Hz, 1H), 5.04 (s, 4H), 2.44 (s, 3H), 
2.29 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 169.9, 165.1, 161.1, 137.4 (2), 136.2, 135.5 (2), 131.8 
(2), 131.6 (2), 127.8 (2), 126.0 (2), 111.2, 106.2, 104.2, 55.7, 53.8, 21.0, 20.1. HRMS (ESI-) m/z 
[MH+] calcd for C23H22NO3S, 390.1164, found 390.1151. 
 
 
(5-((3,5-Dichlorophenyl)thio)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (67): A 
biotage microwave vial was charged with 69 (150 mg, 0.29 mmol, 1 eq.), 3,5-dichlorobenzenethiol 
(52 mg, 0.29 mmol, 1.0 eq.), 1,1′-ferrocenediyl-bis(diphenylphosphine) (16 mg, 0.029 mmol, 0.1 
eq.), Tris(dibenzylideneacetone)dipalladium(0) (13mg, 0.015 mmol, 0.05 eq.), N,N’-
diisopropylethylamine (55 L, 0.39 mmol, 1.1 eq.). The tube was sealed with a cap lined with a 
disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before the 
addition of toluene (3.0 mL) by syringe. The resulting mixture was heated at 120 °C for 18 h, 
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cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to 
give the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.5 mL). The resulting mixture was stirred for 6 h, quenched with saturated sodium bicarbonate 
solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layers 
were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium 
sulfate, filtered, and concentrated.  The residue purified with flash chromatography (SiO2, 1:2 ethyl 
acetate/hexanes) to give the desired product 67 as white amorphous solid (23 mg, 18 %). 1H NMR 
(500 MHz, CDCl3) δ 12.11 (s, 1H), 7.88 (s, 1H), 7.35 – 7.30 (m, 4H), 7.18 (t, J = 1.8 Hz, 1H), 6.93 
(d, J = 1.8 Hz, 2H), 6.75 (s, 1H), 6.60 (s, 1H), 5.10 (s, 4H). 13C NMR (125 MHz, CDCl3) δ 169.7, 
166.0, 161.2, 140.4, 138.0 (2), 136.1(2), 128.2 (2), 126.6 (2), 124.1 (2), 122.8 (2), 111.8, 104.7, 
103.8, 54.9, 53.8. HRMS (ESI+) m/z [MH+] for C21H16Cl2NO3S, 433.0306, found 433.0317. 
 
 
(5-((2,4-Dichlorophenyl)thio)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (68): A 
biotage microwave vial was charged with 69 (150 mg, 0.29 mmol, 1 eq.), 2,4-dichlorobenzenethiol 
(52 mg, 0.29 mmol, 1.0 eq.), JosiPhos (4 mg, 0.001 mmol, 0.02 eq.), palladium (II) acetate (7 mg, 
0.029 mmol, 0.1 eq.), sodium tert-butoxide (41 mg, 0.32 mmol, 1.1 eq.). The tube was sealed with 
a cap lined with a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 
times), before the addition of toluene (1.0 mL) by syringe. The resulting mixture was heated at 
120 °C for 18 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). 
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Solvent was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl 
acetate/hexanes) to give the corresponding 5-substituted product, which was used further as 
obtained, and taken in dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution 
of boron tribromide (0.5 mL). The resulting mixture was stirred for 6 h, quenched with saturated 
sodium bicarbonate solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The 
combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue purified with flash 
chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the desired product 68 as white 
amorphous solid (17 mg, 14 %). 1H NMR (400 MHz, CDCl3) δ 12.21 (s, 1H), 7.89 (s, 1H), 7.42 
(d, J = 2.1 Hz, 1H), 7.32 (s, 5H), 7.11 (dd, J = 8.6, 2.2 Hz, 1H), 6.74 (s, 1H), 6.61 (s, 1H), 6.58 (s, 




(4,6-Dihydroxy-[1,1'-biphenyl]-3-yl)(isoindolin-2-yl)methanone (70): A biotage microwave 
vial was charged with 69 (100 mg, 0.19 mmol, 1 eq.), phenyl boronic acid (549 mg, 0.39 mmol, 
2.0 eq.), and [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium (27 mg, 0.038 mmol, 0.2 
eq). The tube was sealed with a cap lined with a disposable Teflon septum. The tube was evacuated 
and purged with nitrogen (3 times), before the addition of a solvent mixture of toluene (1.0 mL), 
ethanol (1.0 mL), and saturated sodium bicarbonate solution (1.0 mL) by syringe. The resulting 
mixture was heated at 80 °C for 14 h, cooled to rt, and filtered through a small pad of celite (elution 
with ethyl acetate). Solvent was removed and the residue purified by flash chromatography (SiO2, 
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1:3 ethyl acetate/hexanes) to give the corresponding 5-substituted product, which was used further 
as obtained, and taken in dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M 
solution of boron tribromide (0.5 mL). The resulting mixture was stirred for 6 h, quenched with 
saturated sodium bicarbonate solution (5 mL) and extracted with dichloromethane (2 × 10 mL). 
The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried 
over anhydrous sodium sulfate, filtered, and concentrated.  The residue purified with flash 
chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the desired product 70 as white 
amorphous solid (31 mg, 49 %). 1H NMR (500 MHz, CDCl3) δ 11.67 (s, 1H), 7.57 (s, 1H), 7.56 – 
7.41 (m, 5H), 7.34 – 7.28 (m, 4H), 6.63 (s, 1H), 5.78 (s, 1H), 5.11 (s, 4H). 13C NMR (125 MHz, 
CDCl3) δ 170.7, 162.6, 156.8, 136.6, 136.0 (2), 130.4, 129.7 (4), 128.1 (3), 128.0, 122.8, 119.7, 




(5-(furan-2-yl)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (71): A biotage microwave 
vial was charged with 69 (100 mg, 0.19 mmol, 1 eq.), 2-furanylboronic acid (43mg, 0.39 mmol, 
2.0 eq.), tetrakis(triphenylphosphine)palladium (0) (67 mg, 0.06 mmol, 0.3 eq), and cesium 
carbonate (76 mg, 0.23 mmol, 1.2 eq.). The tube was sealed with a cap lined with a disposable 
Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before the addition of 
a solvent mixture of toluene (1.5 mL) and methanol (0.5 mL) by syringe. The resulting mixture 
was heated at 110 °C for 1 h under microwave heating. The reaction mixture was filtered through 
a small pad of celite (elution with ethyl acetate). Solvent was removed and the residue purified by 
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flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the corresponding 5-substituted 
product, which was subjected to hydrogenolysis as obtained. The residue was dissolved in a 
solvent mixture of ethyl acetate (1.5 mL) and ethanol (0.5 mL), followed by the addition of 10% 
palladium on carbon and cyclohexene (0.2 mL). The resulting mixture was heated at 100 °C for 
14 h, filtered through a pad of celite (elution with ethyl acetate), and concentrated. The residue 
purified with flash chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the desired product 
71 as white amorphous solid (13 mg, 14 %). 1H NMR (400 MHz, CDCl3) δ 11.51 (s, 1H), 7.84 (s, 
1H), 7.45 (dd, J = 1.8, 0.8 Hz, 1H), 7.20  7.24 (m, 4H), 6.97 (s, 1H), 6.60 – 6.56 (m, 1H), 6.50 
(br s, 1H), 6.48 (dd, J = 3.4, 1.9 Hz, 1H), 5.07 (s, 4H). 13C NMR (100 MHz, CDCl3) δ 170.6, 162.4, 
156.7, 151.6, 141.3 (3), 128.1 (2), 127.0 (2), 122.8, 112.0, 110.5, 109.1, 106.1, 105.3, 54.0 (2). 
HRMS (ESI+) m/z [M+H+] calcd for C19H16NO4, 322.1079, found 322.1086. 
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Development of the First Hsp90-Selective N-Terminal Inhibitor 
IV.1 Introduction 
Heat shock protein 90 (Hsp90) is responsible for maintaining cellular homeostasis by 
assisting in the maturation of nascent polypeptides and the rematuration of the denatured proteins 
into their biologically active conformations.1-5  There are more than 200 protein substrates (clients) 
that are dependent upon Hsp90 for their maturation and proper function. Many of these client 
proteins are signaling proteins that can lead to tumor initiation, tumor progression, and 
metastasis.6-8 In fact, Hsp90’s clients are associated with all 10 hallmarks of cancer; hence, Hsp90 
facilitates cancer cell growth and survival.9, 10 Hsp90 also folds many of the oncogenic and mutant 
client proteins, which helps to explain the increased dependency of tumor cells on Hsp90.11, 12 
Increased dependency on Hsp90 correlates directly with increased Hsp90 levels in most cancers.13-
16 As shown previously, Hsp90 exists primarily in an activated heteroprotein complex in cancer 
cells, which exhibits >200-fold higher affinity for ATP than the homodimer in normal cells.17 
Similarly the heteroprotein complex also exhibits greater ATPase activity.17 Unlike conventional 
chemotherapy agents that target a single oncogene, enzyme, or receptor, Hsp90 inhibition 
simultaneously disrupts of multiple signaling nodes essential to cancer, and thus, mimics 
combination therapy through a single target.18-21  Since Hsp90 inhibitors accumulate in tumor cells 
more effectively than normal tissues, Hsp90 inhibitors can exhibit a broad therapeutic window. As 
a result, Hsp90 has become a highly sought after target for the development of anti-tumor agents, 
and has led to 17 clinical candidates.21-23 However, the clinical progress of these inhibitors has 
been hampered by modest efficacy, escalated dosing, and adverse effects that include 





All of the Hsp90 inhibitors under clinical investigation bind the N-terminal nucleotide 
binding pocket and exhibit pan-Hsp90 inhibitory activity against  all four Hsp90 isoforms; Hsp90 
(cytosolic and inducible), Hsp90cytosolic and constitutively expressed), Grp94 (endoplasmic 
reticulum located) and TRAP1 (mitochondria localized).29, 30 
  This simplistic model of pan-Hsp90 inhibition for the treatment of cancer requires 
significant modification to address the detriments associated with current Hsp90 inhibitors.31, 32  
The expression of Hsp90 isoforms can vary among cancers, which suggests that a cancer’s 
dependence upon individual isoforms also varies.33-36 In addition, Hsp90 isoforms exhibit 
specificity for client protein substrates and interacts with co-chaperones, which suggests that 
Hsp90 isoforms could be targeted individually.37-41 Consequently, isoform-selective Hsp90 
inhibitors are likely to provide a therapeutic opportunity to minimize off-target toxicity by limiting 
the number of clients affected via Hsp90 inhibition. Among the four isoforms, some specific roles 
for Grp94 and the consequences of Grp94-inhibition have been reported. Isoform-dependent 
clients of Grp94 (e.g. mutant myocilin, immunoglobulins, TLR1, TLR2, TLR9, IGF-1, IGF-2) 
have been identified and Grp94 inhibitors have shown efficacy for the potential treatment of 
glaucoma, multiple myeloma, and cancer metastasis.42-46 The two cytosolic isoforms, Hsp90 and 
Hsp90, are the most relevant for the treatment of cancer as majority of oncogenic proteins are 
dependent upon them for proper function.47  Some isoform-selective clients of the two cytosolic 
isoforms have recently been identified, and proteomic studies have identified survivin, Raf, and 
the hERG channel as Hsp90-dependent clients. c-IAP1 and CXCR4 are dependent upon 
Hsp90.24, 34, 43, 48 However, they have not been confirmed via pharmacological studies. 
Collectively, these prior studies establish that both cytosolic isoforms modulate substrates 





of each Hsp90 isoform represents a new approach to improve the therapeutic potential of Hsp90 
inhibitors. Since the hERG channel is dependent upon the Hsp90 isoform, Hsp90-selective 
inhibitors may avoid the cardiotoxicity often observed in clinical trials with some pan-Hsp90 
inhibitors. In addition, Hsp90-specific inhibitors would enable the identification of Hsp90-
selective clients and provide data to identify the cancers that are driven by Hsp90-dependent 
substrates. 
IV.1.1. Hsp90 
The Hsp90 isoform is located in the cytosol along with the Hsp90 isoform and is 
encoded by the HSPAB1 gene.29, 49 Hsp90 is constitutively expressed, and its expression can be 
induced, but to a lesser extent than Hsp90.49 Overexpression of Hsp90 has been associated with 
chronic tumors.33, 50-54 Most studies do not differentiate between the roles of these two cytosolic 
isoforms but some biochemical and functional differences have been reported.24, 29, 49, 55 The 
Hsp90-isoform plays a key role in early embryonic development, germ cell maturation, 
cytoskeleton stabilization, cellular transformation, and long term cellular adaptation.55-61 
Hsp90is involved with growth promotion, cell cycle regulation, and stress-induced 
cytoprotection.62, 63 Hsp90 interacts with P-glycoproteins, therefore, its expression has been 
associated with drug-resistance.64 A few Hsp90-dependent oncogenic clients have been 
identified, including CXCR4 and CDK6 (unpublished data). Client proteins, co-chaperones and 
partner proteins interacts differently with each cytosolic isoform. For example, the Hsp90 co-
chaperone, GCUNC45, interacts preferentially with Hsp90.65 Recently, Neckers and co-workers 
studied ligand and client protein binding to Hsp90 and Hsp90.40 Using various Hsp90 mutants, 





Collectively, these prior studies establish specific roles of Hsp90 in carcinogenesis and underline 
the need to develop Hsp90-selective inhibitors.  
IV.2. Differences in N-Terminal ATP-Binding Pocket of Hsp90 Isoforms 
Greater than 85% identity is shared between in the N-terminal ATP-binding sites of the 
Hsp90 isoforms, which has limited the development of isoform-selective inhibitors.29, 49 Since 
Grp94 shares the least identity amongst the Hsp90 isoforms, it was the first sought for the 
development of isoform-selective inhibitors. Grp94-selctive inhibitors have been developed and 
are currently being evaluated for various therapeutic applications.21, 44, 45, 66, 67 However, Hsp90 
and Hsp90 are >95% identical within the N-terminal binding site, suggesting that selective 
inhibition of these isoforms would be more challenging. Sequence alignment of the N-terminal 
domain of the Hsp90 isoforms reveals (Figure 35A) that there are only two amino acids that differ 
between Hsp90 versus Hsp90. As shown in Figure 35B, there is a network of water-mediated 
hydrogen bonds that align at the bottom of the pocket surrounding the phenols of radicicol bound 
to each Hsp90 isoform.  The carbonyl and 4-phenol make hydrogen bonds with Thr184 and Asp93 
(numbered for Hsp90) through these water molecules, which are conserved amongst the majority 
of Hsp90 co-crystal structures and mediate hydrogen bonding interactions between ligands and 
Hsp90 isoforms. Leu48, Lys58, Asp93, Ile96, Gly97, Met98, Leu107, Thr109, Phe138, Tyr139, 
Trp162, and Thr184 (numbered for Hsp90) represent the key amino acids within the N-terminal 
ATP-binding pocket and are conserved amongst the four isoforms. Overlay of the Hsp90α and 
Hsp90β co-crystal structures revealed that the ATP binding pocket in Hsp90β contains Ala52 and 
Leu91, in lieu of Ser52and Ile91, which are present in Hsp90α. The Grp94 and Trap1 binding 
pockets contain Val147 and Ile156 in lieu of Leu91, respectively. Based on these observations, we 





the resorcinol ring that creates a unfavorable steric interactions with the bulkier side chains present 
in Hsp90, Grp94, and Trap-1. 
 
IV.3. Development of Resorcinol Analogues Modified at the 4-Position 
IV.3.1. Design of Resorcinol Analogues Modified at the 4-Position for Selective Hsp90-
Inhibition 
To probe the subtle differences about the 3- and the 4-position of the resorcinol ring, 
modifications to the 4-position were pursued. Based on prior experience with the resorcinol-
isoindoline scaffold (Chapter III), it was chosen for the development of new Hsp90-selective  
Figure 35. Differences amongst Hsp90 Isoforms. (A) Sequence alignment of Hsp90 isoforms. 
Key residues comprising N-terminal binding pocket are highlighted in yellow. Residues in blue 
boxes indicate the amino acid difference between Hsp90 isoforms (B) Modeling of Radicicol 
into N-terminal ATP binding site of Hsp90 isoforms: i) Hsp90 (PDB code: 2XAB) ii) 
Hsp90(PDB code: 1UYM) iii) Grp94 (PDB code: 4NH9) iv) Trap-1(PDB code: 4Z1F). 













inhibitors.  Since modification at the 4-position were sought, initial investigation began with 
compound 72 (Figure 36a), which lacks the 4-phenol. Hsp90 inhibitory activity of compound 72 
was confirmed via a fluorescence polarization assay and manifested an apparent Kd of 1.63 M 
against Hsp90. The 2-phenol and the amide moiety of compound 72 mimic the corresponding 2-
 
 
Figure 36. Proposed Hsp90-selective molecules. (a) a new scaffold for Hsp90-selective 
inhibition; Overlay of 73 docked into Hsp90 (PDB code 1UYM, colored green) with N-
terminal ATP binding site of (b) Hsp90 (PDB code: 2XAB) and with (c) Grp94 (PDB code: 






phenol and lactone present in radicicol. The 5-isopropyl produces hydrophobic interactions with 
Phe138 and Val186.   
Molecular modeling studies suggested that the incorporation of bulky substituents at the 4-
position would impart greater selectivity for Hsp90. Therefore, 7382 were proposed to 
investigate the differences between Hsp90 and other Hsp90 isoforms. As shown in Figure 36b & 
36c, 4-cyanomethylene (73) was proposed to accommodate within the ATP-binding pocket of 
Hsp90. The cyanomethyl would not be tolerated in the case of Hsp90 and Grp94, due to 
unfavorable steric interactions with Ile91 in Hsp90 (Figure 36b), and Val187 in Grp94 (Figure 
36c). In addition, the nitrile appears to displace a conserved water molecule in Hsp90 which would 
increase the entropy of binding and thereby enhance affinity. The conserved water molecules are 
located in a semi-hydrophobic environment comprising of Leu48, Leu91, Ala52 and Val186.  
IV.3.2. Synthesis of 4-Modified Resorcinol Analogues  
IV.3.2.1. Synthesis of Compound 72 
Compound 72 was 
synthesized starting from 
commercially available 5-
bromo salicylic acid, 83.68, 69 
Carbodiimide coupling of the 
acid with isoindoline produced 
intermediate 84 (Scheme 10). The isopropyl group at the 5-position was introduced via a Suzuki 
coupling reaction of 84 with potassium isopropenyl trifluoroborate and subsequent reduction of 
the olefin afforded 72.  
 





IV.3.2.2 Syntheses of 
 
For the synthesis of compounds 7382, a revised synthetic scheme allowed for late stage 
diversification to access the desired analogues (Scheme 11). Compound 74 was envisioned as a 
common intermediate to 73, and 7582. As Shown in Scheme 11, bromination of 74 would yield 
the corresponding benzylic bromide (80), which would undergo nucleophilic displacement with 
the requisite nucleophiles to give 73, 77, and 76. Hydrolysis of the nitrile present in 73 would give 
access to the corresponding amide, 79. Oxidation of the benzylic alcohol (74), would generate the 
corresponding aldehyde (78), which could be modified to afford analogues 81 and 82 via Wittig 
olefination and reduction. In addition, reductive amination of 78 would afford 75.  
 








Synthesis of 74 commenced with bromination of methyl 2-methoxy-4-methylbenzoate (85, 
Scheme 12), which occurred in a regioselective manner to give the corresponding 5-bromo 
product, 86.  Benzylic bromination of 86 with N-bromosuccinimide and azaisobutyronitrile 
afforded 87.  Subsequent hydrolysis of the benzyl bromide (87) using calcium carbonate gave the 
corresponding benzylic alcohol, 88.70 88 was converted to methoxy methyl ether (89) using 
methoxymethyl chloride, and N,N-diisopropylethylamine. Ester 89 was hydrolyzed under basic 
conditions to provide the corresponding acid, 90, which upon 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDCI)-mediated coupling with isoindoline gave 91. isopropyl group at the 5-
 





position was introduced as described previously. Demethylation of 92 enlisting boron tribromide 
gave the bromomethyl containing compound 80, as the major product, the corresponding benzylic 
alcohol, 74, was also isolated as a minor product during this transformation. Nucleophilic 
displacement of the benzylic bromide in 80 with methyl amine and methanol gave 76 and 77, 
respectively (Scheme 13).  Similarly, 80 was further modified via potassium cyanide and 18-
crown-6 to furnish 73, which upon basic hydrolysis gave the amide, 79.  
 
Oxidation of the benzylic alcohol (74) to the corresponding benzaldehyde did not work 
(using Dess-Martin periodinane, tetrapropylammonium perruthenate, manganese dioxide), 
because the benzylic positions of the isoindoline were also readily oxidized (Scheme 12). 
Therefore, an alternative route was devised, and oxidation of the benzylic alcohol was 
accomplished before introduction of the isoindoline (Scheme 14). Intermediate 88 was coupled 
with potassium isopropyl trifluoroborate as previously described, to give 93. Compound 93 was  
                







oxidized using manganese dioxide (MnO2) to give the corresponding aldehyde, which upon 
hydrolysis of ester followed by carbodiimide coupling with isoindoline afforded 94. Hydrolysis of 
ester 93 and subsequent coupling with isoindoline furnished aldehyde, 94. However, 
chemoselective reduction of the alkene using diphenyl sulfide did not provide the desired product. 
Therefore, reduction of the alkene prior to oxidation of the alcohol was sought out. The desired 
intermediate 97 was obtained in three steps from alcohol 88. The isopropyl group was incorporated 
 





as previously described to give benzyl alcohol, 96, which underwent oxidation via manganese 
dioxide to give aldehyde 97. 
 Hydrolysis of the ester present in 97 did not proceed under basic conditions. Analysis of 
the side products revealed the likely generation of a carbanion that results from deprotonation of 
the benzylic hydrogen at the 5-position. Consequently, a milder condition was used to hydrolyze 
the ester of 97. Prior studies by Nicolaou and co-workers have demonstrated that trimethyl 
tinhydride can hydrolyze aromatic esters in the presence of other base sensitive moieties.71 
Therefore, the methyl ester 97 was subjected to these conditions, which provided the 
corresponding acid, 98, in good yield. Carbodiimide coupling of the acid gave 95, which upon 
cleavage of the methyl ether using boron tribromide furnished the desired analogue, 78. Aldehyde 
95 served as a common intermediate for the syntheses of the analogues 75, 81, and 82 (Scheme 
14). Treatment of 95 with benzyl carbamate, trifluoroacetic acid, and triethylsilane gave the 
corresponding carbamate, which upon hydrogenolysis under a hydrogen atmosphere and in the 
presence of palladium on carbon, afforded the desired benzyl amine. For the preparation of 81, the 
aldehyde (95) was converted to the corresponding alkyne via utilization of the Bestmann-Ohira 
reagent. Hydrogenation of the alkyne followed by methyl ether cleavage furnished the 4-ethyl 
analogue, 81. Similarly, the iso-butyl analogue was synthesized from aldehyde 94 by a Wittig 
reaction enlisting isopropyl triphenylphosphonium iodide and butyl lithium, followed by reduction 
of the corresponding alkene.   
IV.3.3. Evaluation of 4-Modified Resorcinol Analogues 
The synthesized analogues were evaluated via a fluorescence polarization assay. Analogue 
73 exhibited an apparent Kd of 2.27 M and 0.97 M against Hsp90 and Hsp90, respectively 





benzyl alcohol 74 and benzyl amine 75. The benzaldehyde analogue a manifested an apparent Kd 
of 240 nM for Hsp90and 5-fold selectivity versus Hsp90. This data suggests that aldehyde may 
act as a hydrogen bond accepter. The methoxy methyl ether 76 did not bind Hsp90. Interestingly, 
benzyl bromide 80 manifested increased affinity and selectivity for the Hsp90. Its bioisosteric 
replacement by an isopropyl group (82) decreased affinity. Overall, some analogues did maintain 
or improve affinity for Hsp90 compared to compound 72. The lack of selectivity of 72 versus 
Hsp90 was surprising. Collectively, these results suggested the potential of alternative binding 
modes for these analogues. To better understand the binding interactions of 73 and 78 with 
Hsp90; co-crystal structures of these compounds bound to Hsp90 were solved in collaboration 
with Dr. Robert Matts at Oklahoma State University.  Examination of the co-crystal structures 
revealed some rationale for the poor selectivity manifested by these molecules.  







72 3.21 + 0.43 1.63 + 0.04 2 
73 2.28 + 0.12 0.97 + 0.03 3 
74 4.21 + 0.62 1.97 + 0.07 - 
75 >50 >50 - 
76 >50 >50 - 
77 >100 23.19 + 1.07 4 
78 0.24 + 0.08 1.21 + 0.12 - 
79 15.21 + 1.15 5.50 + 0.51 3 
80 4.98 + 0.97 0.73 + 0.11 7 
81 >50 >50 - 
82 >50 >50 - 
 
As shown in Figure 37a, the cyanomethylene (73) side chain adopts a backward 
conformation instead of the expected forward orientation, which is attributed to the free rotation 
of the methylene group within the binding pocket. This binding mode could not be predicted in 





residue. The co-crystal structure revealed that the side chain of Asn46 shifts 0.6 Å to accommodate 
the cyanomethylene group (Figure 37c and 37d) to produce a hydrogen bond. The carbonyl of 78 
also binds in a similar conformation and interacts favorably with Asn46. The 2-phenol of both 
compounds maintained interactions with Asp88 and Thr179. Only two other co-crystal structures 
of Hsp90 exist (none with the resorcinol core). Therefore, the co-crystal structure of 73 and 79 
were highly beneficial and subsequently used for the design of new Hsp90-selective inhibitors.  
IV.4. Development of a 3-Modified Resorcinol Analogue 
IV.4.1. Design of a 3-Substituted Resorcinol Analogues for Selective Hsp90-Inhibition 
Unfortunately, modification of the 4-position did not increase selectivity, and therefore, an 
alternative strategy was devised based on the newly obtained co-crystal structures of 73 and 78 
bound to Hsp90. It was proposed that the introduction of the substituents at the 3-position would 
allow for exploitation of both the amino acids that differ between Hsp90Ser52, Ile91 and 
Hsp90Ala, Leuand manifest increased selectivity while simultaneously projecting substituents 
to the small exclusive sub-pocket present in Hsp90. Molecular modeling studies suggested that 
the inclusion of a hydroxymethylene group at the 3-position would produce selectivity for Hsp90. 
The methylene group would sterically clash with Ser52 in Hsp90, while the hydoroxyl group 
would produce a steric clash with Ile91 in Hsp90. Similarly, the introduction of a 
hydroxymethylene group would produce unfavorable interactions with Val148 and prohibit Grp94 
binding. In addition, the hydroxyl group would likely displace a conserved water molecule in this 















Figure 37. Co-crystallization of 4-modified resorcinol analogues. (a) Co-crystal structure of 
73 bound Hsp90; (b) co-crystal structure of 79 bound Hsp90cMovement of Asn46 
allows for backward bending of nitrile, Previous position of Asn46 is represented in pink. 
Asn46 in co-crystal structure of 73 is represented in blue. (d) two-dimensional representation 







IV.4.2. Synthesis of a 3-Substituted Resorcinol Analogue 
Synthesis of the proposed analogue 102 commenced via 103, which was prepared 
following a literature procedure. Formylation of 103 via the Duff reaction gave the 3-formyl 
resorcinol intermediate, 104 (Scheme 15). Reduction of aldehyde 104 with sodium borohydride 
furnished the desired product 102.  
 
IV.4.3. Evaluation and Co-Crystallization of 102 
 
Figure 38. Proposed modification at the 3-position of resorcinol. (a) Structure of 102. 
Docking pose of compound 102 in Hsp90(colored green) overlaid with (b) Hsp90 N-
terminal ATP- binding site (colored pink) and with (c) Grp94 N-terminal ATP binding site. 









Upon preparation of analogue 102, it was evaluated via a 
fluorescence polarization and found to manifest an apparent Kd of 
4.27 M for Hsp90. More importantly, it manifested selectivity 
(>24-fold) over other isoforms (Figure 39). The co-crystal structure 
of the compound 102 (KUNB30) bound to Hsp90 was then solved 
in collaboration with Dr. Robert Matts, which suggested that the 
benzyl alcohol has displaced a conserved water molecule. The 
benzylic alcohol made hydrogen bonding interactions with the 
backbone of Leu43.  
 
IV.5. Development of KUNB31 
IV.5.1 Design of KUNB31 
Flexibility associated with the 
hydroxymethylene group in KUNB30 
exhibits a significant entropic penalty 
upon binding. Therefore, it was proposed 
that the introduction of a ring constrained 
variant would reduce the entropic penalty 
and enhanced binding affinity. Using the 
co-crystal structure of KUNB30, it was 
envisioned that introduction of a heterocyclic ring system that joined the 3- and 4-positions of the 
resorcinol ring would illicit such properties. Therefore, benzoisoxazole 105 was designed and 
sought after for biological evaluation.  
    
 
Figure 39. Apparent Kd of 
analogue 102 (KUNB30). 
 






IV.5.2. Synthesis and Evaluation of KUNB31 
Analogue 105 was synthesized from 104 enlisting triflic acid and sodium azide (Scheme 
16).72 The two regeoisomeric isooxazole products were separated by column chromatography, and 
the structure of 105 was confirmed by X-ray crystallography. Analogue 105 (KUNB31) 
manifested an apparent Kd of 180 nM against Hsp90, and exhibited ~50-fold selectivity versus 
Hsp90 and Grp94. 
IV.6. Cellular Studies 
IV.6.1. Anti-Proliferation Activity 
  Once the Hsp90-selective inhibitors, KUNB30 and KUNB31, were identified, cellular 
studies commenced to evaluate the effect of Hsp90-inhibition on cancer cell lines (Table 14). 
Growth inhibitory activity manifested by these compounds was evaluated against NCI-H23 (lung 
cancer), MCF-7 (breast cancer), and SkBr3(breast cancer) cells. KUNB31 manifested an IC50’s of  
 
6.74 + 1.10µM, 28.27 + 1.47µM and 38.21 + 2.75 µM against NCI H23, MCF-7, and Skbr3 cells, 
respectively. KUNB30 was more efficacious in cells and manifested an IC50 of 3.90 + 0.33, 13.67 
+ 1.46, 9.13 + 1.03 against NCI H23, MCF-7, and Skbr3 cells, respectively. These studies 
 





confirmed that selective inhibition of the Hsp90isoform manifests growth inhibitory activity 
against cancer cells. 
Table 14. Anti-proliferative activity of KUNB30 and KUNB31 against cancer cells 




NCI-H23 3.90 + 0.33 6.74 + 1.10 
MCF-7 13.67 + 1.46 28.27 + 1.47 
SkBr3 9.13 + 1.03 38.21 + 2.75 
 
IV.6.2. Western Blot Analyses 
 
 After determination of anti-proliferation activity, western blot analyses were conducted on 
NCI-H23 cell lysates that were treated with KUNB31. Since, Hsp90 inhibition induces the 
degradation of client proteins via ubiquitin-proteasome pathway, levels of Hsp90-dependent 
clients were evaluated upon administration of KUNB31 in NCI-H23 cells. Additionally, 
immunoblots for Hsp90 and Hsp70 were also obtained to evaluate the induction of the heat-shock 
response. As shown in Figure 41, KUNB31 induced the degradation of Hsp90dependent clients 
c-IAP1, CXCR4, and CDK6 without the induction of Hsp70 and Hsp90 levels. Similar to genetic 
knockdown studies, Hsp90-dependent clients Raf and survivin were less sensitive to Hsp90-
 





inhibition. Degradation of non-selective client Erk5 was also observed. These results suggest that 
Hsp90 inhibition limits the detrimental induction of the heat shock response, and hence, 
represents an alternative approach to pan-Hsp90 inhibition. 
IV.7. Conclusions and Future Directions  
Using a structure-based design, the first small molecule N-terminal inhibitors of the 
Hsp90 isoform have been developed. These inhibitors manifest anti-proliferation activity against 
cancer cell lines, and induce the degradation of Hsp90 client proteins. Hence, Hsp90 inhibitors 
represent a new class of Hsp90 inhibitors for the treatment of cancer. In addition, Hsp90-selective 
inhibitors will serve as useful probes to identify of Hsp90-dependent clients and enable the 
identification of specific roles played by individual isoforms.  
 Induction of the pro-survival heat shock response has limited the clinical success of current 
pan-Hsp90 inhibitors. Induction of heat shock response results in higher levels of Hsp90, which 
leads to decreased occupancy of the target by such inhibitors. Consequently, the induction of heat 
shock response results in poor efficacy by Hsp90 inhibitors and leads to dosing and scheduling 
complications. In our preliminary studies, Hsp90-inhibitors did not exhibit these detrimental 
activities, which suggests that selective Hsp90 inhibition is a useful alternative to pan-Hsp90 
inhibition.  
 Prior to this work, there were only two other co-crystal structure of Hsp90bound to an 
inhibitor reported. This work produced co-crystal structures of three inhibitors bound to Hsp90, 
which can be used to design future isoform-selective inhibitors. The Co-crystal structure of 
KUNB30 bound to Hsp90 represents the first co-crystal structure of a resorcinol based inhibitor 
bound to Hsp90. Co-crystallization of KUNB31 is underway in collaboration with the Robert 





IV.8. Methods and Experiments 
All reactions were performed in oven-dried glassware under argon atmosphere unless 
otherwise stated. Dichloromethane (DCM), tetrahydrofuran (THF), and toluene were passed 
through a column of activated alumina prior to use. Anhydrous methanol, acetonitrile, N,N-
dimethylformamide (DMF), and carbon tetrachloride (CCl4) were purchased and used without 
further purification. Flash column chromatography was performed using silica gel (40−63 μm 
particle size). The 1H (500 and 400 MHz) and 13C NMR (125 and 100 MHz) spectra were recorded 
on 500 and 400 MHz spectrometer. Data are reported as p = pentet, q = quartet, t = triplet, d = 
doublet, s = singlet, br s = broad singlet, m = multiplet; coupling constant(s) in Hz. Infrared spectra 
were obtained using FT/IR spectrometer. High resolution mass spectral data were obtained on a 
time-of-flight mass spectrometer and analysis was performed using electrospray ionization.  
 
(5-Bromo-2-hydroxyphenyl)(isoindolin-2-yl)methanone (84): 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (5.20 g, 27.64 mmol, 2.0 eq.) was added to a stirred solution 
of 83 (3.0 g, 13.82 mmol, 1 eq.), isoindoline hydrochloride (3.22 g, 20.73 mmol, 1.5 eq.), 1-
hydroxybenzotriazole (3.73 g, 27.64 mmol, 2 eq.) N,N-diisopropylethylamine (4.81 mL, 27.64 
mmol, 2.0 eq.) in dichloromethane (150 mL) at 0 °C. The resulting solution was stirred at rt for 14 
h before quenching with saturated sodium bicarbonate solution (120 mL). The organic layer was 
washed with 1 M hydrochloric acid solution (120 mL) and saturated sodium chloride solution (120 
mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash 





amorphous solid. 1H NMR (400 MHz, CDCl3) δ 10.92 (s, 1H), 7.73 (d, J = 2.2 Hz, 1H), 7.48 (dd, 
J = 8.8, 2.4 Hz, 1H), 7.34 (s, 4H), 6.94 (d, J = 8.8 Hz, 1H), 5.10 (s, 4H). 13C NMR (100MHz, 
CDCl3) δ 169.4, 159.4, 136.1 (2), 134.8, 130.5, 128.2 (2), 122.8 (2), 120.2, 118.7 110.2, 55.8, 53.3. 
HRMS (ESI+) m/z [M + H+] calcd for C15H13BrNO2, 318.0130, found 318.0119. 
 
(2-Hydroxy-5-isopropylphenyl)(isoindolin-2-yl)methanone (72): A biotage microwave vial 
was charged with 84 (1.0 g, 3.42 mmol, 1 eq.), triethylamine (0.62 mL, 4.44 mmol, 1.3 eq.), [1,1′ 
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (278 mg, 0.34 mmol, 0.1 eq.), potassium 
isopropenyltrifluoroborate (604 mg, 4.10 mmol, 1.2 eq.). The tube was sealed with a cap lined 
with a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), 
before the addition of 2-propanol (17 mL) by syringe. The resulting mixture was heated at 100 °C 
for 6 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent 
was removed and the residue purified by flash chromatography (SiO2, 1:4 ethyl acetate/hexanes) 
to afford (2-hydroxy-5-(prop-1-en-2-yl)phenyl)(isoindolin-2-yl)methanone, which was used 
further as obtained. Palladium on carbon (10%) was added to a solution of (2-hydroxy-5-(prop-1-
en-2-yl)phenyl)(isoindolin-2-yl)methanone in ethyl acetate (25 mL). The suspension was stirred 
for 16 h under a hydrogen atmosphere before it was filtered through a pad of celite and eluted with 
EtOAc (20 mL). The eluent was concentrated to afford 72 (652 mg, 67.5 %) as a white amorphous 
solid. 1H NMR (400 MHz, CDCl3) δ 10.44 (s, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.28 (s, 4H), 6.92 (d, 
J = 8.5 Hz, 1H), 5.06 (s, 4H), 2.88 (hept, J = 7.0 Hz, 1H), 1.24 (d, J = 6.9 Hz, 6H). 13C NMR (100 





55.8, 53.5, 33.6, 24.4 (2). HRMS (ESI+) m/z [M + H+] calcd for C18H20NO2, 282.1494, found 
282.1483. 
 
Methyl 5-bromo-2-methoxy-4-methylbenzoate (86): A solution of bromine in chloroform was 
added dropwise to a solution of 85 (10.0 g, 55.4 mmol, 1.0 eq.) in chloroform at 0 °C (250 mL).  
The resulting mixture was stirred at rt for 4 h before quenching with 10% aqueous solution of 
sodium thiosulfate (200 mL). The organic layer was washed with saturated sodium bicarbonate 
solution (2 × 200 mL) and saturated sodium chloride solution (200 mL), dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:9 ethyl acetate/hexanes) to afford 86 (12.81 g, 89.2 %) as a light brown amorphous solid. 
1H NMR (400 MHz, CDCl3) δ 7.93 (dt, J = 7.1, 4.0 Hz, 1H), 6.82 (t, J = 4.0 Hz, 1H), 3.97 – 3.76 
(m, 6H), 2.38 (dt, J = 6.5, 4.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 165.2, 158.5, 144.0, 135.2, 
118.9, 114.8, 114.6, 56.3, 52.2, 23.7. HRMS (ESI+) m/z [M + H+] calcd for C10H12BrO3, 258.9969, 
found 258.9973. 
 
Methyl 5-bromo-4-(bromomethyl)-2-methoxybenzoate (87): A solution of 86 (12.8g, 48.8 
mmol), N-bromosuccinimide (9.68 g, 54.78 mmol, 1.1 eq.), azobisisobutyronitrile (1.64 g, 9.96 
mmol, 0.2 eq.) in carbon tetrachloride was heated at 70 oC.  After 14 h, solvent was removed and 
the residue purified by flash chromatography (SiO2, 1:9 ethyl acetate/hexanes) to afford 87 (13.92 
g, 71.3 %) as a white amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.60 (s, 1H), 





123.0, 114.6, 109.5, 56.7, 52.7, 39.3. HRMS (ESI+) m/z [M + H+] calcd for C10H11Br2O3, 
336.9075, found 336.9079. 
 
Methyl 5-bromo-4-(hydroxymethyl)-2-methoxybenzoate (88): Calcium carbonate (11.3 g, 
113.4 mmol, 3 eq.) was added to a solution of 87 (12.8 g, 37.8 mmol, 1 eq.) in dioxane (100 mL) 
and water (100 mL). The resulting mixture was heated at 120 °C in a sealed tube for 16 h. The 
reaction mixture was cooled to rt, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:5 ethyl acetate/hexanes) to afford 88 (8.2 g, 79.2%) as a colorless 
amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.9 (s, 1H), 7.2 (d, J = 0.9 Hz, 1H), 4.7 (dd, J = 
5.7, 1.0 Hz, 2H), 3.9 (s, 3H), 3.9 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 165.5, 159.0, 145.7, 
135.3, 120.0, 111.9, 111.3, 64.8, 56.5, 52.5. HRMS (ESI+) m/z [M + H+] calcd for C10H12BrO4, 
274.9919, found 274.9923. 
 
Methyl 5-bromo-2-methoxy-4-((methoxymethoxy)methyl)benzoate (89): A solution of 88 (3.2 
g, 11.63 mmol, 1.0 eq.) in dichloromethane (116 mL) was cooled to 0 °C before the addition of  
N,N-diisopropylethylamine (12.13 mL, 69.79 mmol, 6.0 eq.) and 6M solution of 
chloromethoxymethyl ether (11.8 ml, 69.79 mmol, 6.0 eq.). The reaction was allowed to reach at 
rt and stirred for 14 h before quenching with saturated sodium bicarbonate solution (60 mL). The 
aqueous layer was extracted with dichloromethane (2 × 60 mL) and the combined organic layers 
were washed with saturated sodium chloride solution (150 ml), dried over anhydrous sodium 





acetone/dichloromethane) to afford 89 (2.82 g, 76.1%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.97 (s, 1H), 7.18 (d, J = 0.9 Hz, 1H), 4.80 (s, 2H), 4.64 (d, J = 0.9 Hz, 2H), 3.93 (s, 3H), 
3.89 (s, 3H), 3.44 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 165.4, 158.9, 143.4, 135.4, 120.3, 112.4, 
111.8, 96.6, 68.9, 56.6, 55.9, 52.4. HRMS (ESI+) m/z [M + H+] calcd for C12H16BrO5, 319.0181, 
found 319.0187. 
 
5-Bromo-2-methoxy-4-((methoxymethoxy)methyl)benzoic acid (90): Lithium hydroxide 
monohydrate (5.37 g, 128.0 mmol, 10.0 eq. ) was added to a solution of 89 (4.08 g, 12.8 mmol, 1 
eq.) in a solvent mixture of tetrahydrofuran (43 mL), water (43 mL), methanol (43 mL). The 
resulting mixture was stirred at rt for 16 h and concentrated. The residue was treated with 1 M 
hydrochloric acid and pH was adjusted to 2. The resulting suspension was extracted with ethyl 
acetate (3 × 100 mL), the combined organic layers were washed with saturated sodium chloride 
solution, dried over anhydrous sodium sulfate, filtered and concentrated to afford 90 (3.26 g, 83.2 
%) as a light brown solid. 1H NMR (500 MHz, CDCl3) δ 10.59 (s, 1H), 8.33 (s, 1H), 7.30 (s, 1H), 
4.83 (s, 2H), 4.67 (d, J = 0.9 Hz, 2H), 4.12 (s, 3H), 3.46 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
164.1, 157.5, 145.5, 137.1, 117.8, 113.9, 111.6, 96.7, 68.7, 57.3, 56.0. HRMS (ESI+) m/z [M + 
H+] calcd for C11H14BrO5, 305.0025, found 305.0028. 
 
(5-Bromo-2-methoxy-4-((methoxymethoxy)methyl)phenyl)(isoindolin-2-yl)methanone (91): 





stirred solution of 90 (1.0 g, 3.27 mmol, 1 eq.), isoindoline hydrochloride (663 mg, 4.26 mmol, 
1.3 eq.), 1-hydroxybenzotriazole (1.0 g, 6.54 mmol, 2 eq.) N-,N-diisopropylethylamine (1.72 mL, 
9.81 mmol, 3.0 eq.) in dichloromethane (33 mL) at 0 °C. The resulting solution was stirred at rt 
for 14 h before quenching with saturated sodium bicarbonate solution (30 mL). The organic layer 
was washed with 1 M hydrochloric acid solution (30 mL) and saturated sodium chloride solution 
(30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:3 hexanes/ethylacetate) to afford 91 (1.22 g, 91.8%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 7.37 – 7.26 (m, 3H), 7.19 – 7.12 (m, 2H), 4.99 (s, 2H), 
4.82 (s, 2H), 4.68 (s, 2H), 4.62 (s, 2H), 3.88 (s, 3H), 3.48 (s, 3H). HRMS (ESI+) m/z [M + H+] 
calcd for C11H14BrO5, 452.1072, found 452.1066. 
 
Isoindolin-2-yl(5-isopropyl-2-methoxy-4-((methoxymethoxy)methyl)phenyl)methanone 
(92): A biotage microwave vial was charged with 91 (1.0 g, 2.46 mmol, 1 eq.), 
Tetrakis(triphenylphosphine)palladium (0) (277 mg, 0.24 mmol, 0.1 eq.), cesium carbonate (2.4 g, 
7.4 mmol, 3 eq.), and potassium isopropenyltrifluoroborate (427 mg, 2.88 mmol, 1.2 eq.). The tube 
was sealed with a cap lined with a disposable Teflon septum. The tube was evacuated and purged 
with nitrogen (3 times), before the addition of tetrahydrofuran (10.8 mL) and water (1.2 mL) by 
syringe. The resulting mixture was heated at 100 °C for 24 h, cooled to rt, and filtered through a 
small pad of celite (elution with ethyl acetate). Solvent was removed and the residue purified by 
flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to afford isoindolin-2-yl(2-methoxy-4-





obtained. Palladium on carbon (10%) was added to a solution of Isoindolin-2-yl(2-methoxy-4-
((methoxymethoxy)methyl)-5-(prop-1-en-2-yl)phenyl)methanone in ethyl acetate (25 mL). The 
suspension was stirred for 16 h under a hydrogen atmosphere before it was filtered through a pad 
of celite and eluted with EtOAc (20 mL). The eluent was concentrated to afford 92 (530 mg, 58.3 
%) as a light brown amorphous solid. 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.6 Hz, 1H), 7.60 
(td, J = 7.6, 1.1 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.41 (t, J = 7.5 Hz, 1H), 7.21 (s, 1H), 6.94 (s, 
1H), 4.94 (s, 2H), 4.67 (s, 2H), 4.63 (s, 2H), 3.70 (s, 3H), 3.37 (s, 3H), 3.05 (h, J = 6.8 Hz, 1H), 
1.15 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 168.7, 166.3, 155.0, 141.6, 139.0, 138.4, 134.1, 131.6, 
128.7, 125.7, 125.4, 125.2, 123.7, 111.2, 96.0, 66.8, 56.1, 55.7, 48.7, 28.4, 24.0 (2). HRMS (ESI+) 
m/z [M + Na+] calcd for C22H27NO4Na, 392.1838, found 392.1838. 
 
(4-(Bromomethyl)-2-hydroxy-5-isopropylphenyl)(isoindolin-2-yl)methanone (80): 1 M 
solution of boron tribromide (1.22 mmol, 1.22 mL, 2 eq.), was added to a solution of 92 (200 mg, 
0.61 mmol) in anhydrous dichloromethane (6.1 ml) at 0 oC. The resulting mixture was stirred at rt 
for 14 h before quenching with saturate sodium bicarbonate solution (5 mL). The aqueous layer 
was extracted with dichloromethane (2 × 10 mL). The combined organic layers were washed with 
saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:50 
acetone/dichloromethane) to afford 80 (98 mg, 43.7 %) as a white solid. Additionally, compound 
74 (38 mg, 20%) was also isolated. 1H NMR (500 MHz, CD2Cl2) δ 7.53 (s, 1H), 7.32 (s, 4H), 6.94 





(125 MHz, CD2Cl2) δ 170.5, 157.3, 139.9 (2), 138.1 (2), 128.1, 126.3, 123.0, 119.4 (2), 119.1 (2), 
118.5, 55.9 (2), 31.0, 24.3 (2). HRMS (ESI+) m/z [M + Na+] calcd for C19H20BrNO2Na, 374.756, 
found 374.0769. 
 
(2-Hydroxy-4-(hydroxymethyl)-5-isopropylphenyl)(isoindolin-2-yl)methanone (74): 1 M 
solution of boron tribromide (1.22 mmol, 1.22 mL, 2 eq.), was added to a solution of 92 (200 mg, 
0.61 mmol) in anhydrous dichloromethane (6.1 ml) at 0 oC. The resulting mixture was stirred at rt 
for 14 h before quenching with saturate sodium bicarbonate solution (5 mL). The aqueous layer 
was extracted with dichloromethane (2 × 10 mL). The combined organic layers were washed with 
saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) 
to afford 74 (38 mg, 20%) as a colorless solid. Additionally, compound 80 (98 mg, 43.7 %) was 
also isolated as a colorless solid. 1H NMR (400 MHz, CDCl3) δ 10.53 (s, 1H), 7.53 (s, 1H), 7.32 
(s, 4H), 7.07 (s, 1H), 5.10 (s, 4H), 4.76 (s, 2H), 3.17 – 3.22 (m, 1H), 1.26 – 1.30 (m, 6H). 13C NMR 
(125 MHz, CDCl3) δ 171.0, 158.0, 150.2, 143.1, 136.7, 136.4, 129.9, 129.1, 126.8, 126.6, 125.2, 
116.9, 116.6, 62.9, 55.8, 53.4, 30.2, 24.5 (2). HRMS (ESI+) m/z [M + H+] calcd for C19H22NO3, 






(2-Hydroxy-5-isopropyl-4-(methoxymethyl)phenyl)(isoindolin-2-yl)methanone (76): Sodium 
methoxide (10.8 mg, 0.20 mmol, 2.5 eq.) was added to a solution of 80 (30 mg, 0.08 mmol, 1 eq.) 
in anhydrous methanol. The resulting mixture was heated at 60 oC for 8h, before quenching with 
1 M hydrochloric acid (2 mL), extracted with ethyl acetate (3 × 3 mL). The combined organic 
layers were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered, 
and concentrated. The residue was purified by flash chromatography (SiO2, 3:10 ethyl 
acetate/hexanes) to afford 76 (13 mg, 49.9 %) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 
10.45 (s, 1H), 7.52 (s, 1H), 7.29 (d, J = 19.5 Hz, 4H), 7.02 (s, 1H), 5.09 (s, 4H), 4.50 (s, 2H), 3.43 
(s, 3H), 3.14 – 3.46 (m, 1H), 1.28 (d, J = 6.9 Hz, 7H). 13C NMR (100 MHz, CDCl3) δ 170.8, 157.4, 
140.4 (2), 137.0 (2), 127.8, 124.9(2), 122.6, 117.8 (2), 116.6, 72.1, 58.3 (3), 28.0, 24.2 (2). HRMS 
(ESI+) m/z [M + Na+] calcd for C20H23NO3Na, 348.1576, found 346.1567. 
 
2-(5-Hydroxy-4-(isoindoline-2-carbonyl)-2-isopropylphenyl)acetonitrile (73): Potassium 
cyanide (43 mg, 0.66 mmol, 5.0 eq. ) was added to a solution of  80 (50 mg, 0.14 mmol, 1.0 eq.) 
and 18-crown-6 (71 mg, 0.27 mmol, 2.0 eq.) in N,N-dimethylformamide (2.0 mL) at rt. The 
reaction was stirred for 2 h, diluted with water (20 mL), extracted with ethyl acetate (2 × 20 mL). 
The combined organic layers were washed with saturated sodium chloride solution (30 mL), dried 
over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:3 ethyl acetate/hexanes) to afford 73 (39.9 mg, 92.5 %) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 10.53 (s, 1H), 7.54 (s, 1H), 7.32 (d, J = 4.6 Hz, 4H), 7.03 (s, 1H), 





MHz, CDCl3) δ 170.5, 158.0, 136.5, 135.85 (2) 132.4, 128.1, 125.7 (2), 122.8, 118.6, 117.7, 117.5, 




2.0 M methyl amine  in tetrahydrofuran (0.1 mL, 0.20 mmol, 2.5 eq.) was added to a solution of 
80 (30 mg, 0.08 mmol, 1 eq.) in tetrahydrofuran (1 mL). The resulting mixture was stirred at rt for 
6 h, and concentrated. The residue was purified by flash chromatography (SiO2, 1:10 
methanol/dichloromethane) to afford 77 (8 mg, 28 %) as a colorless oil. 1H NMR (500 MHz, 
CDCl3) δ 7.43 (s, 1H), 7.32 (d, J = 4.7 Hz, 4H), 6.97 (s, 1H), 5.07 (s, 5H), 3.78 (s, 2H), 3.21 (p, J 
= 6.8 Hz, 1H), 2.54 (s, 3H), 1.27 (d, J = 6.8 Hz, 7H). 13C NMR (125 MHz, CDCl3) δ 171.1, 157.4, 
142.4, 137.2, 136.2, 128.0 (2), 125.0 (2), 122.8 (2), 118.7, 118.1, 55.5, 53.3, 52.7, 36.5, 28.2, 24.4 
(2). HRMS (ESI+) m/z [M + H+] calcd for C20H25N2O2, 325.1916, found 325.1904. 
 
2-(5-Hydroxy-4-(isoindoline-2-carbonyl)-2-isopropylphenyl)acetamide (79): 30 % Hydrogen 
peroxide (0.10 mL, 0.19 mmol, 3.0 eq.) and 2M solution of sodium hydroxide (95 µl, 0.19 mmol, 
3.0 eq.) was added to a solution of 73 (20 mg, 0.062 mmol, 1.0 eq.) in a solvent mixture of ethanol 





addition of water (3 mL). The resulting mixture was extracted with ethyl acetate (3 × 5 mL).  The 
combined organic layers were washed with saturated sodium chloride solution (10 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated The residue was purified by preparatory TLC 
(SiO2, 1:9 acetone/dichloromethane) to give 79 as a colorless amorphous solid (12 mg. 54.4 %). 
1H NMR (500 MHz, CDCl3) δ 10.6 (s, 1H), 7.6 (s, 1H), 7.3 (d, J = 5.0 Hz, 4H), 6.9 (s, 1H), 5.4 (s, 
2H), 5.1 (s, 4H), 3.6 (s, 2H), 3.1 (hept, J = 6.8 Hz, 1H), 1.3 (d, J = 6.8 Hz, 7H). 13C NMR (125 
MHz, CDCl3) δ 172.7, 170.7, 158.0, 137.9 (2), 137.7, 135.9, 128.2, 126.0 (2), 122.9, 119.8(2), 
117.2, 55.9, 53.5, 41.3, 28.9, 24.4 (2). HRMS (ESI+) m/z [M + H+] calcd for C20H22N2O3, 
339.1709, found 339.1699. 
 
Methyl 4-formyl-2-methoxy-5-(prop-1-en-2-yl)benzoate (93): A biotage microwave vial was 
charged with 88 (0.75 g, 2.7 mmol, 1 eq.), tetrakis(triphenylphosphine)palladium(0) (312 mg, 0.27 
mmol, 0.1 eq.), cesium carbonate (2.68 g, 8.25 mmol, 3 eq.), and potassium 
isopropenyltrifluoroborate (440 mg, 2.97 mmol, 1.2 eq.). The tube was sealed with a cap lined 
with a disposable teflon septum. The tube was evacuated and purged with nitrogen (3 times), 
before the addition of tetrahydrofuran (21.6 mL) and water (2.4 mL) by syringe. The resulting 
mixture was heated at 100 °C for 24 h, cooled to rt, and filtered through a small pad of celite 
(elution with ethyl acetate). Solvent was removed and the residue was purified by flash 
chromatography (SiO2, 1:3 ethyl acetate/hexanes) to afford 93 as a colorless amorphous solid (580 
mg, 90 %). 1H NMR (400 MHz, CDCl3) δ 7.57 (s, 1H), 7.14 (s, 1H), 5.19 (p, J = 1.7 Hz, 1H), 4.82 





(100 MHz, CDCl3) δ 166.7, 158.4, 144.0, 143.3, 134.2, 131.3, 118.1, 116.1, 110.9, 62.5, 56.1, 
52.1, 24.8. HRMS (ESI+) m/z [M + H+] calcd for C13H17O4, 237.1126, found 237.1122. 
 
4-(Isoindoline-2-carbonyl)-5-methoxy-2-(prop-1-en-2-yl)benzaldehyde (94): Manganese 
dioxide (2.80 g, 24.0 mol, 10.0 eq.) was added to a solution of 93 (550 mg, 2.40  mmol, 1.0 eq.) 
in dichloromethane (120 mL) at rt. The resulting mixture was stirred at rt for 16 h, filtered through 
a small pad of celite, eluted with ethyl acetate, and concentrated. Solvent was removed to give the 
corresponding aldehyde which was used further as obtained. Lithium hydroxide monohydrate (1.0 
g, 24.0 mmol) was added to a solution of the aldehyde in methanol (8 mL), tetrahydrofuran (8 
mL), and water (8 mL). The resulting mixture was stirred for 14 h at rt. The residue was treated 
with 1 M hydrochloric acid and pH was adjusted to 2. The resulting suspension was extracted with 
ethyl acetate (3 × 50 mL), the combined organic layers were washed with saturated sodium 
chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to 
afford the corresponding acid as off-white solid which was used further as obtained. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (1.53 g, 4.80 mmol) was added to a stirred solution of the acid, 
isoindoline hydrochloride (485 mg, 3.12 mmol), 1-hydroxybenzotriazole (735 mg, 4.8 mmol), 
N,N-diisopropylethylamine (1.25 mL, 7.20 mmol) in dichloromethane (24 mL) at 0 °C. The 
resulting solution was stirred at rt for 14 h before quenching with saturated sodium bicarbonate 
solution (20 mL). The organic layer was washed with 1 M hydrochloric acid solution (15 mL) and 
saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and 





to afford 94 as a light brown amorphous solid (331 mg, 43%). HRMS (ESI+) m/z [M + H+] calcd 
for C20H20NO3, 322.1443, found 322.1449 
 
Methyl 4-(hydroxymethyl)-5-isopropyl-2-methoxybenzoate (96): Palladium on carbon (10%,) 
was added to a solution of 93 (500 mg, 2.11 mmol) in ethyl acetate (6 mL). The suspension was 
stirred for 16 h under a hydrogen atmosphere before it was filtered through a pad of celite and 
eluted with EtOAc (20 mL). The eluent was concentrated to afford 96 (476 mg, 94.2 %) as a 
colorless amorphous solid. 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 1H), 7.06 (s, 1H), 4.78 (s, 2H), 
3.88 (s, 3H), 3.84 (s, 3H), 3.06 (hept, J = 6.9 Hz, 1H), 1.22 (d, J = 6.8 Hz, 6H). 13C NMR (100 
MHz, CDCl3) δ 167.1, 157.5, 143.7, 137.9, 128.9, 118.9, 111.1, 62.5, 56.3, 52.2, 28.0, 23.9 (2). 
HRMS (ESI+) m/z [M + Na+] calcd for C13H18O4Na, 261.1103, found 261.1091 
 
Methyl 4-formyl-5-isopropyl-2-methoxybenzoate (97): Manganese dioxide (1.64 g, 18.8 mmol, 
10.0 eq.) was added to a solution of 96 (450 mg, 1.88 mmo0l, 1.0 eq.) in dichloromethane at rt. 
The resulting mixture was stirred at rt for 16 h, filtered through a small pad of celite, eluted with 
ethyl acetate, and concentrated. The residue was purified by flash chromatography (SiO2, 1:6 ethyl 
acetate/hexanes) to afford 97 (367.3 mg, 82.7 %) as a yellow colorless solid. 1H NMR (400 MHz, 
CDCl3) δ 10.44 (s, 1H), 7.77 (s, 1H), 7.40 (s, 1H), 3.91 (d, J = 3.5 Hz, 6H), 3.84 – 3.75 (m, 1H), 





125.6, 112.0, 56.4, 52.5, 27.2, 24.2 (2). HRMS (ESI+) m/z [M + H+] calcd for C13H17O4, 237.1127, 
found 237.1117. 
 
4-Formyl-5-isopropyl-2-methoxybenzoic acid (98): Trimethyltinhydroxide (3.63 g, 20.1 mmol, 
4.0 eq.) was added to solution of 97 (1.12 g, 5.03 mmol, 1.0 eq.) in 1,2 dichloroethane (25 mL). 
The resulting mixture was heated at 75 °C for 50 h, cooled to rt, and concentrated. The residue 
was suspended in ethyl acetate (100 mL), washed with 1 M hydrochloric acid (3 × 60 mL) and 
saturated sodium chloride solution (100 mL). The solvent was removed to afford 98 (952 mg, 85.1 
%) as a colorless amorphous solid. 1H NMR (400 MHz, CDCl3) δ 10.74 (br s, 1H), 10.52 (s, 1H), 
8.27 (s, 1H), 7.53 (s, 1H), 4.13 (s, 3H), 3.79 – 4.13 (m, 1H), 1.36 (d, J = 6.8 Hz, 6H). 13C NMR 
(100 MHz, CDCl3) δ 190.4, 164.9, 156.2, 145.1, 137.5, 132.6, 122.3, 111.5, 57.3, 27.4, 24.3. 
HRMS (ESI-) m/z [M  H+] calcd for C12H13O4, 221.0814, found 221.0809. 
 
4-(Isoindoline-2-carbonyl)-2-isopropyl-5-methoxybenzaldehyde (95): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (1.63 g, 8.54 mmol, 2.0 eq.) was added to a stirred solution 
of 98 (950 mg, 4.27 mmol, 1 eq.), isoindoline hydrochloride (731 mg, 4.70 mmol, 1.1 eq.), 1-
hydroxybenzotriazole (635 mg, 4.70 mmol, 1.1 eq.) N,N-diisopropylethylamine (3.26 mL, 18.8 
mmol, 4.4 eq.) in dichloromethane 42 mL) at 0 °C. The resulting solution was stirred at rt for 14 h 
before quenching with saturated sodium bicarbonate solution (30 mL). The organic layer was 





mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by 
flash chromatography (SiO2, 3:10 hexanes/ethyl acetate) to afford 95 (1.22 g, 91.8%) as a white 
amorphous solid. 1H NMR (400 MHz, CDCl3) δ 10.47 (s, 1H), 7.48 – 7.21 (m, 5H), 7.15 (d, J = 
7.4 Hz, 1H), 5.01 (s, 2H), 4.58 (s, 2H), 4.02 – 3.76 (m, 4H), 1.32 (d, J = 6.8 Hz, 7H). 13C NMR 
(100 MHz, CDCl3) δ 190.8, 167.6, 153.7, 144.9, 136.4, 136.4, 134.4, 132.5, 128.0, 127.7, 126.1, 
123.3, 122.7, 111.2, 56.1, 53.4, 52.3, 27.3, 24.4 (2). HRMS (ESI+) m/z [M + Na+] calcd for 
C20H21NO3Na, 346.1419, found 346.1404. 
 
5-Hydroxy-4-(isoindoline-2-carbonyl)-2-isopropylbenzaldehyde (78): 1 M solution of boron 
tribromide (1.22 mmol, 1.22 mL, 2 eq.), was added to a solution of 95 (200 mg, 0.61 mmol) in 
anhydrous dichloromethane (6.1 ml) at 0 oC. The resulting mixture was stirred at rt for 14 h before 
quenching with saturate sodium bicarbonate solution (5 mL). The aqueous layer was extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (20 mL), dried over sodium sulfate, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:50 acetone/dichloromethane) to afford 78 
(121.8 mg, 63.7 %) as a colorless solid. 1H NMR (400 MHz, CDCl3) δ 10.31 (s, 1H), 10.11 (s, 
1H), 7.64 (s, 1H), 7.43 (s, 1H), 7.37 – 7.29 (m, 4H), 5.08 (s, 5H), 3.93 (h, J = 6.9 Hz, 1H), 1.34 (d, 






Benzyl (4-(isoindoline-2-carbonyl)-2-isopropyl-5-methoxybenzyl)carbamate (99): Benzyl 
carbamate (109 mg, 0.72 mmol, 3.0 eq.), triethyl silane (114 µl, 0.72 mmol, 3.0 eq.) and 
trifluoroacetic acid (36 µl, 0.48 mmol. 2.0 eq.) were added to a solution of 78 (75 mg, 0.24 mmol, 
1.0 eq.) in acetonitrile (2.5 mL). The resulting mixture was stirred for 24 h before quenching with 
saturated sodium bicarbonate solution (10 mL). The aqueous layer was extracted with ethyl acetate 
(2 × 10 mL). The combined organic layers were washed with saturated sodium chloride solution 
(15 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:2 ethyl acetate/hexanes) to afford 99 (93.7 mg, 87.9 %) as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 10.52 (s, 1H), 7.50 (s, 1H), 7.41 – 7.27 (m, 9H), 6.92 (s, 1H), 
5.15 (s, 3H), 5.06 (s, 4H), 4.45 (d, J = 5.9 Hz, 2H), 3.20 – 3.05 (m, 1H), 1.27 (d, J = 6.8 Hz, 6H). 
13C NMR (100 MHz, CDCl3) δ 170.8, 157.7, 156.4, 136.7, 136.6, 136.0, 128.7(3), 128.3 (2), 128.3 
(2), 128.0, 125.3 (2), 122.8 (2), 117.0, 116.8, 67.1, 55.6, 55.3, 42.4, 28.2, 24.3 (2). HRMS (ESI+) 
m/z [M + H+] calcd for C27H29N2O4, 445.2127, found 445.2131. 
 
(4-(Aminomethyl)-2-hydroxy-5-isopropylphenyl) (isoindolin-2-yl)methanone (75): Palladium 
on carbon (10%) was added to a solution of 99 (93 mg, 0.21 mmol) in ethyl acetate (5 mL). The 





of celite and eluted with EtOAc (20 mL). The eluent was concentrated to afford 75 (36 mg, 55.6 
%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 7.31 (s, 4H), 6.99 (s, 1H), 5.08 
(s, 4H), 3.91 (s, 2H), 3.17 (hept, J = 6.8 Hz, 1H), 1.28 (d, J = 6.8 Hz, 6H). 13C NMR (100 MHz, 
CDCl3) δ 171.0, 157.7, 145.4, 136.4, 136.1 (2), 128.0 (2), 125.1, 122.8 (2), 116.6, 116.4, 53.6 (2), 
43.4, 28.1, 24.5 (2). HRMS (ESI+) m/z [M + H+] calcd for C19H23N2O2, 311.1760, found 311.1774. 
 
(4-Ethynyl-5-isopropyl-2-methoxyphenyl)(isoindolin-2-yl)methanone (100): Dimethyl-1-
diazo-2-oxopropylphosphonate  (60 µL, 0.40 mmol, 1.2 eq.) was added to a stirred solution of 
aldehyde 95 (100 mg, 0.31 mmol, 1.0 eq.) and potassium carbonate (86 mg, 0.62 mmol, 2.0 eq.) 
in methanol (3.1 mL). The resulting mixture was stirred for 24 h at rt and diluted with ethyl acetate 
(10 mL). The organic layer was washed with saturated sodium bicarbonate solution (10 mL), dried 
over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:3 ethyl acetate/hexanes) to afford 100 (77.1 mg, 78.1 %) as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.23 (m, 3H), 7.21 (s, 1H), 7.13 (d, J = 7.4 Hz, 1H), 7.05 
(s, 1H), 4.98 (s, 2H), 4.58 (s, 2H), 3.81 (d, J = 1.3 Hz, 3H), 3.82 – 3.40 (m, 1H), 3.33 (s, 1H), 1.24 
(d, J = 7.1 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 168.1, 152.9, 144.3, 136.7, 136.5, 127.9, 127.8, 
127.6, 124.7, 123.2, 122.9, 122.7, 115.5, 82.0, 81.8, 56.0, 53.4, 52.2, 31.0, 23.3 (2). HRMS (ESI+) 






(4-Ethyl-5-isopropyl-2-methoxyphenyl)(isoindolin-2-yl)methanone (81): Palladium on carbon 
(10%) was added to a solution of 95 (75 mg, 0.23 mmol) in ethyl acetate (10 mL). The suspension 
was stirred for 16 h under a hydrogen atmosphere before it was filtered through a pad of celite and 
eluted with EtOAc (20 mL). The eluent was concentrated to afford (4-ethyl-5-isopropyl-2-
methoxyphenyl)(isoindolin-2-yl)methanone (72.1 mg, 97.6 %) as a colorless amorphous solid. 1H 
NMR (400 MHz, CDCl3) δ 7.37 – 7.24 (m, 3H), 7.19 (s, 1H), 7.14 (d, J = 7.4 Hz, 1H), 6.75 (s, 
1H), 5.00 (s, 2H), 4.63 (s, 2H), 3.83 (s, 3H), 3.11 – 3.18 (m, 1H), 2.71 (q, J = 7.5 Hz, 2H), 1.21 – 
1.27 (m, 9H). 13C NMR (100 MHz, CDCl3) δ 168.1, 152.9, 144.3, 136.7, 136.5, 127.9, 127.8, 
127.6, 124.7, 123.2, 122.9, 122.7, 115.5, 82.0, 81.8, 56.0, 53.4, 52.2, 31.0, 23.3 (2). HRMS (ESI+) 
m/z [M + H+] calcd for C21H26NO2, 324.1963, found 324.1969. 1 M solution of boron tribromide 
(0.38 mmol, 0.38 mL, 2 eq.), was added to a solution of (4-ethyl-5-isopropyl-2-
methoxyphenyl)(isoindolin-2-yl)methanone (60 mg, 0.19 mmol) in anhydrous dichloromethane (2 
mL) at 0 oC. The resulting mixture was stirred at rt for 14 h before quenching with saturate sodium 
bicarbonate solution (5 mL). The aqueous layer was extracted with dichloromethane (2 × 10 mL). 
The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried 
over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:2 ethyl acetate/hexanes) to afford 81 (33.2 mg, 56.7 %) as a pale yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 10.54 (s, 1H), 7.40 (s, 1H), 7.30 – 7.18 (m, 4H), 6.75 (s, 1H), 
5.02 (s, 4H), 3.09 (hept, J = 6.7 Hz, 1H), 2.61 (q, J = 7.6 Hz, 2H), 1.15 – 1.21 (m, 9H). 13C NMR 
(100 MHz, CDCl3) δ 171.3, 157.9, 147.3, 136.7, 136.2 (2), 128.0, 124.9, 122.8 (2), 117.5 (2), 
115.0, 56.1 (2),28.2, 25.8, 24.5 (2), 15.4. HRMS (ESI+) m/z [M + H+] calcd for C20H24NO2, 







1.6 M Solution of n-butyl lithium in hexanes (0.32 mL, 0.5 mmol, 2.0 eq.) was added to a 
suspension of isopropyltriphenylphosphonium iodide (216 mg, 0.5 mmol, 1.0 eq.) in 
tetrahydrofuran (1 mL) at 0 oC. The resulting mixture was stirred for 30 min before the addition 
of a solution of 95 (80 mg, 0.25 mmol, 1.0 eq.) in tetrahydrofuran (1 mL) at 0 oC. The reaction 
was warmed to rt and stirred for 5 h before quenching with water (10 mL). The aqueous layer was 
extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (20 mL), dried over sodium sulfate, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:5 ethyl acetate/hexanes) to afford 101 (66.6 
mg, 75.9 %) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.24 (m, 4H), 7.16 (d, J = 
5.1 Hz, 2H), 6.78 (s, 1H), 6.25 (s, 1H), 5.14 – 5.12 (m, 1H), 5.01 (s, 2H), 4.93 – 4.85 (m, 1H), 4.67 
(s, 2H), 3.84 (s, 3H), 1.99 (s, 3H), 1.91 (s, 3H), 1.81 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 168.6, 
153.8, 144.8, 138.8, 136.9, 136.7, 136.5, 135.7, 127.8, 127.6, 127.5, 125.0, 124.6, 123.3, 122.7, 
115.7, 113.0, 56.0, 53.6, 52.2, 26.4, 24.2, 19.7.  HRMS (ESI+) m/z [M + H+] calcd for C23H26NO2, 






(2-Hydroxy-4-isobutyl-5-isopropylphenyl)(isoindolin-2-yl)methanone (82): Palladium on 
carbon (10%) was added to a solution of 101 (60 mg, 0.17 mmol) in ethyl acetate (5 mL). The 
suspension was stirred for 16 h under a hydrogen atmosphere before it was filtered through a pad 
of celite and eluted with EtOAc (20 mL). The eluent was concentrated to afford (4-isobutyl-5-
isopropyl-2-methoxyphenyl)(isoindolin-2-yl)methanone (56.3 mg, 94.2 %) as a colorless 
amorphous solid. 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.22 (m, 3H), 7.20 (s, 1H), 7.14 (d, J = 7.3 
Hz, 1H), 6.67 (s, 1H), 5.00 (s, 2H), 4.62 (s, 2H), 3.81 (s, 3H), 3.13 (hept, J = 6.9 Hz, 1H), 2.54 (d, 
J = 7.2 Hz, 2H), 1.85 (dp, J = 13.6, 6.8 Hz, 1H), 1.20 (d, J = 6.8 Hz, 6H), 0.97 (d, J = 6.6 Hz, 6H). 
13C NMR (100 MHz, CDCl3) δ 169.2, 152.8, 141.3, 139.8, 137.0, 136.8, 127.8, 127.5, 124.9, 
124.8, 123.2, 122.7, 113.2, 55.9, 53.5, 52.2, 42.6, 30.4, 28.4, 24.4 (2), 22.8 (2). HRMS (ESI+) m/z 
[M + H+] calcd for C23H30NO2, 352.2277, found 352.2275. 1 M solution of boron tribromide (0.34 
mmol, 0.34 mL, 2 eq.), was added to a solution of (4-isobutyl-5-isopropyl-2-
methoxyphenyl)(isoindolin-2-yl)methanone (60 mg, 0.17 mmol) in anhydrous dichloromethane (2 
mL) at 0 oC. The resulting mixture was stirred at rt for 14 h before quenching with saturate sodium 
bicarbonate solution (5 mL). The aqueous layer was extracted with dichloromethane (2 × 10 mL). 
The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried 
over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:3 ethyl acetate/hexanes) to afford 82 (33.2 mg, 56.7 %) as a colorless amorphous solid.  
1H NMR (500 MHz, CDCl3) δ 10.60 (s, 1H), 7.48 (s, 1H), 7.32 (s, 4H), 6.77 (s, 1H), 5.10 (s, 4H), 
3.16 (hept, J = 6.8 Hz, 1H), 2.51 (d, J = 7.2 Hz, 2H), 1.87 (dt, J = 13.5, 6.8 Hz, 1H), 1.26 (d, J = 
6.8 Hz, 7H), 0.96 (d, J = 6.6 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 171.3, 157.4, 144.8, 137.3, 
136.2 (2), 128.0, 125.1, 122.8, 119.1, 115.2, 55.9, 53.5, 42.2, 30.1, 28.3, 24.7 (2), 22.9 (2). HRMS 






2,6-Dihydroxy-3-(isoindoline-2-carbonyl)-5-isopropylbenzaldehyde (104): A solution of 103 
(400 mg, 1.34 mmol, 1 eq.), hexamethylenetetramine (376 mg, 2.68 mmol, 2.0 eq.) in 
trifluoroacetic acid was heated at 100 C for 14 h in a sealed tube, cooled to rt, and solvent was 
removed. The residue was treated with 3 M hydrochloric acid and the resulting mixture was heated 
at 60 oC for 3 h. The mixture was cooled to rt, diluted with water (20 ml), extracted with ethyl 
acetate (2 × 20 mL). The organic layer was washed with water (30 ml), saturated sodium 
bicarbonate solution (30 mL), and saturated sodium chloride solution (30 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:9 ethyl acetate/hexanes) to afford 104 (312.2 mg, 71.8 %) as a pale 
yellow amorphous solid. 1H NMR (500 MHz, CDCl3) δ 13.06 (s, 1H), 12.74 (s, 1H), 10.44 (s, 1H), 
7.74 (s, 1H), 7.34 (d, J = 2.2 Hz, 4H), 5.12 (s, 4H), 3.36 – 3.27 (m, 1H), 1.28 (d, J = 6.9 Hz, 6H). 
13C NMR (125 MHz, CDCl3) δ 195.1, 170.7, 165.0, 164.0, 135.7, 133.5 (2), 128.2 (2), 126.2, 122.8 
(2), 110.1, 106.9, 54.8 (2), 26.1, 22.7 (2). HRMS (ESI+) m/z [M + H+] calcd for C19H20NO4, 
338.2120, found 338.2117. 
 
(2,4-Dihydroxy-3-(hydroxymethyl)-5-isopropylphenyl)(isoindolin-2-yl)methanone (102): 





eq.) in a solvent mixture of tetrahydrofuran (1.5 mL) and methanol (0.5 mL) at oC. The resulting 
mixture was stirred at rt for 1 h before the addition of 1 M hydrochloric acid (2 mL). The aqueous 
layer was extracted with ethyl acetate (2 × 5 mL), and the combined organic layers washed with 
saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by preparatory TLC (SiO2, 1:3 ethyl acetate/hexanes) to 
give 102 as a colorless amorphous solid (14.2 mg, 72.2 %). 1H NMR (500 MHz, CDCl3) δ 11.72 
(s, 1H), 8.76 (s, 1H), 7.43 (s, 1H), 7.32 (s, 4H), 5.11 (s, 6H), 3.34 – 3.24 (m, 1H), 2.31 (s, 1H), 
1.28 (d, J = 6.9 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 171.7, 158.6, 157.1, 136.2 (2), 128.0, 
126.3 (2), 125.5, 122.8 (2), 111.4, 108.3, 59.3, 54.2 (2), 26.6, 23.1 (2). HRMS (ESI+) m/z [M + 
H+] calcd for C19H21NO4, 328.1549, found 328.1543. 
 
(4-Hydroxy-7-isopropylbenzo[d]isoxazol-5-yl)(isoindolin-2-yl)methanone (105): Triflic acid 
(79 µL, 0.90 mmol, 6.0 eq.) and sodium azide (15 mg, 0.23 mmol, 1.5 eq.) were added to a solution 
of 104 (50 mg, 0.15 mmol, 1.0 eq.) in acetonitrile (1.5 mL) at rt. The resulting mixture was stirred 
for 5 min and concentrated. The residue was treated with water (2 mL) and ethyl acetate (3 mL). 
The aqueous layer was extracted with ethyl acetate (2 × 3 mL) and the combined organic layers 
washed with saturated sodium chloride solution (6 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified using preparatory TLC (SiO2, 1:3 ethyl 
acetate/hexanes) to afford 105 as a white amorphous solid. (18.3 mg, 37.8 %). Additionally, 106 
(13.1, 27.1 %) was also isolated as a white amorphous solid.   1H NMR (400 MHz, CDCl3) δ 12.42 





1H), 1.45 (d, J = 7.1 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 171.1, 163.7, 156.1, 145.2, 135.9, 
128.2 (2), 126.5 (2), 122.8 (2), 121.6, 112.9, 110.4, 54.2 (2), 29.4, 22.7 (2). HRMS (ESI+) m/z [M 
+ H+] calcd for C19H19N2O3, 323.1396, found 323.1392. 
 
(4-Hydroxy-5-isopropylbenzo[d]isoxazol-7-yl)(isoindolin-2-yl)methanone (106): 1H NMR 
(400 MHz, CDCl3; δ 9.59 (s, 1H), 9.10 (s, 1H), 7.60 (s, 1H), 7.45 – 7.26 (m, 3H), 7.16 (d, J = 7.4 
Hz, 1H), 5.17 (s, 2H), 4.91 (s, 2H), 3.18 (h, J = 7.0 Hz, 1H), 1.06 (d, J = 6.9 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 167.9, 157.9, 151.0, 145.2, 136.5, 135.8, 130.0, 129.4, 128.1, 127.9, 123.1, 
122.8, 112.6, 109.5, 53.9, 53.3, 26.4, 22.9 (2). HRMS (ESI+) m/z [M + H+] calcd for C19H19N2O3, 
323.1396, found 323.1399. 
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                                 The Development of Hsp90-Selective Inhibitors 
 
V.1. Introduction  
The development of isoform-selective inhibitors of the Hsp90 protein folding machinery 
represents a new paradigm for anti-cancer drug discovery.1-8 The limited success of pan-inhibitors 
in clinical trials warrants the development of alternative strategies to modulate Hsp90.9-11 Isoform-
selective inhibitors represent one such approach as individual Hsp90 isoforms have been 
associated with oncogenesis and genetic knockdowns of individual isoforms resulted in depletion 
of selected oncogenic proteins.2, 12-15 Towards this objective, Grp94-selective inhibitors (BnIm, 
KUNG29, WS-13) have been identified and are currently under investigation for the potential 
treatment of breast, blood, and liver cancer.5, 8, 16, 17 Additionally, Grp94 inhibitors are being 
investigated for the treatment of glaucoma and metastatic cancer.13  Chapter IV described 
development of the first Hsp90-selective inhibitor (KUNB31) and preliminary studies show that 
Hsp90-inhibition induced the degradation of client proteins without induction of Hsp90 and 
Hsp70 levels. Hence, Hsp90-selective inhibitors may overcome the detriments of the heat-shock 
response, which is one of the major concerns associated with pan-Hsp90 inhibitors. While a Trap-
1-selective inhibitor has yet to be identified, selective inhibition of Trap-1 has been accomplished 
by mitochondrial targeting methods.4 Hence, for complete deconvolution of all Hsp90-isoforms, 
the development of Hsp90-selective inhibitors was pursued and is described in this chapter.  
V.1.1. Hsp90 Isoform 
The Hsp90 isoform resides in the cytosol and is encoded by the HSP90AA1 gene.18, 19 
The primary amino acid sequence in Hsp90 is 86% identical and 93% similar to Hsp90, while 
the N-terminal ATP binding site is more than 95% identical between these two isoforms.20, 21 Prior 
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studies have identified only few biochemical differences between Hsp90 and Hsp90
Hsp90 readily dimerizes when compared to Hsp90. Unlike Hsp90, Hsp90 does not interact 
with microtubules. Hsp90is more inducible than Hsp90 and its cellular roles involve growth 
promotion, cell cycle regulation, and stress-induced cytoprotection. Hsp90 knockout in mice was 
shown non-lethal and resulted in  dysfunctional spermocytes in male mice.26-28 Hsp90-knockout 
in mice exhibit compromised cellular differentiation.29 These studies suggest that unlike Hsp90, 
Hsp90 is not essential for survival. However, Hsp90 has tissue specific roles that cannot be 
compensated by Hsp90. Hsp90 is overexpressed in cancers and has been associated with poor 
prognosis of breast cancer, pancreatic carcinoma, and leukemia.30-36 Prior studies have shown that 
genetic knockdown of Hsp90 results in the degradation several oncogenic client proteins. 
Therefore, the administration of an Hsp90-selective inhibitors could selectively inhibit some 
cancers. 
Hsp90 is responsible for the proliferation and metastasis of many cancers. Hsp90 is also 
responsible for hERG channel maturation and trafficking.3 siRNA knockdown of Hsp90 disrupts 
hERG maturation, which may cause the cardiotoxicity observed with pan-Hsp90 inhibitors in the 
clinic. Despite this problems, selective inhibition of Hsp90 is of interest as a chemical probe to 
further delineate the biological impact of isoform-selective inhibition and to validate that small 
molecule inhibition of Hsp90 does in fact lead to the cardiotoxicity observed with its genetic 
knockdown. Maturation of Hsp90 client hERG channel occurs within the cell, while extracellular 
Hsp90 has been implicated as an anti-cancer target.30, 34, 37, 38 Extracellular Hsp90 activates 
MMP-2 and promote tumor invasion .39-41 Both the intra and extracellular functioning of Hsp90 
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highlight the advantages of its selective inhibition, and studies to produce Hsp90-selective 
inhibitors may be useful for anti-cancer applications.  
V.2. Identification of a Lead Compound for the Development of Hsp90-Selective Inhibitors 
V.2.1. Binding of Radicicol and PU3 with Hsp90 versus Hsp90 
 
Hsp90 and Hsp90 share more than 95% similarity in their N-terminal ATP-binding 
pocket. As described in chapter IV, only two amino acids differ in the ATP-binding pocket of 
Hsp90 (Ser52, Ile91) and Hsp90(Ala52, Leu91). The bulkier side chains of Ser52 and Ile91 in 
Hsp90 produced a steric clash with Hsp90-selective inhibitor, KUNB31, providing selectivity 
for Hsp90. For the development of an Hsp90-selective inhibitor, these steric interactions would 
 
Figure 42. Differences in binding of ligands between Hsp90 and Hsp90 (a) co-crystal 
structure of PU3 bound to Hsp90(PDB: 1UY6); (b) co-crystal structure of PU3 bound to 
Hsp90 (PDB: 1UYM); (C) co-crystal structure of radicicol bound to Hsp90 (PDB: 4EKG); 




not be relevant. Hence, the hydrogen bonding interactions manifested by the phenols with Ser52 
(Ala in other three isoforms) were sought for further evaluation.  
Purine derived compound, PU3, is the only known Hsp90 inhibitor that has been co-
crystallized with both Hsp90 and Hsp90 (PDB: 1UYM and 1UY6). A comparison of the two 
co-crystal structures revealed that PU3 binds to both isoforms similarly.42 The only difference in 
binding is the interaction between the N-6 amine and Ser52 (Figure 42a & 42b) in Hsp90. The 
N-6 amine produces two additional water-mediated hydrogen bonding interactions with Ser52 of 
Hsp90 These interactions are not present in Hsp90due to the presence of Ala52Similar to 
purine-derived inhibitors, resorcinol-based inhibitors also produce a stronger hydrogen bonding 
network with Hsp90. Radicicol has never been co-crystallized with Hsp90; its co-crystal 
structures with Hsp90 and Hsc82 (yeast homologue of Hsp90) have been solved.43 Comparison 
of the primary sequences of these proteins shows that Hsc82 contains Ala38, in lieu of Ser52 in 
Hsp90, and Ala52 in Hsp90, and is more similar to Hsp90Table 15. Evaluation of the co-
crystal structure of radicicol bound to Hsp90 shows that the presence of Ser52 (Figure 42c & 
42d), as opposed to Ala52 in Hsp90β, results in a stronger hydrogen bonding network. Conserved 
water molecules in Hsp90 coordinate with Ser52, whereas in Hsp90/Hsc82, Ala52 alters this 
spatial arrangement.   
Table 15. Difference in Hsp90, Hsp90, and yeast Hsp90 (Hsc82) ATP binding pocket 
Protein 
Residues (numbered for Hsp90) 
52 91 92 141 154 
Hsp90 Ser IlE Val Ala His 
Hsp90 Ala Leu Val Ala His 
Hsc82 Ala Ile Ile Arg Ser 
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Interestingly, these additional hydrogen bonds result in only 3-fold selectivity for Hsp90 
versus Hsp90as radicicol manifested an apparent Kd of 4 nM for Hsp90 versus 15 nM for 
Hsp90 in a thermal shift calorimetry assay.20 Prior studies by Vilma and co-workers have 
provided insights into the differences in binding of radicicol to both cytosolic isoforms. The 
intrinsic enthalpy of binding (H) for radicicol is 10 kJ higher for Hsp90than Hsp90, which 
should result in a greater difference in dissociation constants (Kd). However, binding of radicicol 
to Hsp90 results in greater entropy when compared to Hsp90, which accounts for the observed 
difference in dissociation constants. This observation can be rationalized by greater 
hydrophobicity with Hsp90 when compared to Hsp90(Table 16), and consequently radicicol 
produces more hydrophobic interactions within the Hsp90 binding pocket and results in greater 
entropy contribution.44 Collectively, these studies suggest that the interactions manifested by the 
ligand with Ser52 are critical for the development of an Hsp90-selective inhibitor. 
Table 16. Relative hydrophobicity of Hsp90 isoforms  
Protein Hydrophobic Hydrophilic Ratio 
Hsp90 1.46 0.97 1.5 
Hsp90 1.73 0.82 2 
Grp94 2.98 0.63 5 
Trap-1 2.2 0.72 3 
 
V.2.2. Synthesis and Evaluation of 4-Amino 2-Phenol Analogues  
The development of Hsp90-selective inhibitors commenced via optimization of the 5-
bromo resorcinol compound, 61 (Chapter III) to probe the hydrogen bonding interactions with 
Ser52. At first, conversion of the 4-phenol to the aniline was proposed. The 5-bromo substituent 
was replaced with an isopropyl group, and analogues with electron withdrawing groups on the 
nitrogen were also evaluated. Syntheses of the proposed analogues (109, 111113, Scheme 17) 
264 
 
commenced via bromination of the 4-amino-2-methoxybenzoic acid (107) to give 108. 
Carbodiimide coupling of the acid (108) with isoindoline gave 109, which upon methyl ether 
cleavage using boron tribromide gave the desired product, 110. Suzuki coupling of 109 with 
potassium isopropenyl trifluoroborate, followed by palladium-catalyzed hydrogenation under a 
hydrogen atmosphere furnished the 5-isopropyl intermediate 111, which upon treatment with 
boron tribromide gave 112.  The aniline was modified to the corresponding cyanamide by enlisting 
cyanogen bromide. 
 
The 4-amino-2-phenol analogues 110, 112, and 113 were evaluated in a fluorescence 
polarization assay and did not exhibit selectivity for Hsp90Table 17. These analogues were 
less efficacious than the corresponding 4-phenol (61). This data suggested that the 4-phenol is 
producing more efficacious interactions with Ser52 than the corresponding aniline.  
 
 
Scheme 17. Syntheses of 4-amino-2-phenol analogues. 
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Table 17. Evaluation of 4-amino-2-phenol analogues 






61 0.025 + 0.01 0.033 + 0.01 - 
110 0.22+0.01 0.50+0.01 2 
112 0.46+0.22 0.71+013 1.5 
113 0.18 + 0.01 0.42 + 0.05 2 
 
In a parallel, additional scaffolds were also evaluated for selective Hsp90inhibition. As 
shown in Figure 43, the 3-position of resorcinol moiety was modified to improved interactions 
with Ser52 (KUNA01, KUNA02). 
Unfortunately, an Hsp90-selective 
inhibitor could not be identified. Research 
groups from academia and industry screened 
several known Hsp90 inhibitors to identify 
isoform-selective inhibitors but these efforts 
were not productive.2, 45, 46 
V.2.3. Identification of the Monophenol-Isoindoline Scaffold for Selective Hsp90-Inhibition 
 After these failed attempts, a different strategy was devised to exploit the hydrogen 
bonding network that surrounds the resorcinol ring. As previously mentioned, only the 4-phenol 
of the resorcinol interacts with Ser52 in Hsp90 (Ala 
in Hsp90Grp94, and Trap1). Hence it should drive 
selectivity for Hsp90. The 2-phenol interacts 
similarly with both the Hsp90 and Hsp90 ATP-
binding pockets (Figure 42). While collectively the 
resorcinol moiety results in 3-fold selectivity for 
                 
Figure 43. Additional studies towards selective  
                 Hsp90-inhibition.  
   




Hsp90, the individual contribution of each phenol had never been evaluated for binding with 
individual isoforms. Therefore, compounds that lacks the 4-phenol were considered for evaluation. 
We had access to compound 72, that lacks 4-phenol (Chapter IV). Additionally, compound 114, 
which lacks the 2-phenol was synthesized using a reported procedure.47 These compounds were 
evaluated in a fluorescence polarization assay and their binding affinities for Hsp90 and Hsp90 
were determined. While compound, 72 manifested 2-fold selectivity for Hsp90, compound 114 
bound Hsp90with 10-fold selectivity. The selectivity of 114 confirmed our hypothesis that 
exclusive interactions of the 4-phenol with Ser52 could lead to an Hsp90-selective inhibitor. 
Therefore, further development of 114 was pursued.  
V.3. Development of the Monophenol-Isoindoline Scaffold for Selective Hsp90 Inhibition 
 It was proposed that substituents at the 4- and 5-positions may change the electronic nature 
and spatial arrangement of the 4-phenol and alter its hydrogen bonding interactions with Ser52. 
Therefore, two different series were proposed for investigation of 114 analogues: (1) replacements 
of the 4-phenol, and (2) Modification of the 5-position of the resorcinol. Initially, replacement of 
the 4-phenol with the corresponding aniline and meothoxy group were proposed, as well as 
heterocycles adjoining the 4- and the 5-positions (Series I, Figure 45). In a second series, 
modifications of the 5-position were also pursued (Series II, Figure 45) 
V.3.1. Syntheses of Series I and Series II Analogues 
            Compound 115, 121, and 126 were synthesized following a literature procedure.47 The 
synthesis of 116 commenced with 4-amino benzoic acid, which upon electrophilic bromination 
and subsequent carbodiimide coupling with isoindoline gave 132. Suzuki coupling of 132 with 
isopropenyl trifluoroborate and subsequent hydrogenation of the olefin gave the desired analogue 
116.48 Analogues 117120 were synthesized by an EDCI-mediated coupling of isoindoline with 
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commercially available appropriate heterocyclic carboxylic acids. Analogues 129130 were 
synthesized from 128, which upon treatment with sodium borohydride and methyl magnesium 
bromide gave 129 and 130, respectively (Scheme 18).  
 
V.3.2. Evaluation of Series I and Series II Analogues 
               Upon preparation, compounds 115130 were evaluated in a fluorescence polarization 
assay. As shown in Table 18, replacement of the 4-phenol with an aniline (116) or methyl ether 
(115) decreased affinity, which suggested that the 4-phenol acts as a hydrogen bond donor. The 
heterocycles were also inactive, which suggests that spatial arrangement of the hydrogen bond 
donor at the 4-position is important. Replacement of the isopropyl with a chlorine, bromine, or 
tert-butyl substituents enhanced selectivity for Hsp90. Analogue 130 manifested the highest 
 





affinity for Hsp90, which indicated potential interactions of the tertiary alcohol with Asn84. 
Compound 126 was chosen for further optimization based on these observed trends.  
 
V.4. Modification to the Isoindoline Core of 126  
Prior studies on the resorcinol-isoindoline scaffold have shown that modifications to the 5-
position of the isoindoline ring system modulate Hsp90 affinity and cellular efficacy.47, 48 The co-
crystal structure of compound 121 bound to Hsp90 has been reported previously, which shows 
that the benzene ring of the isoindoline projects towards the solvent exposed region of the N-
terminal ATP-binding site (Figure 46a).47 Substituents at the 5-position of the isoindoline may 
interact with the surrounding hydrophilic residues (Asp54, Lys58, Figure 46a). Therefore, 
 




compounds 133138 were proposed (Figure 46b). Additionally, an analogue containing a 2,3-
dihydro-1H-pyrrolo[3,4-c]pyridine in lieu of isoindoline was also sought.     








115 68.09 + 3.96 >100 2-fold 
116 >100 >100 - 
117 >100 >100 - 
118 >100 >100 - 
119 >100 >100 - 
120 >100 >100 - 
121 2.62 + 0.08 >200 >75-fold 
122 7.90 + 1.18 >200 >25-fold 
123 4.69 + 0.27 >200 >42-fold 
124 >100 >100 - 
125 >100 >100 - 
126 2.73 + 0.19 >200 >73-fold 
127 >100 >100 - 
128 >100 >100 - 
129 7.11 + 0.42 57.17 + 0.88 8-fold 
130 0.65 + 0.04 12.92 + 1.92 19-fold 
 
V.4.1. Synthesis of Analogues with Modification to the Isoindoline Core 
The proposed analogues 133138 were prepared via an EDCI-mediated coupling of 3-
bromo-4-hydroxybenzoic acid (Scheme 19) with the requisite isodindolines. 138 was prepared by 
methyl ether cleavage of 137 using boron tribromide.  
V.4.2 Evaluation of Analogues with Modification to the Isoindoline Core 
 
 The isoindoline analogues 133139 were evaluated in a fluorescence polarization assay. 
Incorporation of bulkier substituents on the isoindoline ring did not improve Hsp90 affinity 
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(Table 19). However, introduction of a fluorine, chlorine or phenol substituents was tolerated at 
the 5-position. The inclusion of a bulkier bromine and methyl ester decreased affinity.  
 
V.5. Preliminary Studies to Probe the Inducible Binding Pocket 
Prior studies demonstrated conformational flexibility in amino acid residues 104111 of 
Hsp90/Hsp90 as they can adopt various conformations (-helix, closed loop, and open loop)  
upon binding to an inhibitor.45 These conformational variations produce an additional binding 
pocket within the Hsp90Hsp90 ATP binding site, which can produce beneficial interactions 
with inhibitors.49, 50  A survey of the co-crystal structures bound to various ligands provided further 
insights. The purine and benzamide class of Hsp90 inhibitors induced this additional binding 
pocket, whereas the resorcinol and ansamycin classes of inhibitors did not. Structurally, induction 
of this additional binding pocket has been associated with three-dimensional conformations of the 
amino acid residues 104111.51-54 As shown in Figure 47, these residues adopt an -helix  
 
Figure 46. Proposed modification to isoindoline core. (a) Previously reported co-crystal 
structure of 121 (PDB: 3XHX) (b) Proposed isoindoline analogues 
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(BIIB021), an open loop (17-DMAG), or a closed loop (AUY-922) conformation. The additional 
binding pocket is induced only when these residues adopt the -helix conformation in the case of 
BIIB021bound to Hsp90. However, when these residues adopt an open or a closed loop 
conformation, the binding pocket is blocked by Phe124. Recently, Shen and co-workers obtained 
a co-crystal structure of resorcinol-derived inhibitor that demonstrated an additional binding 
pocket about the 5-position of the resorcinol ring.55 In the co-crystal structure, the residues 
104111 were shown to adopt a -helix conformation. This was the first time when a resorcinol-
based compound, similar to purine-based inhibitors, was shown to induce the additional binding 
pocket about the 5-position of resorcinol ring.   
 
As shown in Chapter III, our resorcinol based inhibitors were expected to induce a similar 
binding pocket as the incorporation of benzyl thioethers (6568) and phenyl amines (64) were 
more beneficial than the corresponding 5-bromo containing compound (61). To determine whether 
a similar binding pocket can be induced with the monophenol 126, two analogues 140 and 141 
were proposed (Scheme 20). Preparation of these analogues is described in Scheme 20. The 4-
 




phenol on 3-bromo-4-hydroxybenzic acid was modified to the corresponding benzyl ether, which 
upon carbodiimide coupling with isoindoline afforded 142.  Subsequent palladium-catalyzed 
coupling of 142 with thiophenol or N-methyl aniline, followed by cleavage of benzyl ethers using 
boron tribromide afforded 140 and 141, respectively. Analogue 141 manifested a 3-fold 
improvement in affinity as compared to 126, whereas thiophenyl ether 140 manifested similar 
affinity as 126. 
Table 19.  Evaluation of isoindoline analogues in FP assay 
Compound Hsp90 Hsp90 
Selectivity for 
Hsp90 
133 8.04 + 0.15 >200 >24-fold 
134 6.17 + 1.24 >200 >32-fold 
135 >200 >200 - 
136 94.47 + 27.31 >200 >2-fold 
137 11.59 + 2.62 >200 >17-fold 
138 13.25 + 3.20 >200 >15-fold 
139 8.21 + 0.59 >200 >24-fold 
 
This data suggests that the thiophenyl ether and the N-phenylamine substituents are 
tolerated at the 5-position. Therefore, modification to the 5-position of 126 induces this 
conformational change and creates the additional binding pocket. While these analogues 
maintained high selectivity for Hsp90over Hsp90-isoform, their selectivity over Grp94 was 
only ~5-fold, due to the binding of these substituents in adjacent Grp94-exclusive binding pocket 
(discussed in Chapter III). These findings are highly important and suggests this sub-pocket can 





Figure 47. Binding modes of ligands in Hsp90 N-terminal binding pocket. (a)Structure of 17-
DMAG, BII021, and AUY 922; (b) Apo-Hsp90 (PDB: 1YER); (b) 17-DMAG (PDB: 1OSF); 
(c) BII021 (PDB: 3qdd); (d)AUY922 (PDB: 2VCI); (e) Overlay of co-crystal structure of Apo-
Hsp90 (gray)with BIIB021 bound to Hsp90 (green); (f) Proposed binding mode of 140 in 
Hsp90 binding pocket.  
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V.6. Cellular Efficacy of Hsp90-Selective Inhibitors 
Once the Hsp90-selective inhibitors were identified, cellular studies commenced to 
evaluate the effect of Hsp90-inhibition on the growth of breast cancer cell lines (MCF-7 and 
SkBr3). The anti-proliferation activities are summarized in Table 19. 126 manifested an IC50 of 
48.34 + 5.64 M and 40 + 3.21M against the MCF-7 and Skbr3 cancer cell lines, respectively.  
 
Interestingly, 5-tert butyl analogue, 121, manifested a 6-fold improvement in cellular efficacy. 
Incorporation of a fluorine or a chlorine substituent at the 5-position of the isoindoline also 
improved anti-proliferation activity. Similarly, the thiophenyl ether analogue 140 was also more 
efficacious, and manifested an IC50 of 11.57 + 1.16 M and 12.96 + 1.67 M against the MCF-7 
and SKBr3 cell lines, respectively.  
V.7. Western Blot Analyses of Compound 126 
Prior studies in the Blagg laboratory have led to the identification of a few Hsp90-
selective and Hsp90-selective clients via genetic knockdown of individual isoforms in PC3 cells 
(Figure 48). These studies identified CXCR4 and CDK6 as Hsp90-dependent clients, whereas 
 
Scheme 20. Syntheses and evaluation of compounds 140 and 141. 
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survivin, Raf, c-Src, and hERG were identified as the Hsp90-dependent client proteins.  
Additionally, Erk5, and Akt were degraded upon knockdown of either Hsp90 or Hsp90, 
indicating an overlapping roles for both isoforms. To verify these findings, western blot analyses 
were conducted on PC cell lysates that were treated with the Hsp90-selective inhibitor 126. As 
shown in Figure 46, 126 induced the degradation of Hsp90 client protein Raf. Additionally, levels 
of Akt and Her2 were also degraded. In contrast to genetic knock down studies, levels of CDK6 
were also depleted, which indicates a difference between the genetic knockdown and 
pharmacological studies. 
Table 20. Evaluation of Hsp90-selective inhibitors in MTS assay 
                                                 
Compound MCF-7 SKBr3 
121 7.32 + 1.19 8.87 + 2.23 
126 48.34 + 5.64 40 + 3.21 
130 20.51+ 3.93 22.29 + 2.61 
133 22.36 + 2.76 5.17 + 1.16 
134 9.69 + 1.71 7.28 +  2.68 
140 11.57 + 1.16 12.96 + 1.67 





V.8. Evaluation of Compound 126 and 
KUNB31 in NCI-60 Cell Panel 
The isoform selective-inhibitors 126 and 
KUNB31 were also evaluated in a NCI-60 panel 
to evaluate the dependence of different cancers 
upon individual Hsp90 isoforms. The screening 
results showed that isoform-selective inhibitors 
affect cancer cell lines differently that pan-
inhibitors. While the Hsp90 selective inhibitor, 
compound 126, was more efficacious against 
A549, NCI-H322, HT29, and OVCAR-5 cancer 
cell lines (Figure 49), the Hsp90-selective 
inhibitor, KUNB31, manifested higher efficacy against MOLT-4, NCI-H23, SNB-75, MCF-7, and 
MDA-MB231 cells (Figure 50). These studies confirm that isoform-selective inhibitors modulate 
different cancer pathways and provide a more selective approach to treat various cancers.  
V.9. Conclusions and Future Directions 
By taking advantage of the hydrogen boding network that aligns at the bottom of the Hsp90 
ATP-biding pocket, the first Hsp90-selective inhibitors have been identified. We have shown 
that the hydrogen bonding interaction manifested by the 4-phenol of the resorcinol-based Hsp90 
inhibitors with Ser52 provides selectivity for Hsp90. Modification of 126 resulted in analogues 
that potentially change the conformation of Hsp90and open an extended binding pocket near the 
5-position of the resorcinol ring. These compounds showed growth inhibitory activity against the 
      
Figure 48. Western Blot analyses of  
 126 in PC3-MM2 cell. “H” represents a 
concentration 3 × IC50;  
while “L” represents a concentration  
of 0.5 × IC50. IC50 of KUNA21 was 






















Figure 50. Evaluation of KUNB31 in NCI-60 cell panel. 
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MCF-7 and SkBr3 cell lines and represent a new class of Hsp90 inhibitors for the treatment of 
cancer. Co-crystallization of these inhibitors is currently in progress in collaboration with Dr. 
Robert Matts at the Oklahoma State University. 
Isoform-selective inhibition of Hsp90 represents an innovative approach that has the 
potential to overcome the detriments associated with current pan-Hsp90 inhibitors. Our efforts 
have provided isoform-selective inhibitors for three of the four Hsp90 isoforms. NCI-60 panel 
screening of compound 126 and KUNB31 identified cancer cell lines that are more sensitive to 
inhibition of the Hsp90 and Hsp90 isoforms, respectively. These findings provide a clinical 
potential for each class of Hsp90 isoform-selective inhibitor. In addition, future studies that utilize 
Hsp90-, Hsp90-, and Grp94-selective inhibitors will also enhance our understanding of the 
dependence of client proteins upon each isoform and may provide opportunities to target a more 
selective group of cancers.  
V.10. Methods and Experiments 
All reactions were performed in oven-dried glassware under argon atmosphere unless 
otherwise stated. Dichloromethane (DCM), tetrahydrofuran (THF), and toluene were passed 
through a column of activated alumina prior to use. Anhydrous methanol, acetonitrile, and N-
methyl-2-pyrrolidone (NMP) were purchased and used without further purification. Flash column 
chromatography was performed using silica gel (40−63 μm particle size). The 1H (500 and 400 
MHz) and 13C NMR (125 and 100 MHz) spectra were recorded on 500 and 400 MHz spectrometer. 
Data are reported as p = pentet, q = quartet, t = triplet, d = doublet, s = singlet, br s = broad singlet, 
m = multiplet; coupling constant(s) in Hz. Infrared spectra were obtained using FT/IR 
spectrometer. High resolution mass spectral data were obtained on a time-of-flight mass 




4-Amino-5-bromo-2-methoxybenzoic acid (108): N-bromosuccinimide (2.79 g, 15.7 mmol, 1.05 
eq.) was added to a solution of 107 (2.5 g, 14.9 mmol, 1.0 eq.) in acetonitrile (75 mL). The resulting 
mixture was heated at 60 oC for 14 h, cooled to rt, diluted with water (100 mL), and extracted with 
ethyl acetate (3 × 100 mL). The combined organic layers were washed with saturated sodium 
chloride solution, dried over sodium sulfate, filtered, and concentrated to give 4-amino-5-bromo-
2-methoxybenzoic acid (2.80 g, 77.1 %) as light brown amorphous solid. 1H NMR (500 MHz, 
DMSO-d6) δ 11.87 (s, 1H), 7.73 (s, 1H), 6.44 (s, 1H), 6.04 (s, 2H), 3.72 (s, 3H). 
13C NMR (125 
MHz, DMSO) δ 165.3, 160.2, 150.8, 135.9, 108.2, 97.7, 97.0, 55.5.  HRMS (ESI) m/z [M  H+] 
calcd for C9H7BrNO3, 255.9609, found 255.9604. 
 
(4-Amino-5-bromo-2-methoxyphenyl)(isoindolin-2-yl)methanone (109): 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (3.89 g, 20.32 mmol, 2.0 eq.) was added to a stirred solution 
of 108 (2.5 g, 10.16 mmol, 1 eq.), isoindoline hydrochloride (2.05 mg, 13.20 mmol, 1.3 eq.), 1-
hydroxybenzotriazole (3.11 g, 20.32 mmol, 2 eq.) N,N-diisopropylethylamine (5.30 mL, 30.48 
mmol, 3.0 eq.) in dichloromethane (100 mL) at 0 °C. The resulting solution was stirred at rt for 14 
h before quenching with saturated sodium bicarbonate solution (100 mL). The organic layer was 
washed sodium chloride solution (100 mL), dried over sodium sulfate, filtered and concentrated. 
The residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 109 
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(2.31 g, 65.7%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.38 (s, 1H), 7.35 – 7.25 (m, 3H), 
7.18 – 7.13 (m, 1H), 6.35 (s, 1H), 4.96 (s, 2H), 4.66 (s, 2H), 4.29 (s, 2H), 3.78 (s, 3H). 13C NMR 
(125 MHz, CDCl3) δ 167.5, 156.2, 146.3, 136.9, 136.7, 131.9, 127.8, 127.6, 123.2, 122.7, 118.4, 
99.9, 98.6, 56.0, 53.6, 52. HRMS (ESI+) m/z [M + H+] calcd for C16H16BrN2O2, 347.0395, found 
347.0398. 
 
(4-Amino-5-bromo-2-hydroxyphenyl)(isoindolin-2-yl)methanone (110): 1 M solution of boron 
tribromide (0.60 mmol, 0.60 mL, 2 eq.), was added to a solution of 109 (104.2 mg, 0.30 mmol) in 
anhydrous dichloromethane (6 mL) at 0 oC. The resulting mixture was stirred at rt for 14 h before 
quenching with saturate sodium bicarbonate solution (5 mL). The aqueous layer was extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (20 mL), dried over sodium sulfate, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:6 ethyl acetate/hexanes) to afford 110 (67.7, 
mg, 67.81 %) as a colorless amorphous solid. 1H NMR (500 MHz, CDCl3) δ 11.88 (s, 1H), 7.73 
(s, 1H), 7.33 (s, 4H), 6.36 (s, 1H), 5.10 (s, 4H). 13C NMR (125 MHz, CDCl3) δ 170.0, 162.3, 148.4, 
136.0 (2), 132.4 (2), 128.0, 122.8 (2), 108.5, 102.8, 97.8, 55.1 (2). HRMS (ESI+) m/z [M + H+] 




(4-Amino-5-isopropyl-2-methoxyphenyl)(isoindolin-2-yl)methanone (111): A biotage 
microwave vial was charged with 110 (1.0 g, 2.46 mmol, 1 eq.), [1,1′-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (251 mg, 
0.32 mmol, 0.2 eq.), triethylamine (289 µl, 2.1 mmol, 1.3 eq.), and potassium 
isopropenyltrifluoroborate (309 mg, 2.10 mmol, 1.3 eq.). The tube was sealed with a cap lined with 
a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before 
the addition of 2-propanol (8 mL) by syringe. The resulting mixture was heated at 100 °C for 6 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to 
afford (4-amino-2-methoxy-5-(prop-1-en-2-yl)phenyl)(isoindolin-2-yl)methanone, which was 
used as obtained and dissolved in ethyl acetate (15 mL).  Palladium on carbon (10%) was added 
to this solution and the suspension was stirred for 16 h under a hydrogen atmosphere before it was 
filtered through a pad of celite and eluted with ethyl acetate (20 mL). The eluent was concentrated 
to afford 111 (318.3 mg, 64.9 %) as a colorless amorphous solid. 1H NMR (500 MHz CDCl3) δ 
7.34 – 7.23 (m, 3H), 7.16 – 7.12 (m, 1H), 7.10 (s, 1H), 6.27 (s, 1H), 4.99 (s, 2H), 4.66 (s, 2H), 
3.92 – 3.81 (m, 2H), 3.78 (s, 3H), 2.83 (hept, J = 6.8 Hz, 1H), 1.24 (d, J = 6.8 Hz, 6H). 13C NMR 
(125 MHz, CDCl3) δ 169.4, 154.6, 145.9, 137.3, 136.9, 127.7, 127.5, 125.7, 124.9, 123.2, 122.6, 
117.3, 98.8, 55.8, 53.6, 52.3, 27.4, 22.5 (2). HRMS (ESI+) m/z [M + H+] calcd for C19H23N2O2, 




(4-Amino-2-hydroxy-5-isopropylphenyl)(isoindolin-2-yl)methanone (112): 1 M solution of 
boron tribromide (0.32 mmol, 0.60 mL, 2 eq.), was added to a solution of 111 (50 mg, 0.16 mmol) 
in anhydrous dichloromethane (3 mL) at 0 °C. The resulting mixture was stirred at rt for 14 h 
before quenching with saturate sodium bicarbonate solution (5 mL). The aqueous layer was 
extracted with dichloromethane (2 × 10 mL). The combined organic layers were washed with 
saturated sodium chloride solution (20 mL), dried over sodium sulfate, filtered and concentrated. 
The residue was purified by flash chromatography (SiO2, 1:6 ethyl acetate/hexanes) to afford 112 
(59.3 mg, 28.1 %) as a colorless amorphous solid. 1H NMR (500 MHz, CDCl3) δ 11.52 (s, 1H), 
7.42 (d, J = 0.6 Hz, 1H), 7.31 (s, 4H), 6.26 (s, 1H), 5.10 (s, 4H), 4.08 (d, J = 45.9 Hz, 2H), 2.90 – 
2.81 (m, 1H), 1.31 (d, J = 6.8 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 171.6, 160.8, 148.5, 136.4, 
127.9 (2), 126.0 (2), 122.7 (2), 107.3, 102.8, 54.8 (2), 27.4, 22.8 (2). HRMS (ESI+) m/z [M + H+] 
calcd for C18H21N2O2, 297.1603, found 297.1609. 
 
N-(5-Hydroxy-4-(isoindoline-2-carbonyl)-2-isopropylphenyl)cyanamide (113): Cyanogen 
bromide (35 mg, 0.32 mmol, 2eq.) was added to a solution of 112 (50 mg, 0.16 mmol, 1 eq.) in 
diethyl ether at oC. The resulting mixture stirred for 14h at rt, diluted with ethyl acetate (10 mL), 
washed with water (10 mL) and saturated sodium chloride solution (10 mL). The organic layer 
was dried over sodium sulfate, filtered and concentrated. The residue was taken in 
dichloromethane (2 mL) and 1M solution of boron tribromide (0.32 mL, 0.32 mmol, 2.0 eq.) was 
added at 0 oC. The resulting mixture was stirred at rt for 14 h before quenching with saturate 
sodium bicarbonate solution (5 mL). The aqueous layer was extracted with dichloromethane (2 × 
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10 mL). The combined organic layers were washed with saturated sodium chloride solution (15 
mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:6 ethyl acetate/hexanes) to afford 113 (25.0 mg, 48.6 %) as a colorless 
amorphous solid. 1H NMR (500 MHz, Methylene Chloride-d2) δ 11.38 (s, 1H), 7.54 (s, 1H), 7.32 
(s, 4H), 6.83 (s, 1H), 6.03 (s, 1H), 5.08 (s, 5H), 2.80 (hept, J = 6.8 Hz, 1H), 1.30 (d, J = 6.8 Hz, 
7H). 13C NMR (125 MHz, CD2Cl2) δ 170.6, 160.6, 139.0 (2), 128.1, 126.6 (3), 124.3, 122.9, 112.7, 
110.2, 104.3 (2), 54.9 (2), 27.4, 22.9 (2). HRMS (ESI+) m/z [M + H+] calcd for C20H20N3O2, 
334.1556, found 334.1565.  
 
(4-Amino-3-bromophenyl)(isoindolin-2-yl)methanone (132): 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (4.32 g, 37.02 mmol, 2.0 eq.) was added to a stirred solution 
of 4-amino-3-bromobenzoic acid (4.0 g, 18.51 mmol, 1 eq.), isoindoline hydrochloride (4.32 g, 
27.77 mmol, 1.5 eq.), 1-hydroxybenzotriazole (5.0 g, 37.02 mmol, 2 eq.) N-,N-
diisopropylethylamine (6.44 mL, 37.02 mmol, 2.0 eq.) in dichloromethane (200 mL) at 0 °C. The 
resulting solution was stirred at rt for 14 h before quenching with saturated sodium bicarbonate 
solution (150 mL). The organic layer was washed sodium chloride solution (150 mL), dried over 
sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (SiO2, 
1:2 hexanes/ethyl acetate) to afford 132 (4.33 g, 73.8 %) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.74 (d, J = 1.9 Hz, 1H), 7.41 (dd, J = 8.2, 1.9 Hz, 1H), 7.36 – 7.25 (m, 3H), 7.19 (d, J 
= 7.3 Hz, 1H), 6.79 (d, J = 8.3 Hz, 1H), 5.00 (s, 2H), 4.86 (s, 2H), 4.38 (br s, 2H). 13C NMR (100 
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MHz, CDCl3) δ 169.1, 146.1, 136.7, 136.6, 132.3, 128.1, 128.0, 127.7, 127.2, 123.1, 122.6, 114.9, 
108.5, 55.4, 52.9. HRMS (ESI+) m/z [M + H+] calcd for C15H14BrN2O, 318.1243, found 318.1241. 
 
(4-Amino-3-isopropylphenyl)(isoindolin-2-yl)methanone (116): A biotage microwave vial was 
charged with 132 (1.0 g, 3.15 mmol, 1 eq.), [1,1′-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (251 mg, 
0.32 mmol, 0.2 eq.), triethylamine (289 µl, 2.1 mmol, 1.3 eq.), and potassium 
isopropenyltrifluoroborate (309 mg, 2.10 mmol, 1.3 eq.). The tube was sealed with a cap lined with 
a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before 
the addition of 2-propanol (8 mL) by syringe. The resulting mixture was heated at 100 °C for 6 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to 
afford (4-amino-2-methoxy-5-(prop-1-en-2-yl)phenyl)(isoindolin-2-yl)methanone, which was 
used as obtained and dissolved in ethyl acetate (15 mL).  Palladium on carbon (10%) was added 
to this solution and the suspension was stirred for 16 h under a hydrogen atmosphere before it was 
filtered through a pad of celite and eluted with ethyl acetate (20 mL). The eluent was concentrated 
to afford 116 (318.3 mg, 64.9 %) as a colorless amorphous solid. 1H NMR (400 MHz, CD2Cl2) δ 
7.40 (d, J = 1.9 Hz, 1H), 7.35 – 7.12 (m, 5H), 6.69 (dd, J = 8.2, 1.2 Hz, 1H), 4.94 – 4.83 (m, 4H), 
4.05 (br s, 2H), 2.95 2.88 (m, 1H), 1.27 (d, J = 6.9 Hz, 6H). 13C NMR (100 MHz, CD2Cl2) δ 
170.6, 145.6, 137.2, 131.8, 127.5, 126.6, 126.1, 125.3, 122.8, 122.5, 114.6, 55.2, 52.5, 27.7, 22.0. 
13 C NMR (100 MHz, CD2Cl2) δ 170.6, 145.6, 137.2 (2), 131.8, 127.5, 126.6, 126.1 (2), 125.3 (2), 
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122.8, 122.5, 114.6, 55.2, 52.5, 27.7, 22.0. HRMS (ESI+) m/z [M + H+] calcd for C18H21N2O, 
281.1654, found 281.1642. 
 
(1H-Indol-5-yl)(isoindolin-2-yl)methanone  (117): 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (142 mg, 0.74 mmol, 2.0 eq.) was added to a stirred solution of 1H-indole-5-
carboxylic acid (59 mg, 0.37 mmol, 1 eq.), isoindoline hydrochloride (87 mg, 0.46 mmol, 1.5 eq.), 
1-hydroxybenzotriazole (100 mg, 0.74 mmol, 2 eq.) N-,N-diisopropylethylamine (0.141 mL, 0.81 
mmol, 2.2 eq.) in dichloromethane (4 mL) at 0 °C. The resulting solution was stirred at rt for 14 h 
before the addition of saturated sodium bicarbonate solution (4 mL). The organic layer was washed 
with 1 N HCl (2 × 3 mL) and saturated sodium chloride solution (3 mL), dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 1:3 hexanes/ethyl acetate) to afford 117 (56 mg, 57.8 %) as a colorless oil. 
1H NMR (400 
MHz, CDCl3) δ 8.61 (s, 1H), 7.91 (s, 1H), 7.43 (s, 2H), 7.14 (d, J = 7.5 Hz, 1H), 6.62 (t, J = 2.4 
Hz, 1H), 5.09 (s, 2H), 4.88 (s, 2H). 13C NMR (125 MHz, CDCl3) δ 172.0, 137.0, 136.8, 128.4, 
127.9, 127.6, 127.5, 125.7 (2), 123.1, 122.6, 121.4, 120.2, 111.4, 103.4, 55.6, 52.8. HRMS (ESI+) 
m/z [M + H+] calcd for C17H15N2O, 263.1184 found, 263.1182 
 
(1H-benzo[d]imidazol-5-yl)(isoindolin-2-yl)methanone (118): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (142 mg, 0.74 mmol, 2.0 eq.) was added to a stirred solution 
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of 1H-benzo[d]imidazole-5-carboxylic acid (60 mg, 0.37 mmol, 1 eq.), isoindoline hydrochloride 
(87 mg, 0.46 mmol, 1.5 eq.), 1-hydroxybenzotriazole (100 mg, 0.74 mmol, 2 eq.) N-,N-
diisopropylethylamine (0.141 mL, 0.81 mmol, 2.2 eq.) in dichloromethane (4 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (4 mL). The organic layer was washed with 1 N HCl (2 × 3 mL) and saturated sodium 
chloride solution (3 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  The 
residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 118 (60 
mg, 61.3 %) as a colorless oil.1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.93 (s, 1H), 7.67 (d, J 
= 8.5 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.41 – 7.24 (m, 3H), 7.14 (d, J = 7.4 Hz, 1H), 5.06 (s, 2H), 
4.82 (s, 2H). 13C NMR (125 MHz, CDCl3) δ 167.5, 142.9, 141.7, 136.5, 136.2, 134.5, 131.2, 128.9, 
128.0, 127.8, 125.5, 124.4, 123.7, 123.1, 54.0, 52.9. HRMS (ESI+) m/z [M + H+] calcd for 
C16H14N3O, 264.1137 found, 264.1129.  
 
Benzofuran-5-yl(isoindolin-2-yl)methanone (119): 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (142 mg, 0.74 mmol, 2.0 eq.) was added to a stirred solution of benzofuran-5-
carboxylic acid (60 mg, 0.37 mmol, 1 eq.), isoindoline hydrochloride (87 mg, 0.46 mmol, 1.5 eq.), 
1-hydroxybenzotriazole (100 mg, 0.74 mmol, 2 eq.) N-,N-diisopropylethylamine (0.141 mL, 0.81 
mmol, 2.2 eq.) in dichloromethane (4 mL) at 0 °C. The resulting solution was stirred at rt for 14 h 
before the addition of saturated sodium bicarbonate solution (4 mL). The organic layer was washed 
with 1 N HCl (2 × 3 mL) and saturated sodium chloride solution (3 mL), dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography 
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(SiO2, 1:3 hexanes/ethyl acetate) to afford 119 (60 mg, 67.4 %) as a colorless oil. 
1H NMR (500 
MHz, CDCl3) δ 7.85 (dd, J = 1.7, 0.7 Hz, 1H), 7.71 (d, J = 2.2 Hz, 1H), 7.58 (dt, J = 8.5, 0.9 Hz, 
1H), 7.54 (dd, J = 8.5, 1.7 Hz, 1H), 7.39 – 7.27 (m, 3H), 7.15 (d, J = 7.5 Hz, 1H), 6.85 (dd, J = 
2.2, 0.9 Hz, 1H), 5.07 (s, 2H), 4.82 (s, 2H). 13C NMR (125 MHz, CDCl3) δ 170.9, 155.7, 146.3, 
136.7, 136.6, 131.8, 128.0, 127.7, 127.6, 123.7, 123.2, 122.6, 120.6, 111.7, 107.1, 55.5, 52.8. 
HRMS (ESI+) m/z [M + H+] calcd for C17H14NO2, 264.1025 found, 264.1021  
 
(1H-benzo[d][1,2,3]triazol-5-yl)(isoindolin-2-yl)methanone (120): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (142 mg, 0.74 mmol, 2.0 eq.) was added to a stirred solution 
of 1H-benzo[d][1,2,3]triazole-5-carboxylic acid (60 mg, 0.37 mmol, 1 eq.), isoindoline 
hydrochloride (87 mg, 0.46 mmol, 1.5 eq.), 1-hydroxybenzotriazole (100 mg, 0.74 mmol, 2 eq.) 
N-,N-diisopropylethylamine (0.141 mL, 0.81 mmol, 2.2 eq.) in dichloromethane (4 mL) at 0 °C 
The resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (4 mL). The organic layer was washed with 1 N HCl (2 × 3 mL) and saturated sodium 
chloride solution (3 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 120 (53 
mg, 56.4 %) as a colorless oil. 1H NMR (400 MHz, CDCl3-CD3OD δ 8.12 (s, 1H), 7.88 (d, J = 8.6 
Hz, 1H), 7.63 (dd, J = 8.5, 1.4 Hz, 1H), 7.42 – 7.28 (m, 3H), 7.15 (d, J = 7.4 Hz, 1H), 5.09 (s, 2H), 
4.82 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 170.2, 147.7, 136.2 (2), 136.1(2), 128.2, 127.9 (2), 






dimethylaminopropyl) carbodiimide (192 mg, 2.0 mmol, 2.0 eq.) was added to a stirred solution 
of 4-hydroxy-3-(trifluoromethyl)benzoic acid (206 mg, 1.0 mmol, 1 eq.), isoindoline 
hydrochloride (233 mg, 1.5 mmol, 1.5 eq.), 1-hydroxybenzotriazole (306 mg, 2.0 mmol, 2 eq.) N-
,N-diisopropylethylamine (0.39 mL, 2.2 mmol, 2.2 eq.) in dichloromethane (10 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (10 mL). The organic layer was washed with 1 N HCl (2 × 10 mL) and saturated sodium 
chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 122 (164 
mg, 53.8 %) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 2.2 Hz, 1H), 7.55 (dd, J 
= 8.4, 2.2 Hz, 1H), 7.21 (s, 6H), 7.12 (d, J = 7.4 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 4.94 (s, 2H), 
4.76 (s, 2H). 13C NMR (125 MHz, CDCl3) δ 168.3, 155.9, 135.1, 135.0, 131.4, 126.9, 126.6, 126.1, 
125.3 (q, J = 5.2 Hz), 123.6 (q, J = 269 Hz), 121.9, 121.4, 116.0, 115.8 (q, J = 30.2 Hz), 54.1, 51.7. 
19F NMR (376 MHz, CDCl3) δ -63.0. HRMS (ESI+) m/z [M + H
+] calcd for C16H13F3NO2, 
306.0742 found, 306.0754. 
 
(3-Chloro-4-hydroxyphenyl)(isoindolin-2-yl)methanone (123): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (149 mg, 1.16 mmol, 2.0 eq.) was added to a stirred solution 
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of 3-chloro-4-hydroxybenzoic acid (100 mg, 0.55 mmol, 1 eq.), isoindoline hydrochloride (128 
mg, 0.82 mmol, 1.5 eq.), 1-hydroxybenzotriazole (211 mg, 1.10 mmol, 2 eq.) N-,N-
diisopropylethylamine (0.21 mL, 1.21 mmol, 2.2 eq.) in dichloromethane (6 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (5 mL). The organic layer was washed with 1 N HCl (2 × 5 mL) and saturated sodium 
chloride solution (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 123 (82 
mg, 54.6 %) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 2.0 Hz, 1H), 7.47 (d, J 
= 8.4 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.19 (d, J = 7.3 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 5.02 (s, 2H), 
4.84 (s, 2H).13C NMR (125 MHz, CDCl3-CD3OD) δ 169.2, 153.8, 136.4, 136.3, 129.3, 128.9, 
128.1, 127.8, 127.6, 123.1, 122.6, 120.4, 116.4, 55.3, 52.9.  HRMS (ESI+) m/z [M + H+] calcd for 
C15H13ClNO2, 274.0635 found 274.0640. 
 
(4-hydroxy-3-nitrophenyl)(isoindolin-2-yl)methanone (124): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (192 mg, 2.0 mmol, 2.0 eq.) was added to a stirred solution 
of 4-hydroxy-3-nitrobenzoic acid (183 mg, 1.0 mmol, 1 eq.), isoindoline hydrochloride (233 mg, 
1.5 mmol, 1.5 eq.), 1-hydroxybenzotriazole (306 mg, 2.0 mmol, 2 eq.) N-,N-
diisopropylethylamine (0.39 mL, 2.2 mmol, 2.2 eq.) in dichloromethane (10 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (10 mL). The organic layer was washed with 1 N HCl (2 × 10 mL) and saturated sodium 
chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
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residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 124 (207 
mg, 72.8 %) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.40 (d, J = 2.2 Hz, 1H), 7.86 (dd, J 
= 8.7, 2.2 Hz, 1H), 7.37 – 7.11 (m, 5H), 5.02 (s, 2H), 4.86 (s, 2H).13C NMR (125 MHz, CDCl3) δ 
167.6, 156.4, 136.7 (2), 136.1, 136.0, 128.6, 128.3, 127.9, 124.5, 123.2, 122.7, 120.7, 55.3, 53.1. 
HRMS (ESI+) m/z [M - H+] calcd for C15H11NO2, 283.0719, found 283.0725. 
 
2-Hydroxy-5-(isoindoline-2-carbonyl)benzonitrile (125): 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (586 mg, 3.06 mmol, 2.0 eq.) was added to a stirred solution of 4-hydroxy-3-
nitrobenzoic acid (250 mg, 1.53 mmol, 1 eq.), isoindoline hydrochloride ( 356 mg, 3.06 mmol, 1.5 
eq.), 1-hydroxybenzotriazole (470 mg, 3.06 mmol, 2 eq.) N-,N-diisopropylethylamine (1.12 mL, 
6.42 mmol, 4.2 eq.) in dichloromethane (16 mL) at 0 °C The resulting solution was stirred at rt for 
14 h before the addition of saturated sodium bicarbonate solution (15 mL). The organic layer was 
washed with 1 N HCl (2 × 15 mL) and saturated sodium chloride solution (15 mL), dried over 
anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 125 (162 mg, 61.5 %) as a colorless 
oil. 1H NMR (500 MHz, CDCl3- CD3OD) δ 7.72 (dd, J = 9.3, 2.2 Hz, 1H), 7.62 (ddd, J = 10.9, 
8.0, 2.2 Hz, 1H), 7.317.23 (m, 3H), 7.16 (t, J = 8.7 Hz, 1H), 6.97 (t, J = 8.6 Hz, 1H), 4.95 (d, J = 
11.5 Hz, 2H), 4.80 (d, J = 9.1 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 168.8, 162.0, 136.0, 135.9, 
133.8, 132.4, 128.1, 127.8, 127.5, 123.0, 122.6, 116.6, 116.4, 99.8, 55.3, 52.9. HRMS (ESI+) m/z 





dimethylaminopropyl) carbodiimide (192 mg, 2.0 mmol, 2.0 eq.) was added to a stirred solution 
of 4-hydroxy-3-iodobenzoic acid (264 mg, 1.0 mmol, 1 eq.), isoindoline hydrochloride (233 mg, 
1.5 mmol, 1.5 eq.), 1-hydroxybenzotriazole (306 mg, 2.0 mmol, 2 eq.) N-,N-
diisopropylethylamine (0.39 mL, 2.2 mmol, 2.2 eq.) in dichloromethane (10 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (25 mL) and ethyl acetate (50 mL). The organic layer was washed with 1 N HCl (2 × 25 
mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, 
and concentrated. The residue was triturated with dichloromethane to afford 127 (166 mg, 45.6 %) 
as an off-white amorphous solid. 1H NMR (400 MHz, DMSO-d6) δ 11.29 – 11.14 (br s, 1H), 7.64 
(d, J = 7.3 Hz, 1H), 7.46 – 7.27 (m, 5H), 6.92 (dd, J = 11.1, 1.6 Hz, 1H), 4.82 (s, 2H), 4.64 (s, 2H).  
13C NMR (100 MHz, DMSO-d6) δ 163.3, 157.7, 136.4, 135.9, 132.1, 132.0, 127.5, 127.4, 123.0, 
122.9, 117.3,104.7, 103.8, 51.7 (2). HRMS (ESI+) m/z [M + H+] calcd for C15H13INO2, 365.9991, 
found 365.9998.  
 
1-(2-Hydroxy-5-(isoindoline-2-carbonyl)phenyl)ethan-1-one (128): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (4.26 g, 22.20 mmol, 2.0 eq.) was added to a stirred solution 
of 3-chloro-4-hydroxybenzoic acid (2.0 g, 11.10 mmol, 1 eq.), isoindoline hydrochloride (2.59 g, 
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16.7 mmol, 1.5 eq.), 1-hydroxybenzotriazole (2.99 g, 22.2 mmol, 2 eq.) N-,N-
diisopropylethylamine (8.12 mL, 46.62 mmol, 4.2 eq.) in dichloromethane (110 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (100 mL). The organic layer was washed with 1 N HCl (2 × 100 mL) and saturated sodium 
chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 128 (2.12 
g, 67.8 %) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 12.49 (s, 1H), 8.09 (d, J = 2.1 Hz, 1H), 
7.75 (dd, J = 8.6, 2.1 Hz, 1H), 7.39 – 7.28 (m, 3H), 7.20 (d, J = 7.5 Hz, 1H), 7.06 (d, J = 8.6 Hz, 
1H), 5.05 (s, 2H), 4.86 (s, 2H), 2.69 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 204.7, 169.2, 163.9, 
136.4 (2), 134.9, 131.1, 128.2, 127.8, 127.5, 123.2, 122.6, 119.6, 118.5, 55.4, 53.0, 27.0. HRMS 
(ESI+) m/z [M + H+] calcd for C17H16NO3, 282.1130, found 282.1135.  
 
(4-Hydroxy-3-(1-hydroxyethyl)phenyl)(isoindolin-2-yl)methanone (129): Sodium 
borohydride (12 mg, 0.35 mmol, 1.5 eq.) was added to a solution of 128 (56 mg, 0.2 mmol, 1.0 
eq.) in a solvent mixture of tetrahydrofuran (0.5 mL) and methanol (1.5 mL) at 0 C. The resulting 
mixture was stirred for 1 h at rt before the addition of saturated ammonium chloride solution (2 
mL). The aqueous layer was extracted with ethyl acetate (2 × 3 mL). The combined organic layers 
were washed with saturated sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:2 
hexanes/ethyl acetate) to afford 129 (25 mg, 45.22 %) as a colorless oil. 1H NMR (400 MHz, 
CD3OD) δ 7.65 (d, J = 2.2 Hz, 1H), 7.42 – 7.33 (m, 2H), 7.33 – 7.20 (m, 3H), 6.85 (d, J = 8.3 Hz, 
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1H), 5.18 (q, J = 6.4 Hz, 1H), 4.94 (s, 2H), 1.45 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CD3OD) 
δ 172.9, 157.5, 137.9, 137.1, 133.7, 128.8, 128.6, 128.4, 128.1, 126.4, 123.8, 123.6, 115.9, 66.3, 
56.3, 53.6, 24.1. HRMS (ESI+) m/z [M + H+] calcd for 284.1287, C17H18NO3, found 284.1281. 
 
(4-Hydroxy-3-(2-hydroxypropan-2-yl)phenyl)(isoindolin-2-yl)methanone (130): 1 M solution 
of methyl magnesium bromide in tetrahydrofuran (0.24mL, 0.24 mmol, 1.2 eq.) was added to a 
solution of 128 (56 mg, 0.2 mmol, 1.0 eq.) in tetrahydrofuran (2.0 mL) 0 C. The resulting mixture 
was stirred for 1 h at 0 C before the addition of saturated ammonium chloride solution (2 mL). 
The aqueous layer was extracted with ethyl acetate (2 × 3 mL). The combined organic layers were 
washed with saturated sodium chloride solution (5 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:2 
hexanes/ethyl acetate) to afford 130 (19 mg, 33.2 %) as a colorless oil. 1H NMR (400 MHz, CDCl3) 
δ 9.83 (s, 1H), 7.35 – 7.25 (m, 5H), 7.16 (d, J = 7.3 Hz, 1H), 6.82 (d, J = 8.3 Hz, 1H), 4.98 (s, 2H), 
4.80 (s, 2H), 4.59 (br s, 1H), 1.62 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 171.1, 158.0, 136.6, 
136.4, 132.1, 128.0, 127.7, 127.6, 127.0, 125.3, 123.1, 122.6, 117.3, 75.4, 55.4, 52.9, 31.1, 30.2. 





dimethylaminopropyl) carbodiimide (88 mg, 0.46 mmol, 2.0 eq.) was added to a stirred solution 
of 3-bromo-4-hydroxybenzoic acid (50 mg, 0.23 mmol, 1 eq.), 5-fluoroisoindoline hydrochloride 
(48 mg, 0.28 mmol, 1.2 eq.), 1-hydroxybenzotriazole (62 mg, 0.46 mmol, 2 eq.) N-,N-
diisopropylethylamine (0.17 mL, 0.97 mmol, 4.2 eq.) in dichloromethane 3.0 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (3 mL). The organic layer was washed with 1 N HCl (2 × 3 mL) and saturated sodium 
chloride solution (3 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to afford 133 (58 
mg, 76.1 %) as a light gray amorphous solid. 1H NMR (400 MHz, CDCl3) δ 10.48 (s, 1H), 7.45 
(d, J = 2.2 Hz, 1H), 7.35-7.25 (m, 3H), 7.27 – 7.24 (m, 2H), 6.97 (d, J = 8.5 Hz, 1H), 5.10 (s, 4H), 
2.92 (hept, J = 7.0 Hz, 1H), 1.29 (d, J = 6.9 Hz, 6H). 19F NMR (376 MHz, CDCl3) δ -114.55. 
13C 
NMR (125 MHz, CDCl3) δ 172.6, 167.1 (d, J = 120 Hz), 160.9, 144.7, 143.6, 138.3, 137.7, 133.5, 
129.7, 121.0, 119.6 (d, J = 23 Hz), 115.2 (d, J = 23 Hz), 114.1, 59.3, 57.1. HRMS (ESI+) m/z [M 
+ H+] calcd for C15H12BrFNO2, 336.0035, found 336.0042. 
 
(3-Bromo-4-hydroxyphenyl)(5-chloroisoindolin-2-yl)methanone (134): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (47 mg, 0.24 mmol, 2.0 eq.) was added to a stirred solution 
of 3-bromo-4-hydroxybenzoic acid (25 mg, 0.12 mmol, 1 eq.), 5-chloroisoindoline hydrochloride 
(26 mg, 0.13 mmol, 1.2 eq.), 1-hydroxybenzotriazole (38 mg, 0.24 mmol, 2 eq.) N-,N-
diisopropylethylamine (0.09 mL, 0.51 mmol, 4.2 eq.) in dichloromethane (2.0 mL) at 0 °C The 
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resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (15 mL) and ethyl acetate (15 mL). The organic layer was washed with 1 N HCl (2 × 10 
mL) and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, 
and concentrated. The residue was triturated with dichloromethane (5 mL) to afford 134 (26 mg, 
65.0 %) as a white amorphous solid. 1H NMR (500 MHz, CD3OD) δ 8.08 – 7.46 (m, 3H), 7.29 – 
7.05 (m, 2H), 6.77 (d, J = 8.4 Hz, 1H), 4.77 – 4.67 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 169.2, 
153.4, 138.7, 135.3, 131.8, 131.1, 127.5, 127.2, 124.3, 124.0, 123.9, 122.7, 115.6, 54.2, 52.0. 
HRMS (ESI+) m/z [M + H+] calcd for C15H12ClBrNO2, 351.9740, found 351.9747. 
 
(3-Bromo-4-hydroxyphenyl)(5-bromoisoindolin-2-yl)methanone (135): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (44 mg, 0.23 mmol, 2.0 eq.) was added to a stirred solution 
of 3-bromo-4-hydroxybenzoic acid (25 mg, 0.12 mmol, 1 eq.), 5-bromoisoindoline hydrochloride 
(33 mg, 0.14 mmol, 1.2 eq.), 1-hydroxybenzotriazole (31 mg, 0.23 mmol, 2 eq.) N-,N-
diisopropylethylamine (0.09 mL, 0.48 mmol, 4.2 eq.) in dichloromethane (2.0 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (15 mL) and ethyl acetate (15 mL). The organic layer was washed with 1 N HCl (2 × 10 
mL) and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, 
and concentrated. The residue was purified by flash chromatography (SiO2, 1:19 
acetone/dichloromethane) to afford 135 (27 mg, 58.4 %) as a colorless oil. 1H NMR (500 MHz, 
CDCl3-CD3OD) δ 7.86 – 7.76 (m, 1H), 7.52 – 7.37 (m, 2H), 7.27 – 7.14 (m, 1H), 6.97 (d, J = 8.5 
Hz, 1H), 4.96 – 4.86 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 170.7, 157.4, 139.3, 136.4, 133.3, 
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131.7, 128.9, 128.8, 126.8, 125.3, 122.1, 116.7, 110.6, 55.6, 53.2. HRMS (ESI+) m/z [M + H+] 
calcd for C15H12Br2NO2, 395.9235, found 395.9251.  
 
Methyl 2-(3-bromo-4-hydroxybenzoyl)isoindoline-5-carboxylate (136): 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (88 mg, 0.46 mmol, 2.0 eq.) was added to a stirred solution 
of 3-bromo-4-hydroxybenzoic acid (50 mg, 0.23 mmol, 1 eq), methyl isoindoline-5-carboxylate 
hydrochloride (58 mg, 0.27 mmol, 1.2 eq.), 1-hydroxybenzotriazole (62 mg, 0.46 mmol, 2 eq.) N-
,N-diisopropylethylamine (0.17 mL, 0.97 mmol, 4.2 eq.) in dichloromethane (3.0 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (15 mL) and ethyl acetate (15 mL). The organic layer was washed with 1 N HCl (2 × 10 
mL) and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, 
and concentrated. The residue was triturated with dichloromethane (5 mL) to afford 136 (42 mg, 
47.9 %) as a pale yellow amorphous solid. 1H NMR (500 MHz, CD3OD) δ 8.04 – 7.91 (m, 2H), 
7.81 (d, J = 2.1 Hz, 1H), 7.53 – 7.35 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 5.00 – 4.95 (m, 4H), 3.91 
– 3.89 (m, 3H). 13C NMR (125 MHz), CD3OD δ 171.0, 168.2, 157.8, 143.1, 138.3, 133.7 (2), 
131.2, 130.5, 129.7, 129.1, 125.1, 124.1, 110.8, 56.0, 53.6, 52.7. HRMS (ESI+) m/z [M + H+] 





dimethylaminopropyl) carbodiimide (88 mg, 0.46 mmol, 2.0 eq.) was added to a stirred solution 
of 3-bromo-4-hydroxybenzoic acid (50 mg, 0.23 mmol, 1 eq.), 5-methoxyisoindoline 
hydrochloride (52 mg, 0.28 mmol, 1.2 eq.), 1-hydroxybenzotriazole (62 mg, 0.46 mmol, 2 eq.) N-
,N-diisopropylethylamine (0.17 mL, 0.97 mmol, 4.2 eq.) in dichloromethane (3.0 mL) at 0 °C The 
resulting solution was stirred at rt for 14 h before the addition of saturated sodium bicarbonate 
solution (15 mL) and ethyl acetate (15 mL). The organic layer was washed with 1 N HCl (2 × 10 
mL) and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, 
and concentrated. The residue was triturated with dichloromethane (5 mL) to afford 137 (32 mg, 
41.3 %) as a white amorphous solid. 1H NMR (500 MHz, CD3OD) δ 7.58 (d, J = 2.0 Hz, 1H), 7.28 
(dd, J = 8.4, 2.1 Hz, 1H), 7.056.93 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.786.59 (m, 2H), 4.66 – 
4.57 (m, 4H), 3.603.57 (m, 3H).13C NMR (125 MHz, CD3OD) δ 169.6, 159.9, 156.3, 137.8, 
137.0, 132.2, 127.8, 127.6, 123.1, 115.4, 113.9, 109.4, 107.1, 53.6, 54.4, 52.1. HRMS (ESI+) m/z 
[M - H+] calcd for C16H13BrNO3, 346.0079 found 346.0089. 
 
(3-Bromo-4-hydroxyphenyl)(5-hydroxyisoindolin-2-yl)methanone (138): Boron tribromide 
(1M solution in dichloromethane, 0.12 mL, 0.12 mmol, 2.0 eq. ) was added to a solution of 136 
(20 mg, 0.-06 mmol, 1.0 eq.) at 0 C. the resulting mixture was stirred at rt for 6 h before the addition 
of saturated sodium bicarbonate solution (10 mL) and ethyl acetate (10 mL). The organic layer 
was washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, 
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filtered, and concentrated. The residue was triturated with dichloromethane (2 mL) to afford 138 
(14 mg, 70.2 %) as pale yellow amorphous solid. 1H NMR (500 MHz, Methanol-d4) δ 7.78 (d, J = 
2.0 Hz, 1H), 7.48 (dd, J = 8.4, 2.1 Hz, 1H), 7.16 – 7.04 (m, 1H), 6.98 (dd, J = 8.4, 1.3 Hz, 1H), 
6.81 – 6.64 (m, 2H), 4.86 4.77(m, 4H). 13C NMR (125 MHz, CD3OD) δ 171.0, 158.6, 157.6, 
138.7, 133.6, 129.7, 129.0, 127.9, 124.5, 116.8, 116.2, 110.7, 110.2, 56.0, 53.5. HRMS (ESI+) m/z 
[M + H+] calcd for C15H13BrNO3, 334.0079, found 334.0094. 
 
(3-Bromo-4-hydroxyphenyl)(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)methanone (139):  
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (47 mg, 0.24 mmol, 2.0 eq.) was added to a 
stirred solution of 3-bromo-4-hydroxybenzoic acid (25 mg, 0.12 mmol, 1 eq), 2,3-dihydro-1H-
pyrrolo[3,4-c]pyridine dihydrobromide (37 mg, 0.13 mmol, 1.2 eq.), 1-hydroxybenzotriazole ( 38 
mg, 0.24 mmol, 2 eq.) N-,N-diisopropylethylamine (0.09 mL, 0.51 mmol, 4.2 eq.) in 
dichloromethane (2.0 mL) at 0 °C The resulting solution was stirred at rt for 14 h before the 
addition of saturated sodium bicarbonate solution (15 mL) and ethyl acetate (15 mL). The organic 
layer was washed with 1 N HCl (2 × 10 mL) and saturated sodium chloride solution (10 mL), dried 
over anhydrous sodium sulfate, filtered, and concentrated. The residue was triturated with 
dichloromethane (5 mL) to afford 139 (21 mg, 54.3 %) as a white amorphous solid. 1H NMR (500 
MHz, Methanol-d4) δ 8.62 – 8.43 (m, 2H), 7.81 (d, J = 2.1 Hz, 1H), 7.52 – 7.33 (m, 2H), 6.97 (d, 
J = 8.4 Hz, 1H), 5.03 – 4.95 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 171.1, 158.5, 148.9, 148.5, 
145.0, 135.1, 133.7, 129.2, 128.8, 119.9, 117.1, 111.1, 55.0, 52.7. HRMS (ESI+) m/z [M + H+] 




(4-(Benzyloxy)-3-bromophenyl)(isoindolin-2-yl)methanone (142): ):  Potassium carbonate 
(10.22 g, 73.6 mmol, 4 eq) was added to a solution of 3-Bromo-4-hydroxybenzoic acid (4 g, 18.4 
mmol, 1.0 eq) of acetonitrile (150 mL). Subsequently, benzyl bromide (4.37 mL, 4.05 mmol, 2.2 
eq) was added dropwise, and the reaction was heated at 80 C for 14 h. Upon cooling, the reaction 
mixture was filtered, the residue washed with ethyl acetate (100 mL), and concentrated. The 
resulting white solid (7.0 g, 17.8 mmol, 1 eq) was then suspended in a solvent mixture of 
tertrahydrofuran (60 mL), water (20 mL) and methanol (20 mL) and lithium hydroxide (1.29 g, 
53.4 mmol, 3 eq) was added. The reaction stirred for 16 hours at room temperature, and 
concentrated. The residue was treated with 1 M hydrochloric acid solution and pH was adjusted to 
2. The resulting mixture was extracted with ethyl acetate (3 × 100 mL). The combined organic 
layers were washed with saturated sodium chloride solution (200 mL), dried over anhydrous 
sodium sulfated, and concentrated. The resulting acid (5.19 g, 16.9 mmol, 1 eq) was added to a 
stirred solution of isoindoline hydrochloride (3.22 g, 25.35 mmol, 1.5 eq.), 1- 
hydroxybenzotriazole (3.73 g, 33.8 mmol, 2 eq.) N,N-diisopropylethylamine (4.81 mL, 33.8 mmol, 
2.0 eq.) in dichloromethane (170 mL) at 0 °C. The resulting solution was stirred at rt for 14 h 
before quenching with saturated sodium bicarbonate solution (120 mL). The organic layer was 
washed with 1 M hydrochloric acid solution (120 mL) and saturated sodium chloride solution (120 
mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by 
flash chromatography (SiO2, 1:4 hexanes/ethyl acetate) to afford 142 (3.24 g, 43 %) as a light 
brown amorphous solid. 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 2.0 Hz, 1H), 7.55 – 7.47 (m, 
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3H), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (dq, J = 14.0, 6.8 Hz, 4H), 7.19 (d, J = 7.3 Hz, 1H), 6.99 (d, J 
= 8.5 Hz, 1H), 5.23 (s, 2H), 5.01 (s, 2H), 4.83 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 168.8, 156.6, 
136.4, 136.2 (2), 132.7, 130.5, 128.9 (2), 128.3, 128.1, 128.0, 127.8 (2), 127.2, 123.2, 122.7, 113.3, 
112.5, 71.1, 55.3, 52.9. HRMS (ESI+) m/z [M + H+] calcd for C22H19BrNO2, 408.0599, found 
408.0591. 
 
(4-Hydroxy-3-(phenylthio)phenyl)(isoindolin-2-yl)methanone (140): A biotage microwave 
vial was charged with 142 (100 mg, 0.25 mmol, 1 eq.), thiophenol (42 l, 0.45 mmol, 1.9 eq.), 
1,1′-ferrocenediyl-bis(diphenylphosphine) (45 mg, 0.05 mmol, 0.2 eq.), 
Tris(dibenzylideneacetone)dipalladium(0) (31 mg, 0.05 mmol, 0.2 eq.), N,N’-
diisopropylethylamine (79 L, 0.46 mmol, 1.9 eq.). The tube was sealed with a cap lined with a 
disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before the 
addition of toluene (3.0 mL) by syringe. The resulting mixture was heated at 120 °C for 18 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to 
give the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.6 mL). The resulting mixture was stirred for 6 h, quenched with saturated sodium bicarbonate 
solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layers 
were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium 
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sulfate, filtered, and concentrated. The residue purified with flash chromatography (SiO2, 1:2 ethyl 
acetate/hexanes) to give the desired product 140 as white amorphous solid (36 mg, 41 1H NMR 
(400 MHz, CDCl3) δ 7.83 (d, J = 2.1 Hz, 1H), 7.66 (dd, J = 8.4, 2.2 Hz, 1H), 7.36 – 7.25 (m, 4H), 
7.23 – 7.11 (m, 5H), 6.82 (s, 1H), 5.01 (s, 2H), 4.82 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 169.2, 
158.8, 136.6, 136.5, 136.0, 135.2, 131.7, 129.8, 129.6 (2), 128.1, 127.8, 127.7, 126.9 (2), 123.1, 
122.6, 117.4, 115.8, 55.3, 52.9. HRMS (ESI+) m/z [M + H+] calcd for C21H18NO2S, 348.1058, 
found 348.1051. 
 
(4-hydroxy-3-(methyl(phenyl)amino)phenyl)(isoindolin-2-yl)methanone: A biotage 
microwave vial was charged with 142 (100 mg, 0.25 mmol, 1 eq.), N-methyl aniline (44 l, 0.36 
mmol, 1.5 eq.), RuPhos (10 mg, 0.02 mmol, 0.08 eq.), Tris(dibenzylideneacetone)dipalladium(0) 
(22 mg, 0.02 mmol, 0.1 eq.), sodium tert-butoxide (35 mg, 0.36 mmol, 1.5 eq.). The tube was 
sealed with a cap lined with a disposable Teflon septum. The tube was evacuated and purged with 
nitrogen (3 times), before the addition of toluene (3.0 mL) by syringe. The resulting mixture was 
heated at 120 °C for 18 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl 
acetate). Solvent was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl 
acetate/hexanes) to give the corresponding 5-substituted product, which was used further as 
obtained, and taken in dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution 
of boron tribromide (0.6 mL). The resulting mixture was stirred for 6 h, quenched with saturated 
sodium bicarbonate solution (5 mL) and extracted with dichloromethane (2 × 10 mL). The 
combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over 
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anhydrous sodium sulfate, filtered, and concentrated. The residue purified with flash 
chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the desired product 141 as white 
amorphous solid (36 mg, 41 %). 1H NMR (400 MHz, CDCl3) δ 7.49 (dd, J = 8.4, 2.1 Hz, 1H), 7.41 
(d, J = 2.1 Hz, 1H), 7.30 (dd, J = 9.9, 4.3 Hz, 3H), 7.25 – 7.22 (m, 1H), 7.17 (d, J = 7.3 Hz, 1H), 
7.12 (d, J = 8.4 Hz, 1H), 6.89 (tt, J = 7.3, 1.0 Hz, 1H), 6.79 – 6.74 (m, 2H), 6.35 (s, 1H), 4.98 (s, 
2H), 4.80 (s, 2H), 3.24 (s, 3H).13C NMR (101 MHz, CDCl3) δ 169.7, 154.6, 149.2, 136.6 (2), 
135.9, 129.9, 129.5 (2), 128.0, 127.7, 127.5, 126.9, 123.1, 122.6, 120.0, 115.5, 115.4 (2), 55.3, 
52.8, 40.3. HRMS (ESI+) m/z [M + H+] calcd for C22H21N2O2, 345.1603, found 345.1612. 
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